CA3142664A1 - Combination therapy comprising an anti-cd25 antibody drug conjugate and a further agent - Google Patents
Combination therapy comprising an anti-cd25 antibody drug conjugate and a further agent Download PDFInfo
- Publication number
- CA3142664A1 CA3142664A1 CA3142664A CA3142664A CA3142664A1 CA 3142664 A1 CA3142664 A1 CA 3142664A1 CA 3142664 A CA3142664 A CA 3142664A CA 3142664 A CA3142664 A CA 3142664A CA 3142664 A1 CA3142664 A1 CA 3142664A1
- Authority
- CA
- Canada
- Prior art keywords
- agent
- individual
- treatment
- adc
- bcl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003795 chemical substances by application Substances 0.000 title claims abstract description 363
- 229940049595 antibody-drug conjugate Drugs 0.000 title abstract description 214
- 239000000611 antibody drug conjugate Substances 0.000 title abstract description 196
- 238000002648 combination therapy Methods 0.000 title abstract description 16
- 238000011282 treatment Methods 0.000 claims abstract description 312
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 289
- 229940124302 mTOR inhibitor Drugs 0.000 claims abstract description 141
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims abstract description 141
- 201000011510 cancer Diseases 0.000 claims abstract description 90
- 238000000034 method Methods 0.000 claims description 347
- 210000004027 cell Anatomy 0.000 claims description 193
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 159
- 208000035475 disorder Diseases 0.000 claims description 113
- 229950009667 camidanlumab tesirine Drugs 0.000 claims description 102
- 239000003814 drug Substances 0.000 claims description 96
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 75
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 75
- 201000009277 hairy cell leukemia Diseases 0.000 claims description 61
- LQBVNQSMGBZMKD-UHFFFAOYSA-N venetoclax Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=NC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCOCC1 LQBVNQSMGBZMKD-UHFFFAOYSA-N 0.000 claims description 55
- 239000000203 mixture Substances 0.000 claims description 54
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims description 50
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical group ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 claims description 49
- 210000005170 neoplastic cell Anatomy 0.000 claims description 49
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical group C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims description 48
- OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical group O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 claims description 48
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 claims description 48
- 229960002707 bendamustine Drugs 0.000 claims description 47
- 229960001467 bortezomib Drugs 0.000 claims description 47
- 201000010099 disease Diseases 0.000 claims description 46
- 229950002550 copanlisib Drugs 0.000 claims description 45
- 229960003452 romidepsin Drugs 0.000 claims description 45
- 108010091666 romidepsin Proteins 0.000 claims description 45
- OHRURASPPZQGQM-UHFFFAOYSA-N romidepsin Natural products O1C(=O)C(C(C)C)NC(=O)C(=CC)NC(=O)C2CSSCCC=CC1CC(=O)NC(C(C)C)C(=O)N2 OHRURASPPZQGQM-UHFFFAOYSA-N 0.000 claims description 45
- 229960000237 vorinostat Drugs 0.000 claims description 45
- OGSBUKJUDHAQEA-WMCAAGNKSA-N pralatrexate Chemical group C1=NC2=NC(N)=NC(N)=C2N=C1CC(CC#C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OGSBUKJUDHAQEA-WMCAAGNKSA-N 0.000 claims description 44
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 claims description 43
- 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 claims description 43
- 206010025323 Lymphomas Diseases 0.000 claims description 42
- 229960000214 pralatrexate Drugs 0.000 claims description 42
- 230000002062 proliferating effect Effects 0.000 claims description 41
- 229960001183 venetoclax Drugs 0.000 claims description 40
- JOGKUKXHTYWRGZ-UHFFFAOYSA-N dactolisib Chemical compound O=C1N(C)C2=CN=C3C=CC(C=4C=C5C=CC=CC5=NC=4)=CC3=C2N1C1=CC=C(C(C)(C)C#N)C=C1 JOGKUKXHTYWRGZ-UHFFFAOYSA-N 0.000 claims description 39
- 208000032839 leukemia Diseases 0.000 claims description 38
- 208000035269 cancer or benign tumor Diseases 0.000 claims description 37
- 229950006418 dactolisib Drugs 0.000 claims description 36
- -1 lxazomib Chemical compound 0.000 claims description 36
- 241000282414 Homo sapiens Species 0.000 claims description 35
- 229960005167 everolimus Drugs 0.000 claims description 35
- 229960003445 idelalisib Drugs 0.000 claims description 35
- GYLDXIAOMVERTK-UHFFFAOYSA-N 5-(4-amino-1-propan-2-yl-3-pyrazolo[3,4-d]pyrimidinyl)-1,3-benzoxazol-2-amine Chemical compound C12=C(N)N=CN=C2N(C(C)C)N=C1C1=CC=C(OC(N)=N2)C2=C1 GYLDXIAOMVERTK-UHFFFAOYSA-N 0.000 claims description 34
- 229950009216 sapanisertib Drugs 0.000 claims description 33
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims description 32
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims description 32
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims description 31
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims description 31
- 208000036170 B-Cell Marginal Zone Lymphoma Diseases 0.000 claims description 30
- 201000000439 HCL-V Diseases 0.000 claims description 30
- 208000010956 Hairy cell leukemia variant Diseases 0.000 claims description 30
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims description 30
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 claims description 30
- 208000021937 marginal zone lymphoma Diseases 0.000 claims description 30
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 29
- DWZAEMINVBZMHQ-UHFFFAOYSA-N 1-[4-[4-(dimethylamino)piperidine-1-carbonyl]phenyl]-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea Chemical compound C1CC(N(C)C)CCN1C(=O)C(C=C1)=CC=C1NC(=O)NC1=CC=C(C=2N=C(N=C(N=2)N2CCOCC2)N2CCOCC2)C=C1 DWZAEMINVBZMHQ-UHFFFAOYSA-N 0.000 claims description 28
- 229960002930 sirolimus Drugs 0.000 claims description 28
- RGHYDLZMTYDBDT-UHFFFAOYSA-N 2-amino-8-ethyl-4-methyl-6-(1H-pyrazol-5-yl)-7-pyrido[2,3-d]pyrimidinone Chemical compound O=C1N(CC)C2=NC(N)=NC(C)=C2C=C1C=1C=CNN=1 RGHYDLZMTYDBDT-UHFFFAOYSA-N 0.000 claims description 27
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 26
- BUROJSBIWGDYCN-GAUTUEMISA-N AP 23573 Chemical compound C1C[C@@H](OP(C)(C)=O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 BUROJSBIWGDYCN-GAUTUEMISA-N 0.000 claims description 25
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 24
- 239000002246 antineoplastic agent Substances 0.000 claims description 24
- 229940127089 cytotoxic agent Drugs 0.000 claims description 24
- 239000004052 folic acid antagonist Substances 0.000 claims description 24
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 23
- 230000003432 anti-folate effect Effects 0.000 claims description 23
- 229940127074 antifolate Drugs 0.000 claims description 23
- 229950008209 gedatolisib Drugs 0.000 claims description 23
- 238000004519 manufacturing process Methods 0.000 claims description 23
- 229960000435 oblimersen Drugs 0.000 claims description 23
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 claims description 22
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 21
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 claims description 20
- 229960000485 methotrexate Drugs 0.000 claims description 20
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 19
- 230000002496 gastric effect Effects 0.000 claims description 19
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims description 19
- 206010006187 Breast cancer Diseases 0.000 claims description 18
- 208000026310 Breast neoplasm Diseases 0.000 claims description 18
- 206010009944 Colon cancer Diseases 0.000 claims description 18
- 208000017604 Hodgkin disease Diseases 0.000 claims description 18
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 18
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 18
- 229940079156 Proteasome inhibitor Drugs 0.000 claims description 18
- 239000003207 proteasome inhibitor Substances 0.000 claims description 18
- 229960000235 temsirolimus Drugs 0.000 claims description 18
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 17
- 206010033128 Ovarian cancer Diseases 0.000 claims description 17
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 17
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 17
- 206010017758 gastric cancer Diseases 0.000 claims description 17
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 17
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 17
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 17
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 17
- 201000011549 stomach cancer Diseases 0.000 claims description 17
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 17
- HRNLUBSXIHFDHP-UHFFFAOYSA-N N-(2-aminophenyl)-4-[[[4-(3-pyridinyl)-2-pyrimidinyl]amino]methyl]benzamide Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC1=NC=CC(C=2C=NC=CC=2)=N1 HRNLUBSXIHFDHP-UHFFFAOYSA-N 0.000 claims description 16
- 230000001684 chronic effect Effects 0.000 claims description 16
- 201000010536 head and neck cancer Diseases 0.000 claims description 16
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 16
- 230000001926 lymphatic effect Effects 0.000 claims description 16
- 201000001441 melanoma Diseases 0.000 claims description 16
- 201000002528 pancreatic cancer Diseases 0.000 claims description 16
- FPOHNWQLNRZRFC-ZHACJKMWSA-N panobinostat Chemical compound CC=1NC2=CC=CC=C2C=1CCNCC1=CC=C(\C=C\C(=O)NO)C=C1 FPOHNWQLNRZRFC-ZHACJKMWSA-N 0.000 claims description 16
- 239000002935 phosphatidylinositol 3 kinase inhibitor Substances 0.000 claims description 16
- 210000004881 tumor cell Anatomy 0.000 claims description 16
- IUVCFHHAEHNCFT-INIZCTEOSA-N 2-[(1s)-1-[4-amino-3-(3-fluoro-4-propan-2-yloxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-6-fluoro-3-(3-fluorophenyl)chromen-4-one Chemical compound C1=C(F)C(OC(C)C)=CC=C1C(C1=C(N)N=CN=C11)=NN1[C@@H](C)C1=C(C=2C=C(F)C=CC=2)C(=O)C2=CC(F)=CC=C2O1 IUVCFHHAEHNCFT-INIZCTEOSA-N 0.000 claims description 15
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 15
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 15
- IVTVGDXNLFLDRM-HNNXBMFYSA-N Tomudex Chemical compound C=1C=C2NC(C)=NC(=O)C2=CC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)S1 IVTVGDXNLFLDRM-HNNXBMFYSA-N 0.000 claims description 15
- NCNRHFGMJRPRSK-MDZDMXLPSA-N belinostat Chemical compound ONC(=O)\C=C\C1=CC=CC(S(=O)(=O)NC=2C=CC=CC=2)=C1 NCNRHFGMJRPRSK-MDZDMXLPSA-N 0.000 claims description 15
- INVTYAOGFAGBOE-UHFFFAOYSA-N entinostat Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC(=O)OCC1=CC=CN=C1 INVTYAOGFAGBOE-UHFFFAOYSA-N 0.000 claims description 15
- 201000003444 follicular lymphoma Diseases 0.000 claims description 15
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 15
- 229940121372 histone deacetylase inhibitor Drugs 0.000 claims description 15
- SWZXEVABPLUDIO-WSZYKNRRSA-N n-[(2s)-3-methoxy-1-[[(2s)-3-methoxy-1-[[(2s)-1-[(2r)-2-methyloxiran-2-yl]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]-2-methyl-1,3-thiazole-5-carboxamide Chemical compound N([C@@H](COC)C(=O)N[C@@H](COC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)[C@]1(C)OC1)C(=O)C1=CN=C(C)S1 SWZXEVABPLUDIO-WSZYKNRRSA-N 0.000 claims description 15
- 210000004214 philadelphia chromosome Anatomy 0.000 claims description 15
- NGWSFRIPKNWYAO-SHTIJGAHSA-N salinosporamide A Chemical compound C([C@@H]1[C@H](O)[C@]23C(=O)O[C@]2([C@H](C(=O)N3)CCCl)C)CCC=C1 NGWSFRIPKNWYAO-SHTIJGAHSA-N 0.000 claims description 15
- VAZAPHZUAVEOMC-UHFFFAOYSA-N tacedinaline Chemical compound C1=CC(NC(=O)C)=CC=C1C(=O)NC1=CC=CC=C1N VAZAPHZUAVEOMC-UHFFFAOYSA-N 0.000 claims description 15
- BWDQBBCUWLSASG-MDZDMXLPSA-N (e)-n-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1h-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide Chemical compound C=1NC2=CC=CC=C2C=1CCN(CCO)CC1=CC=C(\C=C\C(=O)NO)C=C1 BWDQBBCUWLSASG-MDZDMXLPSA-N 0.000 claims description 14
- MAUCONCHVWBMHK-UHFFFAOYSA-N 3-[(dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)-oxomethyl]phenoxy]ethyl]-2-benzofurancarboxamide Chemical compound O1C2=CC=CC=C2C(CN(C)C)=C1C(=O)NCCOC1=CC=C(C(=O)NO)C=C1 MAUCONCHVWBMHK-UHFFFAOYSA-N 0.000 claims description 14
- SJVQHLPISAIATJ-ZDUSSCGKSA-N 8-chloro-2-phenyl-3-[(1S)-1-(7H-purin-6-ylamino)ethyl]-1-isoquinolinone Chemical compound C1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)=CC2=CC=CC(Cl)=C2C(=O)N1C1=CC=CC=C1 SJVQHLPISAIATJ-ZDUSSCGKSA-N 0.000 claims description 14
- CWHUFRVAEUJCEF-UHFFFAOYSA-N BKM120 Chemical compound C1=NC(N)=CC(C(F)(F)F)=C1C1=CC(N2CCOCC2)=NC(N2CCOCC2)=N1 CWHUFRVAEUJCEF-UHFFFAOYSA-N 0.000 claims description 14
- BLMPQMFVWMYDKT-NZTKNTHTSA-N carfilzomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)[C@]1(C)OC1)NC(=O)CN1CCOCC1)CC1=CC=CC=C1 BLMPQMFVWMYDKT-NZTKNTHTSA-N 0.000 claims description 14
- JLYAXFNOILIKPP-KXQOOQHDSA-N navitoclax Chemical compound C([C@@H](NC1=CC=C(C=C1S(=O)(=O)C(F)(F)F)S(=O)(=O)NC(=O)C1=CC=C(C=C1)N1CCN(CC1)CC1=C(CCC(C1)(C)C)C=1C=CC(Cl)=CC=1)CSC=1C=CC=CC=1)CN1CCOCC1 JLYAXFNOILIKPP-KXQOOQHDSA-N 0.000 claims description 14
- STUWGJZDJHPWGZ-LBPRGKRZSA-N (2S)-N1-[4-methyl-5-[2-(1,1,1-trifluoro-2-methylpropan-2-yl)-4-pyridinyl]-2-thiazolyl]pyrrolidine-1,2-dicarboxamide Chemical compound S1C(C=2C=C(N=CC=2)C(C)(C)C(F)(F)F)=C(C)N=C1NC(=O)N1CCC[C@H]1C(N)=O STUWGJZDJHPWGZ-LBPRGKRZSA-N 0.000 claims description 13
- BEUQXVWXFDOSAQ-UHFFFAOYSA-N 2-methyl-2-[4-[2-(5-methyl-2-propan-2-yl-1,2,4-triazol-3-yl)-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepin-9-yl]pyrazol-1-yl]propanamide Chemical compound CC(C)N1N=C(C)N=C1C1=CN(CCOC=2C3=CC=C(C=2)C2=CN(N=C2)C(C)(C)C(N)=O)C3=N1 BEUQXVWXFDOSAQ-UHFFFAOYSA-N 0.000 claims description 13
- JUSFANSTBFGBAF-IRXDYDNUSA-N 3-[2,4-bis[(3s)-3-methylmorpholin-4-yl]pyrido[2,3-d]pyrimidin-7-yl]-n-methylbenzamide Chemical compound CNC(=O)C1=CC=CC(C=2N=C3N=C(N=C(C3=CC=2)N2[C@H](COCC2)C)N2[C@H](COCC2)C)=C1 JUSFANSTBFGBAF-IRXDYDNUSA-N 0.000 claims description 13
- HPLNQCPCUACXLM-PGUFJCEWSA-N ABT-737 Chemical compound C([C@@H](CCN(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 HPLNQCPCUACXLM-PGUFJCEWSA-N 0.000 claims description 13
- YUXMAKUNSXIEKN-BTJKTKAUSA-N BGT226 Chemical compound OC(=O)\C=C/C(O)=O.C1=NC(OC)=CC=C1C1=CC=C(N=CC2=C3N(C=4C=C(C(N5CCNCC5)=CC=4)C(F)(F)F)C(=O)N2C)C3=C1 YUXMAKUNSXIEKN-BTJKTKAUSA-N 0.000 claims description 13
- 229960005079 pemetrexed Drugs 0.000 claims description 13
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 claims description 13
- JWGVUDPAMQEIJU-INIZCTEOSA-N 1-[4-[4-(1-cyclopropylsulfonylcyclopropyl)-6-[(3s)-3-methylmorpholin-4-yl]pyrimidin-2-yl]phenyl]-3-(2-hydroxyethyl)thiourea Chemical compound C[C@H]1COCCN1C1=CC(C2(CC2)S(=O)(=O)C2CC2)=NC(C=2C=CC(NC(=S)NCCO)=CC=2)=N1 JWGVUDPAMQEIJU-INIZCTEOSA-N 0.000 claims description 12
- XDLYKKIQACFMJG-UHFFFAOYSA-N 2-amino-8-[4-(2-hydroxyethoxy)cyclohexyl]-6-(6-methoxypyridin-3-yl)-4-methylpyrido[2,3-d]pyrimidin-7-one Chemical compound C1=NC(OC)=CC=C1C(C1=O)=CC2=C(C)N=C(N)N=C2N1C1CCC(OCCO)CC1 XDLYKKIQACFMJG-UHFFFAOYSA-N 0.000 claims description 12
- BJVRNXSHJLDZJR-UHFFFAOYSA-N 3-(1-methyl-4-morpholin-4-ylpyrazolo[3,4-d]pyrimidin-6-yl)phenol Chemical compound N1=C2N(C)N=CC2=C(N2CCOCC2)N=C1C1=CC=CC(O)=C1 BJVRNXSHJLDZJR-UHFFFAOYSA-N 0.000 claims description 12
- PSICWGWNIOOULV-UHFFFAOYSA-N 5-[4-amino-1-(2,2-diethoxyethyl)pyrazolo[3,4-d]pyrimidin-3-yl]-1,3-benzoxazol-2-amine Chemical compound CCOC(Cn1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc12)OCC PSICWGWNIOOULV-UHFFFAOYSA-N 0.000 claims description 12
- KVLFRAWTRWDEDF-IRXDYDNUSA-N AZD-8055 Chemical compound C1=C(CO)C(OC)=CC=C1C1=CC=C(C(=NC(=N2)N3[C@H](COCC3)C)N3[C@H](COCC3)C)C2=N1 KVLFRAWTRWDEDF-IRXDYDNUSA-N 0.000 claims description 12
- RFSMUFRPPYDYRD-CALCHBBNSA-N Ku-0063794 Chemical compound C1=C(CO)C(OC)=CC=C1C1=CC=C(C(=NC(=N2)N3C[C@@H](C)O[C@@H](C)C3)N3CCOCC3)C2=N1 RFSMUFRPPYDYRD-CALCHBBNSA-N 0.000 claims description 12
- 108010064641 ONX 0912 Proteins 0.000 claims description 12
- LNFBAYSBVQBKFR-UHFFFAOYSA-N [7-(6-aminopyridin-3-yl)-3,5-dihydro-2h-1,4-benzoxazepin-4-yl]-(3-fluoro-2-methyl-4-methylsulfonylphenyl)methanone Chemical compound CC1=C(F)C(S(C)(=O)=O)=CC=C1C(=O)N1CC2=CC(C=3C=NC(N)=CC=3)=CC=C2OCC1 LNFBAYSBVQBKFR-UHFFFAOYSA-N 0.000 claims description 12
- 229950008805 abexinostat Drugs 0.000 claims description 12
- 229950010482 alpelisib Drugs 0.000 claims description 12
- 229950003628 buparlisib Drugs 0.000 claims description 12
- 229960002438 carfilzomib Drugs 0.000 claims description 12
- 108010021331 carfilzomib Proteins 0.000 claims description 12
- 229950004949 duvelisib Drugs 0.000 claims description 12
- 229950002736 marizomib Drugs 0.000 claims description 12
- VYXJULKGMXJVGI-XIFFEERXSA-N n-(4-hydroxyphenyl)-3-[6-[(3s)-3-(morpholin-4-ylmethyl)-3,4-dihydro-1h-isoquinoline-2-carbonyl]-1,3-benzodioxol-5-yl]-n-phenyl-5,6,7,8-tetrahydroindolizine-1-carboxamide Chemical compound C1=CC(O)=CC=C1N(C=1C=CC=CC=1)C(=O)C1=C2CCCCN2C(C=2C(=CC=3OCOC=3C=2)C(=O)N2[C@@H](CC3=CC=CC=C3C2)CN2CCOCC2)=C1 VYXJULKGMXJVGI-XIFFEERXSA-N 0.000 claims description 12
- BIWKXNFEOZXNLX-BBHIFXBUSA-N oleuropein aglycone Chemical compound COC(=O)C1=CO[C@@H](O)\C(=C\C)[C@@H]1CC(=O)OCCC1=CC=C(O)C(O)=C1 BIWKXNFEOZXNLX-BBHIFXBUSA-N 0.000 claims description 12
- CGBJSGAELGCMKE-UHFFFAOYSA-N omipalisib Chemical compound COC1=NC=C(C=2C=C3C(C=4C=NN=CC=4)=CC=NC3=CC=2)C=C1NS(=O)(=O)C1=CC=C(F)C=C1F CGBJSGAELGCMKE-UHFFFAOYSA-N 0.000 claims description 12
- 229950005750 oprozomib Drugs 0.000 claims description 12
- 229960004432 raltitrexed Drugs 0.000 claims description 12
- 229960001302 ridaforolimus Drugs 0.000 claims description 12
- NGWSFRIPKNWYAO-UHFFFAOYSA-N salinosporamide A Natural products N1C(=O)C(CCCl)C2(C)OC(=O)C21C(O)C1CCCC=C1 NGWSFRIPKNWYAO-UHFFFAOYSA-N 0.000 claims description 12
- 229950001269 taselisib Drugs 0.000 claims description 12
- AKCRNFFTGXBONI-UHFFFAOYSA-N torin 1 Chemical compound C1CN(C(=O)CC)CCN1C1=CC=C(N2C(C=CC3=C2C2=CC(=CC=C2N=C3)C=2C=C3C=CC=CC3=NC=2)=O)C=C1C(F)(F)F AKCRNFFTGXBONI-UHFFFAOYSA-N 0.000 claims description 12
- GUXXEUUYCAYESJ-UHFFFAOYSA-N torin 2 Chemical compound C1=NC(N)=CC=C1C1=CC=C(N=CC2=C3N(C=4C=C(C=CC=4)C(F)(F)F)C(=O)C=C2)C3=C1 GUXXEUUYCAYESJ-UHFFFAOYSA-N 0.000 claims description 12
- MFAQYJIYDMLAIM-UHFFFAOYSA-N torkinib Chemical compound C12=C(N)N=CN=C2N(C(C)C)N=C1C1=CC2=CC(O)=CC=C2N1 MFAQYJIYDMLAIM-UHFFFAOYSA-N 0.000 claims description 12
- 229940121344 umbralisib Drugs 0.000 claims description 12
- QDOGZMBPRITPMZ-XIQIGJHASA-N N-[4-[4-amino-3-(2-amino-1,3-benzoxazol-5-yl)pyrazolo[3,4-d]pyrimidin-1-yl]butyl]-3-[2-[2-[2-[2-[2-[2-[2-[2-[4-[2-[(1R,2R,4S)-4-[(2R)-2-[(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-2,3,10,14,20-pentaoxo-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraen-12-yl]propyl]-2-methoxycyclohexyl]oxyethoxymethyl]triazol-1-yl]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]propanamide Chemical compound [H][C@@]1(C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCOCC2=CN(CCOCCOCCOCCOCCOCCOCCOCCOCCC(=O)NCCCCN3N=C(C4=C3N=CN=C4N)C3=CC4=C(OC(N)=N4)C=C3)N=N2)[C@@H](C1)OC QDOGZMBPRITPMZ-XIQIGJHASA-N 0.000 claims description 11
- DEBZOPZQKONWTK-KWCYVHTRSA-N oleuropein aglycone Natural products COC(=O)C1=CO[C@H](C)[C@@H](C=O)[C@@H]1CC(=O)OCCc1ccc(O)c(O)c1 DEBZOPZQKONWTK-KWCYVHTRSA-N 0.000 claims description 11
- 229950008089 omipalisib Drugs 0.000 claims description 11
- 229950001576 voxtalisib Drugs 0.000 claims description 11
- 238000009097 single-agent therapy Methods 0.000 claims description 9
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims description 4
- 201000011263 bladder neck cancer Diseases 0.000 claims description 4
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims description 4
- VDOCQQKGPJENHJ-UHFFFAOYSA-N methyl n-[4-[4-morpholin-4-yl-1-[1-(pyridin-3-ylmethyl)piperidin-4-yl]pyrazolo[3,4-d]pyrimidin-6-yl]phenyl]carbamate Chemical compound C1=CC(NC(=O)OC)=CC=C1C1=NC(N2CCOCC2)=C(C=NN2C3CCN(CC=4C=NC=CC=4)CC3)C2=N1 VDOCQQKGPJENHJ-UHFFFAOYSA-N 0.000 claims description 2
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 claims 5
- PZBCKZWLPGJMAO-UHFFFAOYSA-N copanlisib Chemical group C1=CC=2C3=NCCN3C(NC(=O)C=3C=NC(N)=NC=3)=NC=2C(OC)=C1OCCCN1CCOCC1 PZBCKZWLPGJMAO-UHFFFAOYSA-N 0.000 claims 2
- YKLIKGKUANLGSB-HNNXBMFYSA-N idelalisib Chemical compound C1([C@@H](NC=2[C]3N=CN=C3N=CN=2)CC)=NC2=CC=CC(F)=C2C(=O)N1C1=CC=CC=C1 YKLIKGKUANLGSB-HNNXBMFYSA-N 0.000 claims 2
- MIMNFCVQODTQDP-NDLVEFNKSA-N oblimersen Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(S)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)CO)[C@@H](O)C1 MIMNFCVQODTQDP-NDLVEFNKSA-N 0.000 claims 2
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 abstract description 2
- 239000005022 packaging material Substances 0.000 description 73
- 239000000126 substance Substances 0.000 description 63
- 239000000523 sample Substances 0.000 description 54
- 230000014509 gene expression Effects 0.000 description 53
- MWYDSXOGIBMAET-UHFFFAOYSA-N 2-amino-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydro-1H-imidazo[1,2-c]quinazolin-5-ylidene]pyrimidine-5-carboxamide Chemical compound NC1=NC=C(C=N1)C(=O)N=C1N=C2C(=C(C=CC2=C2N1CCN2)OCCCN1CCOCC1)OC MWYDSXOGIBMAET-UHFFFAOYSA-N 0.000 description 46
- 239000004615 ingredient Substances 0.000 description 43
- IFSDAJWBUCMOAH-HNNXBMFYSA-N idelalisib Chemical compound C1([C@@H](NC=2C=3N=CNC=3N=CN=2)CC)=NC2=CC=CC(F)=C2C(=O)N1C1=CC=CC=C1 IFSDAJWBUCMOAH-HNNXBMFYSA-N 0.000 description 35
- 150000001875 compounds Chemical class 0.000 description 32
- 210000001744 T-lymphocyte Anatomy 0.000 description 30
- 229940079593 drug Drugs 0.000 description 29
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 27
- 108090000623 proteins and genes Proteins 0.000 description 27
- 230000004044 response Effects 0.000 description 26
- 102000004169 proteins and genes Human genes 0.000 description 24
- IBXPAFBDJCXCDW-MHFPCNPESA-A [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].Cc1cn([C@H]2C[C@H](O)[C@@H](COP([S-])(=O)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3CO)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c3nc(N)[nH]c4=O)n3ccc(N)nc3=O)n3cnc4c3nc(N)[nH]c4=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3ccc(N)nc3=O)n3cnc4c3nc(N)[nH]c4=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].Cc1cn([C@H]2C[C@H](O)[C@@H](COP([S-])(=O)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3CO)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c3nc(N)[nH]c4=O)n3ccc(N)nc3=O)n3cnc4c3nc(N)[nH]c4=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3ccc(N)nc3=O)n3cnc4c3nc(N)[nH]c4=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O IBXPAFBDJCXCDW-MHFPCNPESA-A 0.000 description 23
- 230000000694 effects Effects 0.000 description 23
- 230000002489 hematologic effect Effects 0.000 description 22
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 21
- 210000004369 blood Anatomy 0.000 description 20
- 239000008280 blood Substances 0.000 description 20
- 230000008901 benefit Effects 0.000 description 19
- 210000001519 tissue Anatomy 0.000 description 19
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 18
- 239000000427 antigen Substances 0.000 description 18
- 102000036639 antigens Human genes 0.000 description 18
- 108091007433 antigens Proteins 0.000 description 18
- 125000000217 alkyl group Chemical group 0.000 description 16
- YUOCYTRGANSSRY-UHFFFAOYSA-N pyrrolo[2,3-i][1,2]benzodiazepine Chemical group C1=CN=NC2=C3C=CN=C3C=CC2=C1 YUOCYTRGANSSRY-UHFFFAOYSA-N 0.000 description 15
- 125000005647 linker group Chemical group 0.000 description 14
- WBXPDJSOTKVWSJ-ZDUSSCGKSA-N pemetrexed Chemical compound C=1NC=2NC(N)=NC(=O)C=2C=1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 WBXPDJSOTKVWSJ-ZDUSSCGKSA-N 0.000 description 14
- SVNJBEMPMKWDCO-KCHLEUMXSA-N (2s)-2-[[(2s)-3-carboxy-2-[[2-[[(2s)-5-(diaminomethylideneamino)-2-[[4-oxo-4-[[4-(4-oxo-8-phenylchromen-2-yl)morpholin-4-ium-4-yl]methoxy]butanoyl]amino]pentanoyl]amino]acetyl]amino]propanoyl]amino]-3-hydroxypropanoate Chemical compound C=1C(=O)C2=CC=CC(C=3C=CC=CC=3)=C2OC=1[N+]1(COC(=O)CCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C([O-])=O)CCOCC1 SVNJBEMPMKWDCO-KCHLEUMXSA-N 0.000 description 13
- 235000018102 proteins Nutrition 0.000 description 13
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 12
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 12
- 150000001413 amino acids Chemical group 0.000 description 12
- 210000003289 regulatory T cell Anatomy 0.000 description 12
- 238000002560 therapeutic procedure Methods 0.000 description 12
- 102000003964 Histone deacetylase Human genes 0.000 description 11
- 108090000353 Histone deacetylase Proteins 0.000 description 11
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 11
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 11
- 238000000338 in vitro Methods 0.000 description 11
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 11
- 206010042971 T-cell lymphoma Diseases 0.000 description 10
- 208000037844 advanced solid tumor Diseases 0.000 description 10
- 230000004071 biological effect Effects 0.000 description 10
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 10
- 229950011110 tacedinaline Drugs 0.000 description 10
- 230000001225 therapeutic effect Effects 0.000 description 10
- 208000003950 B-cell lymphoma Diseases 0.000 description 9
- 230000003833 cell viability Effects 0.000 description 9
- 239000000562 conjugate Substances 0.000 description 9
- 231100000433 cytotoxic Toxicity 0.000 description 9
- 230000001472 cytotoxic effect Effects 0.000 description 9
- 235000019152 folic acid Nutrition 0.000 description 9
- 239000011724 folic acid Substances 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 8
- 125000003342 alkenyl group Chemical group 0.000 description 8
- 238000001574 biopsy Methods 0.000 description 8
- 229940014144 folate Drugs 0.000 description 8
- 125000001475 halogen functional group Chemical group 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 7
- 101100289995 Caenorhabditis elegans mac-1 gene Proteins 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 108060003951 Immunoglobulin Proteins 0.000 description 7
- 102000038030 PI3Ks Human genes 0.000 description 7
- 108091007960 PI3Ks Proteins 0.000 description 7
- 230000001363 autoimmune Effects 0.000 description 7
- 229940098773 bovine serum albumin Drugs 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 230000018109 developmental process Effects 0.000 description 7
- 230000036039 immunity Effects 0.000 description 7
- 102000018358 immunoglobulin Human genes 0.000 description 7
- 239000003112 inhibitor Substances 0.000 description 7
- 230000037353 metabolic pathway Effects 0.000 description 7
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 7
- 230000004962 physiological condition Effects 0.000 description 7
- 241000894007 species Species 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 6
- 239000012828 PI3K inhibitor Substances 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 238000001516 cell proliferation assay Methods 0.000 description 6
- 230000003013 cytotoxicity Effects 0.000 description 6
- 231100000135 cytotoxicity Toxicity 0.000 description 6
- 238000003745 diagnosis Methods 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- OMRPLUKQNWNZAV-CONSDPRKSA-N (6as)-3-[3-[[(6as)-2-methoxy-8-(4-methoxyphenyl)-11-oxo-6a,7-dihydropyrrolo[2,1-c][1,4]benzodiazepin-3-yl]oxy]propoxy]-8-(4-aminophenyl)-2-methoxy-6a,7-dihydropyrrolo[2,1-c][1,4]benzodiazepin-11-one Chemical compound C1=CC(OC)=CC=C1C1=CN2C(=O)C3=CC(OC)=C(OCCCOC=4C(=CC=5C(=O)N6C=C(C[C@H]6C=NC=5C=4)C=4C=CC(N)=CC=4)OC)C=C3N=C[C@@H]2C1 OMRPLUKQNWNZAV-CONSDPRKSA-N 0.000 description 5
- 108010063104 Apoptosis Regulatory Proteins Proteins 0.000 description 5
- 102000010565 Apoptosis Regulatory Proteins Human genes 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 5
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 5
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 5
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 5
- 102000044159 Ubiquitin Human genes 0.000 description 5
- 108090000848 Ubiquitin Proteins 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 5
- 229960002949 fluorouracil Drugs 0.000 description 5
- MXAYKZJJDUDWDS-LBPRGKRZSA-N ixazomib Chemical compound CC(C)C[C@@H](B(O)O)NC(=O)CNC(=O)C1=CC(Cl)=CC=C1Cl MXAYKZJJDUDWDS-LBPRGKRZSA-N 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 230000002195 synergetic effect Effects 0.000 description 5
- 208000023275 Autoimmune disease Diseases 0.000 description 4
- 208000009329 Graft vs Host Disease Diseases 0.000 description 4
- 108010033040 Histones Proteins 0.000 description 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 102000035195 Peptidases Human genes 0.000 description 4
- 108091005804 Peptidases Proteins 0.000 description 4
- 208000027190 Peripheral T-cell lymphomas Diseases 0.000 description 4
- 239000004365 Protease Substances 0.000 description 4
- 208000031672 T-Cell Peripheral Lymphoma Diseases 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 125000005907 alkyl ester group Chemical group 0.000 description 4
- 125000000304 alkynyl group Chemical group 0.000 description 4
- 125000003118 aryl group Chemical group 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 230000030833 cell death Effects 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 208000029742 colonic neoplasm Diseases 0.000 description 4
- 229960004679 doxorubicin Drugs 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 208000024908 graft versus host disease Diseases 0.000 description 4
- 230000037449 immunogenic cell death Effects 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 208000020968 mature T-cell and NK-cell non-Hodgkin lymphoma Diseases 0.000 description 4
- 230000010534 mechanism of action Effects 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 210000002381 plasma Anatomy 0.000 description 4
- 125000004076 pyridyl group Chemical group 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 210000000130 stem cell Anatomy 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 125000001544 thienyl group Chemical group 0.000 description 4
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 3
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 241000282693 Cercopithecidae Species 0.000 description 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 3
- 241000283073 Equus caballus Species 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 description 3
- 238000000719 MTS assay Methods 0.000 description 3
- 231100000070 MTS assay Toxicity 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 3
- 206010038389 Renal cancer Diseases 0.000 description 3
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 3
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
- 230000001594 aberrant effect Effects 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 229940100198 alkylating agent Drugs 0.000 description 3
- 239000002168 alkylating agent Substances 0.000 description 3
- 125000002947 alkylene group Chemical group 0.000 description 3
- 230000008485 antagonism Effects 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 230000000690 anti-lymphoma Effects 0.000 description 3
- 230000000340 anti-metabolite Effects 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 229940100197 antimetabolite Drugs 0.000 description 3
- 239000002256 antimetabolite Substances 0.000 description 3
- 238000003491 array Methods 0.000 description 3
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 3
- 229960000397 bevacizumab Drugs 0.000 description 3
- 239000000090 biomarker Substances 0.000 description 3
- 229930195731 calicheamicin Natural products 0.000 description 3
- HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 210000001072 colon Anatomy 0.000 description 3
- 238000012790 confirmation Methods 0.000 description 3
- 230000002596 correlated effect Effects 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 238000004132 cross linking Methods 0.000 description 3
- 229960004397 cyclophosphamide Drugs 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 3
- 235000008191 folinic acid Nutrition 0.000 description 3
- 239000011672 folinic acid Substances 0.000 description 3
- JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 3
- 125000000623 heterocyclic group Chemical group 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 3
- 201000010982 kidney cancer Diseases 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 229960001691 leucovorin Drugs 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 208000014018 liver neoplasm Diseases 0.000 description 3
- 230000004807 localization Effects 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 230000036210 malignancy Effects 0.000 description 3
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 3
- 239000004005 microsphere Substances 0.000 description 3
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 description 3
- 229960001156 mitoxantrone Drugs 0.000 description 3
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 206010041823 squamous cell carcinoma Diseases 0.000 description 3
- 230000001131 transforming effect Effects 0.000 description 3
- 229960000575 trastuzumab Drugs 0.000 description 3
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 3
- VQSJAWPFQCXIOB-VODLGYORSA-N 2,3-dihydroxypropyl [(1r,2r,3s,4r,5r,6s)-2,3,6-trihydroxy-4,5-diphosphonooxycyclohexyl] hydrogen phosphate Chemical compound OCC(O)COP(O)(=O)O[C@@H]1[C@H](O)[C@H](O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H]1O VQSJAWPFQCXIOB-VODLGYORSA-N 0.000 description 2
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 2
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 2
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 description 2
- 208000002267 Anti-neutrophil cytoplasmic antibody-associated vasculitis Diseases 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 206010003908 B-cell small lymphocytic lymphoma Diseases 0.000 description 2
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 2
- 208000023328 Basedow disease Diseases 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 102000040850 Class 1 family Human genes 0.000 description 2
- 108091071897 Class 1 family Proteins 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108010092160 Dactinomycin Proteins 0.000 description 2
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 2
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 2
- 206010018364 Glomerulonephritis Diseases 0.000 description 2
- 208000015023 Graves' disease Diseases 0.000 description 2
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 2
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 208000005777 Lupus Nephritis Diseases 0.000 description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 2
- 229940124647 MEK inhibitor Drugs 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 2
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 208000031845 Pernicious anaemia Diseases 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 description 2
- 206010041067 Small cell lung cancer Diseases 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 208000024780 Urticaria Diseases 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 230000033289 adaptive immune response Effects 0.000 description 2
- 201000006966 adult T-cell leukemia Diseases 0.000 description 2
- 238000011366 aggressive therapy Methods 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 229960000548 alemtuzumab Drugs 0.000 description 2
- 229960003437 aminoglutethimide Drugs 0.000 description 2
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 2
- 230000002491 angiogenic effect Effects 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 238000009175 antibody therapy Methods 0.000 description 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229960004562 carboplatin Drugs 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000033077 cellular process Effects 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- JROFGZPOBKIAEW-UHFFFAOYSA-N chembl2132692 Chemical compound N1C=2C(OC)=CC=CC=2C=C1C(=C1C(N)=NC=NN11)N=C1C1CCC(C(O)=O)CC1 JROFGZPOBKIAEW-UHFFFAOYSA-N 0.000 description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- 238000011284 combination treatment Methods 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 238000011254 conventional chemotherapy Methods 0.000 description 2
- IBAHLNWTOIHLKE-UHFFFAOYSA-N cyano cyanate Chemical compound N#COC#N IBAHLNWTOIHLKE-UHFFFAOYSA-N 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 239000000824 cytostatic agent Substances 0.000 description 2
- 239000002254 cytotoxic agent Substances 0.000 description 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 2
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- VLCYCQAOQCDTCN-UHFFFAOYSA-N eflornithine Chemical compound NCCCC(N)(C(F)F)C(O)=O VLCYCQAOQCDTCN-UHFFFAOYSA-N 0.000 description 2
- 230000006565 epigenetic process Effects 0.000 description 2
- 229960001904 epirubicin Drugs 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- CHPZKNULDCNCBW-UHFFFAOYSA-N gallium nitrate Chemical compound [Ga+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O CHPZKNULDCNCBW-UHFFFAOYSA-N 0.000 description 2
- 229960003297 gemtuzumab ozogamicin Drugs 0.000 description 2
- 229960002989 glutamic acid Drugs 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- AKWHREAVLKZDDE-UHFFFAOYSA-N hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone Chemical compound CCCCCCCC=CC=CC=CCCCC(=O)CCC=CCC(=O)CCCC(=O)CCCCCCC(=O)C(C)=O AKWHREAVLKZDDE-UHFFFAOYSA-N 0.000 description 2
- 230000003463 hyperproliferative effect Effects 0.000 description 2
- 229960000908 idarubicin Drugs 0.000 description 2
- 229960001101 ifosfamide Drugs 0.000 description 2
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 229960003648 ixazomib Drugs 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 229940043355 kinase inhibitor Drugs 0.000 description 2
- 229960003881 letrozole Drugs 0.000 description 2
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- DHMTURDWPRKSOA-RUZDIDTESA-N lonafarnib Chemical compound C1CN(C(=O)N)CCC1CC(=O)N1CCC([C@@H]2C3=C(Br)C=C(Cl)C=C3CCC3=CC(Br)=CN=C32)CC1 DHMTURDWPRKSOA-RUZDIDTESA-N 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 206010025135 lupus erythematosus Diseases 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 2
- 229960001428 mercaptopurine Drugs 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- QZGIWPZCWHMVQL-UIYAJPBUSA-N neocarzinostatin chromophore Chemical compound O1[C@H](C)[C@H](O)[C@H](O)[C@@H](NC)[C@H]1O[C@@H]1C/2=C/C#C[C@H]3O[C@@]3([C@@H]3OC(=O)OC3)C#CC\2=C[C@H]1OC(=O)C1=C(O)C=CC2=C(C)C=C(OC)C=C12 QZGIWPZCWHMVQL-UIYAJPBUSA-N 0.000 description 2
- 150000002825 nitriles Chemical group 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 229960001756 oxaliplatin Drugs 0.000 description 2
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- 229960005184 panobinostat Drugs 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 229960002087 pertuzumab Drugs 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 2
- 229960004618 prednisone Drugs 0.000 description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 229960004622 raloxifene Drugs 0.000 description 2
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000013074 reference sample Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 229960004641 rituximab Drugs 0.000 description 2
- 229940095743 selective estrogen receptor modulator Drugs 0.000 description 2
- 239000000333 selective estrogen receptor modulator Substances 0.000 description 2
- CYOHGALHFOKKQC-UHFFFAOYSA-N selumetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1Cl CYOHGALHFOKKQC-UHFFFAOYSA-N 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 229960003787 sorafenib Drugs 0.000 description 2
- 208000017572 squamous cell neoplasm Diseases 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- PVYJZLYGTZKPJE-UHFFFAOYSA-N streptonigrin Chemical compound C=1C=C2C(=O)C(OC)=C(N)C(=O)C2=NC=1C(C=1N)=NC(C(O)=O)=C(C)C=1C1=CC=C(OC)C(OC)=C1O PVYJZLYGTZKPJE-UHFFFAOYSA-N 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 229960001603 tamoxifen Drugs 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- 229960001196 thiotepa Drugs 0.000 description 2
- 206010043778 thyroiditis Diseases 0.000 description 2
- 229960003087 tioguanine Drugs 0.000 description 2
- 229960003989 tocilizumab Drugs 0.000 description 2
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 229960000241 vandetanib Drugs 0.000 description 2
- UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 description 2
- 229960004528 vincristine Drugs 0.000 description 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
- NNJPGOLRFBJNIW-HNNXBMFYSA-N (-)-demecolcine Chemical compound C1=C(OC)C(=O)C=C2[C@@H](NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-HNNXBMFYSA-N 0.000 description 1
- WDQLRUYAYXDIFW-RWKIJVEZSA-N (2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-4-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound O[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1 WDQLRUYAYXDIFW-RWKIJVEZSA-N 0.000 description 1
- FLWWDYNPWOSLEO-HQVZTVAUSA-N (2s)-2-[[4-[1-(2-amino-4-oxo-1h-pteridin-6-yl)ethyl-methylamino]benzoyl]amino]pentanedioic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1C(C)N(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FLWWDYNPWOSLEO-HQVZTVAUSA-N 0.000 description 1
- CGMTUJFWROPELF-YPAAEMCBSA-N (3E,5S)-5-[(2S)-butan-2-yl]-3-(1-hydroxyethylidene)pyrrolidine-2,4-dione Chemical compound CC[C@H](C)[C@@H]1NC(=O)\C(=C(/C)O)C1=O CGMTUJFWROPELF-YPAAEMCBSA-N 0.000 description 1
- TVIRNGFXQVMMGB-OFWIHYRESA-N (3s,6r,10r,13e,16s)-16-[(2r,3r,4s)-4-chloro-3-hydroxy-4-phenylbutan-2-yl]-10-[(3-chloro-4-methoxyphenyl)methyl]-6-methyl-3-(2-methylpropyl)-1,4-dioxa-8,11-diazacyclohexadec-13-ene-2,5,9,12-tetrone Chemical compound C1=C(Cl)C(OC)=CC=C1C[C@@H]1C(=O)NC[C@@H](C)C(=O)O[C@@H](CC(C)C)C(=O)O[C@H]([C@H](C)[C@@H](O)[C@@H](Cl)C=2C=CC=CC=2)C/C=C/C(=O)N1 TVIRNGFXQVMMGB-OFWIHYRESA-N 0.000 description 1
- XRBSKUSTLXISAB-XVVDYKMHSA-N (5r,6r,7r,8r)-8-hydroxy-7-(hydroxymethyl)-5-(3,4,5-trimethoxyphenyl)-5,6,7,8-tetrahydrobenzo[f][1,3]benzodioxole-6-carboxylic acid Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H](CO)[C@@H]2C(O)=O)=C1 XRBSKUSTLXISAB-XVVDYKMHSA-N 0.000 description 1
- XRBSKUSTLXISAB-UHFFFAOYSA-N (7R,7'R,8R,8'R)-form-Podophyllic acid Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C(CO)C2C(O)=O)=C1 XRBSKUSTLXISAB-UHFFFAOYSA-N 0.000 description 1
- AESVUZLWRXEGEX-DKCAWCKPSA-N (7S,9R)-7-[(2S,4R,5R,6R)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione iron(3+) Chemical compound [Fe+3].COc1cccc2C(=O)c3c(O)c4C[C@@](O)(C[C@H](O[C@@H]5C[C@@H](N)[C@@H](O)[C@@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO AESVUZLWRXEGEX-DKCAWCKPSA-N 0.000 description 1
- JXVAMODRWBNUSF-KZQKBALLSA-N (7s,9r,10r)-7-[(2r,4s,5s,6s)-5-[[(2s,4as,5as,7s,9s,9ar,10ar)-2,9-dimethyl-3-oxo-4,4a,5a,6,7,9,9a,10a-octahydrodipyrano[4,2-a:4',3'-e][1,4]dioxin-7-yl]oxy]-4-(dimethylamino)-6-methyloxan-2-yl]oxy-10-[(2s,4s,5s,6s)-4-(dimethylamino)-5-hydroxy-6-methyloxan-2 Chemical compound O([C@@H]1C2=C(O)C=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C2[C@@H](O[C@@H]2O[C@@H](C)[C@@H](O[C@@H]3O[C@@H](C)[C@H]4O[C@@H]5O[C@@H](C)C(=O)C[C@@H]5O[C@H]4C3)[C@H](C2)N(C)C)C[C@]1(O)CC)[C@H]1C[C@H](N(C)C)[C@H](O)[C@H](C)O1 JXVAMODRWBNUSF-KZQKBALLSA-N 0.000 description 1
- INAUWOVKEZHHDM-PEDBPRJASA-N (7s,9s)-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-7-[(2r,4s,5s,6s)-5-hydroxy-6-methyl-4-morpholin-4-yloxan-2-yl]oxy-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical compound Cl.N1([C@H]2C[C@@H](O[C@@H](C)[C@H]2O)O[C@H]2C[C@@](O)(CC=3C(O)=C4C(=O)C=5C=CC=C(C=5C(=O)C4=C(O)C=32)OC)C(=O)CO)CCOCC1 INAUWOVKEZHHDM-PEDBPRJASA-N 0.000 description 1
- RCFNNLSZHVHCEK-IMHLAKCZSA-N (7s,9s)-7-(4-amino-6-methyloxan-2-yl)oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical compound [Cl-].O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)C1CC([NH3+])CC(C)O1 RCFNNLSZHVHCEK-IMHLAKCZSA-N 0.000 description 1
- NOPNWHSMQOXAEI-PUCKCBAPSA-N (7s,9s)-7-[(2r,4s,5s,6s)-4-(2,3-dihydropyrrol-1-yl)-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione Chemical compound N1([C@H]2C[C@@H](O[C@@H](C)[C@H]2O)O[C@H]2C[C@@](O)(CC=3C(O)=C4C(=O)C=5C=CC=C(C=5C(=O)C4=C(O)C=32)OC)C(=O)CO)CCC=C1 NOPNWHSMQOXAEI-PUCKCBAPSA-N 0.000 description 1
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
- IEXUMDBQLIVNHZ-YOUGDJEHSA-N (8s,11r,13r,14s,17s)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(3-hydroxypropyl)-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(O)CCCO)[C@@]2(C)C1 IEXUMDBQLIVNHZ-YOUGDJEHSA-N 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
- AGNGYMCLFWQVGX-AGFFZDDWSA-N (e)-1-[(2s)-2-amino-2-carboxyethoxy]-2-diazonioethenolate Chemical compound OC(=O)[C@@H](N)CO\C([O-])=C\[N+]#N AGNGYMCLFWQVGX-AGFFZDDWSA-N 0.000 description 1
- HKWJHKSHEWVOSS-OMDJCSNQSA-N 1,2-dihexadecanoyl-sn-glycero-3-phospho-(1D-myo-inositol-3,4-bisphosphate) Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC)COP(O)(=O)O[C@H]1[C@H](O)[C@@H](O)[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H]1O HKWJHKSHEWVOSS-OMDJCSNQSA-N 0.000 description 1
- SZPQTEWIRPXBTC-KFOWTEFUSA-N 1,2-dipalmitoyl-sn-glycero-3-phospho-(1'D-myo-inositol-3'-phosphate) Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC)COP(O)(=O)O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OP(O)(O)=O)[C@H]1O SZPQTEWIRPXBTC-KFOWTEFUSA-N 0.000 description 1
- FONKWHRXTPJODV-DNQXCXABSA-N 1,3-bis[2-[(8s)-8-(chloromethyl)-4-hydroxy-1-methyl-7,8-dihydro-3h-pyrrolo[3,2-e]indole-6-carbonyl]-1h-indol-5-yl]urea Chemical compound C1([C@H](CCl)CN2C(=O)C=3NC4=CC=C(C=C4C=3)NC(=O)NC=3C=C4C=C(NC4=CC=3)C(=O)N3C4=CC(O)=C5NC=C(C5=C4[C@H](CCl)C3)C)=C2C=C(O)C2=C1C(C)=CN2 FONKWHRXTPJODV-DNQXCXABSA-N 0.000 description 1
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
- BTOTXLJHDSNXMW-POYBYMJQSA-N 2,3-dideoxyuridine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(=O)NC(=O)C=C1 BTOTXLJHDSNXMW-POYBYMJQSA-N 0.000 description 1
- BOMZMNZEXMAQQW-UHFFFAOYSA-N 2,5,11-trimethyl-6h-pyrido[4,3-b]carbazol-2-ium-9-ol;acetate Chemical compound CC([O-])=O.C[N+]1=CC=C2C(C)=C(NC=3C4=CC(O)=CC=3)C4=C(C)C2=C1 BOMZMNZEXMAQQW-UHFFFAOYSA-N 0.000 description 1
- QCXJFISCRQIYID-IAEPZHFASA-N 2-amino-1-n-[(3s,6s,7r,10s,16s)-3-[(2s)-butan-2-yl]-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-10-propan-2-yl-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]-4,6-dimethyl-3-oxo-9-n-[(3s,6s,7r,10s,16s)-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-3,10-di(propa Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N=C2C(C(=O)N[C@@H]3C(=O)N[C@H](C(N4CCC[C@H]4C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]3C)=O)[C@@H](C)CC)=C(N)C(=O)C(C)=C2O2)C2=C(C)C=C1 QCXJFISCRQIYID-IAEPZHFASA-N 0.000 description 1
- VNBAOSVONFJBKP-UHFFFAOYSA-N 2-chloro-n,n-bis(2-chloroethyl)propan-1-amine;hydrochloride Chemical compound Cl.CC(Cl)CN(CCCl)CCCl VNBAOSVONFJBKP-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- YIMDLWDNDGKDTJ-QLKYHASDSA-N 3'-deamino-3'-(3-cyanomorpholin-4-yl)doxorubicin Chemical compound N1([C@H]2C[C@@H](O[C@@H](C)[C@H]2O)O[C@H]2C[C@@](O)(CC=3C(O)=C4C(=O)C=5C=CC=C(C=5C(=O)C4=C(O)C=32)OC)C(=O)CO)CCOCC1C#N YIMDLWDNDGKDTJ-QLKYHASDSA-N 0.000 description 1
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
- PWMYMKOUNYTVQN-UHFFFAOYSA-N 3-(8,8-diethyl-2-aza-8-germaspiro[4.5]decan-2-yl)-n,n-dimethylpropan-1-amine Chemical compound C1C[Ge](CC)(CC)CCC11CN(CCCN(C)C)CC1 PWMYMKOUNYTVQN-UHFFFAOYSA-N 0.000 description 1
- IWCQHVUQEFDRIW-UHFFFAOYSA-N 3-[1-[[4-(6-phenyl-8H-imidazo[4,5-g]quinoxalin-7-yl)phenyl]methyl]piperidin-4-yl]-1H-benzimidazol-2-one Chemical compound O=c1[nH]c2ccccc2n1C1CCN(Cc2ccc(cc2)-c2[nH]c3cc4ncnc4cc3nc2-c2ccccc2)CC1 IWCQHVUQEFDRIW-UHFFFAOYSA-N 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- PTBDIHRZYDMNKB-UHFFFAOYSA-M 3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate Chemical compound OCC(C)(CO)C([O-])=O PTBDIHRZYDMNKB-UHFFFAOYSA-M 0.000 description 1
- CLPFFLWZZBQMAO-UHFFFAOYSA-N 4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile Chemical compound C1=CC(C#N)=CC=C1C1N2C=NC=C2CCC1 CLPFFLWZZBQMAO-UHFFFAOYSA-N 0.000 description 1
- DODQJNMQWMSYGS-QPLCGJKRSA-N 4-[(z)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-1-phenylbut-1-en-2-yl]phenol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 DODQJNMQWMSYGS-QPLCGJKRSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- IDPUKCWIGUEADI-UHFFFAOYSA-N 5-[bis(2-chloroethyl)amino]uracil Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- WYXSYVWAUAUWLD-SHUUEZRQSA-N 6-azauridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=N1 WYXSYVWAUAUWLD-SHUUEZRQSA-N 0.000 description 1
- 229960005538 6-diazo-5-oxo-L-norleucine Drugs 0.000 description 1
- YCWQAMGASJSUIP-YFKPBYRVSA-N 6-diazo-5-oxo-L-norleucine Chemical compound OC(=O)[C@@H](N)CCC(=O)C=[N+]=[N-] YCWQAMGASJSUIP-YFKPBYRVSA-N 0.000 description 1
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 description 1
- WDHAAJIGSXNPFO-UHFFFAOYSA-N 8h-pyrido[2,3-d]pyrimidin-7-one Chemical compound N1=CN=C2NC(=O)C=CC2=C1 WDHAAJIGSXNPFO-UHFFFAOYSA-N 0.000 description 1
- HDZZVAMISRMYHH-UHFFFAOYSA-N 9beta-Ribofuranosyl-7-deazaadenin Natural products C1=CC=2C(N)=NC=NC=2N1C1OC(CO)C(O)C1O HDZZVAMISRMYHH-UHFFFAOYSA-N 0.000 description 1
- 208000026872 Addison Disease Diseases 0.000 description 1
- CEIZFXOZIQNICU-UHFFFAOYSA-N Alternaria alternata Crofton-weed toxin Natural products CCC(C)C1NC(=O)C(C(C)=O)=C1O CEIZFXOZIQNICU-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010061424 Anal cancer Diseases 0.000 description 1
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 1
- 102000014654 Aromatase Human genes 0.000 description 1
- 108010078554 Aromatase Proteins 0.000 description 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical class C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 108091008875 B cell receptors Proteins 0.000 description 1
- 239000012664 BCL-2-inhibitor Substances 0.000 description 1
- 102000051485 Bcl-2 family Human genes 0.000 description 1
- 108700038897 Bcl-2 family Proteins 0.000 description 1
- 229940123711 Bcl2 inhibitor Drugs 0.000 description 1
- 208000009137 Behcet syndrome Diseases 0.000 description 1
- VGGGPCQERPFHOB-MCIONIFRSA-N Bestatin Chemical compound CC(C)C[C@H](C(O)=O)NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1 VGGGPCQERPFHOB-MCIONIFRSA-N 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- 229940122361 Bisphosphonate Drugs 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- MBABCNBNDNGODA-LTGLSHGVSA-N Bullatacin Natural products O=C1C(C[C@H](O)CCCCCCCCCC[C@@H](O)[C@@H]2O[C@@H]([C@@H]3O[C@H]([C@@H](O)CCCCCCCCCC)CC3)CC2)=C[C@H](C)O1 MBABCNBNDNGODA-LTGLSHGVSA-N 0.000 description 1
- KGGVWMAPBXIMEM-JQFCFGFHSA-N Bullatacinone Natural products O=C(C[C@H]1C(=O)O[C@H](CCCCCCCCCC[C@H](O)[C@@H]2O[C@@H]([C@@H]3O[C@@H]([C@@H](O)CCCCCCCCCC)CC3)CC2)C1)C KGGVWMAPBXIMEM-JQFCFGFHSA-N 0.000 description 1
- KGGVWMAPBXIMEM-ZRTAFWODSA-N Bullatacinone Chemical compound O1[C@@H]([C@@H](O)CCCCCCCCCC)CC[C@@H]1[C@@H]1O[C@@H]([C@H](O)CCCCCCCCCC[C@H]2OC(=O)[C@H](CC(C)=O)C2)CC1 KGGVWMAPBXIMEM-ZRTAFWODSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 125000000172 C5-C10 aryl group Chemical group 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- SHHKQEUPHAENFK-UHFFFAOYSA-N Carboquone Chemical compound O=C1C(C)=C(N2CC2)C(=O)C(C(COC(N)=O)OC)=C1N1CC1 SHHKQEUPHAENFK-UHFFFAOYSA-N 0.000 description 1
- 241000399988 Carinoma Species 0.000 description 1
- AOCCBINRVIKJHY-UHFFFAOYSA-N Carmofur Chemical compound CCCCCCNC(=O)N1C=C(F)C(=O)NC1=O AOCCBINRVIKJHY-UHFFFAOYSA-N 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 101150015280 Cel gene Proteins 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 1
- XCDXSSFOJZZGQC-UHFFFAOYSA-N Chlornaphazine Chemical compound C1=CC=CC2=CC(N(CCCl)CCCl)=CC=C21 XCDXSSFOJZZGQC-UHFFFAOYSA-N 0.000 description 1
- MKQWTWSXVILIKJ-LXGUWJNJSA-N Chlorozotocin Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](C=O)NC(=O)N(N=O)CCCl MKQWTWSXVILIKJ-LXGUWJNJSA-N 0.000 description 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 208000006344 Churg-Strauss Syndrome Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 229930188224 Cryptophycin Natural products 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 230000007067 DNA methylation Effects 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- NNJPGOLRFBJNIW-UHFFFAOYSA-N Demecolcine Natural products C1=C(OC)C(=O)C=C2C(NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-UHFFFAOYSA-N 0.000 description 1
- 108010002156 Depsipeptides Proteins 0.000 description 1
- AUGQEEXBDZWUJY-ZLJUKNTDSA-N Diacetoxyscirpenol Chemical compound C([C@]12[C@]3(C)[C@H](OC(C)=O)[C@@H](O)[C@H]1O[C@@H]1C=C(C)CC[C@@]13COC(=O)C)O2 AUGQEEXBDZWUJY-ZLJUKNTDSA-N 0.000 description 1
- AUGQEEXBDZWUJY-UHFFFAOYSA-N Diacetoxyscirpenol Natural products CC(=O)OCC12CCC(C)=CC1OC1C(O)C(OC(C)=O)C2(C)C11CO1 AUGQEEXBDZWUJY-UHFFFAOYSA-N 0.000 description 1
- ZQZFYGIXNQKOAV-OCEACIFDSA-N Droloxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=C(O)C=CC=1)\C1=CC=C(OCCN(C)C)C=C1 ZQZFYGIXNQKOAV-OCEACIFDSA-N 0.000 description 1
- 229930193152 Dynemicin Natural products 0.000 description 1
- 101710201734 E3 protein Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- AFMYMMXSQGUCBK-UHFFFAOYSA-N Endynamicin A Natural products C1#CC=CC#CC2NC(C=3C(=O)C4=C(O)C=CC(O)=C4C(=O)C=3C(O)=C3)=C3C34OC32C(C)C(C(O)=O)=C(OC)C41 AFMYMMXSQGUCBK-UHFFFAOYSA-N 0.000 description 1
- SAMRUMKYXPVKPA-VFKOLLTISA-N Enocitabine Chemical compound O=C1N=C(NC(=O)CCCCCCCCCCCCCCCCCCCCC)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 SAMRUMKYXPVKPA-VFKOLLTISA-N 0.000 description 1
- 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 description 1
- 206010014982 Epidermal and dermal conditions Diseases 0.000 description 1
- OBMLHUPNRURLOK-XGRAFVIBSA-N Epitiostanol Chemical compound C1[C@@H]2S[C@@H]2C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 OBMLHUPNRURLOK-XGRAFVIBSA-N 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 229930189413 Esperamicin Natural products 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 241000289695 Eutheria Species 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- MPJKWIXIYCLVCU-UHFFFAOYSA-N Folinic acid Natural products NC1=NC2=C(N(C=O)C(CNc3ccc(cc3)C(=O)NC(CCC(=O)O)CC(=O)O)CN2)C(=O)N1 MPJKWIXIYCLVCU-UHFFFAOYSA-N 0.000 description 1
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 1
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000024869 Goodpasture syndrome Diseases 0.000 description 1
- 241000282575 Gorilla Species 0.000 description 1
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 108091005772 HDAC11 Proteins 0.000 description 1
- 208000016621 Hearing disease Diseases 0.000 description 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
- 102100039996 Histone deacetylase 1 Human genes 0.000 description 1
- 102100039385 Histone deacetylase 11 Human genes 0.000 description 1
- 102100039999 Histone deacetylase 2 Human genes 0.000 description 1
- 102100021455 Histone deacetylase 3 Human genes 0.000 description 1
- 102100022537 Histone deacetylase 6 Human genes 0.000 description 1
- 102100038715 Histone deacetylase 8 Human genes 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001035024 Homo sapiens Histone deacetylase 1 Proteins 0.000 description 1
- 101001035011 Homo sapiens Histone deacetylase 2 Proteins 0.000 description 1
- 101000899282 Homo sapiens Histone deacetylase 3 Proteins 0.000 description 1
- 101000899330 Homo sapiens Histone deacetylase 6 Proteins 0.000 description 1
- 101001032118 Homo sapiens Histone deacetylase 8 Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- 241000282620 Hylobates sp. Species 0.000 description 1
- MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 description 1
- 208000010159 IgA glomerulonephritis Diseases 0.000 description 1
- 206010021263 IgA nephropathy Diseases 0.000 description 1
- 208000011821 Indolent B-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 208000027601 Inner ear disease Diseases 0.000 description 1
- 101710125507 Integrase/recombinase Proteins 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 1
- 239000003798 L01XE11 - Pazopanib Substances 0.000 description 1
- 239000002118 L01XE12 - Vandetanib Substances 0.000 description 1
- JLERVPBPJHKRBJ-UHFFFAOYSA-N LY 117018 Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCC3)=CC=2)C2=CC=C(O)C=C2S1 JLERVPBPJHKRBJ-UHFFFAOYSA-N 0.000 description 1
- 208000017119 Labyrinth disease Diseases 0.000 description 1
- 241000283953 Lagomorpha Species 0.000 description 1
- 229920001491 Lentinan Polymers 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000289581 Macropus sp. Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- VJRAUFKOOPNFIQ-UHFFFAOYSA-N Marcellomycin Natural products C12=C(O)C=3C(=O)C4=C(O)C=CC(O)=C4C(=O)C=3C=C2C(C(=O)OC)C(CC)(O)CC1OC(OC1C)CC(N(C)C)C1OC(OC1C)CC(O)C1OC1CC(O)C(O)C(C)O1 VJRAUFKOOPNFIQ-UHFFFAOYSA-N 0.000 description 1
- 229930126263 Maytansine Natural products 0.000 description 1
- IVDYZAAPOLNZKG-KWHRADDSSA-N Mepitiostane Chemical compound O([C@@H]1[C@]2(CC[C@@H]3[C@@]4(C)C[C@H]5S[C@H]5C[C@@H]4CC[C@H]3[C@@H]2CC1)C)C1(OC)CCCC1 IVDYZAAPOLNZKG-KWHRADDSSA-N 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- VFKZTMPDYBFSTM-KVTDHHQDSA-N Mitobronitol Chemical compound BrC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-KVTDHHQDSA-N 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- HRHKSTOGXBBQCB-UHFFFAOYSA-N Mitomycin E Natural products O=C1C(N)=C(C)C(=O)C2=C1C(COC(N)=O)C1(OC)C3N(C)C3CN12 HRHKSTOGXBBQCB-UHFFFAOYSA-N 0.000 description 1
- 241000289390 Monotremata Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- WWGBHDIHIVGYLZ-UHFFFAOYSA-N N-[4-[3-[[[7-(hydroxyamino)-7-oxoheptyl]amino]-oxomethyl]-5-isoxazolyl]phenyl]carbamic acid tert-butyl ester Chemical compound C1=CC(NC(=O)OC(C)(C)C)=CC=C1C1=CC(C(=O)NCCCCCCC(=O)NO)=NO1 WWGBHDIHIVGYLZ-UHFFFAOYSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- SYNHCENRCUAUNM-UHFFFAOYSA-N Nitrogen mustard N-oxide hydrochloride Chemical compound Cl.ClCC[N+]([O-])(C)CCCl SYNHCENRCUAUNM-UHFFFAOYSA-N 0.000 description 1
- KGTDRFCXGRULNK-UHFFFAOYSA-N Nogalamycin Natural products COC1C(OC)(C)C(OC)C(C)OC1OC1C2=C(O)C(C(=O)C3=C(O)C=C4C5(C)OC(C(C(C5O)N(C)C)O)OC4=C3C3=O)=C3C=C2C(C(=O)OC)C(C)(O)C1 KGTDRFCXGRULNK-UHFFFAOYSA-N 0.000 description 1
- 229930187135 Olivomycin Natural products 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 208000005225 Opsoclonus-Myoclonus Syndrome Diseases 0.000 description 1
- 241000289371 Ornithorhynchus anatinus Species 0.000 description 1
- 239000012270 PD-1 inhibitor Substances 0.000 description 1
- 239000012668 PD-1-inhibitor Substances 0.000 description 1
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 description 1
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- VREZDOWOLGNDPW-ALTGWBOUSA-N Pancratistatin Chemical compound C1=C2[C@H]3[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)[C@@H]3NC(=O)C2=C(O)C2=C1OCO2 VREZDOWOLGNDPW-ALTGWBOUSA-N 0.000 description 1
- VREZDOWOLGNDPW-MYVCAWNPSA-N Pancratistatin Natural products O=C1N[C@H]2[C@H](O)[C@H](O)[C@H](O)[C@H](O)[C@@H]2c2c1c(O)c1OCOc1c2 VREZDOWOLGNDPW-MYVCAWNPSA-N 0.000 description 1
- 241001504519 Papio ursinus Species 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 206010034277 Pemphigoid Diseases 0.000 description 1
- 201000011152 Pemphigus Diseases 0.000 description 1
- 108010057150 Peplomycin Proteins 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- KMSKQZKKOZQFFG-HSUXVGOQSA-N Pirarubicin Chemical compound O([C@H]1[C@@H](N)C[C@@H](O[C@H]1C)O[C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1CCCCO1 KMSKQZKKOZQFFG-HSUXVGOQSA-N 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010036105 Polyneuropathy Diseases 0.000 description 1
- HFVNWDWLWUCIHC-GUPDPFMOSA-N Prednimustine Chemical compound O=C([C@@]1(O)CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)[C@@H](O)C[C@@]21C)COC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 HFVNWDWLWUCIHC-GUPDPFMOSA-N 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102100035548 Protein Bop Human genes 0.000 description 1
- 108050008794 Protein Bop Proteins 0.000 description 1
- 102100024924 Protein kinase C alpha type Human genes 0.000 description 1
- 101710109947 Protein kinase C alpha type Proteins 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- 208000003782 Raynaud disease Diseases 0.000 description 1
- 208000012322 Raynaud phenomenon Diseases 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- OWPCHSCAPHNHAV-UHFFFAOYSA-N Rhizoxin Natural products C1C(O)C2(C)OC2C=CC(C)C(OC(=O)C2)CC2CC2OC2C(=O)OC1C(C)C(OC)C(C)=CC=CC(C)=CC1=COC(C)=N1 OWPCHSCAPHNHAV-UHFFFAOYSA-N 0.000 description 1
- 239000008156 Ringer's lactate solution Substances 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- NSFWWJIQIKBZMJ-YKNYLIOZSA-N Roridin A Chemical compound C([C@]12[C@]3(C)[C@H]4C[C@H]1O[C@@H]1C=C(C)CC[C@@]13COC(=O)[C@@H](O)[C@H](C)CCO[C@H](\C=C\C=C/C(=O)O4)[C@H](O)C)O2 NSFWWJIQIKBZMJ-YKNYLIOZSA-N 0.000 description 1
- 108010040181 SF 1126 Proteins 0.000 description 1
- 101100434411 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) ADH1 gene Proteins 0.000 description 1
- 206010061934 Salivary gland cancer Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 229920000519 Sizofiran Polymers 0.000 description 1
- 231100000632 Spindle poison Toxicity 0.000 description 1
- 201000008736 Systemic mastocytosis Diseases 0.000 description 1
- BXFOFFBJRFZBQZ-QYWOHJEZSA-N T-2 toxin Chemical compound C([C@@]12[C@]3(C)[C@H](OC(C)=O)[C@@H](O)[C@H]1O[C@H]1[C@]3(COC(C)=O)C[C@@H](C(=C1)C)OC(=O)CC(C)C)O2 BXFOFFBJRFZBQZ-QYWOHJEZSA-N 0.000 description 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 229940126624 Tacatuzumab tetraxetan Drugs 0.000 description 1
- CGMTUJFWROPELF-UHFFFAOYSA-N Tenuazonic acid Natural products CCC(C)C1NC(=O)C(=C(C)/O)C1=O CGMTUJFWROPELF-UHFFFAOYSA-N 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 206010043561 Thrombocytopenic purpura Diseases 0.000 description 1
- 201000007023 Thrombotic Thrombocytopenic Purpura Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 101710183280 Topoisomerase Proteins 0.000 description 1
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 208000003441 Transfusion reaction Diseases 0.000 description 1
- UMILHIMHKXVDGH-UHFFFAOYSA-N Triethylene glycol diglycidyl ether Chemical compound C1OC1COCCOCCOCCOCC1CO1 UMILHIMHKXVDGH-UHFFFAOYSA-N 0.000 description 1
- FYAMXEPQQLNQDM-UHFFFAOYSA-N Tris(1-aziridinyl)phosphine oxide Chemical compound C1CN1P(N1CC1)(=O)N1CC1 FYAMXEPQQLNQDM-UHFFFAOYSA-N 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 description 1
- 108091005906 Type I transmembrane proteins Proteins 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 241000289674 Vombatidae Species 0.000 description 1
- 206010047741 Vulval cancer Diseases 0.000 description 1
- UJVUMTUBMCYKBK-BNOPZSDTSA-N [(2r)-2-hexadecanoyloxy-3-[hydroxy-[(2r,3r,5s,6r)-2,3,5,6-tetrahydroxy-4-phosphonooxycyclohexyl]oxyphosphoryl]oxypropyl] hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC)COP(O)(=O)OC1[C@H](O)[C@H](O)C(OP(O)(O)=O)[C@H](O)[C@H]1O UJVUMTUBMCYKBK-BNOPZSDTSA-N 0.000 description 1
- SPJCRMJCFSJKDE-ZWBUGVOYSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] 2-[4-[bis(2-chloroethyl)amino]phenyl]acetate Chemical compound O([C@@H]1CC2=CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)C(=O)CC1=CC=C(N(CCCl)CCCl)C=C1 SPJCRMJCFSJKDE-ZWBUGVOYSA-N 0.000 description 1
- IFJUINDAXYAPTO-UUBSBJJBSA-N [(8r,9s,13s,14s,17s)-17-[2-[4-[4-[bis(2-chloroethyl)amino]phenyl]butanoyloxy]acetyl]oxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-yl] benzoate Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@H]4OC(=O)COC(=O)CCCC=1C=CC(=CC=1)N(CCCl)CCCl)C)CC2=CC=3OC(=O)C1=CC=CC=C1 IFJUINDAXYAPTO-UUBSBJJBSA-N 0.000 description 1
- IHGLINDYFMDHJG-UHFFFAOYSA-N [2-(4-methoxyphenyl)-3,4-dihydronaphthalen-1-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]methanone Chemical compound C1=CC(OC)=CC=C1C(CCC1=CC=CC=C11)=C1C(=O)C(C=C1)=CC=C1OCCN1CCCC1 IHGLINDYFMDHJG-UHFFFAOYSA-N 0.000 description 1
- XZSRRNFBEIOBDA-CFNBKWCHSA-N [2-[(2s,4s)-4-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1h-tetracen-2-yl]-2-oxoethyl] 2,2-diethoxyacetate Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC(OC)=C4C(=O)C=3C(O)=C21)(O)C(=O)COC(=O)C(OCC)OCC)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 XZSRRNFBEIOBDA-CFNBKWCHSA-N 0.000 description 1
- HKGATZAPXCCEJR-OWRSNIELSA-N [4-[[(2s)-2-[[(2s)-2-[3-[2-[2-[2-[2-[2-[2-[2-[2-[3-(2,5-dioxopyrrol-1-yl)propanoylamino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]propanoylamino]-3-methylbutanoyl]amino]propanoyl]amino]phenyl]methyl (6s,6as)-3-[5-[[(6as)-2-methoxy-8-methyl-1 Chemical compound N([C@H](C(=O)N[C@@H](C)C(=O)NC1=CC=C(C=C1)COC(=O)N1C=2C=C(C(=CC=2C(=O)N2C=C(C)C[C@H]2[C@@H]1O)OC)OCCCCCOC1=CC2=C(C(N3C=C(C)C[C@H]3C=N2)=O)C=C1OC)C(C)C)C(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCNC(=O)CCN1C(=O)C=CC1=O HKGATZAPXCCEJR-OWRSNIELSA-N 0.000 description 1
- ZOZKYEHVNDEUCO-XUTVFYLZSA-N aceglatone Chemical compound O1C(=O)[C@H](OC(C)=O)[C@@H]2OC(=O)[C@@H](OC(=O)C)[C@@H]21 ZOZKYEHVNDEUCO-XUTVFYLZSA-N 0.000 description 1
- 229950002684 aceglatone Drugs 0.000 description 1
- 229930183665 actinomycin Natural products 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 102000035181 adaptor proteins Human genes 0.000 description 1
- 108091005764 adaptor proteins Proteins 0.000 description 1
- 101150102866 adc1 gene Proteins 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229950004955 adozelesin Drugs 0.000 description 1
- BYRVKDUQDLJUBX-JJCDCTGGSA-N adozelesin Chemical compound C1=CC=C2OC(C(=O)NC=3C=C4C=C(NC4=CC=3)C(=O)N3C[C@H]4C[C@]44C5=C(C(C=C43)=O)NC=C5C)=CC2=C1 BYRVKDUQDLJUBX-JJCDCTGGSA-N 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229960000473 altretamine Drugs 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229960002749 aminolevulinic acid Drugs 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 229960001220 amsacrine Drugs 0.000 description 1
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
- 201000007538 anal carcinoma Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229960002932 anastrozole Drugs 0.000 description 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
- BBDAGFIXKZCXAH-CCXZUQQUSA-N ancitabine Chemical compound N=C1C=CN2[C@@H]3O[C@H](CO)[C@@H](O)[C@@H]3OC2=N1 BBDAGFIXKZCXAH-CCXZUQQUSA-N 0.000 description 1
- 229950000242 ancitabine Drugs 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 206010002449 angioimmunoblastic T-cell lymphoma Diseases 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 239000012666 anti-BCL-2 combination Substances 0.000 description 1
- 229940043352 anti-BCL-2 combination Drugs 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
- 238000011394 anticancer treatment Methods 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000013059 antihormonal agent Substances 0.000 description 1
- 229940045687 antimetabolites folic acid analogs Drugs 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 1
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 229950003145 apolizumab Drugs 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 150000008209 arabinosides Chemical class 0.000 description 1
- 239000003886 aromatase inhibitor Substances 0.000 description 1
- 229940046844 aromatase inhibitors Drugs 0.000 description 1
- 229950002882 aselizumab Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 108010044540 auristatin Proteins 0.000 description 1
- 201000005000 autoimmune gastritis Diseases 0.000 description 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
- 208000010928 autoimmune thyroid disease Diseases 0.000 description 1
- 229960002756 azacitidine Drugs 0.000 description 1
- 229950011321 azaserine Drugs 0.000 description 1
- 150000001541 aziridines Chemical class 0.000 description 1
- 229950001863 bapineuzumab Drugs 0.000 description 1
- 229960003094 belinostat Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229960000997 bicalutamide Drugs 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229950008548 bisantrene Drugs 0.000 description 1
- 150000004663 bisphosphonates Chemical class 0.000 description 1
- 229960005522 bivatuzumab mertansine Drugs 0.000 description 1
- 229950006844 bizelesin Drugs 0.000 description 1
- 201000000053 blastoma Diseases 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical class N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229960005520 bryostatin Drugs 0.000 description 1
- MJQUEDHRCUIRLF-TVIXENOKSA-N bryostatin 1 Chemical compound C([C@@H]1CC(/[C@@H]([C@@](C(C)(C)/C=C/2)(O)O1)OC(=O)/C=C/C=C/CCC)=C\C(=O)OC)[C@H]([C@@H](C)O)OC(=O)C[C@H](O)C[C@@H](O1)C[C@H](OC(C)=O)C(C)(C)[C@]1(O)C[C@@H]1C\C(=C\C(=O)OC)C[C@H]\2O1 MJQUEDHRCUIRLF-TVIXENOKSA-N 0.000 description 1
- MUIWQCKLQMOUAT-AKUNNTHJSA-N bryostatin 20 Natural products COC(=O)C=C1C[C@@]2(C)C[C@]3(O)O[C@](C)(C[C@@H](O)CC(=O)O[C@](C)(C[C@@]4(C)O[C@](O)(CC5=CC(=O)O[C@]45C)C(C)(C)C=C[C@@](C)(C1)O2)[C@@H](C)O)C[C@H](OC(=O)C(C)(C)C)C3(C)C MUIWQCKLQMOUAT-AKUNNTHJSA-N 0.000 description 1
- MBABCNBNDNGODA-LUVUIASKSA-N bullatacin Chemical compound O1[C@@H]([C@@H](O)CCCCCCCCCC)CC[C@@H]1[C@@H]1O[C@@H]([C@H](O)CCCCCCCCCC[C@@H](O)CC=2C(O[C@@H](C)C=2)=O)CC1 MBABCNBNDNGODA-LUVUIASKSA-N 0.000 description 1
- 208000000594 bullous pemphigoid Diseases 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- 108700002839 cactinomycin Proteins 0.000 description 1
- 229950009908 cactinomycin Drugs 0.000 description 1
- BMLSTPRTEKLIPM-UHFFFAOYSA-I calcium;potassium;disodium;hydrogen carbonate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].OC([O-])=O BMLSTPRTEKLIPM-UHFFFAOYSA-I 0.000 description 1
- ZEWYCNBZMPELPF-UHFFFAOYSA-J calcium;potassium;sodium;2-hydroxypropanoic acid;sodium;tetrachloride Chemical compound [Na].[Na+].[Cl-].[Cl-].[Cl-].[Cl-].[K+].[Ca+2].CC(O)C(O)=O ZEWYCNBZMPELPF-UHFFFAOYSA-J 0.000 description 1
- IVFYLRMMHVYGJH-PVPPCFLZSA-N calusterone Chemical compound C1C[C@]2(C)[C@](O)(C)CC[C@H]2[C@@H]2[C@@H](C)CC3=CC(=O)CC[C@]3(C)[C@H]21 IVFYLRMMHVYGJH-PVPPCFLZSA-N 0.000 description 1
- 229950009823 calusterone Drugs 0.000 description 1
- 229940112129 campath Drugs 0.000 description 1
- 229940127093 camptothecin Drugs 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- OJLHWPALWODJPQ-QNWVGRARSA-N canfosfamide Chemical compound ClCCN(CCCl)P(=O)(N(CCCl)CCCl)OCCS(=O)(=O)C[C@H](NC(=O)CC[C@H](N)C(O)=O)C(=O)N[C@@H](C(O)=O)C1=CC=CC=C1 OJLHWPALWODJPQ-QNWVGRARSA-N 0.000 description 1
- 229950000772 canfosfamide Drugs 0.000 description 1
- 229950007296 cantuzumab mertansine Drugs 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 229960002115 carboquone Drugs 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 229930188550 carminomycin Natural products 0.000 description 1
- XREUEWVEMYWFFA-CSKJXFQVSA-N carminomycin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=C(O)C=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XREUEWVEMYWFFA-CSKJXFQVSA-N 0.000 description 1
- XREUEWVEMYWFFA-UHFFFAOYSA-N carminomycin I Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=C(O)C=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XREUEWVEMYWFFA-UHFFFAOYSA-N 0.000 description 1
- 229960003261 carmofur Drugs 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 229950001725 carubicin Drugs 0.000 description 1
- BBZDXMBRAFTCAA-AREMUKBSSA-N carzelesin Chemical compound C1=2NC=C(C)C=2C([C@H](CCl)CN2C(=O)C=3NC4=CC=C(C=C4C=3)NC(=O)C3=CC4=CC=C(C=C4O3)N(CC)CC)=C2C=C1OC(=O)NC1=CC=CC=C1 BBZDXMBRAFTCAA-AREMUKBSSA-N 0.000 description 1
- 229950007509 carzelesin Drugs 0.000 description 1
- 108010047060 carzinophilin Proteins 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 229950006754 cedelizumab Drugs 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000006364 cellular survival Effects 0.000 description 1
- 229960003115 certolizumab pegol Drugs 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229950008249 chlornaphazine Drugs 0.000 description 1
- 229960001480 chlorozotocin Drugs 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
- 208000013056 classic Hodgkin lymphoma Diseases 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- ACSIXWWBWUQEHA-UHFFFAOYSA-N clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 description 1
- 229960002286 clodronic acid Drugs 0.000 description 1
- 229960002271 cobimetinib Drugs 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 1
- 230000002153 concerted effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 201000003278 cryoglobulinemia Diseases 0.000 description 1
- PSNOPSMXOBPNNV-VVCTWANISA-N cryptophycin 1 Chemical compound C1=C(Cl)C(OC)=CC=C1C[C@@H]1C(=O)NC[C@@H](C)C(=O)O[C@@H](CC(C)C)C(=O)O[C@H]([C@H](C)[C@@H]2[C@H](O2)C=2C=CC=CC=2)C/C=C/C(=O)N1 PSNOPSMXOBPNNV-VVCTWANISA-N 0.000 description 1
- 108010089438 cryptophycin 1 Proteins 0.000 description 1
- 108010090203 cryptophycin 8 Proteins 0.000 description 1
- PSNOPSMXOBPNNV-UHFFFAOYSA-N cryptophycin-327 Natural products C1=C(Cl)C(OC)=CC=C1CC1C(=O)NCC(C)C(=O)OC(CC(C)C)C(=O)OC(C(C)C2C(O2)C=2C=CC=CC=2)CC=CC(=O)N1 PSNOPSMXOBPNNV-UHFFFAOYSA-N 0.000 description 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
- 208000004921 cutaneous lupus erythematosus Diseases 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 229960002806 daclizumab Drugs 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- 230000006196 deacetylation Effects 0.000 description 1
- 238000003381 deacetylation reaction Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 229960005052 demecolcine Drugs 0.000 description 1
- 230000003831 deregulation Effects 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229950003913 detorubicin Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- WVYXNIXAMZOZFK-UHFFFAOYSA-N diaziquone Chemical compound O=C1C(NC(=O)OCC)=C(N2CC2)C(=O)C(NC(=O)OCC)=C1N1CC1 WVYXNIXAMZOZFK-UHFFFAOYSA-N 0.000 description 1
- 229950002389 diaziquone Drugs 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- GOJNABIZVJCYFL-UHFFFAOYSA-M dimethylphosphinate Chemical compound CP(C)([O-])=O GOJNABIZVJCYFL-UHFFFAOYSA-M 0.000 description 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- AMRJKAQTDDKMCE-UHFFFAOYSA-N dolastatin Chemical compound CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)C)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 AMRJKAQTDDKMCE-UHFFFAOYSA-N 0.000 description 1
- 229930188854 dolastatin Natural products 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- ZWAOHEXOSAUJHY-ZIYNGMLESA-N doxifluridine Chemical compound O[C@@H]1[C@H](O)[C@@H](C)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ZWAOHEXOSAUJHY-ZIYNGMLESA-N 0.000 description 1
- 229950005454 doxifluridine Drugs 0.000 description 1
- 229950004203 droloxifene Drugs 0.000 description 1
- NOTIQUSPUUHHEH-UXOVVSIBSA-N dromostanolone propionate Chemical compound C([C@@H]1CC2)C(=O)[C@H](C)C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](OC(=O)CC)[C@@]2(C)CC1 NOTIQUSPUUHHEH-UXOVVSIBSA-N 0.000 description 1
- 229950004683 drostanolone propionate Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 229960005501 duocarmycin Drugs 0.000 description 1
- VQNATVDKACXKTF-XELLLNAOSA-N duocarmycin Chemical compound COC1=C(OC)C(OC)=C2NC(C(=O)N3C4=CC(=O)C5=C([C@@]64C[C@@H]6C3)C=C(N5)C(=O)OC)=CC2=C1 VQNATVDKACXKTF-XELLLNAOSA-N 0.000 description 1
- 229930184221 duocarmycin Natural products 0.000 description 1
- AFMYMMXSQGUCBK-AKMKHHNQSA-N dynemicin a Chemical compound C1#C\C=C/C#C[C@@H]2NC(C=3C(=O)C4=C(O)C=CC(O)=C4C(=O)C=3C(O)=C3)=C3[C@@]34O[C@]32[C@@H](C)C(C(O)=O)=C(OC)[C@H]41 AFMYMMXSQGUCBK-AKMKHHNQSA-N 0.000 description 1
- 229960002224 eculizumab Drugs 0.000 description 1
- FSIRXIHZBIXHKT-MHTVFEQDSA-N edatrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CC(CC)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FSIRXIHZBIXHKT-MHTVFEQDSA-N 0.000 description 1
- 229950006700 edatrexate Drugs 0.000 description 1
- 229960000284 efalizumab Drugs 0.000 description 1
- 229960002759 eflornithine Drugs 0.000 description 1
- XOPYFXBZMVTEJF-PDACKIITSA-N eleutherobin Chemical compound C(/[C@H]1[C@H](C(=CC[C@@H]1C(C)C)C)C[C@@H]([C@@]1(C)O[C@@]2(C=C1)OC)OC(=O)\C=C\C=1N=CN(C)C=1)=C2\CO[C@@H]1OC[C@@H](O)[C@@H](O)[C@@H]1OC(C)=O XOPYFXBZMVTEJF-PDACKIITSA-N 0.000 description 1
- XOPYFXBZMVTEJF-UHFFFAOYSA-N eleutherobin Natural products C1=CC2(OC)OC1(C)C(OC(=O)C=CC=1N=CN(C)C=1)CC(C(=CCC1C(C)C)C)C1C=C2COC1OCC(O)C(O)C1OC(C)=O XOPYFXBZMVTEJF-UHFFFAOYSA-N 0.000 description 1
- 229950000549 elliptinium acetate Drugs 0.000 description 1
- 201000008184 embryoma Diseases 0.000 description 1
- 201000003914 endometrial carcinoma Diseases 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- JOZGNYDSEBIJDH-UHFFFAOYSA-N eniluracil Chemical compound O=C1NC=C(C#C)C(=O)N1 JOZGNYDSEBIJDH-UHFFFAOYSA-N 0.000 description 1
- 229950010213 eniluracil Drugs 0.000 description 1
- 229950011487 enocitabine Drugs 0.000 description 1
- 229950005837 entinostat Drugs 0.000 description 1
- 230000007608 epigenetic mechanism Effects 0.000 description 1
- 229950002973 epitiostanol Drugs 0.000 description 1
- 229930013356 epothilone Natural products 0.000 description 1
- 150000003883 epothilone derivatives Chemical class 0.000 description 1
- 229950009760 epratuzumab Drugs 0.000 description 1
- 229950004292 erlizumab Drugs 0.000 description 1
- 229960001433 erlotinib Drugs 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- 229950002017 esorubicin Drugs 0.000 description 1
- ITSGNOIFAJAQHJ-BMFNZSJVSA-N esorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)C[C@H](C)O1 ITSGNOIFAJAQHJ-BMFNZSJVSA-N 0.000 description 1
- LJQQFQHBKUKHIS-WJHRIEJJSA-N esperamicin Chemical compound O1CC(NC(C)C)C(OC)CC1OC1C(O)C(NOC2OC(C)C(SC)C(O)C2)C(C)OC1OC1C(\C2=C/CSSSC)=C(NC(=O)OC)C(=O)C(OC3OC(C)C(O)C(OC(=O)C=4C(=CC(OC)=C(OC)C=4)NC(=O)C(=C)OC)C3)C2(O)C#C\C=C/C#C1 LJQQFQHBKUKHIS-WJHRIEJJSA-N 0.000 description 1
- 229960001842 estramustine Drugs 0.000 description 1
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- QSRLNKCNOLVZIR-KRWDZBQOSA-N ethyl (2s)-2-[[2-[4-[bis(2-chloroethyl)amino]phenyl]acetyl]amino]-4-methylsulfanylbutanoate Chemical compound CCOC(=O)[C@H](CCSC)NC(=O)CC1=CC=C(N(CCCl)CCCl)C=C1 QSRLNKCNOLVZIR-KRWDZBQOSA-N 0.000 description 1
- 229960005237 etoglucid Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 229960000255 exemestane Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229950011548 fadrozole Drugs 0.000 description 1
- 229950001563 felvizumab Drugs 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 230000000893 fibroproliferative effect Effects 0.000 description 1
- 229960000961 floxuridine Drugs 0.000 description 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 150000002224 folic acids Chemical class 0.000 description 1
- 229950004923 fontolizumab Drugs 0.000 description 1
- 229960004783 fotemustine Drugs 0.000 description 1
- YAKWPXVTIGTRJH-UHFFFAOYSA-N fotemustine Chemical compound CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O YAKWPXVTIGTRJH-UHFFFAOYSA-N 0.000 description 1
- 229960002258 fulvestrant Drugs 0.000 description 1
- 229940044658 gallium nitrate Drugs 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000007045 gastrulation Effects 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000004077 genetic alteration Effects 0.000 description 1
- 231100000118 genetic alteration Toxicity 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 229960002913 goserelin Drugs 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 231100000888 hearing loss Toxicity 0.000 description 1
- 230000010370 hearing loss Effects 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- 230000002267 hypothalamic effect Effects 0.000 description 1
- 229940015872 ibandronate Drugs 0.000 description 1
- 229960003685 imatinib mesylate Drugs 0.000 description 1
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- DBIGHPPNXATHOF-UHFFFAOYSA-N improsulfan Chemical compound CS(=O)(=O)OCCCNCCCOS(C)(=O)=O DBIGHPPNXATHOF-UHFFFAOYSA-N 0.000 description 1
- 229950008097 improsulfan Drugs 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229950004101 inotuzumab ozogamicin Drugs 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 230000007154 intracellular accumulation Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229960005386 ipilimumab Drugs 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 229950000518 labetuzumab Drugs 0.000 description 1
- 229960004891 lapatinib Drugs 0.000 description 1
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 description 1
- 210000002202 late pro-b cell Anatomy 0.000 description 1
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 1
- 229960004942 lenalidomide Drugs 0.000 description 1
- 229940115286 lentinan Drugs 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229950002950 lintuzumab Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 229950001750 lonafarnib Drugs 0.000 description 1
- YROQEQPFUCPDCP-UHFFFAOYSA-N losoxantrone Chemical compound OCCNCCN1N=C2C3=CC=CC(O)=C3C(=O)C3=C2C1=CC=C3NCCNCCO YROQEQPFUCPDCP-UHFFFAOYSA-N 0.000 description 1
- 229950008745 losoxantrone Drugs 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- MQXVYODZCMMZEM-ZYUZMQFOSA-N mannomustine Chemical compound ClCCNC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CNCCCl MQXVYODZCMMZEM-ZYUZMQFOSA-N 0.000 description 1
- 229950008612 mannomustine Drugs 0.000 description 1
- 241001515942 marmosets Species 0.000 description 1
- 229950008001 matuzumab Drugs 0.000 description 1
- WKPWGQKGSOKKOO-RSFHAFMBSA-N maytansine Chemical compound CO[C@@H]([C@@]1(O)C[C@](OC(=O)N1)([C@H]([C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C)[H])\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-RSFHAFMBSA-N 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229960004296 megestrol acetate Drugs 0.000 description 1
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 229950009246 mepitiostane Drugs 0.000 description 1
- 229960005108 mepolizumab Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- VJRAUFKOOPNFIQ-TVEKBUMESA-N methyl (1r,2r,4s)-4-[(2r,4s,5s,6s)-5-[(2s,4s,5s,6s)-5-[(2s,4s,5s,6s)-4,5-dihydroxy-6-methyloxan-2-yl]oxy-4-hydroxy-6-methyloxan-2-yl]oxy-4-(dimethylamino)-6-methyloxan-2-yl]oxy-2-ethyl-2,5,7,10-tetrahydroxy-6,11-dioxo-3,4-dihydro-1h-tetracene-1-carboxylat Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=C(O)C=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1C[C@H](O)[C@H](O)[C@H](C)O1 VJRAUFKOOPNFIQ-TVEKBUMESA-N 0.000 description 1
- HRHKSTOGXBBQCB-VFWICMBZSA-N methylmitomycin Chemical compound O=C1C(N)=C(C)C(=O)C2=C1[C@@H](COC(N)=O)[C@@]1(OC)[C@H]3N(C)[C@H]3CN12 HRHKSTOGXBBQCB-VFWICMBZSA-N 0.000 description 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 229960005485 mitobronitol Drugs 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 229960003539 mitoguazone Drugs 0.000 description 1
- MXWHMTNPTTVWDM-NXOFHUPFSA-N mitoguazone Chemical compound NC(N)=N\N=C(/C)\C=N\N=C(N)N MXWHMTNPTTVWDM-NXOFHUPFSA-N 0.000 description 1
- VFKZTMPDYBFSTM-GUCUJZIJSA-N mitolactol Chemical compound BrC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-GUCUJZIJSA-N 0.000 description 1
- 229950010913 mitolactol Drugs 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 229960000350 mitotane Drugs 0.000 description 1
- 229950007812 mocetinostat Drugs 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 229960001521 motavizumab Drugs 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 229960000951 mycophenolic acid Drugs 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- 201000005962 mycosis fungoides Diseases 0.000 description 1
- DXASQZJWWGZNSF-UHFFFAOYSA-N n,n-dimethylmethanamine;sulfur trioxide Chemical group CN(C)C.O=S(=O)=O DXASQZJWWGZNSF-UHFFFAOYSA-N 0.000 description 1
- NJSMWLQOCQIOPE-OCHFTUDZSA-N n-[(e)-[10-[(e)-(4,5-dihydro-1h-imidazol-2-ylhydrazinylidene)methyl]anthracen-9-yl]methylideneamino]-4,5-dihydro-1h-imidazol-2-amine Chemical compound N1CCN=C1N\N=C\C(C1=CC=CC=C11)=C(C=CC=C2)C2=C1\C=N\NC1=NCCN1 NJSMWLQOCQIOPE-OCHFTUDZSA-N 0.000 description 1
- LBWFXVZLPYTWQI-IPOVEDGCSA-N n-[2-(diethylamino)ethyl]-5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C LBWFXVZLPYTWQI-IPOVEDGCSA-N 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 229960005027 natalizumab Drugs 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 229950004847 navitoclax Drugs 0.000 description 1
- CTMCWCONSULRHO-UHQPFXKFSA-N nemorubicin Chemical compound C1CO[C@H](OC)CN1[C@@H]1[C@H](O)[C@H](C)O[C@@H](O[C@@H]2C3=C(O)C=4C(=O)C5=C(OC)C=CC=C5C(=O)C=4C(O)=C3C[C@](O)(C2)C(=O)CO)C1 CTMCWCONSULRHO-UHQPFXKFSA-N 0.000 description 1
- 229950010159 nemorubicin Drugs 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 208000008795 neuromyelitis optica Diseases 0.000 description 1
- XWXYUMMDTVBTOU-UHFFFAOYSA-N nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 description 1
- 229960002653 nilutamide Drugs 0.000 description 1
- 229950010203 nimotuzumab Drugs 0.000 description 1
- 229960001420 nimustine Drugs 0.000 description 1
- VFEDRRNHLBGPNN-UHFFFAOYSA-N nimustine Chemical compound CC1=NC=C(CNC(=O)N(CCCl)N=O)C(N)=N1 VFEDRRNHLBGPNN-UHFFFAOYSA-N 0.000 description 1
- 229950009266 nogalamycin Drugs 0.000 description 1
- KGTDRFCXGRULNK-JYOBTZKQSA-N nogalamycin Chemical compound CO[C@@H]1[C@@](OC)(C)[C@@H](OC)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=C(O)C=C4[C@@]5(C)O[C@H]([C@H]([C@@H]([C@H]5O)N(C)C)O)OC4=C3C3=O)=C3C=C2[C@@H](C(=O)OC)[C@@](C)(O)C1 KGTDRFCXGRULNK-JYOBTZKQSA-N 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 210000004882 non-tumor cell Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000000633 nuclear envelope Anatomy 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 230000020520 nucleotide-excision repair Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
- CZDBNBLGZNWKMC-MWQNXGTOSA-N olivomycin Chemical class O([C@@H]1C[C@@H](O[C@H](C)[C@@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1)O[C@H]1O[C@@H](C)[C@H](O)[C@@H](OC2O[C@@H](C)[C@H](O)[C@@H](O)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@H](O)[C@H](OC)[C@H](C)O1 CZDBNBLGZNWKMC-MWQNXGTOSA-N 0.000 description 1
- 229960000470 omalizumab Drugs 0.000 description 1
- 229950011093 onapristone Drugs 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 208000008798 osteoma Diseases 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 229960000402 palivizumab Drugs 0.000 description 1
- VREZDOWOLGNDPW-UHFFFAOYSA-N pancratistatine Natural products C1=C2C3C(O)C(O)C(O)C(O)C3NC(=O)C2=C(O)C2=C1OCO2 VREZDOWOLGNDPW-UHFFFAOYSA-N 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 210000001819 pancreatic juice Anatomy 0.000 description 1
- 229960001972 panitumumab Drugs 0.000 description 1
- 229950011485 pascolizumab Drugs 0.000 description 1
- 229960000639 pazopanib Drugs 0.000 description 1
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 description 1
- 229940121655 pd-1 inhibitor Drugs 0.000 description 1
- 201000001976 pemphigus vulgaris Diseases 0.000 description 1
- 208000030940 penile carcinoma Diseases 0.000 description 1
- 201000008174 penis carcinoma Diseases 0.000 description 1
- HLEKYJVHEBHTMR-UHFFFAOYSA-N pentanamide Chemical compound CCCCC(N)=O.CCCCC(N)=O HLEKYJVHEBHTMR-UHFFFAOYSA-N 0.000 description 1
- 229960002340 pentostatin Drugs 0.000 description 1
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
- QIMGFXOHTOXMQP-GFAGFCTOSA-N peplomycin Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCCN[C@@H](C)C=1C=CC=CC=1)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C QIMGFXOHTOXMQP-GFAGFCTOSA-N 0.000 description 1
- 229950003180 peplomycin Drugs 0.000 description 1
- 201000002628 peritoneum cancer Diseases 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 229950003203 pexelizumab Drugs 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 230000000865 phosphorylative effect Effects 0.000 description 1
- 239000003504 photosensitizing agent Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229960000952 pipobroman Drugs 0.000 description 1
- NJBFOOCLYDNZJN-UHFFFAOYSA-N pipobroman Chemical compound BrCCC(=O)N1CCN(C(=O)CCBr)CC1 NJBFOOCLYDNZJN-UHFFFAOYSA-N 0.000 description 1
- NUKCGLDCWQXYOQ-UHFFFAOYSA-N piposulfan Chemical compound CS(=O)(=O)OCCC(=O)N1CCN(C(=O)CCOS(C)(=O)=O)CC1 NUKCGLDCWQXYOQ-UHFFFAOYSA-N 0.000 description 1
- 229950001100 piposulfan Drugs 0.000 description 1
- 229960001221 pirarubicin Drugs 0.000 description 1
- 150000003057 platinum Chemical class 0.000 description 1
- CLSUSRZJUQMOHH-UHFFFAOYSA-L platinum dichloride Chemical compound Cl[Pt]Cl CLSUSRZJUQMOHH-UHFFFAOYSA-L 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 230000007824 polyneuropathy Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229950004406 porfiromycin Drugs 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 229960004694 prednimustine Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 201000000742 primary sclerosing cholangitis Diseases 0.000 description 1
- 210000001948 pro-b lymphocyte Anatomy 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 230000009684 proliferation defect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 239000003909 protein kinase inhibitor Substances 0.000 description 1
- WOLQREOUPKZMEX-UHFFFAOYSA-N pteroyltriglutamic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(=O)NC(CCC(=O)NC(CCC(O)=O)C(O)=O)C(O)=O)C(O)=O)C=C1 WOLQREOUPKZMEX-UHFFFAOYSA-N 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000004943 pyrimidin-6-yl group Chemical group N1=CN=CC=C1* 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- RVEDFFORAVMBLV-UHFFFAOYSA-N pyrrolidine-1,2-dicarboxamide Chemical compound NC(=O)C1CCCN1C(N)=O RVEDFFORAVMBLV-UHFFFAOYSA-N 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 229960003876 ranibizumab Drugs 0.000 description 1
- BMKDZUISNHGIBY-UHFFFAOYSA-N razoxane Chemical compound C1C(=O)NC(=O)CN1C(C)CN1CC(=O)NC(=O)C1 BMKDZUISNHGIBY-UHFFFAOYSA-N 0.000 description 1
- 229960000460 razoxane Drugs 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 210000001350 reed-sternberg cell Anatomy 0.000 description 1
- 230000007363 regulatory process Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 229960003254 reslizumab Drugs 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- OWPCHSCAPHNHAV-LMONGJCWSA-N rhizoxin Chemical compound C/C([C@H](OC)[C@@H](C)[C@@H]1C[C@H](O)[C@]2(C)O[C@@H]2/C=C/[C@@H](C)[C@]2([H])OC(=O)C[C@@](C2)(C[C@@H]2O[C@H]2C(=O)O1)[H])=C\C=C\C(\C)=C\C1=COC(C)=N1 OWPCHSCAPHNHAV-LMONGJCWSA-N 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 229950004892 rodorubicin Drugs 0.000 description 1
- MBABCNBNDNGODA-WPZDJQSSSA-N rolliniastatin 1 Natural products O1[C@@H]([C@@H](O)CCCCCCCCCC)CC[C@H]1[C@H]1O[C@@H]([C@H](O)CCCCCCCCCC[C@@H](O)CC=2C(O[C@@H](C)C=2)=O)CC1 MBABCNBNDNGODA-WPZDJQSSSA-N 0.000 description 1
- IMUQLZLGWJSVMV-UOBFQKKOSA-N roridin A Natural products CC(O)C1OCCC(C)C(O)C(=O)OCC2CC(=CC3OC4CC(OC(=O)C=C/C=C/1)C(C)(C23)C45CO5)C IMUQLZLGWJSVMV-UOBFQKKOSA-N 0.000 description 1
- 229950009092 rovelizumab Drugs 0.000 description 1
- VHXNKPBCCMUMSW-FQEVSTJZSA-N rubitecan Chemical compound C1=CC([N+]([O-])=O)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VHXNKPBCCMUMSW-FQEVSTJZSA-N 0.000 description 1
- 229950005374 ruplizumab Drugs 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 201000003804 salivary gland carcinoma Diseases 0.000 description 1
- 229930182947 sarcodictyin Natural products 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 208000010157 sclerosing cholangitis Diseases 0.000 description 1
- 229950008684 sibrotuzumab Drugs 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229950003804 siplizumab Drugs 0.000 description 1
- 229950001403 sizofiran Drugs 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 238000007390 skin biopsy Methods 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- 229950006551 sontuzumab Drugs 0.000 description 1
- 229950006315 spirogermanium Drugs 0.000 description 1
- ICXJVZHDZFXYQC-UHFFFAOYSA-N spongistatin 1 Natural products OC1C(O2)(O)CC(O)C(C)C2CCCC=CC(O2)CC(O)CC2(O2)CC(OC)CC2CC(=O)C(C)C(OC(C)=O)C(C)C(=C)CC(O2)CC(C)(O)CC2(O2)CC(OC(C)=O)CC2CC(=O)OC2C(O)C(CC(=C)CC(O)C=CC(Cl)=C)OC1C2C ICXJVZHDZFXYQC-UHFFFAOYSA-N 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 229940034785 sutent Drugs 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229950001072 tadocizumab Drugs 0.000 description 1
- 229950004218 talizumab Drugs 0.000 description 1
- 229960003454 tamoxifen citrate Drugs 0.000 description 1
- FQZYTYWMLGAPFJ-OQKDUQJOSA-N tamoxifen citrate Chemical compound [H+].[H+].[H+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 FQZYTYWMLGAPFJ-OQKDUQJOSA-N 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 229950001788 tefibazumab Drugs 0.000 description 1
- 229960004964 temozolomide Drugs 0.000 description 1
- CBPNZQVSJQDFBE-HGVVHKDOSA-N temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CCC2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-HGVVHKDOSA-N 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 229960005353 testolactone Drugs 0.000 description 1
- BPEWUONYVDABNZ-DZBHQSCQSA-N testolactone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(OC(=O)CC4)[C@@H]4[C@@H]3CCC2=C1 BPEWUONYVDABNZ-DZBHQSCQSA-N 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- YFTWHEBLORWGNI-UHFFFAOYSA-N tiamiprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC(N)=NC2=C1NC=N2 YFTWHEBLORWGNI-UHFFFAOYSA-N 0.000 description 1
- 229950011457 tiamiprine Drugs 0.000 description 1
- PLHJCIYEEKOWNM-HHHXNRCGSA-N tipifarnib Chemical compound CN1C=NC=C1[C@](N)(C=1C=C2C(C=3C=C(Cl)C=CC=3)=CC(=O)N(C)C2=CC=1)C1=CC=C(Cl)C=C1 PLHJCIYEEKOWNM-HHHXNRCGSA-N 0.000 description 1
- 229950009158 tipifarnib Drugs 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 229950001802 toralizumab Drugs 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 229950001353 tretamine Drugs 0.000 description 1
- IUCJMVBFZDHPDX-UHFFFAOYSA-N tretamine Chemical compound C1CN1C1=NC(N2CC2)=NC(N2CC2)=N1 IUCJMVBFZDHPDX-UHFFFAOYSA-N 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 229960004560 triaziquone Drugs 0.000 description 1
- PXSOHRWMIRDKMP-UHFFFAOYSA-N triaziquone Chemical compound O=C1C(N2CC2)=C(N2CC2)C(=O)C=C1N1CC1 PXSOHRWMIRDKMP-UHFFFAOYSA-N 0.000 description 1
- 229930013292 trichothecene Natural products 0.000 description 1
- 150000003327 trichothecene derivatives Chemical class 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 229960001670 trilostane Drugs 0.000 description 1
- KVJXBPDAXMEYOA-CXANFOAXSA-N trilostane Chemical compound OC1=C(C#N)C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@@]32O[C@@H]31 KVJXBPDAXMEYOA-CXANFOAXSA-N 0.000 description 1
- NOYPYLRCIDNJJB-UHFFFAOYSA-N trimetrexate Chemical compound COC1=C(OC)C(OC)=CC(NCC=2C(=C3C(N)=NC(N)=NC3=CC=2)C)=C1 NOYPYLRCIDNJJB-UHFFFAOYSA-N 0.000 description 1
- 229960001099 trimetrexate Drugs 0.000 description 1
- 229950000212 trioxifene Drugs 0.000 description 1
- 229960000875 trofosfamide Drugs 0.000 description 1
- UMKFEPPTGMDVMI-UHFFFAOYSA-N trofosfamide Chemical compound ClCCN(CCCl)P1(=O)OCCCN1CCCl UMKFEPPTGMDVMI-UHFFFAOYSA-N 0.000 description 1
- 229950010147 troxacitabine Drugs 0.000 description 1
- RXRGZNYSEHTMHC-BQBZGAKWSA-N troxacitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)OC1 RXRGZNYSEHTMHC-BQBZGAKWSA-N 0.000 description 1
- HDZZVAMISRMYHH-LITAXDCLSA-N tubercidin Chemical compound C1=CC=2C(N)=NC=NC=2N1[C@@H]1O[C@@H](CO)[C@H](O)[C@H]1O HDZZVAMISRMYHH-LITAXDCLSA-N 0.000 description 1
- 229950003364 tucotuzumab celmoleukin Drugs 0.000 description 1
- 108700008509 tucotuzumab celmoleukin Proteins 0.000 description 1
- 210000005102 tumor initiating cell Anatomy 0.000 description 1
- 229950009811 ubenimex Drugs 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 229960001055 uracil mustard Drugs 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229950004362 urtoxazumab Drugs 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 208000012991 uterine carcinoma Diseases 0.000 description 1
- 229950000578 vatalanib Drugs 0.000 description 1
- YCOYDOIWSSHVCK-UHFFFAOYSA-N vatalanib Chemical compound C1=CC(Cl)=CC=C1NC(C1=CC=CC=C11)=NN=C1CC1=CC=NC=C1 YCOYDOIWSSHVCK-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229960004355 vindesine Drugs 0.000 description 1
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 229950004393 visilizumab Drugs 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229960001771 vorozole Drugs 0.000 description 1
- XLMPPFTZALNBFS-INIZCTEOSA-N vorozole Chemical compound C1([C@@H](C2=CC=C3N=NN(C3=C2)C)N2N=CN=C2)=CC=C(Cl)C=C1 XLMPPFTZALNBFS-INIZCTEOSA-N 0.000 description 1
- 201000005102 vulva cancer Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 229950009268 zinostatin Drugs 0.000 description 1
- 229960000641 zorubicin Drugs 0.000 description 1
- FBTUMDXHSRTGRV-ALTNURHMSA-N zorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\NC(=O)C=1C=CC=CC=1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 FBTUMDXHSRTGRV-ALTNURHMSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Abstract
The present disclosure relates to combination therapies for the treatment of pathological conditions, such as cancer. In particular, the present disclosure relates to combination therapies comprising treatment with an anti-CD25 Antibody Drug Conjugate (anti-CD25 ADC) and an anti-BCL-2 agent, an mTOR inhibitor, or a secondary agent.
Description
CONJUGATE AND A FURTHER AGENT
EARLIER APPLICATIONS
This application claims priority from the following three applications: (1) United Kingdom application GB1908227.0 filed on 10 June 2019; (2) United Kingdom application GB1908231.2 filed on 10 June 2019; and (3) United Kingdom application GB1908232.0 filed on 10 June 2019.
FIELD
The present disclosure relates to combination therapies for the treatment of pathological conditions, such as cancer. In particular, the present disclosure relates to combination therapies comprising treatment with an anti-0D25 Antibody Drug Conjugate (anti-ADC) and an anti-BCL-2 agent, an mTOR inhibitor, or a secondary agent.
BACKGROUND
Antibody Therapy Antibody therapy has been established for the targeted treatment of subjects with cancer, immunological and angiogenic disorders (Carter, P. (2006) Nature Reviews Immunology 6:343-357). The use of antibody-drug conjugates (ADC), i.e. immunoconjugates, for the local delivery of cytotoxic or cytostatic agents, i.e. drugs to kill or inhibit tumour cells in the treatment of cancer, targets delivery of the drug moiety to tumours, and intracellular accumulation therein, whereas systemic administration of these unconjugated drug agents may result in unacceptable levels of toxicity to normal cells (Xie et al (2006) Expert. Opin. Biol. Ther. 6(3):281-291; Kovtun eta! (2006) Cancer Res.
66(6):3214-3121;
Law eta! (2006) Cancer Res. 66(4):2328-2337; Wu eta! (2005) Nature Biotech.
23(9):1137-1145; Lambert J. (2005) Current Opin. in Pharmacol. 5:543-549;
Hamann P.
(2005) Expert Opin. Ther. Patents 15(9):1087-1103; Payne, G. (2003) Cancer Cell 3:207-212; Trail eta! (2003) Cancer lmmunol. lmmunother. 52:328-337; Syrigos and Epenetos (1999) Anticancer Research 19:605-614).
The type I transmembrane protein CD25 is present on activated T- and B- cells, some thymocytes, myeloid precursors, and oligodendrocytes. On activated T-cells, it forms heterodimers with the beta- and gamma subunits (CD122 and CD132), thus comprising the high-affinity receptor for IL-2. This ligand represents a survival factor for activated T-cells, as removal of IL-2 leads to immediate death of these cells.
In case of B-cells, CD25 is physiologically expressed in early developmental stages of late pro-B and pre-B cells. Malignancies arising from this stage of B-cell differentiation may thus also express 0D25. Mast cell lesions are also positive for CD25 which is thus considered as a key diagnostic criterion for determination of systemic mastocytosis. In Hodgkin lymphomas, CD25 is reported to be not expressed in Hodgkin-/Reed-Sternberg cells in nodular lymphocyte predominance Hodgkin lymphoma (NLPHL), whereas the same cell type expresses CD25 at varying levels in classical Hodgkin' lymphomas of mixed cellularity type. The general expression levels are reported to be lower than in tumor infiltrating lymphocytes (TILs), which may result in problems demonstrating 0D25 tumor cells in these cases (Levi et al., Merz et al, 1995).
Expression of the target antigen has also been reported for several B- and T-cell-derived subtypes of non-Hodgkin-lymphomas, i.e. B-cell chronic lymphatic leukemia, hairy cell leukemia, small cell lymphocytic lymphoma/chronic lymphocytic leukemia as well as adult T-cell leukemia/lymphoma and anaplastic large cell lymphoma.
0D25 may be localised to the membrane, with some expression observed in the cytoplasm. Soluble 0D25 may also be observed outside of cells, such as in serum.
Therapeutic uses of anti-0O25 ADCs The efficacy of an Antibody Drug Conjugate comprising an anti-0D25 antibody (an anti CD25-ADC) in the treatment of, for example, cancer has been established ¨ see, for example, W02014/057119, W02016/083468, and W02016/166341.
Research continues to further improve the efficacy, tolerability, and clinical utility of anti-CD25 ADCs. To this end, the present authors have identified clinically advantageous combination therapies in which an anti-CD25 ADC is administered in combination with at least one anti-BCL-2 agent, an mTOR inhibitor, or a secondary agent.
SUMMARY
The present authors have determined that the administration of a combination of an anti-CD25 ADC and anti-BCL-2 agent, an mTOR inhibitor, or a secondary agent to an individual leads to unexpected clinical advantages. The present authors have further determined that administration of an anti-CD25 ADC to an individual that has either been treated with, or is being treated with, and anti-BCL-2 agent, an mTOR
inhibitor, or a secondary agent leads to a synergistic increase in treatment efficacy.
Accordingly, in a first aspect the present disclosure provides a method of selecting an individual as suitable for treatment with an anti-CD25 ADC, wherein the individual is selected for treatment with the anti-CD25 ADC if the individual has been treated, or is being treated, with an anti-BCL-2 agent, an mTOR inhibitor, or a secondary agent. The individual may be selected for treatment if the individual is refractory to treatment, or further treatment, with the anti-BCL-2 agent, an mTOR inhibitor, or a secondary agent.
In another aspect, the present disclosure provides a method for treating a disorder in an individual, the method comprising selecting an individual as suitable for treatment by a method of the first aspect, and then administering to the individual an effective amount of the anti-CD25 ADC. The method of treatment may further comprise administering an anti-BCL-2 agent, an mTOR inhibitor, or a secondary agent in combination with the anti-CD25 ADC.
EARLIER APPLICATIONS
This application claims priority from the following three applications: (1) United Kingdom application GB1908227.0 filed on 10 June 2019; (2) United Kingdom application GB1908231.2 filed on 10 June 2019; and (3) United Kingdom application GB1908232.0 filed on 10 June 2019.
FIELD
The present disclosure relates to combination therapies for the treatment of pathological conditions, such as cancer. In particular, the present disclosure relates to combination therapies comprising treatment with an anti-0D25 Antibody Drug Conjugate (anti-ADC) and an anti-BCL-2 agent, an mTOR inhibitor, or a secondary agent.
BACKGROUND
Antibody Therapy Antibody therapy has been established for the targeted treatment of subjects with cancer, immunological and angiogenic disorders (Carter, P. (2006) Nature Reviews Immunology 6:343-357). The use of antibody-drug conjugates (ADC), i.e. immunoconjugates, for the local delivery of cytotoxic or cytostatic agents, i.e. drugs to kill or inhibit tumour cells in the treatment of cancer, targets delivery of the drug moiety to tumours, and intracellular accumulation therein, whereas systemic administration of these unconjugated drug agents may result in unacceptable levels of toxicity to normal cells (Xie et al (2006) Expert. Opin. Biol. Ther. 6(3):281-291; Kovtun eta! (2006) Cancer Res.
66(6):3214-3121;
Law eta! (2006) Cancer Res. 66(4):2328-2337; Wu eta! (2005) Nature Biotech.
23(9):1137-1145; Lambert J. (2005) Current Opin. in Pharmacol. 5:543-549;
Hamann P.
(2005) Expert Opin. Ther. Patents 15(9):1087-1103; Payne, G. (2003) Cancer Cell 3:207-212; Trail eta! (2003) Cancer lmmunol. lmmunother. 52:328-337; Syrigos and Epenetos (1999) Anticancer Research 19:605-614).
The type I transmembrane protein CD25 is present on activated T- and B- cells, some thymocytes, myeloid precursors, and oligodendrocytes. On activated T-cells, it forms heterodimers with the beta- and gamma subunits (CD122 and CD132), thus comprising the high-affinity receptor for IL-2. This ligand represents a survival factor for activated T-cells, as removal of IL-2 leads to immediate death of these cells.
In case of B-cells, CD25 is physiologically expressed in early developmental stages of late pro-B and pre-B cells. Malignancies arising from this stage of B-cell differentiation may thus also express 0D25. Mast cell lesions are also positive for CD25 which is thus considered as a key diagnostic criterion for determination of systemic mastocytosis. In Hodgkin lymphomas, CD25 is reported to be not expressed in Hodgkin-/Reed-Sternberg cells in nodular lymphocyte predominance Hodgkin lymphoma (NLPHL), whereas the same cell type expresses CD25 at varying levels in classical Hodgkin' lymphomas of mixed cellularity type. The general expression levels are reported to be lower than in tumor infiltrating lymphocytes (TILs), which may result in problems demonstrating 0D25 tumor cells in these cases (Levi et al., Merz et al, 1995).
Expression of the target antigen has also been reported for several B- and T-cell-derived subtypes of non-Hodgkin-lymphomas, i.e. B-cell chronic lymphatic leukemia, hairy cell leukemia, small cell lymphocytic lymphoma/chronic lymphocytic leukemia as well as adult T-cell leukemia/lymphoma and anaplastic large cell lymphoma.
0D25 may be localised to the membrane, with some expression observed in the cytoplasm. Soluble 0D25 may also be observed outside of cells, such as in serum.
Therapeutic uses of anti-0O25 ADCs The efficacy of an Antibody Drug Conjugate comprising an anti-0D25 antibody (an anti CD25-ADC) in the treatment of, for example, cancer has been established ¨ see, for example, W02014/057119, W02016/083468, and W02016/166341.
Research continues to further improve the efficacy, tolerability, and clinical utility of anti-CD25 ADCs. To this end, the present authors have identified clinically advantageous combination therapies in which an anti-CD25 ADC is administered in combination with at least one anti-BCL-2 agent, an mTOR inhibitor, or a secondary agent.
SUMMARY
The present authors have determined that the administration of a combination of an anti-CD25 ADC and anti-BCL-2 agent, an mTOR inhibitor, or a secondary agent to an individual leads to unexpected clinical advantages. The present authors have further determined that administration of an anti-CD25 ADC to an individual that has either been treated with, or is being treated with, and anti-BCL-2 agent, an mTOR
inhibitor, or a secondary agent leads to a synergistic increase in treatment efficacy.
Accordingly, in a first aspect the present disclosure provides a method of selecting an individual as suitable for treatment with an anti-CD25 ADC, wherein the individual is selected for treatment with the anti-CD25 ADC if the individual has been treated, or is being treated, with an anti-BCL-2 agent, an mTOR inhibitor, or a secondary agent. The individual may be selected for treatment if the individual is refractory to treatment, or further treatment, with the anti-BCL-2 agent, an mTOR inhibitor, or a secondary agent.
In another aspect, the present disclosure provides a method for treating a disorder in an individual, the method comprising selecting an individual as suitable for treatment by a method of the first aspect, and then administering to the individual an effective amount of the anti-CD25 ADC. The method of treatment may further comprise administering an anti-BCL-2 agent, an mTOR inhibitor, or a secondary agent in combination with the anti-CD25 ADC.
2 In another aspect the disclosure provides a method for treating a disorder in an individual, the method comprising administering to the individual an effective amount of an anti-0D25 ADC and anti-BCL-2 agent, an mTOR inhibitor, or a secondary agent.
The individual may be selected for treatment according to a method according of the first aspect.
The disorder may be a proliferative disease, for example a cancer such as Hodgkin's and non-Hodgkin's Lymphoma, including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, (FL), Mantle Cell lymphoma (MCL), chronic lymphatic lymphoma (CLL), Marginal Zone B-cell lymphoma (MZBL) and leukemias such as Hairy cell leukemia (HCL), Hairy cell leukemia variant (HCL-v), Acute Myeloid Leukaemia (AML), anaplastic large cell lymphoma (ALCL), and Acute Lymphoblastic Leukaemia (ALL) such as Philadelphia chromosome-positive ALL (Ph+ALL) or Philadelphia chromosome-negative ALL (Ph-ALL).
The proliferative disease may be characterised by the presence of a neoplasm comprising both 0D25+ve and 0D25-ve cells.
The proliferative disease may be characterised by the presence of a neoplasm composed of 0D25-ve neoplastic cells, optionally wherein the 0D25-ve neoplastic cells are associated with 0D25+ve non-neoplastic cells such as 0D25+ve T-cells.
The target neoplasm or neoplastic cells may be all or part of a solid tumour.
"Solid tumor" herein will be understood to include solid haematological cancers such as lymphomas (Hodgkin's lymphoma or non-Hodgkin's lymphoma) which are discussed in more detail herein. The solid tumour may be an advanced solid tumour Solid tumors may be neoplasms, including non-haematological cancers, comprising or composed of 0D25+ve neoplastic cells. Solid tumors may be neoplasms, including non-haematological cancers, infiltrated with 0D25+ve cells, such as 0D25+ve T-cells; such solid tumours may lack expression of 0D25 (that is, comprise or be composed of ve neoplastic cells).
For example, the solid tumour may be a tumour with high levels of infiltrating T-cells, such as infiltrating regulatory T-cells (Treg; Menetrier-Caux, C., et al., Targ Oncol (2012) 7:15-28; Arce Vargas et al., 2017, Immunity 46, 1-10; Tanaka, A., et al., Cell Res.
Jan;27(1):109-118). Accordingly, the solid tumour may be pancreatic cancer, breast cancer, colorectal cancer, gastric and oesophageal cancer, leukemia and lymphoma, melanoma, non-small cell lung cancer, ovarian cancer, hepatocellular carcinoma, renal cell carcinoma, and head and neck cancer.
The anti-CD25-ADC may be ADCX25 described herein.
The anti-CD25-ADC may be ADCT-301.
The individual may be selected for treatment according to a method according of the first aspect.
The disorder may be a proliferative disease, for example a cancer such as Hodgkin's and non-Hodgkin's Lymphoma, including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, (FL), Mantle Cell lymphoma (MCL), chronic lymphatic lymphoma (CLL), Marginal Zone B-cell lymphoma (MZBL) and leukemias such as Hairy cell leukemia (HCL), Hairy cell leukemia variant (HCL-v), Acute Myeloid Leukaemia (AML), anaplastic large cell lymphoma (ALCL), and Acute Lymphoblastic Leukaemia (ALL) such as Philadelphia chromosome-positive ALL (Ph+ALL) or Philadelphia chromosome-negative ALL (Ph-ALL).
The proliferative disease may be characterised by the presence of a neoplasm comprising both 0D25+ve and 0D25-ve cells.
The proliferative disease may be characterised by the presence of a neoplasm composed of 0D25-ve neoplastic cells, optionally wherein the 0D25-ve neoplastic cells are associated with 0D25+ve non-neoplastic cells such as 0D25+ve T-cells.
The target neoplasm or neoplastic cells may be all or part of a solid tumour.
"Solid tumor" herein will be understood to include solid haematological cancers such as lymphomas (Hodgkin's lymphoma or non-Hodgkin's lymphoma) which are discussed in more detail herein. The solid tumour may be an advanced solid tumour Solid tumors may be neoplasms, including non-haematological cancers, comprising or composed of 0D25+ve neoplastic cells. Solid tumors may be neoplasms, including non-haematological cancers, infiltrated with 0D25+ve cells, such as 0D25+ve T-cells; such solid tumours may lack expression of 0D25 (that is, comprise or be composed of ve neoplastic cells).
For example, the solid tumour may be a tumour with high levels of infiltrating T-cells, such as infiltrating regulatory T-cells (Treg; Menetrier-Caux, C., et al., Targ Oncol (2012) 7:15-28; Arce Vargas et al., 2017, Immunity 46, 1-10; Tanaka, A., et al., Cell Res.
Jan;27(1):109-118). Accordingly, the solid tumour may be pancreatic cancer, breast cancer, colorectal cancer, gastric and oesophageal cancer, leukemia and lymphoma, melanoma, non-small cell lung cancer, ovarian cancer, hepatocellular carcinoma, renal cell carcinoma, and head and neck cancer.
The anti-CD25-ADC may be ADCX25 described herein.
The anti-CD25-ADC may be ADCT-301.
3 The anti-BCL-2 agent may be Venetoclax (ABT-199), navitoclax (ABT-263), ABT-737, S55746/BCL201, and oblimersen (G3139). Preferably the anti-BCL-2 agent is Venetoclax (A BT-199).
The mTOR inhibitor may be everolimus (RAD001), sirolimus (Rapamycin), 00I-779 (temsirolimus), ridaforolimus (AP-23573), NVP-BEZ235 (dactolisib), BGT226, SF1126, Gedatolisib, Omipalisib, XL765, Ku-0063794, oleuropein aglycone, AZD8055, AZD2014, AZD 3147, sapanisertib (INK128/MLN0128), 0SI027, torin 1, torin 2, torkinib (PP242), VVYE687, ETP45658, PF05212384, PF04691502, XL388, eCF309, RapaLink-1, or Rapalink-2.
The secondary agent may be:
(a) Bendamustine;
(b) a phosphoinositide 3-kinase inhibitor such as copanlisib, idelalisib, duvelisib, Taselisib, Buparlisib, Alpelisib, Umbralisib, Dactolisib, and Voxtalisib;
(c) a proteasome inhibitor such as bortezomib, carfilzomib, lxazomib, Oprozomib, and Salinosporamide A;
(d) an anti-folate such as pralatrexate, methotrexate, pemetrexed, and raltitrexed;
or (e) a HDAC inhibitor such as romidepsin, vorinostat, Abexinostat, belinostat (PXD101), LAQ824, panobinostat (LBH589), entinostat (MS-275), tacedinaline (01994), and mocetinostat (MGCD0103).
The individual may be human. The individual may have cancer, or may have been determined to have cancer. The individual may have, or have been determined to have, a 0D25+ cancer or 0D25+ tumour-associated non-tumour cells, such as 0D25+
infiltrating T-cells.
In the disclosed methods the anti-0D25 ADC may be administered before the anti-agent, mTOR inhibitor, or secondary agent, simultaneous with the anti-BCL-2 agent, mTOR inhibitor, or secondary agent, or after the anti-BCL-2 agent, mTOR
inhibitor, or secondary agent. The disclosed methods may comprise administering a further chemotherapeutic agent to the individual.
In another aspect, the present disclosure provides an anti-0D25 ADC, or a composition comprising an anti-0D25 ADC, for use in a method of treatment as described herein.
In one aspect, the present disclosure provides an anti-BCL-2 agent, an mTOR
inhibitor, or a secondary agent, or a composition comprising an anti-BCL-2 agent, an mTOR
inhibitor, or a secondary agent, for use in a method of treatment as described herein.
In a further aspect, the present disclosure provides for the use of an anti-0D25 ADC or an anti-BCL-2 agent, an mTOR inhibitor, or a secondary agent in the manufacture of a medicament for treating a disorder in an individual, wherein the treatment comprises a method of treatment as described herein.
The mTOR inhibitor may be everolimus (RAD001), sirolimus (Rapamycin), 00I-779 (temsirolimus), ridaforolimus (AP-23573), NVP-BEZ235 (dactolisib), BGT226, SF1126, Gedatolisib, Omipalisib, XL765, Ku-0063794, oleuropein aglycone, AZD8055, AZD2014, AZD 3147, sapanisertib (INK128/MLN0128), 0SI027, torin 1, torin 2, torkinib (PP242), VVYE687, ETP45658, PF05212384, PF04691502, XL388, eCF309, RapaLink-1, or Rapalink-2.
The secondary agent may be:
(a) Bendamustine;
(b) a phosphoinositide 3-kinase inhibitor such as copanlisib, idelalisib, duvelisib, Taselisib, Buparlisib, Alpelisib, Umbralisib, Dactolisib, and Voxtalisib;
(c) a proteasome inhibitor such as bortezomib, carfilzomib, lxazomib, Oprozomib, and Salinosporamide A;
(d) an anti-folate such as pralatrexate, methotrexate, pemetrexed, and raltitrexed;
or (e) a HDAC inhibitor such as romidepsin, vorinostat, Abexinostat, belinostat (PXD101), LAQ824, panobinostat (LBH589), entinostat (MS-275), tacedinaline (01994), and mocetinostat (MGCD0103).
The individual may be human. The individual may have cancer, or may have been determined to have cancer. The individual may have, or have been determined to have, a 0D25+ cancer or 0D25+ tumour-associated non-tumour cells, such as 0D25+
infiltrating T-cells.
In the disclosed methods the anti-0D25 ADC may be administered before the anti-agent, mTOR inhibitor, or secondary agent, simultaneous with the anti-BCL-2 agent, mTOR inhibitor, or secondary agent, or after the anti-BCL-2 agent, mTOR
inhibitor, or secondary agent. The disclosed methods may comprise administering a further chemotherapeutic agent to the individual.
In another aspect, the present disclosure provides an anti-0D25 ADC, or a composition comprising an anti-0D25 ADC, for use in a method of treatment as described herein.
In one aspect, the present disclosure provides an anti-BCL-2 agent, an mTOR
inhibitor, or a secondary agent, or a composition comprising an anti-BCL-2 agent, an mTOR
inhibitor, or a secondary agent, for use in a method of treatment as described herein.
In a further aspect, the present disclosure provides for the use of an anti-0D25 ADC or an anti-BCL-2 agent, an mTOR inhibitor, or a secondary agent in the manufacture of a medicament for treating a disorder in an individual, wherein the treatment comprises a method of treatment as described herein.
4 In another aspect, the disclosure provides a first composition comprising an anti-0D25 ADC for use in a method of treating a disorder in an individual, wherein the treatment comprises administration of the first composition in combination with a second composition comprising an anti-BCL-2 agent, an mTOR inhibitor, or a secondary agent.
Also provided by this aspect is a first composition comprising an anti-BCL-2 agent, an mTOR inhibitor, or a secondary agent for use in a method of treating a disorder in an individual, wherein the treatment comprises administration of the first composition in combination with a second composition comprising an anti-0D25 ADC.
The disorder may be a proliferative disease, for example a cancer such as non-Hodgkin's Lymphoma, including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, (FL), Mantle Cell lymphoma (MCL), chronic lymphatic lymphoma (CLL), and Marginal Zone B-cell lymphoma (MZBL), and leukemias such as Hairy cell leukemia (HCL), Hairy cell leukemia variant (HCL-v), anaplastic large cell lymphoma (ALCL), and Acute Lymphoblastic Leukaemia (ALL) such as Philadelphia chromosome-positive ALL
(Ph+ALL) or Philadelphia chromosome-negative ALL (Ph-ALL).
The anti-0D25-ADC may be ADCX25 described herein.
The anti-0D25-ADC may be ADCT-301.
The anti-BCL-2 agent may be Venetoclax (ABT-199), navitoclax (ABT-263), ABT-737, S55746/BCL201, and oblimersen (G3139). Preferably the anti-BCL-2 agent is Venetoclax (A BT-199).
The mTOR inhibitor may be everolimus (RAD001), sirolimus (Rapamycin), 00I-779 (temsirolimus), ridaforolimus (AP-23573), NVP-BEZ235 (dactolisib), BGT226, SF1126, Gedatolisib, Omipalisib, XL765, Ku-0063794, oleuropein aglycone, AZD8055, AZD2014, AZD 3147, sapanisertib (INK128/MLN0128), 0SI027, torin 1, torin 2, torkinib (PP242), VVYE687, ETP45658, PF05212384, PF04691502, XL388, eCF309, RapaLink-1, or Rapalink-2.
The secondary agent may be:
(a) Bendamustine;
(b) a phosphoinositide 3-kinase inhibitor such as copanlisib, idelalisib, duvelisib, Taselisib, Buparlisib, Alpelisib, Umbralisib, Dactolisib, and Voxtalisib;
(c) a proteasome inhibitor such as bortezomib, carfilzomib, lxazomib, Oprozomib, and Salinosporamide A;
(d) an anti-folate such as pralatrexate, methotrexate, pemetrexed, and raltitrexed;
or (e) a HDAC inhibitor such as romidepsin, vorinostat, Abexinostat, belinostat (PXD101), LAQ824, panobinostat (LBH589), entinostat (MS-275), tacedinaline (01994), and mocetinostat (MGCD0103).
The individual may be human. The individual may have cancer, or may have been determined to have cancer. The individual may have, or have been determined to have, a 0D25+ cancer or 0D25+ tumour-associated non-tumour cells, such as 0D25+
infiltrating T-cells.
The first composition may be administered before the second composition, simultaneous with the second composition, or after the second composition. The treatment may comprise administering a further chemotherapeutic agent to the individual.
In a further aspect, the disclosure provides the use of an anti-0D25 ADC in the manufacture of a medicament for treating a disorder in an individual, wherein the medicament comprises an anti-0D25 ADC, and wherein the treatment comprises administration of the medicament in combination with a composition comprising anti-BCL-2 agent, an mTOR inhibitor, or a secondary agent.
Also provided by this aspect is the use of anti-BCL-2 agent in the manufacture of a medicament for treating a disorder in an individual, wherein the medicament comprises an anti-BCL-2 agent, an mTOR inhibitor, or a secondary agent, and wherein the treatment comprises administration of the medicament in combination with a composition comprising an anti-0D25 ADC.
The disorder may be a proliferative disease, for example a cancer such as Hodgkin's and non-Hodgkin's Lymphoma, including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, (FL), Mantle Cell lymphoma (MCL), chronic lymphatic lymphoma (CLL), Marginal Zone B-cell lymphoma (MZBL) and leukemias such as Hairy cell leukemia (HCL), Hairy cell leukemia variant (HCL-v), Acute Myeloid Leukaemia (AML), anaplastic large cell lymphoma (ALCL), and Acute Lymphoblastic Leukaemia (ALL) such as Philadelphia chromosome-positive ALL (Ph+ALL) or Philadelphia chromosome-negative ALL (Ph-ALL).
The proliferative disease may be characterised by the presence of a neoplasm comprising both 0D25+ve and 0D25-ve cells.
The proliferative disease may be characterised by the presence of a neoplasm composed of 0D25-ve neoplastic cells, optionally wherein the 0D25-ve neoplastic cells are associated with 0D25+ve non-neoplastic cells such as 0D25+ve T-cells.
The target neoplasm or neoplastic cells may be all or part of a solid tumour.
"Solid tumor" herein will be understood to include solid haematological cancers such as lymphomas (Hodgkin's lymphoma or non-Hodgkin's lymphoma) which are discussed in more detail herein. The solid tumour may be an advanced solid tumour.
Solid tumors may be neoplasms, including non-haematological cancers, comprising or composed of 0D25+ve neoplastic cells. Solid tumors may be neoplasms, including non-haematological cancers, infiltrated with 0D25+ve cells, such as 0D25+ve T-cells; such solid tumours may lack expression of 0D25 (that is, comprise or be composed of ve neoplastic cells).
For example, the solid tumour may be a tumour with high levels of infiltrating T-cells, such as infiltrating regulatory T-cells (Treg; Menetrier-Caux, C., et al., Targ Oncol (2012) 7:15-28; Arce Vargas et al., 2017, Immunity 46, 1-10; Tanaka, A., et al., Cell Res.
Jan;27(1):109-118). Accordingly, the solid tumour may be pancreatic cancer, breast cancer, colorectal cancer, gastric and oesophageal cancer, leukemia and lymphoma, melanoma, non-small cell lung cancer, ovarian cancer, hepatocellular carcinoma, renal cell carcinoma, and head and neck cancer.
The anti-CD25 ADC may be ADCX25 as described herein.
The anti-CD25-ADC may be ADCT-301.
The anti-BCL-2 agent may be Venetoclax (ABT-199), navitoclax (ABT-263), ABT-737, 555746/BCL201, and oblimersen (G3139). Preferably the anti-BCL-2 agent is Venetoclax (A BT-199).
The mTOR inhibitor may be everolimus (RAD001), sirolimus (Rapamycin), CCI-779 (temsirolimus), ridaforolimus (AP-23573), NVP-BEZ235 (dactolisib), BGT226, SF1126, Gedatolisib, Omipalisib, XL765, Ku-0063794, oleuropein aglycone, AZD8055, AZD2014, AZD 3147, sapanisertib (INK128/MLN0128), 0SI027, torin 1, torin 2, torkinib (PP242), VVYE687, ETP45658, PF05212384, PF04691502, XL388, eCF309, RapaLink-1, or Rapalink-2.
The secondary agent may be:
(a) Bendamustine;
(b) a phosphoinositide 3-kinase inhibitor such as copanlisib, idelalisib, duvelisib, Taselisib, Buparlisib, Alpelisib, Umbralisib, Dactolisib, and Voxtalisib;
(c) a proteasome inhibitor such as bortezomib, carfilzomib, lxazomib, Oprozomib, and Salinosporamide A;
(d) an anti-folate such as pralatrexate, methotrexate, pemetrexed, and raltitrexed;
or (e) a HDAC inhibitor such as romidepsin, vorinostat, Abexinostat, belinostat (PXD101), LAQ824, panobinostat (LBH589), entinostat (MS-275), tacedinaline (CI994), and mocetinostat (MGCD0103).
The individual may be human. The individual may have cancer, or may have been determined to have cancer. The individual may have, or have been determined to have, a CD25+ cancer or CD25+ tumour-associated non-tumour cells, such as CD25+
infiltrating T-cells.
The medicament may be administered before the composition, simultaneous with the composition, or after the composition. The treatment may comprise administering a further chemotherapeutic agent to the individual.
Another aspect of the disclosure provides a kit comprising:
a first medicament comprising an anti-0D25 ADC;
a package insert comprising instructions for administration of the first medicament according to a method of treatment as disclosed herein. The kit may further comprise a second medicament comprising an anti-BCL-2 agent, an mTOR inhibitor, or a secondary agent.
Another aspect of the disclosure provides a kit comprising:
a first medicament comprising an anti-0D25 ADC, an mTOR inhibitor, or a secondary agent;
a second medicament comprising an anti-BCL-2 agent, an mTOR inhibitor, or a secondary agent; and, optionally, a package insert comprising instructions for administration of the first medicament to an individual in combination with the second medicament for the treatment of a disorder.
Also provided by this aspect is a kit comprising a medicament comprising an anti-0D25 ADC and a package insert comprising instructions for administration of the medicament to an individual in combination with a composition comprising an anti-BCL-2 agent, an mTOR inhibitor, or a secondary agent for the treatment of a disorder.
Further provided by this aspect is a kit comprising a medicament comprising an anti-BCL-2 agent, an mTOR inhibitor, or a secondary agent and a package insert comprising instructions for administration of the medicament to an individual in combination with a composition comprising an anti-0D25 ADC for the treatment of a disorder.
The disorder may be a proliferative disease, for example a cancer such as Hodgkin's and non-Hodgkin's Lymphoma, including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, (FL), Mantle Cell lymphoma (MCL), chronic lymphatic lymphoma (CLL), Marginal Zone B-cell lymphoma (MZBL) and leukemias such as Hairy cell leukemia (HCL), Hairy cell leukemia variant (HCL-v), Acute Myeloid Leukaemia (AML), anaplastic large cell lymphoma (ALCL), and Acute Lymphoblastic Leukaemia (ALL) such as Philadelphia chromosome-positive ALL (Ph+ALL) or Philadelphia chromosome-negative ALL (Ph-ALL).
The proliferative disease may be characterised by the presence of a neoplasm comprising both 0D25+ve and 0D25-ve cells.
The proliferative disease may be characterised by the presence of a neoplasm composed of 0D25-ve neoplastic cells, optionally wherein the 0D25-ve neoplastic cells are associated with 0D25+ve non-neoplastic cells such as 0D25+ve T-cells.
The target neoplasm or neoplastic cells may be all or part of a solid tumour.
"Solid tumor" herein will be understood to include solid haematological cancers such as lymphomas (Hodgkin's lymphoma or non-Hodgkin's lymphoma) which are discussed in more detail herein. The solid tumour may be an advanced solid tumour Solid tumors may be neoplasms, including non-haematological cancers, comprising or composed of 0D25+ve neoplastic cells. Solid tumors may be neoplasms, including non-haematological cancers, infiltrated with 0D25+ve cells, such as 0D25+ve T-cells; such solid tumours may lack expression of 0D25 (that is, comprise or be composed of ve neoplastic cells).
For example, the solid tumour may be a tumour with high levels of infiltrating T-cells, such as infiltrating regulatory T-cells (Treg; Menetrier-Caux, C., et al., Targ Oncol (2012) 7:15-28; Arce Vargas et al., 2017, Immunity 46, 1-10; Tanaka, A., et al., Cell Res.
Jan;27(1):109-118). Accordingly, the solid tumour may be pancreatic cancer, breast cancer, colorectal cancer, gastric and oesophageal cancer, leukemia and lymphoma, melanoma, non-small cell lung cancer, ovarian cancer, hepatocellular carcinoma, renal cell carcinoma, and head and neck cancer.
The anti-CD25 ADC may be ADCX25 as described herein.
The anti-CD25-ADC may be ADCT-301.
The anti-BCL-2 agent may be Venetoclax (ABT-199), navitoclax (ABT-263), ABT-737, 555746/BCL201, and oblimersen (G3139). Preferably the anti-BCL-2 agent is Venetoclax (A BT-199).
The mTOR inhibitor may be everolimus (RAD001), sirolimus (Rapamycin), CCI-779 (temsirolimus), ridaforolimus (AP-23573), NVP-BEZ235 (dactolisib), BGT226, SF1126, Gedatolisib, Omipalisib, XL765, Ku-0063794, oleuropein aglycone, AZD8055, AZD2014, AZD 3147, sapanisertib (INK128/MLN0128), 0SI027, torin 1, torin 2, torkinib (PP242), VVYE687, ETP45658, PF05212384, PF04691502, XL388, eCF309, RapaLink-1, or Rapalink-2.
The secondary agent may be:
(a) Bendamustine;
(b) a phosphoinositide 3-kinase inhibitor such as copanlisib, idelalisib, duvelisib, Taselisib, Buparlisib, Alpelisib, Umbralisib, Dactolisib, and Voxtalisib;
(c) a proteasome inhibitor such as bortezomib, carfilzomib, lxazomib, Oprozomib, and Salinosporamide A;
(d) an anti-folate such as pralatrexate, methotrexate, pemetrexed, and raltitrexed;
or (e) a HDAC inhibitor such as romidepsin, vorinostat, Abexinostat, belinostat (PXD101), LAQ824, panobinostat (LBH589), entinostat (MS-275), tacedinaline (01994), and mocetinostat (MGCD0103).
The individual may be human. The individual may have cancer, or may have been determined to have cancer. The individual may have, or have been determined to have, a 0D25+ cancer or 0D25+ tumour-associated non-tumour cells, such as 0D25+
infiltrating T-cells.
The medicament or composition comprising the anti-0D25 ADC may be administered before the medicament or composition comprising the anti-BCL-2 agent, mTOR
inhibitor, or secondary agent, simultaneous with the medicament or composition comprising the anti-BCL-2 agent, mTOR inhibitor, or secondary agent, or after the medicament or composition comprising the anti-BCL-2 agent, mTOR inhibitor, or secondary agent. The treatment may comprise administering a further chemotherapeutic agent to the individual.
In a yet further aspect, the disclosure provides a composition comprising an anti-0D25 ADC and an anti-BCL-2 agent, mTOR inhibitor, or secondary agent.
Also provided in this aspect of the disclosure is a method of treating a disorder in an individual, the method comprising administering to the individual an effective amount of the composition comprising an anti-0D25 ADC and an anti-BCL-2 agent, an mTOR
inhibitor, or a secondary agent.
Also provided in this aspect of the disclosure is a composition comprising an anti-0D25 ADC and an anti-BCL-2 agent, an mTOR inhibitor, or a secondary agent for use in a method of treating a disorder in an individual.
Also provided in this aspect of the disclosure is the use of a composition comprising an anti-0D25 ADC and an anti-BCL-2 agent, an mTOR inhibitor, or a secondary agent in the manufacture of a medicament for treating a disorder in an individual.
Also provided in this aspect of the disclosure is a kit comprising composition comprising an anti-0D25 ADC and an anti-BCL-2 agent, an mTOR inhibitor, or a secondary agent and a set of instructions for administration of the medicament to an individual for the treatment of a disorder.
The disorder may be a proliferative disease, for example a cancer such as Hodgkin's and non-Hodgkin's Lymphoma, including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, (FL), Mantle Cell lymphoma (MCL), chronic lymphatic lymphoma (CLL), Marginal Zone B-cell lymphoma (MZBL) and leukemias such as Hairy cell leukemia (HCL), Hairy cell leukemia variant (HCL-v), Acute Myeloid Leukaemia (AML), anaplastic large cell lymphoma (ALCL), and Acute Lymphoblastic Leukaemia (ALL) such as Philadelphia chromosome-positive ALL (Ph+ALL) or Philadelphia chromosome-negative ALL (Ph-ALL).
The proliferative disease may be characterised by the presence of a neoplasm comprising both 0D25+ve and 0D25-ve cells.
The proliferative disease may be characterised by the presence of a neoplasm composed of 0D25-ve neoplastic cells, optionally wherein the 0D25-ve neoplastic cells are associated with 0D25+ve non-neoplastic cells such as 0D25+ve T-cells.
The target neoplasm or neoplastic cells may be all or part of a solid tumour.
"Solid tumor" herein will be understood to include solid haematological cancers such as lymphomas (Hodgkin's lymphoma or non-Hodgkin's lymphoma) which are discussed in more detail herein.
Solid tumors may be neoplasms, including non-haematological cancers, comprising or composed of 0D25+ve neoplastic cells. Solid tumors may be neoplasms, including non-haematological cancers, infiltrated with 0D25+ve cells, such as 0D25+ve T-cells; such solid tumours may lack expression of 0D25 (that is, comprise or be composed of ve neoplastic cells).
For example, the solid tumour may be a tumour with high levels of infiltrating T-cells, such as infiltrating regulatory T-cells (Treg; Menetrier-Caux, C., et al., Targ Oncol (2012) 7:15-28; Arce Vargas et al., 2017, Immunity 46, 1-10; Tanaka, A., et al., Cell Res.
Jan;27(1):109-118). Accordingly, the solid tumour may be pancreatic cancer, breast cancer, colorectal cancer, gastric and oesophageal cancer, leukemia and lymphoma, melanoma, non-small cell lung cancer, ovarian cancer, hepatocellular carcinoma, renal cell carcinoma, and head and neck cancer.
The anti-CD25 ADC may be ADCX25 as described herein.
The anti-CD25-ADC may be ADCT-301.
The anti-BCL-2 agent may be Venetoclax (ABT-199), navitoclax (ABT-263), ABT-737, 555746/BCL201, and oblimersen (G3139). Preferably the anti-BCL-2 agent is Venetoclax (A BT-199).
The mTOR inhibitor may be everolimus (RAD001), sirolimus (Rapamycin), CCI-779 (temsirolimus), ridaforolimus (AP-23573), NVP-BEZ235 (dactolisib), BGT226, SF1126, Gedatolisib, Omipalisib, XL765, Ku-0063794, oleuropein aglycone, AZD8055, AZD2014, AZD 3147, sapanisertib (INK128/MLN0128), 0SI027, torin 1, torin 2, torkinib (PP242), VVYE687, ETP45658, PF05212384, PF04691502, XL388, eCF309, RapaLink-1, or Rapalink-2.
The secondary agent may be:
(a) Bendamustine;
(b) a phosphoinositide 3-kinase inhibitor such as copanlisib, idelalisib, duvelisib, Taselisib, Buparlisib, Alpelisib, Umbralisib, Dactolisib, and Voxtalisib;
(c) a proteasome inhibitor such as bortezomib, carfilzomib, lxazomib, Oprozomib, and Salinosporamide A;
(d) an anti-folate such as pralatrexate, methotrexate, pemetrexed, and raltitrexed;
or (e) a HDAC inhibitor such as romidepsin, vorinostat, Abexinostat, belinostat (PXD101), LAQ824, panobinostat (LBH589), entinostat (MS-275), tacedinaline (01994), and mocetinostat (MGCD0103).
The individual may be human. The individual may have cancer, or may have been determined to have cancer. The individual may have, or have been determined to have, a 0D25+ cancer or 0D25+ tumour-associated non-tumour cells, such as 0D25+
infiltrating T-cells.
The treatment may comprise administering a further chemotherapeutic agent to the individual.
DETAILED DESCRIPTION
Antibody Drug Conjugates (ADCs) The present disclosure relates to the improved efficacy of combinations of an ADC and an anti-BCL-2 agent, an mTOR inhibitor, or a secondary agent.
The ADC can deliver a drug to a target location. The target location is preferably a proliferative cell population. The antibody is an antibody for an antigen present on a proliferative cell population. In one aspect the antigen is absent or present at a reduced level in a non-proliferative cell population compared to the amount of antigen present in the proliferative cell population, for example a tumour cell population.
The ADC may comprise a linker which may be cleaved so as to release the drug at the target location. The drug may be a compound selected from RelA, RelB, ReIC, RelD or RelE. Thus, the conjugate may be used to selectively provide a compound RelA, RelB, Rel C, RelD or RelE to the target location.
The linker may be cleaved by an enzyme present at the target location.
The disclosure particularly relates treatment with an anti-0D25 ADC disclosed in W02014/057119, and as herein described.
anti-0O25 ADCs As used herein, the term "0D25-ADC" refers to an ADC in which the antibody component is an anti-0D25 antibody. The term "PBD-ADC" refers to an ADC in which the drug component is a pyrrolobenzodiazepine (PBD) warhead. The term "anti-0D25-ADC"
refers to an ADC in which the antibody component is an anti-0D25 antibody, and the drug component is a PBD warhead.
The ADC may comprise a conjugate of formula L - (DL)p, where DL is of formula I or II:
9 RI-1' R20 R9, R11 a C2' N R7' R7 N C2 C3' 0 R6' ,30 9. 10 R31 rcI R R9 RI R11 Y' ,Y
'R"
C2' R7' R7 2 s-- R22 wherein:
L is an antibody (Ab) which is an antibody that binds to 0D25;
when there is a double bond present between 02' and 03', R12 is selected from the group consisting of:
(ia) 05_10 aryl group, optionally substituted by one or more substituents selected from the group comprising: halo, nitro, cyano, ether, carboxy, ester, 01-7 alkyl, 03-7 heterocyclyl and bis-oxy-01_3 alkylene;
(ib) Ci-s saturated aliphatic alkyl;
(ic) 03-6 saturated cycloalkyl;
*R23 (id) R21 , wherein each of R21, R22 and R23 are independently selected from H, Oi 3 saturated alkyl, 02-3 alkenyl, 02-3 alkynyl and cyclopropyl, where the total number of carbon atoms in the R12 group is no more than 5;
R25b *
(ie) R, wherein one of R25 and R25b is H and the other is selected from:
phenyl, which phenyl is optionally substituted by a group selected from halo, methyl, methoxy; pyridyl; and thiophenyl; and m24 (if) , where R24 is selected from: H; 01-3 saturated alkyl; 02-3 alkenyl; 02-3 alkynyl; cyclopropyl; phenyl, which phenyl is optionally substituted by a group selected from halo, methyl, methoxy; pyridyl; and thiophenyl;
when there is a single bond present between 02' and 03', R12 is R26b , where R26a and R26b are independently selected from H, F, saturated alkyl, 02-3 alkenyl, which alkyl and alkenyl groups are optionally substituted by a group selected from 01-4 alkyl amido and 01-4 alkyl ester; or, when one of R26a and R26b is H, the other is selected from nitrile and a 01-4 alkyl ester;
R6 and R9 are independently selected from H, R, OH, OR, SH, SR, NH2, NHR, NRR', nitro, Me3Sn and halo;
where R and R' are independently selected from optionally substituted 01-12 alkyl, 03-20 heterocyclyl and 05-20 aryl groups;
R7 is selected from H, R, OH, OR, SH, SR, NH2, NHR, NHRR', nitro, Me3Sn and halo;
R" is a 03-12 alkylene group, which chain may be interrupted by one or more heteroatoms, e.g. 0, S, NRN2 (where RN2 is H or 01-4 alkyl), and/or aromatic rings, e.g.
benzene or pyridine;
Y and Y' are selected from 0, S, or NH;
R6', R7', R9' are selected from the same groups as R6, R7 and R9 respectively;
[Formula lj RI-1' is a linker for connection to the antibody (Ab);
R11a is selected from OH, ORA, where RA is 01-4 alkyl, and SON, where z is 2 or 3 and M
is a monovalent pharmaceutically acceptable cation;
R2 and R21 either together form a double bond between the nitrogen and carbon atoms to which they are bound or;
R2 is selected from H and Rc, where Rc is a capping group;
R21 is selected from OH, ORA and SO,M;
when there is a double bond present between 02 and 03, R2 is selected from the group consisting of:
(ia) C5-10 aryl group, optionally substituted by one or more substituents selected from the group comprising: halo, nitro, cyano, ether, carboxy, ester, 01-7 alkyl, 03-7 heterocyclyl and bis-oxy-01_3 alkylene;
(ib) Cis saturated aliphatic alkyl;
(ic) 03-6 saturated cycloalkyl;
(id) R , wherein each of R11, R12 and R13 are independently selected from H, 01-3 saturated alkyl, 02-3 alkenyl, 02-3 alkynyl and cyclopropyl, where the total number of carbon atoms in the R2 group is no more than 5;
R15b R 5a (ie) , wherein one of R15a and R15b is H and the other is selected from:
phenyl, which phenyl is optionally substituted by a group selected from halo, methyl, methoxy; pyridyl; and thiophenyl; and (if) R , where R14 is selected from: H; 01-3 saturated alkyl; 02-3 alkenyl; 02-3 alkynyl; cyclopropyl; phenyl, which phenyl is optionally substituted by a group selected from halo, methyl, methoxy; pyridyl; and thiophenyl;
when there is a single bond present between 02 and 03, R16a R2 is R16b , where R16 and R16b are independently selected from H, F, 01-4 saturated alkyl, 02-3 alkenyl, which alkyl and alkenyl groups are optionally substituted by a group selected from 01-4 alkyl amido and 01-4 alkyl ester; or, when one of R16 and R16b is H, the other is selected from nitrile and a 01-4 alkyl ester;
[Formula llJ
R22 is of formula Illa, formula Illb or formula Illc:
(a) "(Q1Q2-X Illa where A is a 05-7 aryl group, and either (i) Q1 is a single bond, and Q2 is selected from a single bond and -Z-(CH2)n-, where Z is selected from a single bond, 0, S and NH and n is from 1 to 3; or (ii) Q1 is -CH=CH-, and Q2 is a single bond;
Illb (b) RC1 RC3 where;
Rc2 and rc r-sC3 are independently selected from H and unsubstituted 01-2 alkyl;
IIIc (c) where Q is selected from 0-R1-2', S-R1-2' and NRN-R1-2', and RN is selected from H, methyl and ethyl X is selected from the group comprising: 0-R1-2', S-R1-2', 002-R1-2', CO-R1-2', NH-C(=0)-R1-2', \I¨ HN/ \N¨R1-2' \ __________________________________________ /
NHNH-R1-2', CONHNH-R1-2', , NRNR1-2', wherein RN is selected from the group comprising H and 01-4 alkyl;
RI-2' is a linker for connection to the antibody (Ab);
R1 and R11 either together form a double bond between the nitrogen and carbon atoms to which they are bound or;
R1 is H and R11 is selected from OH, ORA and SO,M;
R3 and R31 either together form a double bond between the nitrogen and carbon atoms to which they are bound or;
R3 is H and R31 is selected from OH, ORA and SON.
In some embodiments L-RI-1' or L-RI-2' is a group:
Ab , ====., 2.0y A L
where the asterisk indicates the point of attachment to the PBD, Ab is the antibody, L1 is a cleavable linker, A is a connecting group connecting L1 to the antibody, L2 is a covalent bond or together with -0C(=0)- forms a self-immolative linker.
In some of these embodiments, L1 is enzyme cleavable.
It has previously been shown that such ADCs are useful in the treatment of expressing cancers (see, for example, W02014/057119, which is incorporated by reference herein in its entirety).
The term anti-0D25-ADC may include any embodiment described in WO 2014/057119.
In particular, in preferred embodiments the ADC may have the chemical structure:
0\
ONO
z NH
H
01,0 0 H
0" 0 0 0 , where the Ab is a 0D25 antibody, and the DAR is between 1 and 8.
The antibody may comprise a VH domain comprising a VH CDR1 with the amino acid sequence of SEQ ID NO.3, a VH CDR2 with the amino acid sequence of SEQ ID
NO.4, and a VH CDR3 with the amino acid sequence of SEQ ID NO.5.
In some aspects the antibody component of the anti-0D25-ADC is an antibody comprising: a VH domain comprising a VH CDR1 with the amino acid sequence of SEQ
ID NO.3, a VH CDR2 with the amino acid sequence of SEQ ID NO.4, and a VH CDR3 with the amino acid sequence of SEQ ID NO.5. In some embodiments the antibody comprises a VH domain having the sequence according to SEQ ID NO. 1.
The antibody may further comprise: a VL domain comprising a VL CDR1 with the amino acid sequence of SEQ ID NO.6, a VL CDR2 with the amino acid sequence of SEQ ID
NO.7, and a VL CDR3 with the amino acid sequence of SEQ ID NO.8. In some embodiments the antibody further comprises a VL domain having the sequence according to SEQ ID NO. 2.
In some embodiments the antibody comprises a VH domain and a VL domain, the VH
and VL domains having the sequences of SEQ ID NO. 1 paired with SEQ ID NO. 2.
The VH and VL domain(s) may pair so as to form an antibody antigen binding site that binds 0D25.
In preferred embodiments the antibody is an intact antibody comprising a VH
domain and a VL domain, the VH and VL domains having sequences of SEQ ID NO. 1 and SEQ ID
NO. 2.
In some embodiments the antibody is a fully human monoclonal IgG1 antibody, preferably IgG1,k.
In some embodiments the antibody is the AB12 antibody described in WO
(Genmab A/S).
In an aspect the antibody is an antibody as described herein which has been modified (or further modified) as described below. In some embodiments the antibody is a humanised, deimmunised or resurfaced version of an antibody disclosed herein.
A preferred anti-0D25-ADC for use with the aspects of the present disclosure is ADCX25, as described herein below.
Another preferred anti-0D25-ADC for use with the aspects of the present disclosure is ADCT-301.
ADCx25 ADCx25 is an antibody drug conjugate composed of a human antibody against human 0D25 attached to a pyrrolobenzodiazepine (PBD) warhead via a cleavable linker.
The mechanism of action of ADCX25 depends on 0D25 binding. The 0D25 specific antibody targets the antibody drug conjugate (ADC) to cells expressing 0D25. Upon binding, the ADC internalizes and is transported to the lysosome, where the protease sensitive linker is cleaved and free PBD dimer is released inside the target cell. The released PBD dimer inhibits transcription in a sequence-selective manner, due either to direct inhibition of RNA polymerase or inhibition of the interaction of associated transcription factors. The PBD dimer produces covalent crosslinks that do not distort the DNA double helix and which are not recognized by nucleotide excision repair factors, allowing for a longer effective period (Hartley 2011).
It has the chemical structure:
0\
\ 0 H
Njr\
_ H
01,0 0H
0"
Ab represents Antibody AB12 (fully human monoclonal IgG1, K antibody with the VH and VL sequences SEQ ID NO. 1 and SEQ ID NO. 2, respectively, also known as HuMax-TAC). It is synthesised as described in WO 2014/057119 (Conj AB12-E) and typically has a DAR (Drug to Antibody Ratio) of 2.0+/-0.3.
0D25 binding The "first target protein" (FTP) as used herein is preferably 0D25.
As used herein, "binds 0D25" is used to mean the antibody binds 0D25 with a higher affinity than a non-specific partner such as Bovine Serum Albumin (BSA, Genbank accession no. 0AA76847, version no. 0AA76847.1 GI:3336842, record update date:
Jan 7, 2011 02:30 PM). In some embodiments the antibody binds 0D25 with an association constant (Ka) at least 2, 3, 4, 5, 10, 20, 50, 100, 200, 500, 1000, 2000, 5000, 104, 105 or 106-fold higher than the antibody's association constant for BSA, when measured at physiological conditions. The antibodies of the disclosure can bind 0D25 with a high affinity. For example, in some embodiments the antibody can bind 0D25 with a KD equal to or less than about 10-6 M, such as equal to or less than one of 1 x 10-6, 10-7, 10-8, 10-9,10-1 , 10-11, 10-12, 10-13 or 10-14.
In some embodiments, 0D25 polypeptide corresponds to Genbank accession no.
NP 000408, version no. NP 000408.1 GI:4557667, record update date: Sep 09, 04:59 PM. In one embodiment, the nucleic acid encoding 0D25 polypeptide corresponds to Genbank accession no. NM_000417, version no. NM_000417.2 GI:269973860, record update date: Sep 09, 2012 04:59 PM. In some embodiments, 0D25 polypeptide corresponds to Uniprot/Swiss-Prot accession No. P01589.
Anti-BCL-2 agents Suitable anti- BCL-2 agents include Venetoclax (ABT-199), navitoclax (ABT-263), ABT-737, 555746/BCL201, and oblimersen (G3139). Preferably the anti-BCL-2 agent is Venetoclax (ABT-199).
BCL-2 is localized to the outer membrane of mitochondria, where it plays an important role in promoting cellular survival and inhibiting the actions of pro-apoptotic proteins. The pro-apoptotic proteins in the BCL-2 family, including Bax and Bak, normally act on the mitochondrial membrane to promote permeabilization and release of cytochrome C
and ROS, that are important signals in the apoptosis cascade. These pro-apoptotic proteins are in turn activated by BH3-only proteins, and are inhibited by the function of BCL-2 and its relative BCL-Xl. The dynamic role of pro- and anti-apoptotic proteins, among other proteins, may alter the significance of increased BCL-2 expression in human disease.
However, the wide variety of cancer types associated with aberrant expression of BCL-2 (both haematological and non-haematological solid tumours) is consistent with its role as an apoptotic regulator (see Hanada M., et al., Blood. 1993;82:1820-1828;
Campos L., et al., Blood. 1993;81:3091-3096; Lamers F., et al., Eur J Cancer. 2012;48:3093-3103).
"Anti-BCL-2 agent" is used herein to mean any agent that specifically binds to and/or inhibits a biological activity of BCL-2.
As used herein, "specifically binds BCL-2" is used to mean the agent binds BCL-2 with a higher affinity than a non-specific partner such as Bovine Serum Albumin (BSA, Genbank accession no. CAA76847, version no. CAA76847.1 GI:3336842, record update date:
Jan 7, 2011 02:30 PM). In some embodiments the agent binds BCL-2 with an association constant (Ka) at least 2, 3, 4, 5, 10, 20, 50, 100, 200, 500, 1000, 2000, 5000, 104, 105 or 106-fold higher than the agent's association constant for BSA, when measured at physiological conditions. The agents may bind BCL-2 with a high affinity. For example, in some embodiments the agent can bind BCL-2 with a KD equal to or less than about 10-6 M, such as 1 x 10-6, 10-7, 10-8, 10-9,10-10, 10-11, 10-12, 10_13 or 10-14.
In some embodiments, BCL-2 polypeptide corresponds to Genbank accession no.
AAB72092, version no. AAB72092.1, record update date: Jul 24, 2016 02:22 PM.
In one embodiment, the nucleic acid encoding BCL-2 polypeptide corresponds to Genbank accession no AF021792, version no. AF021792.1, record update date: Jul 24, 02:22 PM. In some embodiments, BCL-2 polypeptide corresponds to Uniprot/Swiss-Prot accession No. Q92934.
To show that anti-CD25 ADCs works synergistically with the anti-BCL-2 agent, a panel of CD25 (+) cell lines will be co-treated with a range of concentration of both anti-CD25 ADC
and the anti-BCL-2 agent. As negative controls, the same panel of cell lines will be treated with a range of concentrations of the anti-BCL-2 agent or with a range of concentration of anti-CD25 ADC and vehicle. After incubation, two parameters will be measured: the amount of surface CD25 (as determined by flow cytometry) and the in vitro cytotoxicity of the combinations (as determined by MTS assays). To determine the cytotoxicity, Cell viability is measured by adding MTS per well and incubating for 4 hours at 37 C. Percentage cell viability is calculated compared to the untreated control.
Cytotoxic synergy is calculated by transforming the cell viability data into fraction affected, and calculating the combination index using the CalcuSyn analysis program.
Anti-CBCL-2 agents suitable for use in the present disclosure include:
a) Venetoclax (ABT-199) i. CAS Number 4 1257044-40-8 (see http://www.cas.org/content/chemical-substances/faqs) Drugbank reference 4 DB11581 (see https://www.drugbank.ca/) iii. Unique Ingredient Identifier (UNII) 4 N54AIC43PW
(see http://www.fda.gov/ForIndustry/DataStandards/SubstanceRegistrationSyst em-UniquelngredientldentifierUNII/default.htm) CI
1-..õ 1_0 1.1 N
- I
H .
0a,N
N) õNH 14111 ,µ
0 0 (7) Formula I: Venetoclax b) Navitoclax (ABT-263) i. CAS Number 4 923564-51-6 (see http://www.cas.org/content/chemical-substances/faqs) ii. Unique Ingredient Identifier (UNII) 4 XKJ5VVK2WD
(see http://www.fda.gov/ForIndustry/DataStandards/SubstanceRegistrationSyst em-UniquelngredientldentifierUNII/default.htm) \\
S=O
fµr \\0 rN NH
N,.õ,) CI
Formula II: Navitoclax i. CAS Number 4 852808-04-9 (see qn.11w.l.r.cas.orgico ntePtirh Pm ir,al-Substances/faqs) ii. Unique Ingredient Identifier (UNII) 4 Z5NFR173NV
(see http://www.fda.gov/ForIndustry/DataStandards/SubstanceRegistrationSyst em-UniquelngredientldentifierUNII/default.htm) H
rN Nr.
N) H
0' -Formula III: ABT-737 d) S55746/BCL201 i. CAS Number 4 1448584-12-0 (see http://www.cas.orq/content/chemical-substances/faqs) r 9 , f**1 r = -'40. -- -%
r = OH
Formula IV: SS55746 e) oblimersen (G3139) i. CAS Number 4 190977-41-4 (see httpl/www ¨1/content/chemical-substances/fags) Drugbank reference 4 DB06650 (see https://www.drugbank.ca/) iii. Unique Ingredient Identifier (UNII) 4 85J5ZP6YSL
(see http://www.fda.gov/ForIndustryLL)ataStandards/SubstanceReqistrationSyst em-Uniquelncre .1) iv. Oligo structure: D(P-thio)(T-C-T-C-C-C-A-G-C-G-T-G-C-G-C-C-A-T) Anti-mTOR agents Suitable mTOR inhibitors include everolimus (RAD001), sirolimus (Rapamycin), (temsirolimus), ridaforolimus (AP-23573), NVP-BEZ235 (dactolisib), BGT226, SF1126, Gedatolisib, Omipalisib, XL765, Ku-0063794, oleuropein aglycone, AZD8055, AZD2014, AZD 3147, sapanisertib (INK128/MLN0128), 0SI027, torin 1, torin 2, torkinib (PP242), VVYE687, ETP45658, PF05212384, PF04691502, XL388, eCF309, RapaLink-1, or Rapalink-2. Preferably the mTOR inhibitor is everolimus.
"mTOR inhibitor" is used herein to mean any agent that specifically binds to and/or inhibits a biological activity of mTOR.
As used herein, "specifically binds mTOR" is used to mean the agent binds mTOR
with a higher affinity than a non-specific partner such as Bovine Serum Albumin (BSA, Genbank accession no. 0AA76847, version no. 0AA76847.1 GI:3336842, record update date:
Jan 7, 2011 02:30 PM). In some embodiments the agent binds mTORwith an association constant (Ka) at least 2, 3, 4, 5, 10, 20, 50, 100, 200, 500, 1000, 2000, 5000, 104, 105 or 106-fold higher than the agent's association constant for BSA, when measured at physiological conditions. The agents may bind mTOR with a high affinity. For example, in some embodiments the agent can bind mTORwith a KD equal to or less than about M, such as 1 x 10-6, 10-7, 10-8, 10-9,10-10, 10-11, 10-12, 10_13 or 10-14.
In some embodiments, mTORpolypeptide corresponds to Genbank accession no.
AAA58486, version no. AAA58486.1, record update date: Jun 23, 2010 09:02 AM.
In one embodiment, the nucleic acid encoding mTORpolypeptide corresponds to Genbank accession no L34075, version no. L34075.1, record update date: Jun 23, 2010 09:02 AM. In some embodiments, mTORpolypeptide corresponds to Uniprot/Swiss-Prot accession No. P42345-1.
To show that anti-0D25 ADCs works synergistically with the mTOR inhibitor, a panel of 0D25 (+) cell lines will be co-treated with a range of concentration of both anti-0D25 ADC
and the mTOR inhibitor. As negative controls, the same panel of cell lines will be treated with a range of concentrations of the mTOR inhibitor or with a range of concentration of anti-0D25 ADC and vehicle. After incubation, two parameters will be measured:
the amount of surface 0D25 (as determined by flow cytometry) and the in vitro cytotoxicity of the combinations (as determined by MTS assays). To determine the cytotoxicity, Cell viability is measured by adding MTS per well and incubating for 4 hours at 37 C.
Percentage cell viability is calculated compared to the untreated control.
Cytotoxic synergy is calculated by transforming the cell viability data into fraction affected, and calculating the combination index using the CalcuSyn analysis program.
mTor inhibitors suitable for use in the present disclosure include:
a) Everolimus i. CAS Number 4 159351-69-6 (see http://www.cas.org/content/chemical-substances/faqs) Drugbank reference 4 DB01590 (see https://www.drugbank.ca/) iii. .. Unique Ingredient Identifier (UNII) 4 9HW64Q8G6G
(see http://www.fda.gov/ForIndustry/DataStandards/SubstanceRegistrationSyst em-UniquelngredientldentifierUNII/default.htm) N,C)Nri3O-1 0 OH
0 'N'O's.
HO
, Formula V: Everolimus, Dihydroxy-12-[(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-y1]-19,30-dimethoxy-15,17,21,23,29,35-hexamethy1-11,36-dioxa-4-azatricyclo[30.3.1.0 hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone b) Sirolimus (Rapamycin) i. CAS Number 4 53123-88-9 (see http://www.cas.org/content/chemical-substances/faqs) Drugbank reference 4 DB00877 (see https://www.drugbank.ca/) iii. Unique Ingredient Identifier (UNII) 4 W36ZG6FT64 (see http://www.fda.gov/ForIndustry/DataStandards/SubstanceRegistrationSyst em-UniquelngredientldentifierUNII/default.htm) HOõ, 0 µ1.1 I
0 Crµ
HO
Formula VI: Sirolimus, (1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-{(2R)-1-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-2-propany1}-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.0-4,9-]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone C) Temsirolimus (00I-779) i. CAS Number 4 162635-04-3 (see http://www.cas.org/content/chemical-substances/faqs) Drugbank reference 4 DB06287 (see https://www.drugbank.ca/) iv. Unique Ingredient Identifier (UNII) 4 624KN6GM2T
(see http://www.fda.gov/ForIndustry/DataStandards/SubstanceRegistrationSyst em-UniquelngredientldentifierUNII/default.htm) HONOH
0õ,A6 0 lip 0 o 0 , 0 Formula VII, Temsirolimus: (1R,2R,4S)-4-{(2R)-2-[(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-10,21-dimethoxy-6,8,12,14,20,26-hexamethy1-1,5,11,28,29-pentaoxo-1,4,5,6,9,10,11,12,13,14,21,22,23,24,25,26,27,28,29,31,32,33,34,34a-tetracosahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontin-3-yl]propy1}-2-methoxycyclohexyl 3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate d) Ridaforolimus (AP-23573), i. CAS Number 4 572924-54-0 (see http://www.cas.org/content/chemical-substances/faqs) ii. Unique Ingredient Identifier (UNII) 4 48Z35KB15K
(see http://www.fda.gov/ForIndustry/DataStandards/SubstanceRegistrationSyst em-UniquelngredientldentifierUNII/default.htm) 0õ10 CNI11(0:- HO OH
0 0 \µ
0 0-".
, Formula VIII, Ridaforolimus: (1R,2R,4S)-4-[(2R)-2-[(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28Z,30S,32S,35R)-1,18-dihydroxy-19,30-dimethoxy-15,17,21,23,29,35-hexamethy1-2,3,10,14,20-pentaoxo-11,36-dioxa-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraen-12-yl]propyl]-2-methoxycyclohexyl dimethylphosphinate e) Dactolisib (NVP-BEZ235) i. CAS Number 4 915019-65-7 (see http://www.cas.org/content/chemical-substances/faqs) ii. Unique Ingredient Identifier (UNII) 4 RUJ6Z9YODT
(see http://www.fda.gov/ForIndustry/DataStandards/SubstanceRegistrationSyst em-UniquelngredientldentifierUNII/default.htm) N
110 -,-Formula IX, Dactolisib: 2-Methy1-2-{443-methy1-2-oxo-8-(quinolin-3-y1)-2,3-dihydro-1H-imidazo[4,5-c]quinolin-1-yliphenyl}propanenitrile f) BGT226 i. CAS Number 4 1245537-68-1 (see http://www.cas.org/content/chemical-substances/faqs) o (c OH
OH
N
Formula X, BGT226: 1,3-dihydro-8-(6-methoxy-3-pyridiny1)-3-methy1-144-(1-piperaziny1)-3-(trifluoromethyl)phenyl]-2H-imidazo[4,5-c]quinolin-2-one, (2Z)-2-butenedioate g) SF1126 i. CAS Number 4 936487-67-1 (see http://www.cas.org/content/chemical-substances/faqs) -1 1! i\JH
=
I
1, -_ I
I -I
.11 Formula XI, SF1126: (8S,14S,17S)-14-(carboxymethyl)-8-(3-guanidinopropy1)-17-(hydroxymethyl)-3,6,9,12,15-pentaoxo-1-(4-(4-oxo-8-phenyl-4H-chromen-2-Amorpholino-4-ium)-2-oxa-7,10,13,16-tetraazaoctadecan-18-oate h) Gedatolisib i. CAS Number 4 1197160-78-3 (see http://www.cas.org/content/chemical-substances/faqs) ii. Unique Ingredient Identifier (UNII) 4 96265TNH2R
(see http://www.fda.gov/ForIndustry/DataStandards/SubstanceRegistrationSyst em-UniquelngredientldentifierUNII/default.htm) 0-Th N J H raN,õ
N
Formula XII, Gedatolisib: 14444-(dimethylamino)piperidine-1-carbonyliphenyl]-344-(4,6-dimorpholin-4-y1-1,3,5-triazin-2-Aphenyliurea i) Omipalisib i. CAS Number 4 1086062-66-9 (see http://www.cas.org/content/chemical-substances/faqs) ii. Unique Ingredient Identifier (UNII) 4 1X8F5A3NAO
(see http://www.fda.gov/ForIndustry/DataStandards/SubstanceRegistrationSyst em-UniquelngredientldentifierUNII/default.htm) 0=S =0 OXN
HN
Formula XIII: 2,4-difluoro-N-R-methoxy-5-(4-pyridazin-4-ylquinolin-6-Apyridin-ylpenzenesulfonamide j) XL765 i. CAS Number 4 934493-76-2 (see http://www.cas.org/content/chemical-substances/faqs) N
N
Formula X: XL765 k) Ku-0063794 i. CAS Number 4 938440-64-3 (see http://www.cas.org/content/chemical-substances/faqs) N
N' N N N OH
Formula XIV: re1-542-[(2R,6S)-2,6-dimethyl-4-morpholinyl]-4-(4-morpholinyl)pyrido[2,3-d]pyrimidin-7-y1]-2-methoxybenzenemethanol I) oleuropein aglycone i. CAS Number 4 31773-95-2 (see http://www.cas.org/content/chemical-substances/faqs) Drugbank reference 4 (see https://www.drugbank.ca/) iii. Unique Ingredient Identifier (UNII) 4 (see http://www.fda.gov/ForIndustry/DataStandards/SubstanceRegistrationSyst em-UniquelngredientldentifierUNII/default.htm) OH
Me 0 HO
CO2Me Formula XV: methyl (4S,5E,6R)-4-12-[2-(3,4-dihydroxyphenyl)ethoxy]-2-oxoethy1]-
Also provided by this aspect is a first composition comprising an anti-BCL-2 agent, an mTOR inhibitor, or a secondary agent for use in a method of treating a disorder in an individual, wherein the treatment comprises administration of the first composition in combination with a second composition comprising an anti-0D25 ADC.
The disorder may be a proliferative disease, for example a cancer such as non-Hodgkin's Lymphoma, including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, (FL), Mantle Cell lymphoma (MCL), chronic lymphatic lymphoma (CLL), and Marginal Zone B-cell lymphoma (MZBL), and leukemias such as Hairy cell leukemia (HCL), Hairy cell leukemia variant (HCL-v), anaplastic large cell lymphoma (ALCL), and Acute Lymphoblastic Leukaemia (ALL) such as Philadelphia chromosome-positive ALL
(Ph+ALL) or Philadelphia chromosome-negative ALL (Ph-ALL).
The anti-0D25-ADC may be ADCX25 described herein.
The anti-0D25-ADC may be ADCT-301.
The anti-BCL-2 agent may be Venetoclax (ABT-199), navitoclax (ABT-263), ABT-737, S55746/BCL201, and oblimersen (G3139). Preferably the anti-BCL-2 agent is Venetoclax (A BT-199).
The mTOR inhibitor may be everolimus (RAD001), sirolimus (Rapamycin), 00I-779 (temsirolimus), ridaforolimus (AP-23573), NVP-BEZ235 (dactolisib), BGT226, SF1126, Gedatolisib, Omipalisib, XL765, Ku-0063794, oleuropein aglycone, AZD8055, AZD2014, AZD 3147, sapanisertib (INK128/MLN0128), 0SI027, torin 1, torin 2, torkinib (PP242), VVYE687, ETP45658, PF05212384, PF04691502, XL388, eCF309, RapaLink-1, or Rapalink-2.
The secondary agent may be:
(a) Bendamustine;
(b) a phosphoinositide 3-kinase inhibitor such as copanlisib, idelalisib, duvelisib, Taselisib, Buparlisib, Alpelisib, Umbralisib, Dactolisib, and Voxtalisib;
(c) a proteasome inhibitor such as bortezomib, carfilzomib, lxazomib, Oprozomib, and Salinosporamide A;
(d) an anti-folate such as pralatrexate, methotrexate, pemetrexed, and raltitrexed;
or (e) a HDAC inhibitor such as romidepsin, vorinostat, Abexinostat, belinostat (PXD101), LAQ824, panobinostat (LBH589), entinostat (MS-275), tacedinaline (01994), and mocetinostat (MGCD0103).
The individual may be human. The individual may have cancer, or may have been determined to have cancer. The individual may have, or have been determined to have, a 0D25+ cancer or 0D25+ tumour-associated non-tumour cells, such as 0D25+
infiltrating T-cells.
The first composition may be administered before the second composition, simultaneous with the second composition, or after the second composition. The treatment may comprise administering a further chemotherapeutic agent to the individual.
In a further aspect, the disclosure provides the use of an anti-0D25 ADC in the manufacture of a medicament for treating a disorder in an individual, wherein the medicament comprises an anti-0D25 ADC, and wherein the treatment comprises administration of the medicament in combination with a composition comprising anti-BCL-2 agent, an mTOR inhibitor, or a secondary agent.
Also provided by this aspect is the use of anti-BCL-2 agent in the manufacture of a medicament for treating a disorder in an individual, wherein the medicament comprises an anti-BCL-2 agent, an mTOR inhibitor, or a secondary agent, and wherein the treatment comprises administration of the medicament in combination with a composition comprising an anti-0D25 ADC.
The disorder may be a proliferative disease, for example a cancer such as Hodgkin's and non-Hodgkin's Lymphoma, including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, (FL), Mantle Cell lymphoma (MCL), chronic lymphatic lymphoma (CLL), Marginal Zone B-cell lymphoma (MZBL) and leukemias such as Hairy cell leukemia (HCL), Hairy cell leukemia variant (HCL-v), Acute Myeloid Leukaemia (AML), anaplastic large cell lymphoma (ALCL), and Acute Lymphoblastic Leukaemia (ALL) such as Philadelphia chromosome-positive ALL (Ph+ALL) or Philadelphia chromosome-negative ALL (Ph-ALL).
The proliferative disease may be characterised by the presence of a neoplasm comprising both 0D25+ve and 0D25-ve cells.
The proliferative disease may be characterised by the presence of a neoplasm composed of 0D25-ve neoplastic cells, optionally wherein the 0D25-ve neoplastic cells are associated with 0D25+ve non-neoplastic cells such as 0D25+ve T-cells.
The target neoplasm or neoplastic cells may be all or part of a solid tumour.
"Solid tumor" herein will be understood to include solid haematological cancers such as lymphomas (Hodgkin's lymphoma or non-Hodgkin's lymphoma) which are discussed in more detail herein. The solid tumour may be an advanced solid tumour.
Solid tumors may be neoplasms, including non-haematological cancers, comprising or composed of 0D25+ve neoplastic cells. Solid tumors may be neoplasms, including non-haematological cancers, infiltrated with 0D25+ve cells, such as 0D25+ve T-cells; such solid tumours may lack expression of 0D25 (that is, comprise or be composed of ve neoplastic cells).
For example, the solid tumour may be a tumour with high levels of infiltrating T-cells, such as infiltrating regulatory T-cells (Treg; Menetrier-Caux, C., et al., Targ Oncol (2012) 7:15-28; Arce Vargas et al., 2017, Immunity 46, 1-10; Tanaka, A., et al., Cell Res.
Jan;27(1):109-118). Accordingly, the solid tumour may be pancreatic cancer, breast cancer, colorectal cancer, gastric and oesophageal cancer, leukemia and lymphoma, melanoma, non-small cell lung cancer, ovarian cancer, hepatocellular carcinoma, renal cell carcinoma, and head and neck cancer.
The anti-CD25 ADC may be ADCX25 as described herein.
The anti-CD25-ADC may be ADCT-301.
The anti-BCL-2 agent may be Venetoclax (ABT-199), navitoclax (ABT-263), ABT-737, 555746/BCL201, and oblimersen (G3139). Preferably the anti-BCL-2 agent is Venetoclax (A BT-199).
The mTOR inhibitor may be everolimus (RAD001), sirolimus (Rapamycin), CCI-779 (temsirolimus), ridaforolimus (AP-23573), NVP-BEZ235 (dactolisib), BGT226, SF1126, Gedatolisib, Omipalisib, XL765, Ku-0063794, oleuropein aglycone, AZD8055, AZD2014, AZD 3147, sapanisertib (INK128/MLN0128), 0SI027, torin 1, torin 2, torkinib (PP242), VVYE687, ETP45658, PF05212384, PF04691502, XL388, eCF309, RapaLink-1, or Rapalink-2.
The secondary agent may be:
(a) Bendamustine;
(b) a phosphoinositide 3-kinase inhibitor such as copanlisib, idelalisib, duvelisib, Taselisib, Buparlisib, Alpelisib, Umbralisib, Dactolisib, and Voxtalisib;
(c) a proteasome inhibitor such as bortezomib, carfilzomib, lxazomib, Oprozomib, and Salinosporamide A;
(d) an anti-folate such as pralatrexate, methotrexate, pemetrexed, and raltitrexed;
or (e) a HDAC inhibitor such as romidepsin, vorinostat, Abexinostat, belinostat (PXD101), LAQ824, panobinostat (LBH589), entinostat (MS-275), tacedinaline (CI994), and mocetinostat (MGCD0103).
The individual may be human. The individual may have cancer, or may have been determined to have cancer. The individual may have, or have been determined to have, a CD25+ cancer or CD25+ tumour-associated non-tumour cells, such as CD25+
infiltrating T-cells.
The medicament may be administered before the composition, simultaneous with the composition, or after the composition. The treatment may comprise administering a further chemotherapeutic agent to the individual.
Another aspect of the disclosure provides a kit comprising:
a first medicament comprising an anti-0D25 ADC;
a package insert comprising instructions for administration of the first medicament according to a method of treatment as disclosed herein. The kit may further comprise a second medicament comprising an anti-BCL-2 agent, an mTOR inhibitor, or a secondary agent.
Another aspect of the disclosure provides a kit comprising:
a first medicament comprising an anti-0D25 ADC, an mTOR inhibitor, or a secondary agent;
a second medicament comprising an anti-BCL-2 agent, an mTOR inhibitor, or a secondary agent; and, optionally, a package insert comprising instructions for administration of the first medicament to an individual in combination with the second medicament for the treatment of a disorder.
Also provided by this aspect is a kit comprising a medicament comprising an anti-0D25 ADC and a package insert comprising instructions for administration of the medicament to an individual in combination with a composition comprising an anti-BCL-2 agent, an mTOR inhibitor, or a secondary agent for the treatment of a disorder.
Further provided by this aspect is a kit comprising a medicament comprising an anti-BCL-2 agent, an mTOR inhibitor, or a secondary agent and a package insert comprising instructions for administration of the medicament to an individual in combination with a composition comprising an anti-0D25 ADC for the treatment of a disorder.
The disorder may be a proliferative disease, for example a cancer such as Hodgkin's and non-Hodgkin's Lymphoma, including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, (FL), Mantle Cell lymphoma (MCL), chronic lymphatic lymphoma (CLL), Marginal Zone B-cell lymphoma (MZBL) and leukemias such as Hairy cell leukemia (HCL), Hairy cell leukemia variant (HCL-v), Acute Myeloid Leukaemia (AML), anaplastic large cell lymphoma (ALCL), and Acute Lymphoblastic Leukaemia (ALL) such as Philadelphia chromosome-positive ALL (Ph+ALL) or Philadelphia chromosome-negative ALL (Ph-ALL).
The proliferative disease may be characterised by the presence of a neoplasm comprising both 0D25+ve and 0D25-ve cells.
The proliferative disease may be characterised by the presence of a neoplasm composed of 0D25-ve neoplastic cells, optionally wherein the 0D25-ve neoplastic cells are associated with 0D25+ve non-neoplastic cells such as 0D25+ve T-cells.
The target neoplasm or neoplastic cells may be all or part of a solid tumour.
"Solid tumor" herein will be understood to include solid haematological cancers such as lymphomas (Hodgkin's lymphoma or non-Hodgkin's lymphoma) which are discussed in more detail herein. The solid tumour may be an advanced solid tumour Solid tumors may be neoplasms, including non-haematological cancers, comprising or composed of 0D25+ve neoplastic cells. Solid tumors may be neoplasms, including non-haematological cancers, infiltrated with 0D25+ve cells, such as 0D25+ve T-cells; such solid tumours may lack expression of 0D25 (that is, comprise or be composed of ve neoplastic cells).
For example, the solid tumour may be a tumour with high levels of infiltrating T-cells, such as infiltrating regulatory T-cells (Treg; Menetrier-Caux, C., et al., Targ Oncol (2012) 7:15-28; Arce Vargas et al., 2017, Immunity 46, 1-10; Tanaka, A., et al., Cell Res.
Jan;27(1):109-118). Accordingly, the solid tumour may be pancreatic cancer, breast cancer, colorectal cancer, gastric and oesophageal cancer, leukemia and lymphoma, melanoma, non-small cell lung cancer, ovarian cancer, hepatocellular carcinoma, renal cell carcinoma, and head and neck cancer.
The anti-CD25 ADC may be ADCX25 as described herein.
The anti-CD25-ADC may be ADCT-301.
The anti-BCL-2 agent may be Venetoclax (ABT-199), navitoclax (ABT-263), ABT-737, 555746/BCL201, and oblimersen (G3139). Preferably the anti-BCL-2 agent is Venetoclax (A BT-199).
The mTOR inhibitor may be everolimus (RAD001), sirolimus (Rapamycin), CCI-779 (temsirolimus), ridaforolimus (AP-23573), NVP-BEZ235 (dactolisib), BGT226, SF1126, Gedatolisib, Omipalisib, XL765, Ku-0063794, oleuropein aglycone, AZD8055, AZD2014, AZD 3147, sapanisertib (INK128/MLN0128), 0SI027, torin 1, torin 2, torkinib (PP242), VVYE687, ETP45658, PF05212384, PF04691502, XL388, eCF309, RapaLink-1, or Rapalink-2.
The secondary agent may be:
(a) Bendamustine;
(b) a phosphoinositide 3-kinase inhibitor such as copanlisib, idelalisib, duvelisib, Taselisib, Buparlisib, Alpelisib, Umbralisib, Dactolisib, and Voxtalisib;
(c) a proteasome inhibitor such as bortezomib, carfilzomib, lxazomib, Oprozomib, and Salinosporamide A;
(d) an anti-folate such as pralatrexate, methotrexate, pemetrexed, and raltitrexed;
or (e) a HDAC inhibitor such as romidepsin, vorinostat, Abexinostat, belinostat (PXD101), LAQ824, panobinostat (LBH589), entinostat (MS-275), tacedinaline (01994), and mocetinostat (MGCD0103).
The individual may be human. The individual may have cancer, or may have been determined to have cancer. The individual may have, or have been determined to have, a 0D25+ cancer or 0D25+ tumour-associated non-tumour cells, such as 0D25+
infiltrating T-cells.
The medicament or composition comprising the anti-0D25 ADC may be administered before the medicament or composition comprising the anti-BCL-2 agent, mTOR
inhibitor, or secondary agent, simultaneous with the medicament or composition comprising the anti-BCL-2 agent, mTOR inhibitor, or secondary agent, or after the medicament or composition comprising the anti-BCL-2 agent, mTOR inhibitor, or secondary agent. The treatment may comprise administering a further chemotherapeutic agent to the individual.
In a yet further aspect, the disclosure provides a composition comprising an anti-0D25 ADC and an anti-BCL-2 agent, mTOR inhibitor, or secondary agent.
Also provided in this aspect of the disclosure is a method of treating a disorder in an individual, the method comprising administering to the individual an effective amount of the composition comprising an anti-0D25 ADC and an anti-BCL-2 agent, an mTOR
inhibitor, or a secondary agent.
Also provided in this aspect of the disclosure is a composition comprising an anti-0D25 ADC and an anti-BCL-2 agent, an mTOR inhibitor, or a secondary agent for use in a method of treating a disorder in an individual.
Also provided in this aspect of the disclosure is the use of a composition comprising an anti-0D25 ADC and an anti-BCL-2 agent, an mTOR inhibitor, or a secondary agent in the manufacture of a medicament for treating a disorder in an individual.
Also provided in this aspect of the disclosure is a kit comprising composition comprising an anti-0D25 ADC and an anti-BCL-2 agent, an mTOR inhibitor, or a secondary agent and a set of instructions for administration of the medicament to an individual for the treatment of a disorder.
The disorder may be a proliferative disease, for example a cancer such as Hodgkin's and non-Hodgkin's Lymphoma, including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, (FL), Mantle Cell lymphoma (MCL), chronic lymphatic lymphoma (CLL), Marginal Zone B-cell lymphoma (MZBL) and leukemias such as Hairy cell leukemia (HCL), Hairy cell leukemia variant (HCL-v), Acute Myeloid Leukaemia (AML), anaplastic large cell lymphoma (ALCL), and Acute Lymphoblastic Leukaemia (ALL) such as Philadelphia chromosome-positive ALL (Ph+ALL) or Philadelphia chromosome-negative ALL (Ph-ALL).
The proliferative disease may be characterised by the presence of a neoplasm comprising both 0D25+ve and 0D25-ve cells.
The proliferative disease may be characterised by the presence of a neoplasm composed of 0D25-ve neoplastic cells, optionally wherein the 0D25-ve neoplastic cells are associated with 0D25+ve non-neoplastic cells such as 0D25+ve T-cells.
The target neoplasm or neoplastic cells may be all or part of a solid tumour.
"Solid tumor" herein will be understood to include solid haematological cancers such as lymphomas (Hodgkin's lymphoma or non-Hodgkin's lymphoma) which are discussed in more detail herein.
Solid tumors may be neoplasms, including non-haematological cancers, comprising or composed of 0D25+ve neoplastic cells. Solid tumors may be neoplasms, including non-haematological cancers, infiltrated with 0D25+ve cells, such as 0D25+ve T-cells; such solid tumours may lack expression of 0D25 (that is, comprise or be composed of ve neoplastic cells).
For example, the solid tumour may be a tumour with high levels of infiltrating T-cells, such as infiltrating regulatory T-cells (Treg; Menetrier-Caux, C., et al., Targ Oncol (2012) 7:15-28; Arce Vargas et al., 2017, Immunity 46, 1-10; Tanaka, A., et al., Cell Res.
Jan;27(1):109-118). Accordingly, the solid tumour may be pancreatic cancer, breast cancer, colorectal cancer, gastric and oesophageal cancer, leukemia and lymphoma, melanoma, non-small cell lung cancer, ovarian cancer, hepatocellular carcinoma, renal cell carcinoma, and head and neck cancer.
The anti-CD25 ADC may be ADCX25 as described herein.
The anti-CD25-ADC may be ADCT-301.
The anti-BCL-2 agent may be Venetoclax (ABT-199), navitoclax (ABT-263), ABT-737, 555746/BCL201, and oblimersen (G3139). Preferably the anti-BCL-2 agent is Venetoclax (A BT-199).
The mTOR inhibitor may be everolimus (RAD001), sirolimus (Rapamycin), CCI-779 (temsirolimus), ridaforolimus (AP-23573), NVP-BEZ235 (dactolisib), BGT226, SF1126, Gedatolisib, Omipalisib, XL765, Ku-0063794, oleuropein aglycone, AZD8055, AZD2014, AZD 3147, sapanisertib (INK128/MLN0128), 0SI027, torin 1, torin 2, torkinib (PP242), VVYE687, ETP45658, PF05212384, PF04691502, XL388, eCF309, RapaLink-1, or Rapalink-2.
The secondary agent may be:
(a) Bendamustine;
(b) a phosphoinositide 3-kinase inhibitor such as copanlisib, idelalisib, duvelisib, Taselisib, Buparlisib, Alpelisib, Umbralisib, Dactolisib, and Voxtalisib;
(c) a proteasome inhibitor such as bortezomib, carfilzomib, lxazomib, Oprozomib, and Salinosporamide A;
(d) an anti-folate such as pralatrexate, methotrexate, pemetrexed, and raltitrexed;
or (e) a HDAC inhibitor such as romidepsin, vorinostat, Abexinostat, belinostat (PXD101), LAQ824, panobinostat (LBH589), entinostat (MS-275), tacedinaline (01994), and mocetinostat (MGCD0103).
The individual may be human. The individual may have cancer, or may have been determined to have cancer. The individual may have, or have been determined to have, a 0D25+ cancer or 0D25+ tumour-associated non-tumour cells, such as 0D25+
infiltrating T-cells.
The treatment may comprise administering a further chemotherapeutic agent to the individual.
DETAILED DESCRIPTION
Antibody Drug Conjugates (ADCs) The present disclosure relates to the improved efficacy of combinations of an ADC and an anti-BCL-2 agent, an mTOR inhibitor, or a secondary agent.
The ADC can deliver a drug to a target location. The target location is preferably a proliferative cell population. The antibody is an antibody for an antigen present on a proliferative cell population. In one aspect the antigen is absent or present at a reduced level in a non-proliferative cell population compared to the amount of antigen present in the proliferative cell population, for example a tumour cell population.
The ADC may comprise a linker which may be cleaved so as to release the drug at the target location. The drug may be a compound selected from RelA, RelB, ReIC, RelD or RelE. Thus, the conjugate may be used to selectively provide a compound RelA, RelB, Rel C, RelD or RelE to the target location.
The linker may be cleaved by an enzyme present at the target location.
The disclosure particularly relates treatment with an anti-0D25 ADC disclosed in W02014/057119, and as herein described.
anti-0O25 ADCs As used herein, the term "0D25-ADC" refers to an ADC in which the antibody component is an anti-0D25 antibody. The term "PBD-ADC" refers to an ADC in which the drug component is a pyrrolobenzodiazepine (PBD) warhead. The term "anti-0D25-ADC"
refers to an ADC in which the antibody component is an anti-0D25 antibody, and the drug component is a PBD warhead.
The ADC may comprise a conjugate of formula L - (DL)p, where DL is of formula I or II:
9 RI-1' R20 R9, R11 a C2' N R7' R7 N C2 C3' 0 R6' ,30 9. 10 R31 rcI R R9 RI R11 Y' ,Y
'R"
C2' R7' R7 2 s-- R22 wherein:
L is an antibody (Ab) which is an antibody that binds to 0D25;
when there is a double bond present between 02' and 03', R12 is selected from the group consisting of:
(ia) 05_10 aryl group, optionally substituted by one or more substituents selected from the group comprising: halo, nitro, cyano, ether, carboxy, ester, 01-7 alkyl, 03-7 heterocyclyl and bis-oxy-01_3 alkylene;
(ib) Ci-s saturated aliphatic alkyl;
(ic) 03-6 saturated cycloalkyl;
*R23 (id) R21 , wherein each of R21, R22 and R23 are independently selected from H, Oi 3 saturated alkyl, 02-3 alkenyl, 02-3 alkynyl and cyclopropyl, where the total number of carbon atoms in the R12 group is no more than 5;
R25b *
(ie) R, wherein one of R25 and R25b is H and the other is selected from:
phenyl, which phenyl is optionally substituted by a group selected from halo, methyl, methoxy; pyridyl; and thiophenyl; and m24 (if) , where R24 is selected from: H; 01-3 saturated alkyl; 02-3 alkenyl; 02-3 alkynyl; cyclopropyl; phenyl, which phenyl is optionally substituted by a group selected from halo, methyl, methoxy; pyridyl; and thiophenyl;
when there is a single bond present between 02' and 03', R12 is R26b , where R26a and R26b are independently selected from H, F, saturated alkyl, 02-3 alkenyl, which alkyl and alkenyl groups are optionally substituted by a group selected from 01-4 alkyl amido and 01-4 alkyl ester; or, when one of R26a and R26b is H, the other is selected from nitrile and a 01-4 alkyl ester;
R6 and R9 are independently selected from H, R, OH, OR, SH, SR, NH2, NHR, NRR', nitro, Me3Sn and halo;
where R and R' are independently selected from optionally substituted 01-12 alkyl, 03-20 heterocyclyl and 05-20 aryl groups;
R7 is selected from H, R, OH, OR, SH, SR, NH2, NHR, NHRR', nitro, Me3Sn and halo;
R" is a 03-12 alkylene group, which chain may be interrupted by one or more heteroatoms, e.g. 0, S, NRN2 (where RN2 is H or 01-4 alkyl), and/or aromatic rings, e.g.
benzene or pyridine;
Y and Y' are selected from 0, S, or NH;
R6', R7', R9' are selected from the same groups as R6, R7 and R9 respectively;
[Formula lj RI-1' is a linker for connection to the antibody (Ab);
R11a is selected from OH, ORA, where RA is 01-4 alkyl, and SON, where z is 2 or 3 and M
is a monovalent pharmaceutically acceptable cation;
R2 and R21 either together form a double bond between the nitrogen and carbon atoms to which they are bound or;
R2 is selected from H and Rc, where Rc is a capping group;
R21 is selected from OH, ORA and SO,M;
when there is a double bond present between 02 and 03, R2 is selected from the group consisting of:
(ia) C5-10 aryl group, optionally substituted by one or more substituents selected from the group comprising: halo, nitro, cyano, ether, carboxy, ester, 01-7 alkyl, 03-7 heterocyclyl and bis-oxy-01_3 alkylene;
(ib) Cis saturated aliphatic alkyl;
(ic) 03-6 saturated cycloalkyl;
(id) R , wherein each of R11, R12 and R13 are independently selected from H, 01-3 saturated alkyl, 02-3 alkenyl, 02-3 alkynyl and cyclopropyl, where the total number of carbon atoms in the R2 group is no more than 5;
R15b R 5a (ie) , wherein one of R15a and R15b is H and the other is selected from:
phenyl, which phenyl is optionally substituted by a group selected from halo, methyl, methoxy; pyridyl; and thiophenyl; and (if) R , where R14 is selected from: H; 01-3 saturated alkyl; 02-3 alkenyl; 02-3 alkynyl; cyclopropyl; phenyl, which phenyl is optionally substituted by a group selected from halo, methyl, methoxy; pyridyl; and thiophenyl;
when there is a single bond present between 02 and 03, R16a R2 is R16b , where R16 and R16b are independently selected from H, F, 01-4 saturated alkyl, 02-3 alkenyl, which alkyl and alkenyl groups are optionally substituted by a group selected from 01-4 alkyl amido and 01-4 alkyl ester; or, when one of R16 and R16b is H, the other is selected from nitrile and a 01-4 alkyl ester;
[Formula llJ
R22 is of formula Illa, formula Illb or formula Illc:
(a) "(Q1Q2-X Illa where A is a 05-7 aryl group, and either (i) Q1 is a single bond, and Q2 is selected from a single bond and -Z-(CH2)n-, where Z is selected from a single bond, 0, S and NH and n is from 1 to 3; or (ii) Q1 is -CH=CH-, and Q2 is a single bond;
Illb (b) RC1 RC3 where;
Rc2 and rc r-sC3 are independently selected from H and unsubstituted 01-2 alkyl;
IIIc (c) where Q is selected from 0-R1-2', S-R1-2' and NRN-R1-2', and RN is selected from H, methyl and ethyl X is selected from the group comprising: 0-R1-2', S-R1-2', 002-R1-2', CO-R1-2', NH-C(=0)-R1-2', \I¨ HN/ \N¨R1-2' \ __________________________________________ /
NHNH-R1-2', CONHNH-R1-2', , NRNR1-2', wherein RN is selected from the group comprising H and 01-4 alkyl;
RI-2' is a linker for connection to the antibody (Ab);
R1 and R11 either together form a double bond between the nitrogen and carbon atoms to which they are bound or;
R1 is H and R11 is selected from OH, ORA and SO,M;
R3 and R31 either together form a double bond between the nitrogen and carbon atoms to which they are bound or;
R3 is H and R31 is selected from OH, ORA and SON.
In some embodiments L-RI-1' or L-RI-2' is a group:
Ab , ====., 2.0y A L
where the asterisk indicates the point of attachment to the PBD, Ab is the antibody, L1 is a cleavable linker, A is a connecting group connecting L1 to the antibody, L2 is a covalent bond or together with -0C(=0)- forms a self-immolative linker.
In some of these embodiments, L1 is enzyme cleavable.
It has previously been shown that such ADCs are useful in the treatment of expressing cancers (see, for example, W02014/057119, which is incorporated by reference herein in its entirety).
The term anti-0D25-ADC may include any embodiment described in WO 2014/057119.
In particular, in preferred embodiments the ADC may have the chemical structure:
0\
ONO
z NH
H
01,0 0 H
0" 0 0 0 , where the Ab is a 0D25 antibody, and the DAR is between 1 and 8.
The antibody may comprise a VH domain comprising a VH CDR1 with the amino acid sequence of SEQ ID NO.3, a VH CDR2 with the amino acid sequence of SEQ ID
NO.4, and a VH CDR3 with the amino acid sequence of SEQ ID NO.5.
In some aspects the antibody component of the anti-0D25-ADC is an antibody comprising: a VH domain comprising a VH CDR1 with the amino acid sequence of SEQ
ID NO.3, a VH CDR2 with the amino acid sequence of SEQ ID NO.4, and a VH CDR3 with the amino acid sequence of SEQ ID NO.5. In some embodiments the antibody comprises a VH domain having the sequence according to SEQ ID NO. 1.
The antibody may further comprise: a VL domain comprising a VL CDR1 with the amino acid sequence of SEQ ID NO.6, a VL CDR2 with the amino acid sequence of SEQ ID
NO.7, and a VL CDR3 with the amino acid sequence of SEQ ID NO.8. In some embodiments the antibody further comprises a VL domain having the sequence according to SEQ ID NO. 2.
In some embodiments the antibody comprises a VH domain and a VL domain, the VH
and VL domains having the sequences of SEQ ID NO. 1 paired with SEQ ID NO. 2.
The VH and VL domain(s) may pair so as to form an antibody antigen binding site that binds 0D25.
In preferred embodiments the antibody is an intact antibody comprising a VH
domain and a VL domain, the VH and VL domains having sequences of SEQ ID NO. 1 and SEQ ID
NO. 2.
In some embodiments the antibody is a fully human monoclonal IgG1 antibody, preferably IgG1,k.
In some embodiments the antibody is the AB12 antibody described in WO
(Genmab A/S).
In an aspect the antibody is an antibody as described herein which has been modified (or further modified) as described below. In some embodiments the antibody is a humanised, deimmunised or resurfaced version of an antibody disclosed herein.
A preferred anti-0D25-ADC for use with the aspects of the present disclosure is ADCX25, as described herein below.
Another preferred anti-0D25-ADC for use with the aspects of the present disclosure is ADCT-301.
ADCx25 ADCx25 is an antibody drug conjugate composed of a human antibody against human 0D25 attached to a pyrrolobenzodiazepine (PBD) warhead via a cleavable linker.
The mechanism of action of ADCX25 depends on 0D25 binding. The 0D25 specific antibody targets the antibody drug conjugate (ADC) to cells expressing 0D25. Upon binding, the ADC internalizes and is transported to the lysosome, where the protease sensitive linker is cleaved and free PBD dimer is released inside the target cell. The released PBD dimer inhibits transcription in a sequence-selective manner, due either to direct inhibition of RNA polymerase or inhibition of the interaction of associated transcription factors. The PBD dimer produces covalent crosslinks that do not distort the DNA double helix and which are not recognized by nucleotide excision repair factors, allowing for a longer effective period (Hartley 2011).
It has the chemical structure:
0\
\ 0 H
Njr\
_ H
01,0 0H
0"
Ab represents Antibody AB12 (fully human monoclonal IgG1, K antibody with the VH and VL sequences SEQ ID NO. 1 and SEQ ID NO. 2, respectively, also known as HuMax-TAC). It is synthesised as described in WO 2014/057119 (Conj AB12-E) and typically has a DAR (Drug to Antibody Ratio) of 2.0+/-0.3.
0D25 binding The "first target protein" (FTP) as used herein is preferably 0D25.
As used herein, "binds 0D25" is used to mean the antibody binds 0D25 with a higher affinity than a non-specific partner such as Bovine Serum Albumin (BSA, Genbank accession no. 0AA76847, version no. 0AA76847.1 GI:3336842, record update date:
Jan 7, 2011 02:30 PM). In some embodiments the antibody binds 0D25 with an association constant (Ka) at least 2, 3, 4, 5, 10, 20, 50, 100, 200, 500, 1000, 2000, 5000, 104, 105 or 106-fold higher than the antibody's association constant for BSA, when measured at physiological conditions. The antibodies of the disclosure can bind 0D25 with a high affinity. For example, in some embodiments the antibody can bind 0D25 with a KD equal to or less than about 10-6 M, such as equal to or less than one of 1 x 10-6, 10-7, 10-8, 10-9,10-1 , 10-11, 10-12, 10-13 or 10-14.
In some embodiments, 0D25 polypeptide corresponds to Genbank accession no.
NP 000408, version no. NP 000408.1 GI:4557667, record update date: Sep 09, 04:59 PM. In one embodiment, the nucleic acid encoding 0D25 polypeptide corresponds to Genbank accession no. NM_000417, version no. NM_000417.2 GI:269973860, record update date: Sep 09, 2012 04:59 PM. In some embodiments, 0D25 polypeptide corresponds to Uniprot/Swiss-Prot accession No. P01589.
Anti-BCL-2 agents Suitable anti- BCL-2 agents include Venetoclax (ABT-199), navitoclax (ABT-263), ABT-737, 555746/BCL201, and oblimersen (G3139). Preferably the anti-BCL-2 agent is Venetoclax (ABT-199).
BCL-2 is localized to the outer membrane of mitochondria, where it plays an important role in promoting cellular survival and inhibiting the actions of pro-apoptotic proteins. The pro-apoptotic proteins in the BCL-2 family, including Bax and Bak, normally act on the mitochondrial membrane to promote permeabilization and release of cytochrome C
and ROS, that are important signals in the apoptosis cascade. These pro-apoptotic proteins are in turn activated by BH3-only proteins, and are inhibited by the function of BCL-2 and its relative BCL-Xl. The dynamic role of pro- and anti-apoptotic proteins, among other proteins, may alter the significance of increased BCL-2 expression in human disease.
However, the wide variety of cancer types associated with aberrant expression of BCL-2 (both haematological and non-haematological solid tumours) is consistent with its role as an apoptotic regulator (see Hanada M., et al., Blood. 1993;82:1820-1828;
Campos L., et al., Blood. 1993;81:3091-3096; Lamers F., et al., Eur J Cancer. 2012;48:3093-3103).
"Anti-BCL-2 agent" is used herein to mean any agent that specifically binds to and/or inhibits a biological activity of BCL-2.
As used herein, "specifically binds BCL-2" is used to mean the agent binds BCL-2 with a higher affinity than a non-specific partner such as Bovine Serum Albumin (BSA, Genbank accession no. CAA76847, version no. CAA76847.1 GI:3336842, record update date:
Jan 7, 2011 02:30 PM). In some embodiments the agent binds BCL-2 with an association constant (Ka) at least 2, 3, 4, 5, 10, 20, 50, 100, 200, 500, 1000, 2000, 5000, 104, 105 or 106-fold higher than the agent's association constant for BSA, when measured at physiological conditions. The agents may bind BCL-2 with a high affinity. For example, in some embodiments the agent can bind BCL-2 with a KD equal to or less than about 10-6 M, such as 1 x 10-6, 10-7, 10-8, 10-9,10-10, 10-11, 10-12, 10_13 or 10-14.
In some embodiments, BCL-2 polypeptide corresponds to Genbank accession no.
AAB72092, version no. AAB72092.1, record update date: Jul 24, 2016 02:22 PM.
In one embodiment, the nucleic acid encoding BCL-2 polypeptide corresponds to Genbank accession no AF021792, version no. AF021792.1, record update date: Jul 24, 02:22 PM. In some embodiments, BCL-2 polypeptide corresponds to Uniprot/Swiss-Prot accession No. Q92934.
To show that anti-CD25 ADCs works synergistically with the anti-BCL-2 agent, a panel of CD25 (+) cell lines will be co-treated with a range of concentration of both anti-CD25 ADC
and the anti-BCL-2 agent. As negative controls, the same panel of cell lines will be treated with a range of concentrations of the anti-BCL-2 agent or with a range of concentration of anti-CD25 ADC and vehicle. After incubation, two parameters will be measured: the amount of surface CD25 (as determined by flow cytometry) and the in vitro cytotoxicity of the combinations (as determined by MTS assays). To determine the cytotoxicity, Cell viability is measured by adding MTS per well and incubating for 4 hours at 37 C. Percentage cell viability is calculated compared to the untreated control.
Cytotoxic synergy is calculated by transforming the cell viability data into fraction affected, and calculating the combination index using the CalcuSyn analysis program.
Anti-CBCL-2 agents suitable for use in the present disclosure include:
a) Venetoclax (ABT-199) i. CAS Number 4 1257044-40-8 (see http://www.cas.org/content/chemical-substances/faqs) Drugbank reference 4 DB11581 (see https://www.drugbank.ca/) iii. Unique Ingredient Identifier (UNII) 4 N54AIC43PW
(see http://www.fda.gov/ForIndustry/DataStandards/SubstanceRegistrationSyst em-UniquelngredientldentifierUNII/default.htm) CI
1-..õ 1_0 1.1 N
- I
H .
0a,N
N) õNH 14111 ,µ
0 0 (7) Formula I: Venetoclax b) Navitoclax (ABT-263) i. CAS Number 4 923564-51-6 (see http://www.cas.org/content/chemical-substances/faqs) ii. Unique Ingredient Identifier (UNII) 4 XKJ5VVK2WD
(see http://www.fda.gov/ForIndustry/DataStandards/SubstanceRegistrationSyst em-UniquelngredientldentifierUNII/default.htm) \\
S=O
fµr \\0 rN NH
N,.õ,) CI
Formula II: Navitoclax i. CAS Number 4 852808-04-9 (see qn.11w.l.r.cas.orgico ntePtirh Pm ir,al-Substances/faqs) ii. Unique Ingredient Identifier (UNII) 4 Z5NFR173NV
(see http://www.fda.gov/ForIndustry/DataStandards/SubstanceRegistrationSyst em-UniquelngredientldentifierUNII/default.htm) H
rN Nr.
N) H
0' -Formula III: ABT-737 d) S55746/BCL201 i. CAS Number 4 1448584-12-0 (see http://www.cas.orq/content/chemical-substances/faqs) r 9 , f**1 r = -'40. -- -%
r = OH
Formula IV: SS55746 e) oblimersen (G3139) i. CAS Number 4 190977-41-4 (see httpl/www ¨1/content/chemical-substances/fags) Drugbank reference 4 DB06650 (see https://www.drugbank.ca/) iii. Unique Ingredient Identifier (UNII) 4 85J5ZP6YSL
(see http://www.fda.gov/ForIndustryLL)ataStandards/SubstanceReqistrationSyst em-Uniquelncre .1) iv. Oligo structure: D(P-thio)(T-C-T-C-C-C-A-G-C-G-T-G-C-G-C-C-A-T) Anti-mTOR agents Suitable mTOR inhibitors include everolimus (RAD001), sirolimus (Rapamycin), (temsirolimus), ridaforolimus (AP-23573), NVP-BEZ235 (dactolisib), BGT226, SF1126, Gedatolisib, Omipalisib, XL765, Ku-0063794, oleuropein aglycone, AZD8055, AZD2014, AZD 3147, sapanisertib (INK128/MLN0128), 0SI027, torin 1, torin 2, torkinib (PP242), VVYE687, ETP45658, PF05212384, PF04691502, XL388, eCF309, RapaLink-1, or Rapalink-2. Preferably the mTOR inhibitor is everolimus.
"mTOR inhibitor" is used herein to mean any agent that specifically binds to and/or inhibits a biological activity of mTOR.
As used herein, "specifically binds mTOR" is used to mean the agent binds mTOR
with a higher affinity than a non-specific partner such as Bovine Serum Albumin (BSA, Genbank accession no. 0AA76847, version no. 0AA76847.1 GI:3336842, record update date:
Jan 7, 2011 02:30 PM). In some embodiments the agent binds mTORwith an association constant (Ka) at least 2, 3, 4, 5, 10, 20, 50, 100, 200, 500, 1000, 2000, 5000, 104, 105 or 106-fold higher than the agent's association constant for BSA, when measured at physiological conditions. The agents may bind mTOR with a high affinity. For example, in some embodiments the agent can bind mTORwith a KD equal to or less than about M, such as 1 x 10-6, 10-7, 10-8, 10-9,10-10, 10-11, 10-12, 10_13 or 10-14.
In some embodiments, mTORpolypeptide corresponds to Genbank accession no.
AAA58486, version no. AAA58486.1, record update date: Jun 23, 2010 09:02 AM.
In one embodiment, the nucleic acid encoding mTORpolypeptide corresponds to Genbank accession no L34075, version no. L34075.1, record update date: Jun 23, 2010 09:02 AM. In some embodiments, mTORpolypeptide corresponds to Uniprot/Swiss-Prot accession No. P42345-1.
To show that anti-0D25 ADCs works synergistically with the mTOR inhibitor, a panel of 0D25 (+) cell lines will be co-treated with a range of concentration of both anti-0D25 ADC
and the mTOR inhibitor. As negative controls, the same panel of cell lines will be treated with a range of concentrations of the mTOR inhibitor or with a range of concentration of anti-0D25 ADC and vehicle. After incubation, two parameters will be measured:
the amount of surface 0D25 (as determined by flow cytometry) and the in vitro cytotoxicity of the combinations (as determined by MTS assays). To determine the cytotoxicity, Cell viability is measured by adding MTS per well and incubating for 4 hours at 37 C.
Percentage cell viability is calculated compared to the untreated control.
Cytotoxic synergy is calculated by transforming the cell viability data into fraction affected, and calculating the combination index using the CalcuSyn analysis program.
mTor inhibitors suitable for use in the present disclosure include:
a) Everolimus i. CAS Number 4 159351-69-6 (see http://www.cas.org/content/chemical-substances/faqs) Drugbank reference 4 DB01590 (see https://www.drugbank.ca/) iii. .. Unique Ingredient Identifier (UNII) 4 9HW64Q8G6G
(see http://www.fda.gov/ForIndustry/DataStandards/SubstanceRegistrationSyst em-UniquelngredientldentifierUNII/default.htm) N,C)Nri3O-1 0 OH
0 'N'O's.
HO
, Formula V: Everolimus, Dihydroxy-12-[(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-y1]-19,30-dimethoxy-15,17,21,23,29,35-hexamethy1-11,36-dioxa-4-azatricyclo[30.3.1.0 hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone b) Sirolimus (Rapamycin) i. CAS Number 4 53123-88-9 (see http://www.cas.org/content/chemical-substances/faqs) Drugbank reference 4 DB00877 (see https://www.drugbank.ca/) iii. Unique Ingredient Identifier (UNII) 4 W36ZG6FT64 (see http://www.fda.gov/ForIndustry/DataStandards/SubstanceRegistrationSyst em-UniquelngredientldentifierUNII/default.htm) HOõ, 0 µ1.1 I
0 Crµ
HO
Formula VI: Sirolimus, (1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-{(2R)-1-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-2-propany1}-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.0-4,9-]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone C) Temsirolimus (00I-779) i. CAS Number 4 162635-04-3 (see http://www.cas.org/content/chemical-substances/faqs) Drugbank reference 4 DB06287 (see https://www.drugbank.ca/) iv. Unique Ingredient Identifier (UNII) 4 624KN6GM2T
(see http://www.fda.gov/ForIndustry/DataStandards/SubstanceRegistrationSyst em-UniquelngredientldentifierUNII/default.htm) HONOH
0õ,A6 0 lip 0 o 0 , 0 Formula VII, Temsirolimus: (1R,2R,4S)-4-{(2R)-2-[(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-10,21-dimethoxy-6,8,12,14,20,26-hexamethy1-1,5,11,28,29-pentaoxo-1,4,5,6,9,10,11,12,13,14,21,22,23,24,25,26,27,28,29,31,32,33,34,34a-tetracosahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontin-3-yl]propy1}-2-methoxycyclohexyl 3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate d) Ridaforolimus (AP-23573), i. CAS Number 4 572924-54-0 (see http://www.cas.org/content/chemical-substances/faqs) ii. Unique Ingredient Identifier (UNII) 4 48Z35KB15K
(see http://www.fda.gov/ForIndustry/DataStandards/SubstanceRegistrationSyst em-UniquelngredientldentifierUNII/default.htm) 0õ10 CNI11(0:- HO OH
0 0 \µ
0 0-".
, Formula VIII, Ridaforolimus: (1R,2R,4S)-4-[(2R)-2-[(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28Z,30S,32S,35R)-1,18-dihydroxy-19,30-dimethoxy-15,17,21,23,29,35-hexamethy1-2,3,10,14,20-pentaoxo-11,36-dioxa-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraen-12-yl]propyl]-2-methoxycyclohexyl dimethylphosphinate e) Dactolisib (NVP-BEZ235) i. CAS Number 4 915019-65-7 (see http://www.cas.org/content/chemical-substances/faqs) ii. Unique Ingredient Identifier (UNII) 4 RUJ6Z9YODT
(see http://www.fda.gov/ForIndustry/DataStandards/SubstanceRegistrationSyst em-UniquelngredientldentifierUNII/default.htm) N
110 -,-Formula IX, Dactolisib: 2-Methy1-2-{443-methy1-2-oxo-8-(quinolin-3-y1)-2,3-dihydro-1H-imidazo[4,5-c]quinolin-1-yliphenyl}propanenitrile f) BGT226 i. CAS Number 4 1245537-68-1 (see http://www.cas.org/content/chemical-substances/faqs) o (c OH
OH
N
Formula X, BGT226: 1,3-dihydro-8-(6-methoxy-3-pyridiny1)-3-methy1-144-(1-piperaziny1)-3-(trifluoromethyl)phenyl]-2H-imidazo[4,5-c]quinolin-2-one, (2Z)-2-butenedioate g) SF1126 i. CAS Number 4 936487-67-1 (see http://www.cas.org/content/chemical-substances/faqs) -1 1! i\JH
=
I
1, -_ I
I -I
.11 Formula XI, SF1126: (8S,14S,17S)-14-(carboxymethyl)-8-(3-guanidinopropy1)-17-(hydroxymethyl)-3,6,9,12,15-pentaoxo-1-(4-(4-oxo-8-phenyl-4H-chromen-2-Amorpholino-4-ium)-2-oxa-7,10,13,16-tetraazaoctadecan-18-oate h) Gedatolisib i. CAS Number 4 1197160-78-3 (see http://www.cas.org/content/chemical-substances/faqs) ii. Unique Ingredient Identifier (UNII) 4 96265TNH2R
(see http://www.fda.gov/ForIndustry/DataStandards/SubstanceRegistrationSyst em-UniquelngredientldentifierUNII/default.htm) 0-Th N J H raN,õ
N
Formula XII, Gedatolisib: 14444-(dimethylamino)piperidine-1-carbonyliphenyl]-344-(4,6-dimorpholin-4-y1-1,3,5-triazin-2-Aphenyliurea i) Omipalisib i. CAS Number 4 1086062-66-9 (see http://www.cas.org/content/chemical-substances/faqs) ii. Unique Ingredient Identifier (UNII) 4 1X8F5A3NAO
(see http://www.fda.gov/ForIndustry/DataStandards/SubstanceRegistrationSyst em-UniquelngredientldentifierUNII/default.htm) 0=S =0 OXN
HN
Formula XIII: 2,4-difluoro-N-R-methoxy-5-(4-pyridazin-4-ylquinolin-6-Apyridin-ylpenzenesulfonamide j) XL765 i. CAS Number 4 934493-76-2 (see http://www.cas.org/content/chemical-substances/faqs) N
N
Formula X: XL765 k) Ku-0063794 i. CAS Number 4 938440-64-3 (see http://www.cas.org/content/chemical-substances/faqs) N
N' N N N OH
Formula XIV: re1-542-[(2R,6S)-2,6-dimethyl-4-morpholinyl]-4-(4-morpholinyl)pyrido[2,3-d]pyrimidin-7-y1]-2-methoxybenzenemethanol I) oleuropein aglycone i. CAS Number 4 31773-95-2 (see http://www.cas.org/content/chemical-substances/faqs) Drugbank reference 4 (see https://www.drugbank.ca/) iii. Unique Ingredient Identifier (UNII) 4 (see http://www.fda.gov/ForIndustry/DataStandards/SubstanceRegistrationSyst em-UniquelngredientldentifierUNII/default.htm) OH
Me 0 HO
CO2Me Formula XV: methyl (4S,5E,6R)-4-12-[2-(3,4-dihydroxyphenyl)ethoxy]-2-oxoethy1]-
5-ethylidene-6-hydroxy-4H-pyran-3-carboxylate rn) AZD8055 i. CAS Number 4 1009298-09-2 (see http://www.cas.org/content/chemical-substances/faqs) N
N
HO
Formula XVI: 5-12,4-big(3S)-3-methyl-4-morpholinylipyrido[2,3-O]pyrimidin-7-y1]-2-methoxy-benzenemethanol n) AZD2014 i. CAS Number 4 1009298-59-2 (see http://www.cas.org/content/chemical-substances/faqs) -.N. =
"/
tt.
N
H Lo .00 Formula XVII: AZD2014 0) AZD 3147 i. CAS Number 4 1101810-02-9 (see http://www.cas.org/content/chemical-substances/faqs) [
vz Formula XVIII: N-14-1441-(Cyclopropylsulfonyl)cyclopropyl]-6-[(3S)-3-methyl-4-morpholinyl]-2-pyrimidinyliphenyli-N'-(2-hydroxyethyl)thiourea p) sapanisertib (INK128/MLN0128) i. CAS Number 4 1224844-38-5 (see http://www.cas.org/content/chemical-substances/faqs) N
"\=N
Formula XIX: 5-(4-Amino-l-propan-2-ylpyrazolo[3,4-O]pyrimidin-3-y1)-1,3-benzoxazol-2-amine q) OSI027 i. CAS Number 4 936890-98-1 (see http://www.cas.org/content/chemical-substances/faqs) ii. Unique Ingredient Identifier (UNII) 4 25MKH1SZOM
(see http://www.fda.gov/ForIndustry/DataStandards/SubstanceRegistrationSyst em-UniquelngredientldentifierUNII/default.htm) NO
NH
OH
Formula XX: 444-amino-5-(7-methoxy-1H-indol-2-Aimidazo[5,1411,2,4]triazin-7-ylicyclohexane-1-carboxylic acid r) Torin 1 i. CAS Number 4 1222998-36-8 (see http://www.cas.org/content/chemical-substances/faqs) (I-1/419 CF3 [I 11 Formula XXI: 144-[4-(1-0xopropyl)-1-piperazinyl]-3-(trifluoromethyl)pheny1]-9-(3-quinoliny1)-benzo[h]-1,6-naphthyridin-2(1H)-one s) Torin 2 i. CAS Number 4 1223001-51-1 (see http://www.cas.org/content/chemical-substances/faqs) F F
Formula XXII: 9-(6-Amino-3-pyridiny1)-143-(trifluoromethyl)phenyli-benzo[h]-1,6-naphthyridin-2(1H)-one t) Torkinib (PP242) i. CAS Number 4 1092351-67-1 (see http://www.cas.org/content/chemical-substances/faqs) N-N
N--µN HN OH
Formula XXIII: 2-(4-Amino- 1-isopropy1-1H-pyrazolo[3,4-d]pyrimidin-3-y1)-1H-indol-5-ol u) VVYE687 i. CAS Number 4 1062161-90-3 (see http://www.cas.org/content/chemical-substances/faqs) L J
JUN.
¨r"-z=N
Formula XXIV: N4444-(4-Morpholiny1)-141-(3-pyridinylmethyl)-4-piperidinyl]-1H-pyrazolo[3,4-d]pyrimidin-6-yl]pheny1]-carbamic acid methyl ester hydrochloride v) ETP45658 i. CAS Number 4 1198357-79-7 (see http://www.cas.org/content/chemical-substances/faqs) Drugbank reference 4 (see https://www.drugbank.ca/) iii. Unique Ingredient Identifier (UNII) 4 (see http://www.fda.gov/ForIndustry/DataStandards/SubstanceRegistrationSyst em-UniquelngredientldentifierUNII/default.htm) I N
HO
Formula XXV: 3[1-Methy1-4-(4-morpholiny1)-1H-pyrazolo[3,4-O]pyrimidin-6-ylphenol w) PF05212384 i. CAS Number 4 1197160-78-3 (see http://www.cas.org/content/chemical-substances/faqs) Drugbank reference 4 DB11896 (see https://www.drugbank.ca/) iii. Unique Ingredient Identifier (UNII) 4 96265TNH2R
(see http://www.fda.gov/ForIndustry/DataStandards/SubstanceRegistrationSyst em-UniquelngredientldentifierUNII/default.htm) te,.0 ' I
I j H H
Formula XXVI: N-[4-[[4-(Dimethylamino)-1-piperidinyl]carbonyl]phenyTN'44-(4,6-di-4-morpholinyl-1,3,5-triazin-2-Aphenyl]urea x) PF04691502 i. CAS Number 4 1013101-36-4 (see http://www.cas.org/content/chemical-substances/faqs) CHs N OCH3 N
HO) Formula XXVII: Amino-8-[trans-4-(2-hydroxyethoxy)cyclohexyl]-6-(6-methoxy-3-pyridiny1)-4-methyl-pyrido[2,3-d]pyrimidin-7(8H)-one y) XL388 i. CAS Number 4 1251156-08-7 (see http://www.cas.org/content/chemical-substances/faqs) /S%
Formula XXVIII: [7-(6-Amino-3-pyridiny1)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl][3-fluoro-2-methy1-4-(methylsulfonyl)phenyl]-metha none z) eCF309 i. CAS Number 4 2001571-40-8 (see http://www.cas.org/content/chemical-substances/faqs) 1-.11 ==
kro - õ
=
Formula XXIX: 3-(2-Amino-5-benzoxazoly1)-1-(2,2-diethoxyethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine aa) RapaLink-1 i. CAS Number 4 1887095-82-0 (see http://www.cas.org/content/chemical-substances/faqs) Ak''%-õH-JetNi , H2N ft --"\O 0 L.0 -, . -_34 p I
Formula XXXI: 40-0-(241-(32-(4-amino-3-(2-aminobenzo[d]oxazol-5-y1)-1 H-pyrazolo[3,4-d]pyrimidin-1-y1)-27-oxo-3,6,9,12,15,18,21,24-octaoxa-28-azadotriaconty1)-1 H-1,2,3-triazol-4-yl)methoxy)ethyl)-rapa mycin bb) Rapalink-2 HzN N
Nz.N
N
7, =vo '..1,0d-^' 0.
Formula XXXII: 40-0-(241-(32-(4-amino-3-(2-aminobenzo[d]oxazol-5-y1)-1 H-pyrazolo[3,4-d]pyrimidin-1-y1)-27-oxo-3,6,9,12,15,18,21,24-heptaoxa-28-azadotriaconty1)-1 H-1,2,3-triazol-4-yl)methoxy)ethyl)-rapamycin Secondary agents The recent development of agents that enhance anti-tumor immunity is rapidly changing the treatment of a broad range of cancers. However, these treatments are not effective in all cancer types, responses are often not durable, and many patients receive little or no benefit from treatment. The prevailing assumption in the oncology field is that only combinations of immune-therapies with other treatment options will ultimately be able to cure cancer patients.
The ADC is well tolerated and active across a range of cancer types, and will likely be one component of combination therapies that increase the response rate and durability of treatment. The purpose of this disclosure is to combine the ADC
with the secondary agent.
A secondary agent as described herein may be an Immune-oncology (10) drug.
Immune-oncology (10) drugs, a type of cancer therapy relying on the body's immune system to help fight cancer, have shown enhanced durability of anti-tumor response.
There are different types of 10, including but not limited to PD1 inhibitors, inhibitors, CLTL4 inhibitors, GITR agonists and 0X40 agonists. Due to the considerable fraction of patients who are not cured by single agent immunotherapies and ultimately relapse, combination treatments with alternative 10 drugs or different therapeutic modalities are needed (see KS Peggs et al.2009, Clinical and Experimental Immunology, 157: 9-19 [doi: 10. 1111/0 365-2249.2009.03912.4; DM
Pardoll 2012 [doi:10.1038/nrc3239]).
Immunogenic cell death (ICD) is a particular form of cell death that stimulates an immune response against dead-cell antigens (released by dying cells) and it is considered as one of the best way to induce an adaptive immune response and improve the efficacy of anti-cancer treatment. This process is frequently suboptimal, calling for combinatorial strategies that attempt to restore the full immunogenicity of cell death for therapeutic purposes. There are several anti-neoplastic agents that can induce ICD such as various anthracyclines (including doxorubicin, epirubicin and idarubicin), alkylating agents (including oxaliplatin and cyclophosphamide), the topoisomerase 11 inhibitor mitoxantrone, and the proteasomal inhibitor Bortezomib.
Antibody-drug conjugates, including those with a PBD warhead, may be particularly suited as combination partners because they are more targeted compared to conventional chemotherapy and expected to offer an increased antigen presentation to infiltrating T cells as has been shown for auristatin-based ADCs.
Combining ADCs with 10 therefore allows for dual benefits: on the one hand, the ADC will directly kill the tumor expressing the target, providing immediate anti-tumor activity, and on the other the immunogenic cell death induced by ADC mediated cell kill may boost a stronger and more durable adaptive immune response, as compared to when the 10 is given as a single agent.
To show that anti-CD25 ADCs works synergistically with the secondary agent, a panel of CD25 (+) cell lines will be co-treated with a range of concentration of both anti-CD25 ADC
and the secondary agent. As negative controls, the same panel of cell lines will be treated with a range of concentrations of the secondary agent or with a range of concentration of anti-CD25 ADC and vehicle. After incubation, two parameters will be measured:
the amount of surface CD25 (as determined by flow cytometry) and the in vitro cytotoxicity of the combinations (as determined by MTS assays). To determine the cytotoxicity, Cell viability is measured by adding MTS per well and incubating for 4 hours at 37 C.
Percentage cell viability is calculated compared to the untreated control.
Cytotoxic synergy is calculated by transforming the cell viability data into fraction affected, and calculating the combination index using the CalcuSyn analysis program.
The secondary agent may be:
(a) Bendamustine;
(b) a phosphoinositide 3-kinase inhibitor such as copanlisib, idelalisib, duvelisib, Taselisib, Buparlisib, Alpelisib, Umbralisib, Dactolisib, and Voxtalisib;
(c) a proteasome inhibitor such as bortezomib, carfilzomib, lxazomib, Oprozomib, and Salinosporamide A;
(d) an anti-folate such as pralatrexate, methotrexate, pemetrexed, and raltitrexed;
or (e) a HDAC inhibitor such as romidepsin, vorinostat, Abexinostat, belinostat (PXD101), LAQ824, panobinostat (LBH589), entinostat (MS-275), tacedinaline (C1994), and mocetinostat (MGCD0103).
Each of these classes of secondary agent is described in more detail below.
Bendamustine Bendamustine is a bifunctional mechlorethamine derivative capable of forming electrophilic alkyl groups that covalently bond to other molecules. Through this function as an alkylating agent, bendamustine causes intra- and inter-strand crosslinks between DNA bases resulting in cell death. It is active against both active and quiescent cells.
Bendamustine has been indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.
i. CAS Number 16506-27-7 (see http://www.cas.org/content/chemical-substances/faqs) ii. Unique Ingredient Identifier (UNII) 9266D9P3PQ
(see http://www.fda. gov/Forl ndustry/DataStandards/SubstanceReg istrationSyst em-Uniquel ngredientldentifierU NI I/default. htm) õrib N _____________________________________ N
CI
Formula XXXII!: Bendamustine, 445-[Bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-ylibutanoic acid Phosphoinositide 3-kinase inhibitors The class 1 family of PI 3-kinase enzymes in vertebrates comprises four distinct protein species of approximately 110 kDa (p110a, p110[3, p1106 and p110y). All class!
enzymes share the majority of their structural features and a common substrate specificity (Rameh and Cantley, 1999; Fry, 2001; Katso et al., 2001). In vitro, all class 1 PI 3-kinases are capable of phosphorylating Ptdlns to PtdIns(3)P, PtdIns(4)P to PtdIns(3,4)P2 and PtdIns(4,5)P2 to PtdIns(3,4,5)P3, with PtdIns(4,5)P2 being considered the preferred lipid substrate in vivo. Class 1 PI 3-kinases are largely cytosolic in resting cells, but upon stimulation are recruited to membranes via interactions with receptors or adaptor proteins. They are thought to function primarily at the plasma membrane, but there have been reports of class 1 PI 3-kinases associated with vesicular and nuclear membranes (Rameh and Cantley, 1999; Fry, 2001; Katso et al., 2001). The cellular roles of class 1 PI
3-kinases are diverse, with evidence linking them to cell size, motility, survival and proliferation in response to numerous signalling systems in many different cell types (Fry, 2001; Katso et al., 2001). The class 1 family is further subdivided into two groups on the basis of their regulatory partners and mechanisms of activation.
Although PI3K was originally characterized two decades ago via its binding to oncogenes and activated RTKs (reviewed in Zhao JJ et al., 2006), its association with human cancer was not established until the late 1990s, when it was shown that the tumor suppressor PTEN acts as a P13-lipid phosphatase. Recent comprehensive cancer genomic analyses have revealed that multiple components of the PI3K pathway are frequently mutated or altered in common human cancers, underscoring the importance of this pathway in cancer (see Wood LD, et al. Science. 2007; Samuels Y, et al. Science. 2004).
"Phosphoinositide 3-kinase inhibitors" (PI3K inhibitors) is used herein to mean any agent that specifically binds to and/or inhibits a biological activity of PI3K.
As used herein, "specifically binds a PI3K" is used to mean the agent binds a PI3K with a higher affinity than a non-specific partner such as Bovine Serum Albumin (BSA, Genbank accession no. 0AA76847, version no. 0AA76847.1 GI:3336842, record update date:
Jan 7, 2011 02:30 PM). In some embodiments the agent binds a PI3K with an association constant (Ka) at least 2, 3, 4, 5, 10, 20, 50, 100, 200, 500, 1000, 2000, 5000, 104, 105 or 106-fold higher than the agent's association constant for BSA, when measured at physiological conditions. The agents may bind a PI3K with a high affinity. For example, in some embodiments the agent can bind a PI3Kwith a KD equal to or less than about 10-6 M, such as 1 x 10-6, 10-7, 10-8, 10-9,10-10, 10-11, 10-12, 10-13 or 10-14.
PI3K inhibitors suitable for use in the present disclosure include:
a) copanlisib i. CAS Number 4 1032568-63-0 (see http://www.cas.org/content/chemical-substances/faqs) Drugbank reference 4 DB12483 (see https://www.drugbank.ca/) iii. Unique Ingredient Identifier (UNII) 4 WI6V529FZ9 (see http://www.fda.gov/ForIndustry/DataStandards/SubstanceRegistrationSyst em-UniquelngredientldentifierUNII/default.htm) N
oCo) Formula XXXIV: copanlisib, 2-Amino-N-17-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo[1,2-c]quinazolin-5-ylipyrimidine-5-carboxamide b) idelalisib i. CAS Number 4 870281-82-6 (see http://www.cas.org/content/chemical-substances/faqs) Drugbank reference 4 DB09054 (see https://www.drugbank.ca/) iii. Unique Ingredient Identifier (UNII) 4 YG5718T5M0 (see http://www.fda.gov/ForIndustry/DataStandards/SubstanceRegistrationSyst em-UniquelngredientldentifierUNII/default.htm) HNIA,, i õ--,-HN N
N
OOP
Formula XXXV: idelalisib, 5-Fluoro-3-pheny1-2-[(1S)-1-(7H-purin-6-ylamino)propyl]-4(3H)-quinazolinone C) ,duvelisib i. CAS Number 4 1201438-56-3 (see http://www.cas.org/content/chemical-substances/faqs) ii. Drugbank reference 4 DB11952 (see https://www.drugbank.ca/) iii. Unique Ingredient Identifier (UNII) 4 610V23S0J1 (see http://www.fda.gov/ForIndustry/DataStandards/SubstanceRegistrationSyst em-UniquelngredientldentifierUNII/default.htm) H
N
ir Nx,\..,,,N
I
HN N
110 N At CI 0 1111.--1 Formula XXXVI: duvelisib, 8-Chloro-2-pheny1-3-[(1S)-1-(3H-purin-6-ylamino)ethyl]-1(2H)-isoquinolinone d) Taselisib i. CAS Number 4 1282512-48-4 (see http://www.cas.org/content/chemical-substances/faqs) ii. Unique Ingredient Identifier (UNII) 4 L08J20299M
(see http://www.fda.gov/ForIndustry/DataStandards/SubstanceRegistrationSyst em-UniquelngredientldentifierUNII/default.htm) 11 µ
c /
N
\ N
-""-LN-----Formula XXXVII: taselisib, 2-{4-12-(1-lsopropyl-3-methyl-1H-1,2,4-triazol-5-y1)-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepin-9-y1]-1H-pyrazol-1-y1}-2-methylpropanamide e) Buparlisib i. CAS Number 4 944396-07-0 (see http://www.cas.org/content/chemical-substances/faqs) ii. Drugbank reference 4 DB11666 (see https://www.drugbank.ca/) iii. Unique Ingredient Identifier (UNII) 4 OZM2Z182GD
(see http://www.fda.gov/ForIndustry/DataStandards/SubstanceRegistrationSyst em-UniquelngredientldentifierUNII/default.htm) N
I F
.-----F
F
)t, r=,,N N N'''''''''') CO
Formula XXXVIII: buparlisib, 5-[2,6-bis(morpholin-4-yOpyrimidin-4-y1]-4-(trifluoromethyl)pyridin-2-a mine f) Alpelisib i. CAS Number 4 1217486-61-7 (see http://www.cas.org/content/chemical-substances/faqs) Drugbank reference 4 (see https://www.drugbank.ca/) iii. Unique Ingredient Identifier (UNII) 4 (see http://www.fda.gov/ForIndustry/DataStandards/SubstanceRegistrationSyst em-UniquelngredientldentifierUNII/default.htm) s N
F F N
Formula XXXIX: alpelisib, (2S)-1-N-14-Methy1-542-(1,1,1-trifluoro-2-methylpropan-2-yOpyridin-4-y1]-1,3-thiazol-2-yl]pyrrolidine-1,2-dicarboxamide g) Umbralisib i. CAS Number 4 1532533-67-7 (see http://www.cas.org/content/chemical-substances/faqs) Drugbank reference 4 DB14989 (see https://www.drugbank.ca/) iii. Unique Ingredient Identifier (UNII) 4 38073MQB2A
(see http://www.fda.gov/ForIndustry/DataStandards/SubstanceRegistrationSyst em-UniquelngredientldentifierUNII/default.htm) F.
1.=
=11112 _ ;
F _ -Formula XL: umbralisib, (S)-2-(1-(4-amino-3-(3-fluoro-4-isopropoxypheny1)-1H-pyrazolo[3,4-d]pyrimidin-1-yOethyl)-6-fluoro-3-(3-fluoropheny1)-4H-chromen-4-one h) Dactolisib i. CAS Number 4 915019-65-7 (see http://www.cas.org/content/chemical-substances/faqs) ii. Drugbank reference 4 DB11651 (see https://www.drugbank.ca/) iii. Unique Ingredient Identifier (UNII) 4 RUJ6Z9YODT
(see http://www.fda.gov/ForIndustry/DataStandards/SubstanceRegistrationSyst em-UniquelngredientldentifierUNII/default.htm) N----N, N
Formula XLI: dactolisib, 2-Methy1-2-{443-methy1-2-oxo-8-(quinolin-3-y1)-2,3-dihydro-1H-imidazo[4,5-c]quinolin-1-yliphenyl}propanenitrile i) Voxtalisib i. CAS Number 4 934493-76-2 (see http://www.cas.org/content/chemical-substances/faqs) ii. Drugbank reference 4 DB12400 (see https://www.drugbank.ca/) iii. Unique Ingredient Identifier (UNII) 4 CVL1685GPH
(see http://www.fda.gov/ForIndustry/DataStandards/SubstanceRegistrationSyst em-UniquelngredientldentifierUNII/default.htm) "Nli- N H2 N --,.
HN
....--Formula XLII:
2-a mino-8-ethy1-4-methy1-6-(1 H-pyrazol-5-y1)-7H,8H-pyrido[2,3-d]pyrimidin-7-one Proteasome inhibitors The proteasome is a large protein complex responsible for degradation of intracellular proteins, a process that requires metabolic energy. Polymerization of ubiquitin, a key molecule known to work in concert with the proteasome, serves as a degradation signal for numerous target proteins; the destruction of a protein is initiated by covalent attachment of a chain consisting of several copies of ubiquitin (more than four ubiquitin molecules), through the concerted actions of a network of proteins, including the El (ubiquitin-activating), E2 (ubiquitin-conjugating) and E3 (ubiquitin-ligating) enzymes. The polymerized ubiquitin chain acts as a signal that shuttles the target proteins to the proteasome, where the substrate is proteolytically broken down. For accurate selection of the proteins, numerous enzymes (e.g., 2 El proteins, approximately 30 E2 proteins and more than 500 different species of E3 in humans) are mobilized with this cascade system.
The set of E3 proteins is highly diverse, because each E3 enzyme usually selectively recognizes a protein substrate for ubiquitylation (see Tanaka 2009, Proc Jpn Acad Ser B
Phys Biol Sci. 2009 Jan; 85(1): 12-36, and citations therein).
The ubiquitin¨proteasome system (UPS) controls almost all basic cellular processes¨
such as progression through the cell cycle, signal transduction, cell death, immune responses, metabolism, protein quality control and development¨by degrading short-lived regulatory or structurally aberrant proteins.
These protein regulatory processes are important also in cancer, and thus, the proteasome is an important regulator of carcinogenesis. Cancers include a variety of cells which, according to the cancer stem cell theory, descend from a small percentage of cancer stem cells, alternatively termed tumor-initiating cells. These cells constitute the subsets that have the ability to propagate the whole variety of cancer and repopulate tumors after cytostatic therapies. Proteasome plays a role in cellular processes in cancer stem cells, but it has been found to have a decreased function in them compared to the rest of cancer cells. In particular, the proteasome has been reported to play a role in the proliferation and pluripotency that is the defining characteristic of cancer cells and cancer stem cells (see Voutsadakis et al., Tumor Biology, Mar. 2017).
"Proteasome inhibitors" is used herein to mean any agent that specifically binds to and/or inhibits a biological activity of a proteasome component.
As used herein, "specifically binds a Proteasome component" is used to mean the agent binds a Proteasome component with a higher affinity than a non-specific partner such as Bovine Serum Albumin (BSA, Genbank accession no. CAA76847, version no.
CAA76847.1 GI:3336842, record update date: Jan 7,2011 02:30 PM). In some embodiments the agent binds a Proteasome component with an association constant (Ka) at least 2, 3, 4, 5, 10, 20, 50, 100, 200, 500, 1000, 2000, 5000, 104, 105 or 106-fold higher than the agent's association constant for BSA, when measured at physiological conditions. The agents may bind a Proteasome component with a high affinity.
For example, in some embodiments the agent can bind a Proteasome component with a KD
equal to or less than about 10-6 M, such as 1 x 10-6, 10-7, 10-8, 10-9,10-10, 10-11, 10-12, 10_13 or 10-14.
Proteasome inhibitors suitable for use in the present disclosure include:
a) bortezomib i. CAS Number 4 179324-69-7 (see http://www.cas.org/content/chemical-substances/faqs) Drugbank reference 4 DB00188 (see https://www.drugbank.ca/) iii. Unique Ingredient Identifier (UNII) 4 69G8BD63PP
(see http://www.fda.gov/ForIndustry/DataStandards/SubstanceRegistrationSyst em-UniquelngredientldentifierUNII/default.htm) 11, N B.,OH
Formula XLIII: bortezomib, [(1R)-3-methy1-1-({(2S)-3-phenyl-2-gpyrazin-2-ylcarbonyl)amindpropanoyllamino)butylporonic acid b) carfilzomib i. CAS Number 4 868540-17-4 (see http://www.cas.org/content/chemical-substances/faqs) Drugbank reference 4 DB08889 (see https://www.drugbank.ca/) iii. Unique Ingredient Identifier (UNII) 4 (see http://www.fda.gov/ForIndustry/DataStandards/SubstanceRegistrationSyst em-UniquelngredientldentifierUNII/default.htm) 10".""fiN N NN
H H
0 0 0 L.0 Formula XLIV: carfilzomib, (2S)-4-Methyl-N-1(2S)-1-1y2S)-4-methy1-1-[12R)-2-methyloxiran-2-y1]-1-oxopentan-2-yliamino]-1-oxo-3-phenylpropan-2-y1]-241(2S)-2-[12-morpholin-4-ylacetyl)amino]-4-phenylbutanoyliamino]pentanamide C) Ixazomib i. CAS Number 4 1072833-77-2 (see http://www.cas.org/content/chemical-substances/faqs) Drugbank reference 4 DB09570 (see https://www.drugbank.ca/) iii. Unique Ingredient Identifier (UNII) 4 71050168A2 (see http://www.fda.gov/ForIndustry/DataStandards/SubstanceRegistrationSyst em-UniquelngredientldentifierUNII/default.htm) HO OH
CI
Formula XLV: Ixazomib, N2-(2,5-Dichlorobenzoy1)-N-1(1R)-1-(dihydroxyboty1)-3-methylbutyliglycinamide d) Oprozomib i. CAS Number 4 935888-69-0 (see http://www.cas.org/content/chemical-substances/faqs) Drugbank reference 4 DB11991 (see https://www.drugbank.ca/) iii. Unique Ingredient Identifier (UNII) 4 MZ37792Y8J
(see http://www.fda.gov/ForIndustry/DataStandards/SubstanceRegistrationSyst em-UniquelngredientldentifierUNII/default.htm) =
Formula XLVI: Oprozomib, N-[(2S)-3-methoxy-1-[[(2S)-3-methoxy-1-[[(2S)-1-[(2R)-methyloxiran-2-y1]-1-oxo-3-phenylpropan-2-yliamino]-1-oxopropan-2-yliamino]-1-oxopropan-2-y1]-2-methy1-1,3-thiazole-5-carboxamide e) Salinosporamide A
i. CAS Number 4 437742-34-2 (see http://www.cas.org/content/chemical-substances/faqs) Drugbank reference 4 DB11762 (see https://www.drugbank.ca/) iii. Unique Ingredient Identifier (UNII) 4 703P9YDP7F
(see http://www.fda.gov/ForIndustry/DataStandards/SubstanceRegistrationSyst em-UniquelngredientldentifierUNII/default.htm) soH
µõOH
õNNH
Th CI
Formula XLVII: Salinosporamide A, (4R,5S)-4-(2-chloroethyl)-141S)-cyclohex-2-enyl(hydroxy)methyl)-5-methyl-6-oxa-2-azabicyclo[3.2.0]heptane-3,7-dione Anti-folates The antifolates were the first class of antimetabolites to enter the clinics 65 years ago.
Their mechanism of action is due to the disruption of the metabolic pathways that require one-carbon moieties supplied by the B9 folate vitamins which they resemble.
While renewing tissues of the bone marrow and intestinal tract are also folate-dependent and are sites of antifolate toxicity, the clinical utility of antifolates was established with the identification of doses and schedules of administration that provided sufficient selectivity to make these drugs effective in the treatment of cancer as well as inflammatory disorders An early anti-folate drug was methotrexate. However, despite its early clinical success, an understanding of the mechanism of action of methotrexate evolved slowly.
Likewise, the efficacy and selectivity of leucovorin "rescue" that allowed the safe administration of high doses of methotrexate was established entirely empirically and, even today, the basis for the selectivity of this regimen is not widely appreciated nor fully understood. The lack of a basic understanding of the biochemical and molecular pharmacology of methotrexate hampered efforts to develop subsequent generations of antifolates that would lead to the realization of the full clinical potential of this class of drugs. Hence, it was more than fifty years after the introduction of methotrexate that the second antifolate, pemetrexed, was approved in 2004 for the treatment of mesothelioma and subsequently non-small cell lung cancer. This was followed by approval of pralatrexate in 2009 for the treatment of cutaneous T-cell lymphoma.
"Anti-folate" is used herein to mean any agent that specifically binds to and/or inhibits a biological activity of a folate metabolism pathway component.
As used herein, "specifically binds a folate metabolism pathway component" is used to mean the agent binds a folate metabolism pathway component with a higher affinity than a non-specific partner such as Bovine Serum Albumin (BSA, Genbank accession no.
0AA76847, version no. 0AA76847.1 GI:3336842, record update date: Jan 7, 2011 02:30 PM). In some embodiments the agent binds a folate metabolism pathway component with an association constant (Ka) at least 2, 3, 4, 5, 10, 20, 50, 100, 200, 500, 1000, 2000, 5000, 104, 105 or 106-fold higher than the agent's association constant for BSA, when measured at physiological conditions. The agents may bind a folate metabolism pathway component with a high affinity. For example, in some embodiments the agent can bind a folate metabolism pathway component with a KD equal to or less than about 10-6 M, such as 1 x 10-6, 10-7, 10-8, 10-9,10-10, 10-11, 10-12, 10_13 or 10-14.
Anti-folates suitable for use in the present disclosure include:
a) pralatrexate i. CAS Number 4 146464-95-1 (see http://www.cas.org/content/chemical-substances/faqs) Drugbank reference 4 DB06813 (see https://www.drugbank.ca/) iii. Unique Ingredient Identifier (UNI I) 4 A8Q8119Q20 (see http://www.fda. gov/Forl ndustry/DataStandards/Substance Reg istrationSyst em-Uniquel ngredientldentifierU NI I/default. htm) Formula XLVIII: pralatrexate, N-(4-{1-[12,4-diaminopteridin-6-34)methyl]but-3-yn-1-yl}benzoy1)-L-glutamic acid SI
NrN COOH
b) methotrexate i. CAS Number 4 59-05-2 (see http://www.cas.org/content/chemical-substances/faqs) Drugbank reference 4 DB00563 (see https://www.drugbank.ca/) iii. Unique Ingredient Identifier (U Nil) 4 YL5FZ2Y5U1 (see http://www.fda.gov/ForIndustry/DataStandards/SubstanceRegistrationSyst em-UniquelngredientldentifierUNII/default.htm) oOH
NrOH
N NH
Formula XLIX: methotrexate, (2S)-2-114-{[(2,4-Diaminopteridin-6-34)methyl](methyl)amino}benzoy0amino]pentanedioic acid c) pemetrexed i. CAS Number 4 137281-23-3 (see http://www.cas.org/content/chemical-substances/faqs) Drugbank reference 4 DB00642 (see https://www.drugbank.ca/) iii. Unique Ingredient Identifier (UNII) 4 04Q9A1Z7N0 (see http://www.fda.gov/ForIndustry/DataStandards/SubstanceRegistrationSyst em-UniquelngredientldentifierUNII/default.htm) HN
N N
Formula L: pemetrexed, (2S)-24[4-12-(2-amino-4-oxo-1,7-dihydro pyrrolo[2,3-d]pyrimidin-5-yOethylibenzoyliamino}
pentanedioic acid d) raltitrexed i. CAS Number 4 112887-68-0 (see http://www.cas.org/content/chemical-substances/faqs) Drugbank reference 4 DB00293 (see https://www.drugbank.ca/) iii. Unique Ingredient Identifier (UNII) 4 FCB9EGG971 (see http://www.fda.gov/ForIndustry/DataStandards/SubstanceRegistrationSyst em-UniquelngredientldentifierUNII/default.htm) HN
OH
OH
Formula LI: raltitrexed, N-115-{methyl[(2-methy1-4-oxo-1,4-dihydroquinazolin-6-yOmethyl]amino}-2-thienyl)carbonyli-L-glutamic acid HDAC inhibitors A crucial role for epigenetic mechanisms in cancer development is demonstrated by a number of studies. Carcinogenesis cannot be explained only by genetic alterations, but also involve epigenetic processes (DNA methylation, histone modifications and non-coding RNA deregulation). Histone modifications include H3 and H4 histones lysine deacetylation that leads to chromatin decondensation. These alterations influence gene transcription including upregulation of several anti-oncogenes and DNA repair genes.
Thus, the epigenetic processes have emerged as novel therapeutic targets in numerous investigations.
The importance of histone deacetylase (HDAC) enzymes in organisms has been demonstrated using the studies with mice knocked out on members of class I
HDACs.
HDAC1-null mice die prenatally with severe proliferation defects and general growth retardation; HDAC2-null mice die the first day after birth for cardiac malformations; and HDAC3-null mice die prenatally for defects in gastrulation. HDACs seem to be important for gene expression. It has been described several times that their levels vary greatly in cancer cells and differ according to the tumor type. HDAC1 is highly expressed in prostate, gastric, lung, esophageal, colon and breast cancers. High levels of HDAC2 were found in colorectal, cervical and gastric cancers. In addition, HDAC3 is overexpressed in colon and breast tumors, whereas HDAC6 is highly expressed in mammary tumors, HDAC8 is overexpressed in neuroblastoma cells and HDAC11 mainly in rhabdomyosarcoma. Increased expression of different HDAC and/or histone hyperacetylation in different cancers is caused by different mechanisms which may affect effects of individual HDAC inhibitors (see Eckschlager et al., Int J Mol Sci.
2017 Jul;
18(7): 1414; and references cited therein).
"HDAC inhibitors" is used herein to mean any agent that specifically binds to and/or inhibits a biological activity of a HDAC.
As used herein, "specifically binds a HDAC" is used to mean the agent binds a HDAC
with a higher affinity than a non-specific partner such as Bovine Serum Albumin (BSA, Genbank accession no. 0AA76847, version no. 0AA76847.1 GI:3336842, record update date: Jan 7, 2011 02:30 PM). In some embodiments the agent binds a HDAC with an association constant (Ka) at least 2, 3, 4, 5, 10, 20, 50, 100, 200, 500, 1000, 2000, 5000, 104, 105 or 106-fold higher than the agent's association constant for BSA, when measured at physiological conditions. The agents may bind a HDAC with a high affinity.
For example, in some embodiments the agent can bind a HDAC with a KD equal to or less than about 10-6 M, such as 1 x 10-6, 10-7, 10-8, 10-9,10-10, 10-11, 10-12, 10_13 or 10-14.
HDAC inhibitors suitable for use in the present disclosure include:
a) romidepsin i. CAS Number 4 128517-07-7 (see http://www.cas.org/content/chemical-substances/faqs) ii. Drugbank reference 4 DB06176 (see https://www.drugbank.ca/) iii. Unique Ingredient Identifier (UNII) 4 CX3T89XQBK
(see http://www.fda.gov/ForIndustry/DataStandards/SubstanceRegistrationSyst em-UniquelngredientldentifierUNII/default.htm) 01:1T1Srs Formula LII: romidepsin, (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-diisopropy1-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone b) vorinostat i. CAS Number 4 149647-78-9 (see http://www.cas.org/content/chemical-substances/faqs) ii. Drugbank reference 4 DB02546 (see https://www.drugbank.ca/) iii. Unique Ingredient Identifier (UNII) 4 58IFB293J1 (see http://www.fda.gov/ForIndustry/DataStandards/SubstanceRegistrationSyst em-UniquelngredientldentifierUNII/default.htm) H
N'OH
H
---õ,_õ,:::,--= 0 Formula LIII:, N-Hydroxy-N'-phenyloctanediamide c) Abexinostat i. CAS Number 4 783355-60-2 (see http://www.cas.org/content/chemical-substances/faqs) Drugbank reference 4 DB12565 (see https://www.drugbank.ca/) iii. Unique Ingredient Identifier (UNII) 4 IY0470654U
(see http://www.fda.gov/ForIndustry/DataStandards/SubstanceRegistrationSyst em-UniquelngredientldentifierUNII/default.htm) IIMr N.OH
Formula LIV: abexinostat, 3-[(Dimethylamino)methyl]-N-{2-14-(hydroxycarbamoyl)phenoxyjethy1}-1-benzofuran-2-carboxamide d) belinostat (PXD101) i. CAS Number 4 866323-14-0 (see http://www.cas.org/content/chemical-substances/faqs) Drugbank reference 4 DB05015 (see https://www.drugbank.ca/) iii. Unique Ingredient Identifier (UNII) 4 F4H96P17NZ
(see http://www.fda.gov/ForIndustry/DataStandards/SubstanceRegistrationSyst em-UniquelngredientldentifierUNII/default.htm) (E) OH
N' osti Formula LV: belinostat, (2E)-N-Hydroxy-3-13-(phenylsulfamoyOphenyliprop-2-enamide e) LAQ824 i. CAS Number 4 404951-53-7 (see http://www.cas.org/content/chemical-substances/faqs) ii. Unique Ingredient Identifier (UNII) 4 V10P524501 (see http://www.fda.gov/ForIndustry/DataStandards/SubstanceRegistrationSyst em-UniquelngredientldentifierUNII/default.htm) OH
HN
HO/
Formula LVI: LAQ824, (2E)-N-hydroxy-344-17(2-hydroxyethyl)[2-(1H-indol-3-yOethyl]aminoimethyliphenyl]-2-propenamide f) panobinostat (LBH589) i. CAS Number 4 404950-80-7 (see http://www.cas.org/content/chemical-substances/faqs) Drugbank reference 4 DB06603 (see https://www.drugbank.ca/) iii. Unique Ingredient Identifier (UNII) 4 9647FM7Y3Z
(see http://www.fda.gov/ForIndustry/DataStandards/SubstanceRegistrationSyst em-UniquelngredientldentifierUNII/default.htm) :E
N'OH
HN N
Formula LVII: panobinostat, N-hydroxy(2E)-3-14-({12-(2-methy1-1H-indo1-3-Aethyliamino}methyl)phenyliprop-2-enimidic acid g) entinostat (MS-275) i. CAS Number 4 209783-80-2 (see http://www.cas.org/content/chemical-substances/faqs) Drugbank reference 4 DB11841 (see https://www.drugbank.ca/) iii. Unique Ingredient Identifier (UNII) 4 1ZNY4FKK9H
(see http://www.fda.gov/ForIndustry/DataStandards/SubstanceRegistrationSyst em-UniquelngredientldentifierUNII/default.htm) H
N
H
...,--Formula LVIII: entinostat, Pyridin-3-ylmethyl N-IT4-112-aminophenyOcarbamoyliphenylimethylicarbamate h) tacedinaline (01994) i. CAS Number 4 112522-64-2 (see http://www.cas.org/content/chemical-substances/faqs) ii. Drugbank reference 4 DB12291 (see https://www.drugbank.ca/) iii. Unique Ingredient Identifier (UNII) 4 UMF554N5FG
(see http://www.fda.gov/ForIndustry/DataStandards/SubstanceRegistrationSyst em-UniquelngredientldentifierUNII/default.htm) II. 0 0 0 H"AN NH2 H
Formula LIX: tacedinaline, N-(2-aminophenyI)-4-acetamidobenzamide i) mocetinostat (MGCD0103) i. CAS Number 4 726169-73-9 (see http://www.cas.org/content/chemical-substances/faqs) ii. Drugbank reference 4 DB11830 (see https://www.drugbank.ca/) iii. Unique Ingredient Identifier (UNII) 4 A6GWB8T96J
(see http://www.fda.gov/ForIndustry/DataStandards/SubstanceRegistrationSyst em-UniquelngredientldentifierUNII/default.htm) Formula LX: mocetinostat, N-(2-aminopheny1)-4-({14-(pyridin-3-Apyrimidin-2-yliamino}methyObenzamide Advantageous properties of the described combinations Both the anti-0D25 ADC and anti-BCL-2 agent, mTOR inhibitor, or secondary agent when used as a single agent in isolation have demonstrated clinical utility ¨
for example, in the treatment of cancer. However, as described herein, combination of the anti-0D25 ADC and anti-BCL-2 agent, mTOR inhibitor, or secondary agent is expected to provide one or more of the following advantages over treatment with either anti-0D25 ADC or anti-BCL-2 agent, mTOR inhibitor, or secondary agent alone:
1) effective treatment of a broader range of cancers;
2) effective treatment of resistant or refractory forms of disorders such as cancer, and individuals with disorders such as cancer who have relapsed after a period of remission;
3) increased response rate to treatment; and / or 4) Increased durability of treatment.
Effective treatment of a broader range of cancers as used herein means that following treatment with the combination a complete response is observed with a greater range of recognised cancer types. That is, a complete response is seen from cancer types not previously reported to completely respond to either anti-0D25 ADC or anti-BCL-2 agent, mTOR inhibitor, or secondary agent alone.
Effective treatment of a resistant, refractory, or relapsed forms as used herein means that following treatment with the combination a complete response is observed in individuals that are either partially or completely resistant or refractory to treatment with either anti-0D25 ADC or anti-BCL-2 agent, mTOR inhibitor, or secondary agent alone (for example, individuals who show no response or only partial response following treatment with either agent alone, or those with relapsed disorder). In some embodiments, a complete response following treatment with the anti-0D25 ADC / anti-BCL-2 agent, mTOR inhibitor, or secondary agent combination is observed at least 10% of individuals that are either partially or completely resistant or refractory to treatment with either anti-0D25 ADC or anti-BCL-2 agent, mTOR inhibitor, or secondary agent alone.
In some embodiments, a complete response following treatment with the anti-0D25 ADC /
anti-BCL-2 agent, mTOR inhibitor, or secondary agent combination is observed at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 98%, or at least 99% of individuals that are either partially or completely resistant or refractory to treatment with either anti-0D25 ADC or anti-BCL-2 agent, mTOR inhibitor, or secondary agent alone.
Increased response rate to treatment as used herein means that following treatment with the combination a complete response is observed in a greater proportion of individuals than is observed following treatment with either anti-0D25 ADC or anti-BCL-2 agent, mTOR inhibitor, or secondary agent alone. In some embodiments, a complete response following treatment with the anti-0D25 ADC / anti-BCL-2 agent, mTOR inhibitor, or secondary agent combination is observed at least 10% of treated individuals.
In some embodiments, a complete response following treatment with the anti-0D25 ADC /
anti-BCL-2 agent, mTOR inhibitor, or secondary agent combination is observed at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 98%, or at least 99% of treated individuals.
Increased durability of treatment as used herein means that average duration of complete response in individuals treated with the combination is longer than in individuals who achieve complete response following treatment with either anti-0D25 ADC or anti-BCL-2 agent, mTOR inhibitor, or secondary agent alone. In some embodiments, the average duration of a complete response following treatment with the anti-0D25 ADC /
anti-BCL-2 agent, mTOR inhibitor, or secondary agent combination is at least 6 months. In some embodiments, the average duration of a complete response following treatment with the anti-0D25 ADC / anti-BCL-2 agent, mTOR inhibitor, or secondary agent combination is at least 12 months, at least 18 months, at least 24 months, at least 3 years, at least 4 years, at least 5 years, at least 6 years, at least 7 years, at least 8 years, at least 9 years, at least 10 years, at least 15 years, or at least 20 years.
'Complete response' is used herein to mean the absence of any clinical evidence of disease in an individual. Evidence may be assessed using the appropriate methodology in the art, for example CT or PET scanning, or biopsy where appropriate. The number of doses required to achieve complete response may be one, two, three, four, five, ten or more. In some embodiments the individuals achieve complete response no more than a year after administration of the first dose, such as no more than 6 months, no more than 3 months, no more than a month, no more than a fortnight, or no more than a week after administration of the first dose.
Treated disorders The combined therapies described herein include those with utility for anticancer activity.
In particular, in certain aspects the therapies include an antibody conjugated, i.e.
covalently attached by a linker, to a PBD drug moiety, i.e. toxin. When the drug is not conjugated to an antibody, the PBD drug has a cytotoxic effect. The biological activity of the PBD drug moiety is thus modulated by conjugation to an antibody. The antibody-drug conjugates (ADC) of the disclosure selectively deliver an effective dose of a cytotoxic agent to tumor tissue whereby greater selectivity, i.e. a lower efficacious dose, may be achieved.
Thus, in one aspect, the present disclosure provides combined therapies comprising administering an anti-0D25 ADC which binds 0D25 for use in therapy, wherein the method comprises selecting a subject based on expression of the target protein.
In one aspect, the present disclosure provides a combined therapy with a label that specifies that the therapy is suitable for use with a subject determined to be suitable for such use. The label may specify that the therapy is suitable for use in a subject has expression of 0D25, such as overexpression of 0D25. The label may specify that the subject has a particular type of cancer.
In a further aspect there is also provided a combined therapy as described herein for use in the treatment of a proliferative disease. Another aspect of the present disclosure provides the use of a conjugate compound in the manufacture of a medicament for treating a proliferative disease.
One of ordinary skill in the art is readily able to determine whether or not a candidate combined therapy treats a proliferative condition for any particular cell type. For example, assays which may conveniently be used to assess the activity offered by a particular compound are described below.
The combined therapies described herein may be used to treat a proliferative disease.
The term "proliferative disease" pertains to an unwanted or uncontrolled cellular proliferation of excessive or abnormal cells which is undesired, such as, neoplastic or hyperplastic growth, whether in vitro or in vivo.
Examples of proliferative conditions include, but are not limited to, benign, pre-malignant, and malignant cellular proliferation, including but not limited to, neoplasms and tumours (e.g. histocytoma, glioma, astrocyoma, osteoma), cancers (e.g. lung cancer, small cell lung cancer, gastrointestinal cancer, bowel cancer, colon cancer, breast carinoma, ovarian carcinoma, prostate cancer, testicular cancer, liver cancer, kidney cancer, bladder cancer, pancreas cancer, brain cancer, sarcoma, osteosarcoma, Kaposi's sarcoma, melanoma), lymphomas, leukemias, psoriasis, bone diseases, fibroproliferative disorders (e.g. of connective tissues), and atherosclerosis. Cancers of interest include, but are not limited to, leukemias and ovarian cancers.
Any type of cell may be treated, including but not limited to, lung, gastrointestinal (including, e.g. bowel, colon), breast (mammary), ovarian, prostate, liver (hepatic), kidney (renal), bladder, pancreas, brain, and skin.
Proliferative disorders of particular interest include, but are not limited to, non-Hodgkin's Lymphoma, including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, (FL), Mantle Cell lymphoma (MCL), chronic lymphatic lymphoma (CLL), and Marginal Zone B-cell lymphoma (MZBL), and leukemias such as Hairy cell leukemia (HCL), Hairy cell leukemia variant (HCL-v), anaplastic large cell lymphoma (ALCL), and Acute Lymphoblastic Leukaemia (ALL) such as Philadelphia chromosome-positive ALL
(Ph+ALL) or Philadelphia chromosome-negative ALL (Ph-ALL).
[Fielding A., Haematologica. 2010 Jan; 95(1): 8-12].
The proliferative disease may be characterised by the presence of a neoplasm comprising both 0D25+ve and 0D25-ve cells.
The proliferative disease may be characterised by the presence of a neoplasm composed of 0D25-ve neoplastic cells, optionally wherein the 0D25-ve neoplastic cells are associated with 0D25+ve non-neoplastic cells such as 0D25+ve T-cells.
The target neoplasm or neoplastic cells may be all or part of a solid tumour.
"Solid tumor" herein will be understood to include solid haematological cancers such as lymphomas (Hodgkin's lymphoma or non-Hodgkin's lymphoma) which are discussed in more detail herein. The solid tumour may be an advanced solid tumour Solid tumors may be neoplasms, including non-haematological cancers, comprising or composed of 0D25+ve neoplastic cells. Solid tumors may be neoplasms, including non-haematological cancers, infiltrated with 0D25+ve cells, such as 0D25+ve T-cells; such solid tumours may lack expression of 0D25 (that is, comprise or be composed of ve neoplastic cells).
For example, the solid tumour may be a tumour with high levels of infiltrating T-cells, such as infiltrating regulatory T-cells (Treg; Menetrier-Caux, C., et al., Targ Oncol (2012) 7:15-28; Arce Vargas et al., 2017, Immunity 46, 1-10; Tanaka, A., et al., Cell Res.
Jan;27(1):109-118). Accordingly, the solid tumour may be pancreatic cancer, breast cancer, colorectal cancer, gastric and oesophageal cancer, leukemia and lymphoma, melanoma, non-small cell lung cancer, ovarian cancer, hepatocellular carcinoma, renal cell carcinoma, and head and neck cancer.
In some embodiments the proliferative disorder is a T-cell lymphoma. In some cases the disorder is anaplastic large cell lymphoma (ALCL), such as ALK-pos or ALK-neg ALCL.
It is contemplated that the combined therapies of the present disclosure may be used to treat various diseases or disorders, e.g. characterized by the overexpression of a tumor antigen. Exemplary conditions or hyperproliferative disorders include benign or malignant tumors; leukemia, haematological, and lymphoid malignancies. Others include neuronal, glial, astrocytal, hypothalamic, glandular, macrophagal, epithelial, stromal, blastocoelic, inflammatory, angiogenic and immunologic, including autoimmune disorders and graft-versus-host disease (GVHD).
Generally, the disease or disorder to be treated is a hyperproliferative disease such as cancer. Examples of cancer to be treated herein include, but are not limited to, carcinoma, lymphoma, blastoma, sarcoma, and leukemia or lymphoid malignancies.
More particular examples of such cancers include squamous cell cancer (e.g.
epithelial squamous cell cancer), lung cancer including small-cell lung cancer, non-small cell lung cancer, adenocarcinoma of the lung and squamous carcinoma of the lung, cancer of the peritoneum, hepatocellular cancer, gastric or stomach cancer including gastrointestinal cancer, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma, breast cancer, colon cancer, rectal cancer, colorectal cancer, endometrial or uterine carcinoma, salivary gland carcinoma, kidney or renal cancer, prostate cancer, vulval cancer, thyroid cancer, hepatic carcinoma, anal carcinoma, penile carcinoma, as well as head and neck cancer.
Autoimmune diseases for which the combined therapies may be used in treatment include rheumatologic disorders (such as, for example, rheumatoid arthritis, SjOgren's syndrome, scleroderma, lupus such as SLE and lupus nephritis, polymyositis/dermatomyositis, cryoglobulinemia, anti-phospholipid antibody syndrome, and psoriatic arthritis), osteoarthritis, autoimmune gastrointestinal and liver disorders (such as, for example, inflammatory bowel diseases (e.g. ulcerative colitis and Crohn's disease), autoimmune gastritis and pernicious anemia, autoimmune hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, and celiac disease), vasculitis (such as, for example, ANCA-associated vasculitis, including Churg-Strauss vasculitis, Wegener's granulomatosis, and polyarteriitis), autoimmune neurological disorders (such as, for example, multiple sclerosis, opsoclonus myoclonus syndrome, myasthenia gravis, neuromyelitis optica, Parkinson's disease, Alzheimer's disease, and autoimmune polyneuropathies), renal disorders (such as, for example, glomerulonephritis, Goodpasture's syndrome, and Berger's disease), autoimmune dermatologic disorders (such as, for example, psoriasis, urticaria, hives, pemphigus vulgaris, bullous pemphigoid, and cutaneous lupus erythematosus), hematologic disorders (such as, for example, thrombocytopenic purpura, thrombotic thrombocytopenic purpura, post-transfusion purpura, and autoimmune hemolytic anemia), atherosclerosis, uveitis, autoimmune hearing diseases (such as, for example, inner ear disease and hearing loss), Behcet's disease, Raynaud's syndrome, organ transplant, graft-versus-host disease (GVHD), and autoimmune endocrine disorders (such as, for example, diabetic-related autoimmune diseases such as insulin-dependent diabetes mellitus (IDDM), Addison's disease, and autoimmune thyroid disease (e.g. Graves' disease and thyroiditis)). More preferred such diseases include, for example, rheumatoid arthritis, ulcerative colitis, ANCA-associated vasculitis, lupus, multiple sclerosis, SjOgren's syndrome, Graves' disease, IDDM, pernicious anemia, thyroiditis, and glomerulonephritis.
In some aspects, the subject has a proliferative disorder selected from (classical) Hodgkin lymphomas, with mixed cellularity type (Hodgkin-/Reed-Sternbert-Cells: 0D25 +/-), or non-Hodgkin lymphoma, including B-cell chronic lymphatic leukemaia, diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, (FL), Mantle Cell lymphoma (MCL), chronic lymphatic lymphoma (CLL), Marginal Zone B-cell lymphoma (MZBL) and leukemias such as Hairy cell leukemia (HCL), Hairy cell leukemia variant (HCL-v), Acute Myeloid Leukaemia (AML), anaplastic large cell lymphoma (ALCL), Acute Lymphoblastic Leukaemia (ALL) such as Philadelphia chromosome-positive ALL (Ph+ALL) or Philadelphia chromosome-negative ALL (Ph-ALL) [Fielding A., Haematologica.
2010 Jan;
95(1): 8-12], small cell lymphocytic lymphoma, adult T-cell leukemia/lymphoma, or anaplastic large cell lymphoma.
In some aspects, the subject has a proliferative disease characterised by the presence of a neoplasm comprising both 0D25+ve and 0D25-ve cells.
The proliferative disease may be characterised by the presence of a neoplasm composed of 0D25-ve neoplastic cells, optionally wherein the 0D25-ve neoplastic cells are associated with 0D25+ve non-neoplastic cells such as 0D25+ve T-cells.
The target neoplasm or neoplastic cells may be all or part of a solid tumour.
Solid tumors may be neoplasms, including non-haematological cancers, comprising or composed of 0D25+ve neoplastic cells. Solid tumors may be neoplasms, including non-haematological cancers, infiltrated with 0D25+ve cells, such as 0D25+ve T-cells; such solid tumours may lack expression of 0D25 (that is, comprise or be composed of ve neoplastic cells). The solid tumour may be an advanced solid tumour.
For example, the solid tumour may be a tumour with high levels of infiltrating T-cells, such as infiltrating regulatory T-cells (Treg; Menetrier-Caux, C., et al., Targ Oncol (2012) 7:15-28; Arce Vargas et al., 2017, Immunity 46, 1-10; Tanaka, A., et al., Cell Res.
Jan;27(1):109-118). Accordingly, the solid tumour may be pancreatic cancer, breast cancer, colorectal cancer, gastric and oesophageal cancer, leukemia and lymphoma, melanoma, non-small cell lung cancer, ovarian cancer, hepatocellular carcinoma, renal cell carcinoma, and head and neck cancer.
Classical Hodgkins lymphoma includes the subtypes nodular sclerosing, lymphocyte predominant, lymphocyte depleted and mixed cellularity. The Hodgkins lymphoma subtype may not be defined. In certain aspects, the patients tested according to the methods here have Hodgkins lymphoma of the nodular sclerosing and mixed cellularity subtypes.
In certain aspects, the subject has diffuse large B cell lymphoma or peripheral T cell lymphoma, including the anaplastic large cell lymphoma and angioimmunoblastic T cell lymphoma subtypes.
Patient Selection In certain aspects, the individuals are selected as suitable for treatment with the combined treatments before the treatments are administered.
As used herein, individuals who are considered suitable for treatment are those individuals who are expected to benefit from, or respond to, the treatment.
Individuals may have, or be suspected of having, or be at risk of having cancer.
Individuals may have received a diagnosis of cancer. In particular, individuals may have, or be suspected of having, or be at risk of having, lymphoma. In some cases, individuals may have, or be suspected of having, or be at risk of having, a solid cancer that has tumour associated non-tumor cells that express 0D25, such as infiltrating cells that express 0D25.
In some aspects, subjects are selected on the basis of the amount or pattern of expression of 0D25. In some aspects, the selection is based on expression of 0D25 at the cell surface in a tissue or structure of interest. So, in some cases, subjects are selected on the basis they have, or are suspected of having, are at risk of having, or have received a diagnosis of a proliferative disease characterized by the presence of a neoplasm comprising or associated with cells having surface expression of 0D25. The neoplasm may be composed of cells having surface expression of 0D25.
In some aspects, subjects are selected on the basis they have a neoplasm comprising both 0D25+ve and 0D25-ve cells. The neoplasm may be composed of 0D25-ve neoplastic cells, optionally wherein the 0D25-ve neoplastic cells are associated with 0D25+ve non-neoplastic cells such as 0D25+ve Tregs. The neoplasm or neoplastic cells may be all or part of a solid tumour. The solid tumour may be partially or wholly 0D25-ve, and may be infiltrated with 0D25+ve cells, such as 0D25+ve Tregs. In preferred aspects, the solid tumour is associated with high-levels of 0D25+ve infiltrating cells, such as Treg cells. In some aspects, the solid tumour is associated with low-levels of 0D25+ve infiltrating cells, such as Treg cells. In some aspects, the solid tumour is not associated with 0D25+ve infiltrating cells, such as Treg cells; for example, the levels of 0D25+ve cells may be below the detection limit. The solid tumour may be an advanced solid tumour.
In some cases, expression of 0D25 in a particular tissue of interest is determined. For example, in a sample of tumor tissue. In some cases, systemic expression of 0D25 is determined. For example, in a sample of circulating fluid such as blood, plasma, serum or lymph.
In some aspects, the subject is selected as suitable for treatment due to the presence of 0D25 expression in a sample. In those cases, subjects without 0D25 expression may be considered not suitable for treatment.
In other aspects, the level of 0D25 expression is used to select a subject as suitable for treatment. Where the level of expression of the target is above a threshold level, the subject is determined to be suitable for treatment.
In some aspects, an subject is indicated as suitable for treatment if cells obtained from the tumour react with antibodies against 0D25 as determined by I HC.
In some aspects, a subject is determined to be suitable for treatment if at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90% or more of all cells in the sample express 0D25. In some aspects disclosed herein, a subject is determined to be suitable for treatment if at least at least 5%
of the cells in the sample express 0D25.
In certain aspects, the target is BCL-2, mTOR, or a secondary target protein.
In some aspects, the selection is based on expression of BCL-2, mTOR, or a secondary target protein.
In some aspects, the selection is based on levels of both 0D25 at the cell surface and BCL-2, mTOR, or the secondary target protein.
In some aspects, the presence of 0D25 and/or in cells in the sample indicates that the individual is suitable for treatment with a combination comprising an anti-0D25 ADC and an anti-BCL-2 agent, an mTOR inhibitor, or a secondary agent. In other aspects, the amount of 0D25 and/or expression must be above a threshold level to indicate that the individual is suitable for treatment. In some aspects, the observation that 0D25 and/or localisation is altered in the sample as compared to a control indicates that the individual is suitable for treatment.
In some aspects, an individual is indicated as suitable for treatment if cells obtained from lymph node or extra nodal sites react with antibodies against 0D25 and/or as determined by IHC.
In some aspects, a patient is determined to be suitable for treatment if at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90% or more of all cells in the sample express 0D25. In some aspects disclosed herein, a patient is determined to be suitable for treatment if at least at least 10%
of the cells in the sample express 0D25.
In some aspects, a patient is determined to be suitable for treatment if at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90% or more of all cells in the sample express. In some aspects disclosed herein, a patient is determined to be suitable for treatment if at least at least 10% of the cells in the sample express.
In some aspects, the individual is selected as suitable for treatment based on their current or previous treatment regime. In some embodiments the individual is selected for treatment with the anti-0D25 ADC if the individual has been treated with an anti-BCL-2 agent, an mTOR inhibitor, or a secondary agent. In some embodiments the individual is selected for treatment with the anti-0D25 ADC if the individual is being treated with an anti-BCL-2 agent, an mTOR inhibitor, or a secondary agent. In some cases the individual is selected for treatment if they are refractory to treatment (or further treatment) with the anti-BCL-2 agent, the mTOR inhibitor, or the secondary agent. In some cases the anti-BCL-2 agent may be Venetoclax. In some cases the mTOR inhibitor may be Everolimus.
In some cases the secondary agent may be bortezomib, In some cases the secondary agent may be Bendamustine, copanlisib, idelalisib, pralatrexate, romidepsin, or vorinostat. In embodiments where the individual is undergoing, or has undergone, treatment with an anti-BCL-2 agent, an mTOR inhibitor, or a secondary agent, the anti-0D25 ADC may be administered in combination with an anti-BCL-2 agent, an mTOR
inhibitor, or a secondary agent, or without continued administration of the anti-BCL-2 agent, an mTOR inhibitor, or a secondary agent.
In some embodiments the anti-0D25 ADC is administered to the selected individual in combination with an anti-BCL-2 agent, an mTOR inhibitor, or a secondary agent.
In some embodiments the anti-0D25 ADC is administered to the selected individual without continued administration of an anti-BCL-2 agent, an mTOR inhibitor, or a secondary agent. The anti-BCL-2 agent is preferably Venetoclax. The mTOR inhibitor is preferably Everolimus. In some cases the secondary agent may be bortezomib, In some cases the secondary agent may be Bendamustine, copanlisib, idelalisib, pralatrexate, romidepsin, or vorinostat.
The term 'refractory to treatment (or further treatment) with the anti-BCL-2 agent, mTOR
inhibitor, or secondary agent' is used herein to mean that the disorder (such as cancer) does not respond, or has ceased to respond, to administration of the anti-BCL-2 agent, mTOR inhibitor, or secondary agent when administered as a monotherapy. In some embodiments, individuals with refractory NHL are identified using the response criteria disclosed in Cheson at al., 2014 (South Asian J Cancer. 2014 Jan-Mar; 3(1): 66-70). In that document, non-responders are defined as individuals where there is either (i) a >50%
increase from nadir in the sum product of diameters of any previously identified abnormal node, or (ii) an appearance of any new lesion during or at the end of therapy.
In some embodiments, individuals with refractory leukaemia are identified as individuals with either stable or progressive disease who have completed one complete treatment cycle, or individual achieving partial response after two or more complete treatment cycles.
Samples The sample may comprise or may be derived from: a quantity of blood; a quantity of serum derived from the individual's blood which may comprise the fluid portion of the blood obtained after removal of the fibrin clot and blood cells; a quantity of pancreatic juice; a tissue sample or biopsy; or cells isolated from said individual.
A sample may be taken from any tissue or bodily fluid. In certain aspects, the sample may include or may be derived from a tissue sample, biopsy, resection or isolated cells from said individual.
In certain aspects, the sample is a tissue sample. The sample may be a sample of tumor tissue, such as cancerous tumor tissue. The sample may have been obtained by a tumor biopsy. In some aspects, the sample is a lymphoid tissue sample, such as a lymphoid lesion sample or lymph node biopsy. In some cases, the sample is a skin biopsy.
In some aspects the sample is taken from a bodily fluid, more preferably one that circulates through the body. Accordingly, the sample may be a blood sample or lymph sample. In some cases, the sample is a urine sample or a saliva sample.
In some cases, the sample is a blood sample or blood-derived sample. The blood derived sample may be a selected fraction of a individual's blood, e.g. a selected cell-containing fraction or a plasma or serum fraction.
A selected cell-containing fraction may contain cell types of interest which may include white blood cells (WBC), particularly peripheral blood mononuclear cells (PBC) and/or granulocytes, and/or red blood cells (RBC). Accordingly, methods according to the present disclosure may involve detection of a first target polypeptide or nucleic acid in the blood, in white blood cells, peripheral blood mononuclear cells, granulocytes and/or red blood cells.
The sample may be fresh or archival. For example, archival tissue may be from the first diagnosis of an individual, or a biopsy at a relapse. In certain aspects, the sample is a fresh biopsy.
The first target polypeptide may be 0D25.
Individual status The individual may be an animal, mammal, a placental mammal, a marsupial (e.g., kangaroo, wombat), a monotreme (e.g., duckbilled platypus), a rodent (e.g., a guinea pig, a hamster, a rat, a mouse), murine (e.g., a mouse), a lagomorph (e.g., a rabbit), avian (e.g., a bird), canine (e.g., a dog), feline (e.g., a cat), equine (e.g., a horse), porcine (e.g., a pig), ovine (e.g., a sheep), bovine (e.g., a cow), a primate, simian (e.g., a monkey or ape), a monkey (e.g., marmoset, baboon), an ape (e.g., gorilla, chimpanzee, orangutang, gibbon), or a human.
Furthermore, the individual may be any of its forms of development, for example, a foetus. In one preferred embodiment, the individual is a human. The terms "subject", "patient" and "individual" are used interchangeably herein.
In some aspects disclosed herein, an individual has, or is suspected as having, or has been identified as being at risk of, cancer. In some aspects disclosed herein, the individual has already received a diagnosis of cancer. The individual may have received a diagnosis of a proliferative disease characterised by the presence of a neoplasm comprising both 0D25+ve and 0D25-ve cells.
The proliferative disease may be characterised by the presence of a neoplasm composed of 0D25-ve neoplastic cells, optionally wherein the 0D25-ve neoplastic cells are associated with 0D25+ve non-neoplastic cells such as 0D25+ve T-cells.
In some cases, the individual has received a diagnosis of a solid tumour containing 0D25+ expressing infiltrating cells.
Solid tumors may be neoplasms, including non-haematological cancers, comprising or composed of 0D25+ve neoplastic cells. Solid tumors may be neoplasms, including non-haematological cancers, infiltrated with 0D25+ve cells, such as 0D25+ve T-cells; such solid tumours may lack expression of 0D25 (that is, comprise or be composed of ve neoplastic cells). The solid tumour may be an advanced solid tumour For example, the solid tumour may be a tumour with high levels of infiltrating T-cells, such as infiltrating regulatory T-cells (Treg; Menetrier-Caux, C., et al., Targ Oncol (2012) 7:15-28; Arce Vargas et al., 2017, Immunity 46, 1-10; Tanaka, A., et al., Cell Res.
Jan;27(1):109-118). Accordingly, the solid tumour may be pancreatic cancer, breast cancer, colorectal cancer, gastric and oesophageal cancer, leukemia and lymphoma, melanoma, non-small cell lung cancer, ovarian cancer, hepatocellular carcinoma, renal cell carcinoma, and head and neck cancer.
The Individual may be undergoing, or have undergone, a therapeutic treatment for that cancer. The subject may, or may not, have previously received ADCX25. In some cases the cancer is lymphoma, including non-Hodgkins lymphoma.
The Individual may be undergoing, or have undergone, treatment with an anti-agent, an mTOR inhibitor, or a secondary agent. In some cases the individual may be refractory to treatment (or further treatment) with the anti-BCL-2 agent, mTOR
inhibitor, or secondary agent. In some cases the anti-BCL-2 agent may be Venetoclax. In some cases the mTOR inhibitor may be Everolimus. In some cases the secondary agent may be bortezomib, In some cases the secondary agent may be Bendamustine, copanlisib, idelalisib, pralatrexate, romidepsin, or vorinostat. In embodiments where the individual is undergoing, or has undergone, treatment with an anti-BCL-2 agent, an mTOR
inhibitor, or a secondary agent, the anti-CD25 ADC may be administered in combination with an anti-BCL-2 agent, an mTOR inhibitor, or a secondary agent, or without continued administration of the anti-BCL-2 agent, an mTOR inhibitor, or a secondary agent.
Controls In some aspects, target expression in the individual is compared to target expression in a control. Controls are useful to support the validity of staining, and to identify experimental artefacts.
In some cases, the control may be a reference sample or reference dataset. The reference may be a sample that has been previously obtained from a individual with a known degree of suitability. The reference may be a dataset obtained from analyzing a reference sample.
Controls may be positive controls in which the target molecule is known to be present, or expressed at high level, or negative controls in which the target molecule is known to be absent or expressed at low level.
Controls may be samples of tissue that are from individuals who are known to benefit from the treatment. The tissue may be of the same type as the sample being tested. For example, a sample of tumor tissue from a individual may be compared to a control sample of tumor tissue from a individual who is known to be suitable for the treatment, such as a individual who has previously responded to the treatment.
In some cases the control may be a sample obtained from the same individual as the test sample, but from a tissue known to be healthy. Thus, a sample of cancerous tissue from a individual may be compared to a non-cancerous tissue sample.
In some cases, the control is a cell culture sample.
In some cases, a test sample is analyzed prior to incubation with an antibody to determine the level of background staining inherent to that sample.
In some cases an isotype control is used. lsotype controls use an antibody of the same class as the target specific antibody, but are not immunoreactive with the sample. Such controls are useful for distinguishing non-specific interactions of the target specific antibody.
The methods may include hematopathologist interpretation of morphology and immunohistochemistry, to ensure accurate interpretation of test results. The method may involve confirmation that the pattern of expression correlates with the expected pattern.
For example, where the amount of CD25 and/or BCL-2, mTOR, or secondary target protein expression is analyzed, the method may involve confirmation that in the test sample the expression is observed as membrane staining, with a cytoplasmic component.
The method may involve confirmation that the ratio of target signal to noise is above a threshold level, thereby allowing clear discrimination between specific and non-specific background signals.
Methods of Treatment The term "treatment," as used herein in the context of treating a condition, pertains generally to treatment and therapy, whether of a human or an animal (e.g., in veterinary applications), in which some desired therapeutic effect is achieved, for example, the inhibition of the progress of the condition, and includes a reduction in the rate of progress, a halt in the rate of progress, regression of the condition, amelioration of the condition, and cure of the condition. Treatment as a prophylactic measure (i.e., prophylaxis, prevention) is also included.
The term "therapeutically-effective amount" or "effective amount" as used herein, pertains to that amount of an active compound, or a material, composition or dosage from comprising an active compound, which is effective for producing some desired therapeutic effect, commensurate with a reasonable benefit/risk ratio, when administered in accordance with a desired treatment regimen.
Similarly, the term "prophylactically-effective amount," as used herein, pertains to that amount of an active compound, or a material, composition or dosage from comprising an active compound, which is effective for producing some desired prophylactic effect, commensurate with a reasonable benefit/risk ratio, when administered in accordance with a desired treatment regimen.
Disclosed herein are methods of therapy. Also provided is a method of treatment, comprising administering to a subject in need of treatment a therapeutically-effective amount of an anti-0D25 ADC and an anti-BCL-2 agent, an mTOR inhibitor, or a secondary agent. The term "therapeutically effective amount" is an amount sufficient to show benefit to a subject. Such benefit may be at least amelioration of at least one symptom. The actual amount administered, and rate and time-course of administration, will depend on the nature and severity of what is being treated. Prescription of treatment, e.g. decisions on dosage, is within the responsibility of general practitioners and other medical doctors. The subject may have been tested to determine their eligibility to receive the treatment according to the methods disclosed herein. The method of treatment may comprise a step of determining whether a subject is eligible for treatment, using a method disclosed herein.
The anti-0D25 ADC comprises an anti-0D25 antibody. The anti-0D25 antibody may be HuMax-TACTm. The ADC may comprise a drug which is a PBD dimer. The ADC may be an anti-0D25-ADC, and in particular, ADCX25 or ADCT-301 (c..micianIumab tesirine,. The ADC may be an ADC disclosed in W02014/057119.
The anti-BCL-2 agent may be Venetoclax (ABT-199), navitoclax (ABT-263), ABT-737, 555746/BCL201, and oblimersen (G3139). Preferably the anti-BCL-2 agent is Venetoclax (A BT-199).
The mTOR inhibitor may be everolimus (RAD001), sirolimus (Rapamycin), 00I-779 (temsirolimus), ridaforolimus (AP-23573), NVP-BEZ235 (dactolisib), BGT226, SF1126, Gedatolisib, Omipalisib, XL765, Ku-0063794, oleuropein aglycone, AZD8055, AZD2014, AZD 3147, sapanisertib (INK128/MLN0128), 0SI027, torin 1, torin 2, torkinib (PP242), VVYE687, ETP45658, PF05212384, PF04691502, XL388, eCF309, RapaLink-1, or Rapalink-2.
The secondary agent may be:
(a) Bendamustine;
(b) a phosphoinositide 3-kinase inhibitor such as copanlisib, idelalisib, duvelisib, Taselisib, Buparlisib, Alpelisib, Umbralisib, Dactolisib, and Voxtalisib;
(C) a proteasome inhibitor such as bortezomib, carfilzomib, lxazomib, Oprozomib, and Salinosporamide A;
(d) an anti-folate such as pralatrexate, methotrexate, pemetrexed, and raltitrexed;
or (e) a HDAC inhibitor such as romidepsin, vorinostat, Abexinostat, belinostat (PXD101), LAQ824, panobinostat (LBH589), entinostat (MS-275), tacedinaline (01994), and mocetinostat (MGCD0103).
The treatment may involve administration of the anti-0D25 ADC / anti-BCL-2 agent combination alone or in further combination with other treatments, either simultaneously or sequentially dependent upon the condition to be treated.
An example method of treatment with the anti-0D25 ADC plus anti-BCL2 combination involves:
(1) identifying an individual has been treated with, or is being treated with an anti-BCL-2 agent, such as Venetoclax;
(2) administering to the individual an anti-0D25 ADC, such as ADCx25; and, optionally (3) administering to the individual an anti-BCL-2 agent, such as Venetoclax in combination with the anti-0D25 ADC (for example, at the same time as the ADC, or after the ADC).
An example method of treatment with the anti-0D25 ADC plus mTOR inhibitor combination involves:
(1) identifying an individual has been treated with, or is being treated with an mTOR inhibitor, such as Everolimus;
(2) administering to the individual an anti-0D25 ADC, such as ADCx25; and, optionally (3) administering to the individual an mTOR inhibitor, such as Everolimus in combination with the anti-0D25 ADC (for example, at the same time as the ADC, or after the ADC).
An example method of treatment with the anti-0D25 ADC plus secondary agent combination iinvolves:
(1) identifying an individual has been treated with, or is being treated with an secondary agent, such as Bendamustine, copanlisib, idelalisib, bortezomib, pralatrexate, romidepsin, or vorinostat;
(2) administering to the individual an anti-0D25 ADC, such as ADCx25; and, optionally (3) administering to the individual an secondary agent, such as Bendamustine, copanlisib, idelalisib, bortezomib, pralatrexate, romidepsin, or vorinostat in combination with the anti-0D25 ADC (for example, at the same time as the ADC, or after the ADC).
Examples of treatments and therapies include, but are not limited to, chemotherapy (the administration of active agents, including, e.g. drugs, such as chemotherapeutics);
surgery; and radiation therapy.
A "chemotherapeutic agent" is a chemical compound useful in the treatment of cancer, regardless of mechanism of action. Classes of chemotherapeutic agents include, but are not limited to: alkylating agents, antimetabolites, spindle poison plant alkaloids, cytotoxic/antitumor antibiotics, topoisomerase inhibitors, antibodies, photosensitizers, and kinase inhibitors. Chemotherapeutic agents include compounds used in "targeted therapy" and conventional chemotherapy.
Examples of chemotherapeutic agents include: Lenalidomide (REVLIMIDO, Celgene), Vorinostat (ZOLINZAO, Merck), Panobinostat (FARYDAKO, Novartis), Mocetinostat (MGCD0103), Everolimus (ZORTRESSO, CERTICANO, Novartis), Bendamustine (TREAKISYMO, RIBOMUSTINO, LEVACTO, TREANDAO, Mundipharma International), erloti nib (TARCEVAO, Genentech/OSI Pharm.), docetaxel (TAXOTEREO, Sanofi-Aventis), 5-FU (fluorouracil, 5-fluorouracil, CAS No. 51-21-8), gemcitabine (GEMZARO, Lilly), PD-0325901 (CAS No. 391210-10-9, Pfizer), cisplatin (cis-diamine, dichloroplatinum(II), CAS No. 15663-27-1), carboplatin (CAS No. 41575-94-4), paclitaxel (TAXOLO, Bristol-Myers Squibb Oncology, Princeton, N.J.), trastuzumab (HERCEPTINO, Genentech), temozolomide (4-methyl-5-oxo- 2,3,4,6,8-pentazabicyclo [4.3.0]
nona-2,7,9-triene- 9-carboxamide, CAS No. 85622-93-1, TEMODARO, TEMODALO, Schering Plough), tamoxifen ((Z)-2-[4-(1,2-diphenylbut-1-enyl)phenoxy]-N,N-dimethylethanamine, NOLVADEXO, ISTUBALO, VALODEX0), and doxorubicin (ADRIAMYCINO), Akti-1/2, HPPD, and rapamycin.
More examples of chemotherapeutic agents include: oxaliplatin (ELOXATINO, Sanofi), bortezomib (VELCADEO, Millennium Pharm.), sutent (SUNITINIBO, 5U11248, Pfizer), letrozole (FEMARAO, Novartis), imatinib mesylate (GLEEVECO, Novartis), XL-518 (Mek inhibitor, Exelixis, WO 2007/044515), ARRY-886 (Mek inhibitor, AZD6244, Array BioPharma, Astra Zeneca), SF-1126 (PI3K inhibitor, Semafore Pharmaceuticals), BEZ-235 (PI3K inhibitor, Novartis), XL-147 (PI3K inhibitor, Exelixis), PTK787/ZK
(Novartis), fulvestrant (FASLODEXO, AstraZeneca), leucovorin (folinic acid), rapamycin (sirolimus, RAPAMUNEO, VVyeth), lapatinib (TYKERBO, G5K572016, Glaxo Smith Kline), lonafarnib (SARASARTM, SCH 66336, Schering Plough), sorafenib (NEXAVARO, BAY43-9006, Bayer Labs), gefitinib (IRESSAO, AstraZeneca), irinotecan (CAMPTOSARO, CPT-11, Pfizer), tipifarnib (ZARNESTRATm, Johnson & Johnson), ABRAXANETM
(Cremophor-free), albumin-engineered nanoparticle formulations of paclitaxel (American Pharmaceutical Partners, Schaumberg, II), vandetanib (rINN, ZD6474, ZACTIMAO, AstraZeneca), chloranmbucil, AG1478, AG1571 (SU 5271; Sugen), temsirolimus (TORISELO, Wyeth), pazopanib (GlaxoSmithKline), canfosfamide (TELCYTAO, Telik), thiotepa and cyclosphosphamide (CYTOXANO, NEOSARO); alkyl sulfonates such as busulfan, improsulfan and piposulfan; aziridines such as benzodopa, carboquone, meturedopa, and uredopa; ethylenimines and methylamelamines including altretamine, triethylenemelamine, triethylenephosphoramide, triethylenethiophosphoramide and trimethylomelamine; acetogenins (especially bullatacin and bullatacinone); a camptothecin (including the synthetic analog topotecan); bryostatin;
callystatin; CC-1065 (including its adozelesin, carzelesin and bizelesin synthetic analogs);
cryptophycins (particularly cryptophycin 1 and cryptophycin 8); dolastatin; duocarmycin (including the synthetic analogs, KW-2189 and CB1-TM1); eleutherobin; pancratistatin; a sarcodictyin;
spongistatin; nitrogen mustards such as chlorambucil, chlornaphazine, chlorophosphamide, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, novembichin, phenesterine, prednimustine, trofosfamide, uracil mustard; nitrosoureas such as carmustine, chlorozotocin, fotemustine, lomustine, nimustine, and ranimnustine; antibiotics such as the enediyne antibiotics (e.g.
calicheamicin, calicheamicin gamma11, calicheamicin omegal1 (Angew Chem. Intl.
Ed.
Engl. (1994) 33:183-186); dynemicin, dynemicin A; bisphosphonates, such as clodronate;
an esperamicin; as well as neocarzinostatin chromophore and related chromoprotein enediyne antibiotic chromophores), aclacinomysins, actinomycin, authramycin, azaserine, bleomycins, cactinomycin, carabicin, carminomycin, carzinophilin, chromomycinis, dactinomycin, daunorubicin, detorubicin, 6-diazo-5-oxo-L-norleucine, morpholino-doxorubicin, cyanomorpholino-doxorubicin, 2-pyrrolino-doxorubicin and deoxydoxorubicin), epirubicin, esorubicin, idarubicin, nemorubicin, marcellomycin, mitomycins such as mitomycin C, mycophenolic acid, nogalamycin, olivomycins, peplomycin, porfiromycin, puromycin, quelamycin, rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, zorubicin; anti-metabolites such as methotrexate and 5-fluorouracil (5-FU); folic acid analogs such as denopterin, methotrexate, pteropterin, trimetrexate; purine analogs such as fludarabine, 6-mercaptopurine, thiamiprine, thioguanine; pyrimidine analogs such as ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine; androgens such as cal usterone, dromostanolone propionate, epitiostanol, mepitiostane, testolactone; anti-adrenals such as aminoglutethimide, mitotane, trilostane; folic acid replenisher such as frolinic acid; aceglatone; aldophosphamide glycoside; aminolevulinic acid;
eniluracil;
amsacrine; bestrabucil; bisantrene; edatraxate; defofamine; demecolcine;
diaziquone;
elfornithine; elliptinium acetate; an epothilone; etoglucid; gallium nitrate;
hydroxyurea;
lentinan; lonidainine; maytansinoids such as maytansine and ansamitocins;
mitoguazone;
mitoxantrone; mopidanmol; nitraerine; pentostatin; phenamet; pirarubicin;
losoxantrone;
podophyllinic acid; 2-ethylhydrazide; procarbazine; PSKO polysaccharide complex (JHS
Natural Products, Eugene, OR); razoxane; rhizoxin; sizofiran; spirogermanium;
tenuazonic acid; triaziquone; 2,2',2"-trichlorotriethylamine; trichothecenes (especially T-2 toxin, verracurin A, roridin A and anguidine); urethan; vindesine;
dacarbazine;
mannomustine; mitobronitol; mitolactol; pipobroman; gacytosine; arabinoside ("Ara-C");
cyclophosphamide; thiotepa; 6-thioguanine; mercaptopurine; methotrexate;
platinum analogs such as cisplatin and carboplatin; vinblastine; etoposide (VP-16);
ifosfamide;
mitoxantrone; vincristine; vinorelbine (NAVELBINE0); novantrone; teniposide;
edatrexate;
daunomycin; aminopterin; capecitabine (XELODAO, Roche); ibandronate; CPT-11;
topoisomerase inhibitor RFS 2000; difluoromethylornithine (DMF0); retinoids such as retinoic acid; and pharmaceutically acceptable salts, acids and derivatives of any of the above. Combinations of agents may be used, such as CHP (doxorubicin, prednisone, cyclophosphamide), or CHOP (doxorubicin, prednisone, cyclophopsphamide, vincristine).
Also included in the definition of "chemotherapeutic agent" are: (i) anti-hormonal agents that act to regulate or inhibit hormone action on tumors such as anti-estrogens and selective estrogen receptor modulators (SERMs), including, for example, tamoxifen (including NOLVADEXO; tamoxifen citrate), raloxifene, droloxifene, 4-hydroxytamoxifen, trioxifene, keoxifene, LY117018, onapristone, and FARESTONO (toremifine citrate); (ii) aromatase inhibitors that inhibit the enzyme aromatase, which regulates estrogen production in the adrenal glands, such as, for example, 4(5)-imidazoles, aminoglutethimide, MEGASEO (megestrol acetate), AROMASINO (exemestane;
Pfizer), formestanie, fadrozole, RIVISORO (vorozole), FEMARAO (letrozole; Novartis), and ARIMIDEXO (anastrozole; AstraZeneca); (iii) anti-androgens such as flutamide, nilutamide, bicalutamide, leuprolide, and goserelin; as well as troxacitabine (a 1,3-dioxolane nucleoside cytosine analog); (iv) protein kinase inhibitors such as MEK
inhibitors (WO 2007/044515); (v) lipid kinase inhibitors; (vi) antisense oligonucleotides, particularly those which inhibit expression of genes in signaling pathways implicated in aberrant cell proliferation, for example, PKC-alpha, Raf and H-Ras, such as oblimersen (GENASENSEO, Genta Inc.); (vii) ribozymes such as VEGF expression inhibitors (e.g., ANGIOZYMEO) and HER2 expression inhibitors; (viii) vaccines such as gene therapy vaccines, for example, ALLOVECTINO, LEUVECTINO, and VAXIDO; PROLEUKINO rIL-2; topoisomerase 1 inhibitors such as LURTOTECANO; ABARELIXO rmRH; (ix) anti-angiogenic agents such as bevacizumab (AVASTINO, Genentech); and pharmaceutically acceptable salts, acids and derivatives of any of the above.
Also included in the definition of "chemotherapeutic agent" are therapeutic antibodies such as alemtuzumab (Campath), bevacizumab (AVASTINO, Genentech); cetuximab (ERBITUXO, lmclone); panitumumab (VECTIBIXO, Amgen), pertuzumab (PERJETATm, OMNITARGTm, 204, Genentech), trastuzumab (HERCEPTINO, Genentech), MDX-060 (Medarex) and the antibody drug conjugate, gemtuzumab ozogamicin (MYLOTARGO, Wyeth).
Humanized monoclonal antibodies with therapeutic potential as chemotherapeutic agents in combination with the conjugates of the disclosure include: alemtuzumab, apolizumab, aselizumab, atlizumab, bapineuzumab, bevacizumab, bivatuzumab mertansine, cantuzumab mertansine, cedelizumab, certolizumab pegol, cidfusituzumab, cidtuzumab, daclizumab, eculizumab, efalizumab, epratuzumab, erlizumab, felvizumab, fontolizumab, gemtuzumab ozogamicin, inotuzumab ozogamicin, ipilimumab, labetuzumab, lintuzumab, matuzumab, mepolizumab, motavizumab, motovizumab, natalizumab, nimotuzumab, nolovizumab, numavizumab, omalizumab, palivizumab, pascolizumab, pecfusituzumab, pectuzumab, pertuzumab, pexelizumab, ralivizumab, ranibizumab, reslivizumab, reslizumab, resyvizumab, rovelizumab, ruplizumab, sibrotuzumab, siplizumab, sontuzumab, tacatuzumab tetraxetan, tadocizumab, talizumab, tefibazumab, tocilizumab, toralizumab, trastuzumab, tucotuzumab celmoleukin, tucusituzumab, umavizumab, urtoxazumab, and visilizumab.
Compositions according to the present disclosure are preferably pharmaceutical compositions. Pharmaceutical compositions according to the present disclosure, and for use in accordance with the present disclosure, may comprise, in addition to the active ingredient, i.e. a conjugate compound, a pharmaceutically acceptable excipient, carrier, buffer, stabiliser or other materials well known to those skilled in the art.
Such materials should be non-toxic and should not interfere with the efficacy of the active ingredient.
The precise nature of the carrier or other material will depend on the route of administration, which may be oral, or by injection, e.g. cutaneous, subcutaneous, or intravenous.
Pharmaceutical compositions for oral administration may be in tablet, capsule, powder or liquid form. A tablet may comprise a solid carrier or an adjuvant. Liquid pharmaceutical compositions generally comprise a liquid carrier such as water, petroleum, animal or vegetable oils, mineral oil or synthetic oil. Physiological saline solution, dextrose or other saccharide solution or glycols such as ethylene glycol, propylene glycol or polyethylene glycol may be included. A capsule may comprise a solid carrier such a gelatin.
For intravenous, cutaneous or subcutaneous injection, or injection at the site of affliction, the active ingredient will be in the form of a parenterally acceptable aqueous solution which is pyrogen-free and has suitable pH, isotonicity and stability. Those of relevant skill in the art are well able to prepare suitable solutions using, for example, isotonic vehicles such as Sodium Chloride Injection, Ringer's Injection, Lactated Ringer's Injection.
Preservatives, stabilisers, buffers, antioxidants and/or other additives may be included, as required.
Dosage It will be appreciated by one of skill in the art that appropriate dosages of the anti-CD25 ADC and/or the anti-BCL-2 agent, mTOR inhibitor, or secondary agent, and compositions comprising these active elements, can vary from subject to subject.
Determining the optimal dosage will generally involve the balancing of the level of therapeutic benefit against any risk or deleterious side effects. The selected dosage level will depend on a variety of factors including, but not limited to, the activity of the particular compound, the route of administration, the time of administration, the rate of excretion of the compound, the duration of the treatment, other drugs, compounds, and/or materials used in combination, the severity of the condition, and the species, sex, age, weight, condition, general health, and prior medical history of the subject. The amount of compound and route of administration will ultimately be at the discretion of the physician, veterinarian, or clinician, although generally the dosage will be selected to achieve local concentrations at the site of action which achieve the desired effect without causing substantial harmful or deleterious side-effects.
In certain aspects, the dosage of anti-CD25 ADC is determined by the expression of CD25 observed in a sample obtained from the subject. Thus, the level or localisation of expression of CD25 in the sample may be indicative that a higher or lower dose of anti-CD25 ADC is required. For example, a high expression level of CD25 may indicate that a higher dose of anti-CD25 ADC would be suitable. In some cases, a high expression level of CD25 may indicate the need for administration of another agent in addition to the anti-CD25 ADC. For example, administration of the anti-CD25 ADC in conjunction with a chemotherapeutic agent. A high expression level of CD25 may indicate a more aggressive therapy.
In certain aspects, the dosage of the anti-BCL-2 agent, mTOR inhibitor, or secondary agent is determined by the expression of observed in a sample obtained from the subject.
Thus, the level or localisation of expression of in the sample may be indicative that a higher or lower dose of anti-BCL-2 agent, mTOR inhibitor, or secondary agent is required.
For example, a high expression level of BCL-2, mTOR, or secondary target protein may indicate that a higher dose of anti-BCL-2 agent, mTOR inhibitor, or secondary agent would be suitable. In some cases, a high expression level of BCL-2, mTOR, or secondary target protein may indicate the need for administration of another agent in addition to the anti-BCL-2 agent, mTOR inhibitor, or secondary agent. For example, administration of the anti-BCL-2 agent, mTOR inhibitor, or secondary agent in conjunction with a chemotherapeutic agent. A high expression level of BCL-2, mTOR, or secondary target protein may indicate a more aggressive therapy.
Administration can be effected in one dose, continuously or intermittently (e.g., in divided doses at appropriate intervals) throughout the course of treatment.
Methods of determining the most effective means and dosage of administration are well known to those of skill in the art and will vary with the formulation used for therapy, the purpose of the therapy, the target cell(s) being treated, and the subject being treated.
Single or multiple administrations can be carried out with the dose level and pattern being selected by the treating physician, veterinarian, or clinician.
In general, a suitable dose of each active compound is in the range of about 100 ng to about 25 mg (more typically about 1 pg to about 10 mg) per kilogram body weight of the subject per day. Where the active compound is a salt, an ester, an amide, a prodrug, or the like, the amount administered is calculated on the basis of the parent compound and so the actual weight to be used is increased proportionately.
In one embodiment, each active compound is administered to a human subject according to the following dosage regime: about 100 mg, 3 times daily.
In one embodiment, each active compound is administered to a human subject according to the following dosage regime: about 150 mg, 2 times daily.
In one embodiment, each active compound is administered to a human subject according to the following dosage regime: about 200 mg, 2 times daily.
However in one embodiment, each conjugate compound is administered to a human subject according to the following dosage regime: about 50 or about 75 mg, 3 or 4 times daily.
In one embodiment, each conjugate compound is administered to a human subject according to the following dosage regime: about 100 or about 125 mg, 2 times daily.
For the anti-0D25 ADC, where it is a PBD bearing ADC, the dosage amounts described above may apply to the conjugate (including the PBD moiety and the linker to the antibody) or to the effective amount of PBD compound provided, for example the amount of compound that is releasable after cleavage of the linker.
The anti-0D25 ADC comprises an anti-0D25 antibody. The anti-0D25 antibody may be HuMax-TACTM. The ADC may comprise a drug which is a PBD dimer. The ADC may be an anti-0D25-ADC, and in particular, ADCX25 or ADCT-301. The ADC may be an ADC disclosed in W02014/057119.
The anti-BCL-2 agent may be Venetoclax (ABT-199), navitoclax (ABT-263), ABT-737, S55746/BCL201, and oblimersen (G3139). Preferably the anti-BCL-2 agent is Venetoclax (A BT-199).
The mTOR inhibitor may be everolimus (RAD001), sirolimus (Rapamycin), 00I-779 (temsirolimus), ridaforolimus (AP-23573), NVP-BEZ235 (dactolisib), BGT226, SF1126, Gedatolisib, Omipalisib, XL765, Ku-0063794, oleuropein aglycone, AZD8055, AZD2014, AZD 3147, sapanisertib (INK128/MLN0128), 0SI027, torin 1, torin 2, torkinib (PP242), VVYE687, ETP45658, PF05212384, PF04691502, XL388, eCF309, RapaLink-1, or Rapalink-2.
The secondary agent may be:
(a) Bendamustine;
(b) a phosphoinositide 3-kinase inhibitor such as copanlisib, idelalisib, duvelisib, Taselisib, Buparlisib, Alpelisib, Umbralisib, Dactolisib, and Voxtalisib;
(c) a proteasome inhibitor such as bortezomib, carfilzomib, lxazomib, Oprozomib, and Salinosporamide A;
(d) an anti-folate such as pralatrexate, methotrexate, pemetrexed, and raltitrexed;
or (e) a HDAC inhibitor such as romidepsin, vorinostat, Abexinostat, belinostat (PXD101), LAQ824, panobinostat (LBH589), entinostat (MS-275), tacedinaline (01994), and mocetinostat (MGCD0103).
Antibodies The term "antibody" herein is used in the broadest sense and specifically covers monoclonal antibodies, polyclonal antibodies, dimers, multimers, multispecific antibodies (e.g., bispecific antibodies), intact antibodies (also described as "full-length" antibodies) and antibody fragments, so long as they exhibit the desired biological activity, for example, the ability to bind 0D25 (Miller et al (2003) Jour. of Immunology 170:4854-4861). Antibodies may be murine, human, humanized, chimeric, or derived from other species such as rabbit, goat, sheep, horse or camel.
An antibody is a protein generated by the immune system that is capable of recognizing and binding to a specific antigen. (Janeway, C., Travers, P., Walport, M., Shlomchik (2001) lmmuno Biology, 5th Ed., Garland Publishing, New York). A target antigen generally has numerous binding sites, also called epitopes, recognized by Complementarity Determining Regions (CDRs) on multiple antibodies. Each antibody that specifically binds to a different epitope has a different structure.
Thus, one antigen may have more than one corresponding antibody. An antibody may comprise a full-length immunoglobulin molecule or an immunologically active portion of a full-length immunoglobulin molecule, i.e., a molecule that contains an antigen binding site that immunospecifically binds an antigen of a target of interest or part thereof, such targets including but not limited to, cancer cell or cells that produce autoimmune antibodies associated with an autoimmune disease. The immunoglobulin can be of any type (e.g.
IgG, IgE, IgM, IgD, and IgA), class (e.g. IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2) or subclass, or allotype (e.g. human G1m1, G1m2, G1m3, non-G1m1 [that, is any allotype other than G1m1], G1m17, G2m23, G3m21, G3m28, G3m11, G3m5, G3m13, G3m14, G3m10, G3m15, G3m16, G3m6, G3m24, G3m26, G3m27, A2m1, A2m2, Km1, Km2 and Km3) of immunoglobulin molecule. The immunoglobulins can be derived from any species, including human, murine, or rabbit origin.
"Antibody fragments" comprise a portion of a full length antibody, generally the antigen binding or variable region thereof. Examples of antibody fragments include Fab, Fab', F(ab')2, and scFv fragments; diabodies; linear antibodies; fragments produced by a Fab expression library, anti-idiotypic (anti-Id) antibodies, CDR (complementary determining region), and epitope-binding fragments of any of the above which immunospecifically bind to cancer cell antigens, viral antigens or microbial antigens, single-chain antibody molecules; and multispecific antibodies formed from antibody fragments.
The term "monoclonal antibody" as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e. the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigenic site. Furthermore, in contrast to polyclonal antibody preparations which include different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen. In addition to their specificity, the monoclonal antibodies are advantageous in that they may be synthesized uncontaminated by other antibodies. The modifier "monoclonal" indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method. For example, the monoclonal antibodies to be used in accordance with the present disclosure may be made by the hybridoma method first described by Kohler eta! (1975) Nature 256:495, or may be made by recombinant DNA methods (see, US 4816567). The monoclonal antibodies may also be isolated from phage antibody libraries using the techniques described in Clackson et al (1991) Nature, 352:624-628; Marks et al (1991) J.
Mol. Biol., 222:581-597 or from transgenic mice carrying a fully human immunoglobulin system (Lonberg (2008) Curr. Opinion 20(4):450-459).
The monoclonal antibodies herein specifically include "chimeric" antibodies in which a portion of the heavy and/or light chain is identical with or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical with or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, so long as they exhibit the desired biological activity (US 4816567; and Morrison et al (1984) Proc. Natl. Acad. Sci. USA, 81:6851-6855).
Chimeric antibodies include "primatized" antibodies comprising variable domain antigen-binding sequences derived from a non-human primate (e.g. Old World Monkey or Ape) and human constant region sequences.
An "intact antibody" herein is one comprising VL and VH domains, as well as a light chain constant domain (CL) and heavy chain constant domains, CH1, CH2 and CH3. The constant domains may be native sequence constant domains (e.g. human native sequence constant domains) or amino acid sequence variant thereof. The intact antibody may have one or more "effector functions" which refer to those biological activities attributable to the Fc region (a native sequence Fc region or amino acid sequence variant Fc region) of an antibody. Examples of antibody effector functions include C1q binding;
complement dependent cytotoxicity; Fc receptor binding; antibody-dependent cell-mediated cytotoxicity (ADCC); phagocytosis; and down regulation of cell surface receptors such as B cell receptor and BCR.
Depending on the amino acid sequence of the constant domain of their heavy chains, intact antibodies can be assigned to different "classes." There are five major classes of intact antibodies: IgA, IgD, IgE, IgG, and IgM, and several of these may be further divided into "subclasses" (isotypes), e.g., IgG1, IgG2, IgG3, IgG4, IgA, and IgA2. The heavy-chain constant domains that correspond to the different classes of antibodies are called a,
N
HO
Formula XVI: 5-12,4-big(3S)-3-methyl-4-morpholinylipyrido[2,3-O]pyrimidin-7-y1]-2-methoxy-benzenemethanol n) AZD2014 i. CAS Number 4 1009298-59-2 (see http://www.cas.org/content/chemical-substances/faqs) -.N. =
"/
tt.
N
H Lo .00 Formula XVII: AZD2014 0) AZD 3147 i. CAS Number 4 1101810-02-9 (see http://www.cas.org/content/chemical-substances/faqs) [
vz Formula XVIII: N-14-1441-(Cyclopropylsulfonyl)cyclopropyl]-6-[(3S)-3-methyl-4-morpholinyl]-2-pyrimidinyliphenyli-N'-(2-hydroxyethyl)thiourea p) sapanisertib (INK128/MLN0128) i. CAS Number 4 1224844-38-5 (see http://www.cas.org/content/chemical-substances/faqs) N
"\=N
Formula XIX: 5-(4-Amino-l-propan-2-ylpyrazolo[3,4-O]pyrimidin-3-y1)-1,3-benzoxazol-2-amine q) OSI027 i. CAS Number 4 936890-98-1 (see http://www.cas.org/content/chemical-substances/faqs) ii. Unique Ingredient Identifier (UNII) 4 25MKH1SZOM
(see http://www.fda.gov/ForIndustry/DataStandards/SubstanceRegistrationSyst em-UniquelngredientldentifierUNII/default.htm) NO
NH
OH
Formula XX: 444-amino-5-(7-methoxy-1H-indol-2-Aimidazo[5,1411,2,4]triazin-7-ylicyclohexane-1-carboxylic acid r) Torin 1 i. CAS Number 4 1222998-36-8 (see http://www.cas.org/content/chemical-substances/faqs) (I-1/419 CF3 [I 11 Formula XXI: 144-[4-(1-0xopropyl)-1-piperazinyl]-3-(trifluoromethyl)pheny1]-9-(3-quinoliny1)-benzo[h]-1,6-naphthyridin-2(1H)-one s) Torin 2 i. CAS Number 4 1223001-51-1 (see http://www.cas.org/content/chemical-substances/faqs) F F
Formula XXII: 9-(6-Amino-3-pyridiny1)-143-(trifluoromethyl)phenyli-benzo[h]-1,6-naphthyridin-2(1H)-one t) Torkinib (PP242) i. CAS Number 4 1092351-67-1 (see http://www.cas.org/content/chemical-substances/faqs) N-N
N--µN HN OH
Formula XXIII: 2-(4-Amino- 1-isopropy1-1H-pyrazolo[3,4-d]pyrimidin-3-y1)-1H-indol-5-ol u) VVYE687 i. CAS Number 4 1062161-90-3 (see http://www.cas.org/content/chemical-substances/faqs) L J
JUN.
¨r"-z=N
Formula XXIV: N4444-(4-Morpholiny1)-141-(3-pyridinylmethyl)-4-piperidinyl]-1H-pyrazolo[3,4-d]pyrimidin-6-yl]pheny1]-carbamic acid methyl ester hydrochloride v) ETP45658 i. CAS Number 4 1198357-79-7 (see http://www.cas.org/content/chemical-substances/faqs) Drugbank reference 4 (see https://www.drugbank.ca/) iii. Unique Ingredient Identifier (UNII) 4 (see http://www.fda.gov/ForIndustry/DataStandards/SubstanceRegistrationSyst em-UniquelngredientldentifierUNII/default.htm) I N
HO
Formula XXV: 3[1-Methy1-4-(4-morpholiny1)-1H-pyrazolo[3,4-O]pyrimidin-6-ylphenol w) PF05212384 i. CAS Number 4 1197160-78-3 (see http://www.cas.org/content/chemical-substances/faqs) Drugbank reference 4 DB11896 (see https://www.drugbank.ca/) iii. Unique Ingredient Identifier (UNII) 4 96265TNH2R
(see http://www.fda.gov/ForIndustry/DataStandards/SubstanceRegistrationSyst em-UniquelngredientldentifierUNII/default.htm) te,.0 ' I
I j H H
Formula XXVI: N-[4-[[4-(Dimethylamino)-1-piperidinyl]carbonyl]phenyTN'44-(4,6-di-4-morpholinyl-1,3,5-triazin-2-Aphenyl]urea x) PF04691502 i. CAS Number 4 1013101-36-4 (see http://www.cas.org/content/chemical-substances/faqs) CHs N OCH3 N
HO) Formula XXVII: Amino-8-[trans-4-(2-hydroxyethoxy)cyclohexyl]-6-(6-methoxy-3-pyridiny1)-4-methyl-pyrido[2,3-d]pyrimidin-7(8H)-one y) XL388 i. CAS Number 4 1251156-08-7 (see http://www.cas.org/content/chemical-substances/faqs) /S%
Formula XXVIII: [7-(6-Amino-3-pyridiny1)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl][3-fluoro-2-methy1-4-(methylsulfonyl)phenyl]-metha none z) eCF309 i. CAS Number 4 2001571-40-8 (see http://www.cas.org/content/chemical-substances/faqs) 1-.11 ==
kro - õ
=
Formula XXIX: 3-(2-Amino-5-benzoxazoly1)-1-(2,2-diethoxyethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine aa) RapaLink-1 i. CAS Number 4 1887095-82-0 (see http://www.cas.org/content/chemical-substances/faqs) Ak''%-õH-JetNi , H2N ft --"\O 0 L.0 -, . -_34 p I
Formula XXXI: 40-0-(241-(32-(4-amino-3-(2-aminobenzo[d]oxazol-5-y1)-1 H-pyrazolo[3,4-d]pyrimidin-1-y1)-27-oxo-3,6,9,12,15,18,21,24-octaoxa-28-azadotriaconty1)-1 H-1,2,3-triazol-4-yl)methoxy)ethyl)-rapa mycin bb) Rapalink-2 HzN N
Nz.N
N
7, =vo '..1,0d-^' 0.
Formula XXXII: 40-0-(241-(32-(4-amino-3-(2-aminobenzo[d]oxazol-5-y1)-1 H-pyrazolo[3,4-d]pyrimidin-1-y1)-27-oxo-3,6,9,12,15,18,21,24-heptaoxa-28-azadotriaconty1)-1 H-1,2,3-triazol-4-yl)methoxy)ethyl)-rapamycin Secondary agents The recent development of agents that enhance anti-tumor immunity is rapidly changing the treatment of a broad range of cancers. However, these treatments are not effective in all cancer types, responses are often not durable, and many patients receive little or no benefit from treatment. The prevailing assumption in the oncology field is that only combinations of immune-therapies with other treatment options will ultimately be able to cure cancer patients.
The ADC is well tolerated and active across a range of cancer types, and will likely be one component of combination therapies that increase the response rate and durability of treatment. The purpose of this disclosure is to combine the ADC
with the secondary agent.
A secondary agent as described herein may be an Immune-oncology (10) drug.
Immune-oncology (10) drugs, a type of cancer therapy relying on the body's immune system to help fight cancer, have shown enhanced durability of anti-tumor response.
There are different types of 10, including but not limited to PD1 inhibitors, inhibitors, CLTL4 inhibitors, GITR agonists and 0X40 agonists. Due to the considerable fraction of patients who are not cured by single agent immunotherapies and ultimately relapse, combination treatments with alternative 10 drugs or different therapeutic modalities are needed (see KS Peggs et al.2009, Clinical and Experimental Immunology, 157: 9-19 [doi: 10. 1111/0 365-2249.2009.03912.4; DM
Pardoll 2012 [doi:10.1038/nrc3239]).
Immunogenic cell death (ICD) is a particular form of cell death that stimulates an immune response against dead-cell antigens (released by dying cells) and it is considered as one of the best way to induce an adaptive immune response and improve the efficacy of anti-cancer treatment. This process is frequently suboptimal, calling for combinatorial strategies that attempt to restore the full immunogenicity of cell death for therapeutic purposes. There are several anti-neoplastic agents that can induce ICD such as various anthracyclines (including doxorubicin, epirubicin and idarubicin), alkylating agents (including oxaliplatin and cyclophosphamide), the topoisomerase 11 inhibitor mitoxantrone, and the proteasomal inhibitor Bortezomib.
Antibody-drug conjugates, including those with a PBD warhead, may be particularly suited as combination partners because they are more targeted compared to conventional chemotherapy and expected to offer an increased antigen presentation to infiltrating T cells as has been shown for auristatin-based ADCs.
Combining ADCs with 10 therefore allows for dual benefits: on the one hand, the ADC will directly kill the tumor expressing the target, providing immediate anti-tumor activity, and on the other the immunogenic cell death induced by ADC mediated cell kill may boost a stronger and more durable adaptive immune response, as compared to when the 10 is given as a single agent.
To show that anti-CD25 ADCs works synergistically with the secondary agent, a panel of CD25 (+) cell lines will be co-treated with a range of concentration of both anti-CD25 ADC
and the secondary agent. As negative controls, the same panel of cell lines will be treated with a range of concentrations of the secondary agent or with a range of concentration of anti-CD25 ADC and vehicle. After incubation, two parameters will be measured:
the amount of surface CD25 (as determined by flow cytometry) and the in vitro cytotoxicity of the combinations (as determined by MTS assays). To determine the cytotoxicity, Cell viability is measured by adding MTS per well and incubating for 4 hours at 37 C.
Percentage cell viability is calculated compared to the untreated control.
Cytotoxic synergy is calculated by transforming the cell viability data into fraction affected, and calculating the combination index using the CalcuSyn analysis program.
The secondary agent may be:
(a) Bendamustine;
(b) a phosphoinositide 3-kinase inhibitor such as copanlisib, idelalisib, duvelisib, Taselisib, Buparlisib, Alpelisib, Umbralisib, Dactolisib, and Voxtalisib;
(c) a proteasome inhibitor such as bortezomib, carfilzomib, lxazomib, Oprozomib, and Salinosporamide A;
(d) an anti-folate such as pralatrexate, methotrexate, pemetrexed, and raltitrexed;
or (e) a HDAC inhibitor such as romidepsin, vorinostat, Abexinostat, belinostat (PXD101), LAQ824, panobinostat (LBH589), entinostat (MS-275), tacedinaline (C1994), and mocetinostat (MGCD0103).
Each of these classes of secondary agent is described in more detail below.
Bendamustine Bendamustine is a bifunctional mechlorethamine derivative capable of forming electrophilic alkyl groups that covalently bond to other molecules. Through this function as an alkylating agent, bendamustine causes intra- and inter-strand crosslinks between DNA bases resulting in cell death. It is active against both active and quiescent cells.
Bendamustine has been indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.
i. CAS Number 16506-27-7 (see http://www.cas.org/content/chemical-substances/faqs) ii. Unique Ingredient Identifier (UNII) 9266D9P3PQ
(see http://www.fda. gov/Forl ndustry/DataStandards/SubstanceReg istrationSyst em-Uniquel ngredientldentifierU NI I/default. htm) õrib N _____________________________________ N
CI
Formula XXXII!: Bendamustine, 445-[Bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-ylibutanoic acid Phosphoinositide 3-kinase inhibitors The class 1 family of PI 3-kinase enzymes in vertebrates comprises four distinct protein species of approximately 110 kDa (p110a, p110[3, p1106 and p110y). All class!
enzymes share the majority of their structural features and a common substrate specificity (Rameh and Cantley, 1999; Fry, 2001; Katso et al., 2001). In vitro, all class 1 PI 3-kinases are capable of phosphorylating Ptdlns to PtdIns(3)P, PtdIns(4)P to PtdIns(3,4)P2 and PtdIns(4,5)P2 to PtdIns(3,4,5)P3, with PtdIns(4,5)P2 being considered the preferred lipid substrate in vivo. Class 1 PI 3-kinases are largely cytosolic in resting cells, but upon stimulation are recruited to membranes via interactions with receptors or adaptor proteins. They are thought to function primarily at the plasma membrane, but there have been reports of class 1 PI 3-kinases associated with vesicular and nuclear membranes (Rameh and Cantley, 1999; Fry, 2001; Katso et al., 2001). The cellular roles of class 1 PI
3-kinases are diverse, with evidence linking them to cell size, motility, survival and proliferation in response to numerous signalling systems in many different cell types (Fry, 2001; Katso et al., 2001). The class 1 family is further subdivided into two groups on the basis of their regulatory partners and mechanisms of activation.
Although PI3K was originally characterized two decades ago via its binding to oncogenes and activated RTKs (reviewed in Zhao JJ et al., 2006), its association with human cancer was not established until the late 1990s, when it was shown that the tumor suppressor PTEN acts as a P13-lipid phosphatase. Recent comprehensive cancer genomic analyses have revealed that multiple components of the PI3K pathway are frequently mutated or altered in common human cancers, underscoring the importance of this pathway in cancer (see Wood LD, et al. Science. 2007; Samuels Y, et al. Science. 2004).
"Phosphoinositide 3-kinase inhibitors" (PI3K inhibitors) is used herein to mean any agent that specifically binds to and/or inhibits a biological activity of PI3K.
As used herein, "specifically binds a PI3K" is used to mean the agent binds a PI3K with a higher affinity than a non-specific partner such as Bovine Serum Albumin (BSA, Genbank accession no. 0AA76847, version no. 0AA76847.1 GI:3336842, record update date:
Jan 7, 2011 02:30 PM). In some embodiments the agent binds a PI3K with an association constant (Ka) at least 2, 3, 4, 5, 10, 20, 50, 100, 200, 500, 1000, 2000, 5000, 104, 105 or 106-fold higher than the agent's association constant for BSA, when measured at physiological conditions. The agents may bind a PI3K with a high affinity. For example, in some embodiments the agent can bind a PI3Kwith a KD equal to or less than about 10-6 M, such as 1 x 10-6, 10-7, 10-8, 10-9,10-10, 10-11, 10-12, 10-13 or 10-14.
PI3K inhibitors suitable for use in the present disclosure include:
a) copanlisib i. CAS Number 4 1032568-63-0 (see http://www.cas.org/content/chemical-substances/faqs) Drugbank reference 4 DB12483 (see https://www.drugbank.ca/) iii. Unique Ingredient Identifier (UNII) 4 WI6V529FZ9 (see http://www.fda.gov/ForIndustry/DataStandards/SubstanceRegistrationSyst em-UniquelngredientldentifierUNII/default.htm) N
oCo) Formula XXXIV: copanlisib, 2-Amino-N-17-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo[1,2-c]quinazolin-5-ylipyrimidine-5-carboxamide b) idelalisib i. CAS Number 4 870281-82-6 (see http://www.cas.org/content/chemical-substances/faqs) Drugbank reference 4 DB09054 (see https://www.drugbank.ca/) iii. Unique Ingredient Identifier (UNII) 4 YG5718T5M0 (see http://www.fda.gov/ForIndustry/DataStandards/SubstanceRegistrationSyst em-UniquelngredientldentifierUNII/default.htm) HNIA,, i õ--,-HN N
N
OOP
Formula XXXV: idelalisib, 5-Fluoro-3-pheny1-2-[(1S)-1-(7H-purin-6-ylamino)propyl]-4(3H)-quinazolinone C) ,duvelisib i. CAS Number 4 1201438-56-3 (see http://www.cas.org/content/chemical-substances/faqs) ii. Drugbank reference 4 DB11952 (see https://www.drugbank.ca/) iii. Unique Ingredient Identifier (UNII) 4 610V23S0J1 (see http://www.fda.gov/ForIndustry/DataStandards/SubstanceRegistrationSyst em-UniquelngredientldentifierUNII/default.htm) H
N
ir Nx,\..,,,N
I
HN N
110 N At CI 0 1111.--1 Formula XXXVI: duvelisib, 8-Chloro-2-pheny1-3-[(1S)-1-(3H-purin-6-ylamino)ethyl]-1(2H)-isoquinolinone d) Taselisib i. CAS Number 4 1282512-48-4 (see http://www.cas.org/content/chemical-substances/faqs) ii. Unique Ingredient Identifier (UNII) 4 L08J20299M
(see http://www.fda.gov/ForIndustry/DataStandards/SubstanceRegistrationSyst em-UniquelngredientldentifierUNII/default.htm) 11 µ
c /
N
\ N
-""-LN-----Formula XXXVII: taselisib, 2-{4-12-(1-lsopropyl-3-methyl-1H-1,2,4-triazol-5-y1)-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepin-9-y1]-1H-pyrazol-1-y1}-2-methylpropanamide e) Buparlisib i. CAS Number 4 944396-07-0 (see http://www.cas.org/content/chemical-substances/faqs) ii. Drugbank reference 4 DB11666 (see https://www.drugbank.ca/) iii. Unique Ingredient Identifier (UNII) 4 OZM2Z182GD
(see http://www.fda.gov/ForIndustry/DataStandards/SubstanceRegistrationSyst em-UniquelngredientldentifierUNII/default.htm) N
I F
.-----F
F
)t, r=,,N N N'''''''''') CO
Formula XXXVIII: buparlisib, 5-[2,6-bis(morpholin-4-yOpyrimidin-4-y1]-4-(trifluoromethyl)pyridin-2-a mine f) Alpelisib i. CAS Number 4 1217486-61-7 (see http://www.cas.org/content/chemical-substances/faqs) Drugbank reference 4 (see https://www.drugbank.ca/) iii. Unique Ingredient Identifier (UNII) 4 (see http://www.fda.gov/ForIndustry/DataStandards/SubstanceRegistrationSyst em-UniquelngredientldentifierUNII/default.htm) s N
F F N
Formula XXXIX: alpelisib, (2S)-1-N-14-Methy1-542-(1,1,1-trifluoro-2-methylpropan-2-yOpyridin-4-y1]-1,3-thiazol-2-yl]pyrrolidine-1,2-dicarboxamide g) Umbralisib i. CAS Number 4 1532533-67-7 (see http://www.cas.org/content/chemical-substances/faqs) Drugbank reference 4 DB14989 (see https://www.drugbank.ca/) iii. Unique Ingredient Identifier (UNII) 4 38073MQB2A
(see http://www.fda.gov/ForIndustry/DataStandards/SubstanceRegistrationSyst em-UniquelngredientldentifierUNII/default.htm) F.
1.=
=11112 _ ;
F _ -Formula XL: umbralisib, (S)-2-(1-(4-amino-3-(3-fluoro-4-isopropoxypheny1)-1H-pyrazolo[3,4-d]pyrimidin-1-yOethyl)-6-fluoro-3-(3-fluoropheny1)-4H-chromen-4-one h) Dactolisib i. CAS Number 4 915019-65-7 (see http://www.cas.org/content/chemical-substances/faqs) ii. Drugbank reference 4 DB11651 (see https://www.drugbank.ca/) iii. Unique Ingredient Identifier (UNII) 4 RUJ6Z9YODT
(see http://www.fda.gov/ForIndustry/DataStandards/SubstanceRegistrationSyst em-UniquelngredientldentifierUNII/default.htm) N----N, N
Formula XLI: dactolisib, 2-Methy1-2-{443-methy1-2-oxo-8-(quinolin-3-y1)-2,3-dihydro-1H-imidazo[4,5-c]quinolin-1-yliphenyl}propanenitrile i) Voxtalisib i. CAS Number 4 934493-76-2 (see http://www.cas.org/content/chemical-substances/faqs) ii. Drugbank reference 4 DB12400 (see https://www.drugbank.ca/) iii. Unique Ingredient Identifier (UNII) 4 CVL1685GPH
(see http://www.fda.gov/ForIndustry/DataStandards/SubstanceRegistrationSyst em-UniquelngredientldentifierUNII/default.htm) "Nli- N H2 N --,.
HN
....--Formula XLII:
2-a mino-8-ethy1-4-methy1-6-(1 H-pyrazol-5-y1)-7H,8H-pyrido[2,3-d]pyrimidin-7-one Proteasome inhibitors The proteasome is a large protein complex responsible for degradation of intracellular proteins, a process that requires metabolic energy. Polymerization of ubiquitin, a key molecule known to work in concert with the proteasome, serves as a degradation signal for numerous target proteins; the destruction of a protein is initiated by covalent attachment of a chain consisting of several copies of ubiquitin (more than four ubiquitin molecules), through the concerted actions of a network of proteins, including the El (ubiquitin-activating), E2 (ubiquitin-conjugating) and E3 (ubiquitin-ligating) enzymes. The polymerized ubiquitin chain acts as a signal that shuttles the target proteins to the proteasome, where the substrate is proteolytically broken down. For accurate selection of the proteins, numerous enzymes (e.g., 2 El proteins, approximately 30 E2 proteins and more than 500 different species of E3 in humans) are mobilized with this cascade system.
The set of E3 proteins is highly diverse, because each E3 enzyme usually selectively recognizes a protein substrate for ubiquitylation (see Tanaka 2009, Proc Jpn Acad Ser B
Phys Biol Sci. 2009 Jan; 85(1): 12-36, and citations therein).
The ubiquitin¨proteasome system (UPS) controls almost all basic cellular processes¨
such as progression through the cell cycle, signal transduction, cell death, immune responses, metabolism, protein quality control and development¨by degrading short-lived regulatory or structurally aberrant proteins.
These protein regulatory processes are important also in cancer, and thus, the proteasome is an important regulator of carcinogenesis. Cancers include a variety of cells which, according to the cancer stem cell theory, descend from a small percentage of cancer stem cells, alternatively termed tumor-initiating cells. These cells constitute the subsets that have the ability to propagate the whole variety of cancer and repopulate tumors after cytostatic therapies. Proteasome plays a role in cellular processes in cancer stem cells, but it has been found to have a decreased function in them compared to the rest of cancer cells. In particular, the proteasome has been reported to play a role in the proliferation and pluripotency that is the defining characteristic of cancer cells and cancer stem cells (see Voutsadakis et al., Tumor Biology, Mar. 2017).
"Proteasome inhibitors" is used herein to mean any agent that specifically binds to and/or inhibits a biological activity of a proteasome component.
As used herein, "specifically binds a Proteasome component" is used to mean the agent binds a Proteasome component with a higher affinity than a non-specific partner such as Bovine Serum Albumin (BSA, Genbank accession no. CAA76847, version no.
CAA76847.1 GI:3336842, record update date: Jan 7,2011 02:30 PM). In some embodiments the agent binds a Proteasome component with an association constant (Ka) at least 2, 3, 4, 5, 10, 20, 50, 100, 200, 500, 1000, 2000, 5000, 104, 105 or 106-fold higher than the agent's association constant for BSA, when measured at physiological conditions. The agents may bind a Proteasome component with a high affinity.
For example, in some embodiments the agent can bind a Proteasome component with a KD
equal to or less than about 10-6 M, such as 1 x 10-6, 10-7, 10-8, 10-9,10-10, 10-11, 10-12, 10_13 or 10-14.
Proteasome inhibitors suitable for use in the present disclosure include:
a) bortezomib i. CAS Number 4 179324-69-7 (see http://www.cas.org/content/chemical-substances/faqs) Drugbank reference 4 DB00188 (see https://www.drugbank.ca/) iii. Unique Ingredient Identifier (UNII) 4 69G8BD63PP
(see http://www.fda.gov/ForIndustry/DataStandards/SubstanceRegistrationSyst em-UniquelngredientldentifierUNII/default.htm) 11, N B.,OH
Formula XLIII: bortezomib, [(1R)-3-methy1-1-({(2S)-3-phenyl-2-gpyrazin-2-ylcarbonyl)amindpropanoyllamino)butylporonic acid b) carfilzomib i. CAS Number 4 868540-17-4 (see http://www.cas.org/content/chemical-substances/faqs) Drugbank reference 4 DB08889 (see https://www.drugbank.ca/) iii. Unique Ingredient Identifier (UNII) 4 (see http://www.fda.gov/ForIndustry/DataStandards/SubstanceRegistrationSyst em-UniquelngredientldentifierUNII/default.htm) 10".""fiN N NN
H H
0 0 0 L.0 Formula XLIV: carfilzomib, (2S)-4-Methyl-N-1(2S)-1-1y2S)-4-methy1-1-[12R)-2-methyloxiran-2-y1]-1-oxopentan-2-yliamino]-1-oxo-3-phenylpropan-2-y1]-241(2S)-2-[12-morpholin-4-ylacetyl)amino]-4-phenylbutanoyliamino]pentanamide C) Ixazomib i. CAS Number 4 1072833-77-2 (see http://www.cas.org/content/chemical-substances/faqs) Drugbank reference 4 DB09570 (see https://www.drugbank.ca/) iii. Unique Ingredient Identifier (UNII) 4 71050168A2 (see http://www.fda.gov/ForIndustry/DataStandards/SubstanceRegistrationSyst em-UniquelngredientldentifierUNII/default.htm) HO OH
CI
Formula XLV: Ixazomib, N2-(2,5-Dichlorobenzoy1)-N-1(1R)-1-(dihydroxyboty1)-3-methylbutyliglycinamide d) Oprozomib i. CAS Number 4 935888-69-0 (see http://www.cas.org/content/chemical-substances/faqs) Drugbank reference 4 DB11991 (see https://www.drugbank.ca/) iii. Unique Ingredient Identifier (UNII) 4 MZ37792Y8J
(see http://www.fda.gov/ForIndustry/DataStandards/SubstanceRegistrationSyst em-UniquelngredientldentifierUNII/default.htm) =
Formula XLVI: Oprozomib, N-[(2S)-3-methoxy-1-[[(2S)-3-methoxy-1-[[(2S)-1-[(2R)-methyloxiran-2-y1]-1-oxo-3-phenylpropan-2-yliamino]-1-oxopropan-2-yliamino]-1-oxopropan-2-y1]-2-methy1-1,3-thiazole-5-carboxamide e) Salinosporamide A
i. CAS Number 4 437742-34-2 (see http://www.cas.org/content/chemical-substances/faqs) Drugbank reference 4 DB11762 (see https://www.drugbank.ca/) iii. Unique Ingredient Identifier (UNII) 4 703P9YDP7F
(see http://www.fda.gov/ForIndustry/DataStandards/SubstanceRegistrationSyst em-UniquelngredientldentifierUNII/default.htm) soH
µõOH
õNNH
Th CI
Formula XLVII: Salinosporamide A, (4R,5S)-4-(2-chloroethyl)-141S)-cyclohex-2-enyl(hydroxy)methyl)-5-methyl-6-oxa-2-azabicyclo[3.2.0]heptane-3,7-dione Anti-folates The antifolates were the first class of antimetabolites to enter the clinics 65 years ago.
Their mechanism of action is due to the disruption of the metabolic pathways that require one-carbon moieties supplied by the B9 folate vitamins which they resemble.
While renewing tissues of the bone marrow and intestinal tract are also folate-dependent and are sites of antifolate toxicity, the clinical utility of antifolates was established with the identification of doses and schedules of administration that provided sufficient selectivity to make these drugs effective in the treatment of cancer as well as inflammatory disorders An early anti-folate drug was methotrexate. However, despite its early clinical success, an understanding of the mechanism of action of methotrexate evolved slowly.
Likewise, the efficacy and selectivity of leucovorin "rescue" that allowed the safe administration of high doses of methotrexate was established entirely empirically and, even today, the basis for the selectivity of this regimen is not widely appreciated nor fully understood. The lack of a basic understanding of the biochemical and molecular pharmacology of methotrexate hampered efforts to develop subsequent generations of antifolates that would lead to the realization of the full clinical potential of this class of drugs. Hence, it was more than fifty years after the introduction of methotrexate that the second antifolate, pemetrexed, was approved in 2004 for the treatment of mesothelioma and subsequently non-small cell lung cancer. This was followed by approval of pralatrexate in 2009 for the treatment of cutaneous T-cell lymphoma.
"Anti-folate" is used herein to mean any agent that specifically binds to and/or inhibits a biological activity of a folate metabolism pathway component.
As used herein, "specifically binds a folate metabolism pathway component" is used to mean the agent binds a folate metabolism pathway component with a higher affinity than a non-specific partner such as Bovine Serum Albumin (BSA, Genbank accession no.
0AA76847, version no. 0AA76847.1 GI:3336842, record update date: Jan 7, 2011 02:30 PM). In some embodiments the agent binds a folate metabolism pathway component with an association constant (Ka) at least 2, 3, 4, 5, 10, 20, 50, 100, 200, 500, 1000, 2000, 5000, 104, 105 or 106-fold higher than the agent's association constant for BSA, when measured at physiological conditions. The agents may bind a folate metabolism pathway component with a high affinity. For example, in some embodiments the agent can bind a folate metabolism pathway component with a KD equal to or less than about 10-6 M, such as 1 x 10-6, 10-7, 10-8, 10-9,10-10, 10-11, 10-12, 10_13 or 10-14.
Anti-folates suitable for use in the present disclosure include:
a) pralatrexate i. CAS Number 4 146464-95-1 (see http://www.cas.org/content/chemical-substances/faqs) Drugbank reference 4 DB06813 (see https://www.drugbank.ca/) iii. Unique Ingredient Identifier (UNI I) 4 A8Q8119Q20 (see http://www.fda. gov/Forl ndustry/DataStandards/Substance Reg istrationSyst em-Uniquel ngredientldentifierU NI I/default. htm) Formula XLVIII: pralatrexate, N-(4-{1-[12,4-diaminopteridin-6-34)methyl]but-3-yn-1-yl}benzoy1)-L-glutamic acid SI
NrN COOH
b) methotrexate i. CAS Number 4 59-05-2 (see http://www.cas.org/content/chemical-substances/faqs) Drugbank reference 4 DB00563 (see https://www.drugbank.ca/) iii. Unique Ingredient Identifier (U Nil) 4 YL5FZ2Y5U1 (see http://www.fda.gov/ForIndustry/DataStandards/SubstanceRegistrationSyst em-UniquelngredientldentifierUNII/default.htm) oOH
NrOH
N NH
Formula XLIX: methotrexate, (2S)-2-114-{[(2,4-Diaminopteridin-6-34)methyl](methyl)amino}benzoy0amino]pentanedioic acid c) pemetrexed i. CAS Number 4 137281-23-3 (see http://www.cas.org/content/chemical-substances/faqs) Drugbank reference 4 DB00642 (see https://www.drugbank.ca/) iii. Unique Ingredient Identifier (UNII) 4 04Q9A1Z7N0 (see http://www.fda.gov/ForIndustry/DataStandards/SubstanceRegistrationSyst em-UniquelngredientldentifierUNII/default.htm) HN
N N
Formula L: pemetrexed, (2S)-24[4-12-(2-amino-4-oxo-1,7-dihydro pyrrolo[2,3-d]pyrimidin-5-yOethylibenzoyliamino}
pentanedioic acid d) raltitrexed i. CAS Number 4 112887-68-0 (see http://www.cas.org/content/chemical-substances/faqs) Drugbank reference 4 DB00293 (see https://www.drugbank.ca/) iii. Unique Ingredient Identifier (UNII) 4 FCB9EGG971 (see http://www.fda.gov/ForIndustry/DataStandards/SubstanceRegistrationSyst em-UniquelngredientldentifierUNII/default.htm) HN
OH
OH
Formula LI: raltitrexed, N-115-{methyl[(2-methy1-4-oxo-1,4-dihydroquinazolin-6-yOmethyl]amino}-2-thienyl)carbonyli-L-glutamic acid HDAC inhibitors A crucial role for epigenetic mechanisms in cancer development is demonstrated by a number of studies. Carcinogenesis cannot be explained only by genetic alterations, but also involve epigenetic processes (DNA methylation, histone modifications and non-coding RNA deregulation). Histone modifications include H3 and H4 histones lysine deacetylation that leads to chromatin decondensation. These alterations influence gene transcription including upregulation of several anti-oncogenes and DNA repair genes.
Thus, the epigenetic processes have emerged as novel therapeutic targets in numerous investigations.
The importance of histone deacetylase (HDAC) enzymes in organisms has been demonstrated using the studies with mice knocked out on members of class I
HDACs.
HDAC1-null mice die prenatally with severe proliferation defects and general growth retardation; HDAC2-null mice die the first day after birth for cardiac malformations; and HDAC3-null mice die prenatally for defects in gastrulation. HDACs seem to be important for gene expression. It has been described several times that their levels vary greatly in cancer cells and differ according to the tumor type. HDAC1 is highly expressed in prostate, gastric, lung, esophageal, colon and breast cancers. High levels of HDAC2 were found in colorectal, cervical and gastric cancers. In addition, HDAC3 is overexpressed in colon and breast tumors, whereas HDAC6 is highly expressed in mammary tumors, HDAC8 is overexpressed in neuroblastoma cells and HDAC11 mainly in rhabdomyosarcoma. Increased expression of different HDAC and/or histone hyperacetylation in different cancers is caused by different mechanisms which may affect effects of individual HDAC inhibitors (see Eckschlager et al., Int J Mol Sci.
2017 Jul;
18(7): 1414; and references cited therein).
"HDAC inhibitors" is used herein to mean any agent that specifically binds to and/or inhibits a biological activity of a HDAC.
As used herein, "specifically binds a HDAC" is used to mean the agent binds a HDAC
with a higher affinity than a non-specific partner such as Bovine Serum Albumin (BSA, Genbank accession no. 0AA76847, version no. 0AA76847.1 GI:3336842, record update date: Jan 7, 2011 02:30 PM). In some embodiments the agent binds a HDAC with an association constant (Ka) at least 2, 3, 4, 5, 10, 20, 50, 100, 200, 500, 1000, 2000, 5000, 104, 105 or 106-fold higher than the agent's association constant for BSA, when measured at physiological conditions. The agents may bind a HDAC with a high affinity.
For example, in some embodiments the agent can bind a HDAC with a KD equal to or less than about 10-6 M, such as 1 x 10-6, 10-7, 10-8, 10-9,10-10, 10-11, 10-12, 10_13 or 10-14.
HDAC inhibitors suitable for use in the present disclosure include:
a) romidepsin i. CAS Number 4 128517-07-7 (see http://www.cas.org/content/chemical-substances/faqs) ii. Drugbank reference 4 DB06176 (see https://www.drugbank.ca/) iii. Unique Ingredient Identifier (UNII) 4 CX3T89XQBK
(see http://www.fda.gov/ForIndustry/DataStandards/SubstanceRegistrationSyst em-UniquelngredientldentifierUNII/default.htm) 01:1T1Srs Formula LII: romidepsin, (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-diisopropy1-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone b) vorinostat i. CAS Number 4 149647-78-9 (see http://www.cas.org/content/chemical-substances/faqs) ii. Drugbank reference 4 DB02546 (see https://www.drugbank.ca/) iii. Unique Ingredient Identifier (UNII) 4 58IFB293J1 (see http://www.fda.gov/ForIndustry/DataStandards/SubstanceRegistrationSyst em-UniquelngredientldentifierUNII/default.htm) H
N'OH
H
---õ,_õ,:::,--= 0 Formula LIII:, N-Hydroxy-N'-phenyloctanediamide c) Abexinostat i. CAS Number 4 783355-60-2 (see http://www.cas.org/content/chemical-substances/faqs) Drugbank reference 4 DB12565 (see https://www.drugbank.ca/) iii. Unique Ingredient Identifier (UNII) 4 IY0470654U
(see http://www.fda.gov/ForIndustry/DataStandards/SubstanceRegistrationSyst em-UniquelngredientldentifierUNII/default.htm) IIMr N.OH
Formula LIV: abexinostat, 3-[(Dimethylamino)methyl]-N-{2-14-(hydroxycarbamoyl)phenoxyjethy1}-1-benzofuran-2-carboxamide d) belinostat (PXD101) i. CAS Number 4 866323-14-0 (see http://www.cas.org/content/chemical-substances/faqs) Drugbank reference 4 DB05015 (see https://www.drugbank.ca/) iii. Unique Ingredient Identifier (UNII) 4 F4H96P17NZ
(see http://www.fda.gov/ForIndustry/DataStandards/SubstanceRegistrationSyst em-UniquelngredientldentifierUNII/default.htm) (E) OH
N' osti Formula LV: belinostat, (2E)-N-Hydroxy-3-13-(phenylsulfamoyOphenyliprop-2-enamide e) LAQ824 i. CAS Number 4 404951-53-7 (see http://www.cas.org/content/chemical-substances/faqs) ii. Unique Ingredient Identifier (UNII) 4 V10P524501 (see http://www.fda.gov/ForIndustry/DataStandards/SubstanceRegistrationSyst em-UniquelngredientldentifierUNII/default.htm) OH
HN
HO/
Formula LVI: LAQ824, (2E)-N-hydroxy-344-17(2-hydroxyethyl)[2-(1H-indol-3-yOethyl]aminoimethyliphenyl]-2-propenamide f) panobinostat (LBH589) i. CAS Number 4 404950-80-7 (see http://www.cas.org/content/chemical-substances/faqs) Drugbank reference 4 DB06603 (see https://www.drugbank.ca/) iii. Unique Ingredient Identifier (UNII) 4 9647FM7Y3Z
(see http://www.fda.gov/ForIndustry/DataStandards/SubstanceRegistrationSyst em-UniquelngredientldentifierUNII/default.htm) :E
N'OH
HN N
Formula LVII: panobinostat, N-hydroxy(2E)-3-14-({12-(2-methy1-1H-indo1-3-Aethyliamino}methyl)phenyliprop-2-enimidic acid g) entinostat (MS-275) i. CAS Number 4 209783-80-2 (see http://www.cas.org/content/chemical-substances/faqs) Drugbank reference 4 DB11841 (see https://www.drugbank.ca/) iii. Unique Ingredient Identifier (UNII) 4 1ZNY4FKK9H
(see http://www.fda.gov/ForIndustry/DataStandards/SubstanceRegistrationSyst em-UniquelngredientldentifierUNII/default.htm) H
N
H
...,--Formula LVIII: entinostat, Pyridin-3-ylmethyl N-IT4-112-aminophenyOcarbamoyliphenylimethylicarbamate h) tacedinaline (01994) i. CAS Number 4 112522-64-2 (see http://www.cas.org/content/chemical-substances/faqs) ii. Drugbank reference 4 DB12291 (see https://www.drugbank.ca/) iii. Unique Ingredient Identifier (UNII) 4 UMF554N5FG
(see http://www.fda.gov/ForIndustry/DataStandards/SubstanceRegistrationSyst em-UniquelngredientldentifierUNII/default.htm) II. 0 0 0 H"AN NH2 H
Formula LIX: tacedinaline, N-(2-aminophenyI)-4-acetamidobenzamide i) mocetinostat (MGCD0103) i. CAS Number 4 726169-73-9 (see http://www.cas.org/content/chemical-substances/faqs) ii. Drugbank reference 4 DB11830 (see https://www.drugbank.ca/) iii. Unique Ingredient Identifier (UNII) 4 A6GWB8T96J
(see http://www.fda.gov/ForIndustry/DataStandards/SubstanceRegistrationSyst em-UniquelngredientldentifierUNII/default.htm) Formula LX: mocetinostat, N-(2-aminopheny1)-4-({14-(pyridin-3-Apyrimidin-2-yliamino}methyObenzamide Advantageous properties of the described combinations Both the anti-0D25 ADC and anti-BCL-2 agent, mTOR inhibitor, or secondary agent when used as a single agent in isolation have demonstrated clinical utility ¨
for example, in the treatment of cancer. However, as described herein, combination of the anti-0D25 ADC and anti-BCL-2 agent, mTOR inhibitor, or secondary agent is expected to provide one or more of the following advantages over treatment with either anti-0D25 ADC or anti-BCL-2 agent, mTOR inhibitor, or secondary agent alone:
1) effective treatment of a broader range of cancers;
2) effective treatment of resistant or refractory forms of disorders such as cancer, and individuals with disorders such as cancer who have relapsed after a period of remission;
3) increased response rate to treatment; and / or 4) Increased durability of treatment.
Effective treatment of a broader range of cancers as used herein means that following treatment with the combination a complete response is observed with a greater range of recognised cancer types. That is, a complete response is seen from cancer types not previously reported to completely respond to either anti-0D25 ADC or anti-BCL-2 agent, mTOR inhibitor, or secondary agent alone.
Effective treatment of a resistant, refractory, or relapsed forms as used herein means that following treatment with the combination a complete response is observed in individuals that are either partially or completely resistant or refractory to treatment with either anti-0D25 ADC or anti-BCL-2 agent, mTOR inhibitor, or secondary agent alone (for example, individuals who show no response or only partial response following treatment with either agent alone, or those with relapsed disorder). In some embodiments, a complete response following treatment with the anti-0D25 ADC / anti-BCL-2 agent, mTOR inhibitor, or secondary agent combination is observed at least 10% of individuals that are either partially or completely resistant or refractory to treatment with either anti-0D25 ADC or anti-BCL-2 agent, mTOR inhibitor, or secondary agent alone.
In some embodiments, a complete response following treatment with the anti-0D25 ADC /
anti-BCL-2 agent, mTOR inhibitor, or secondary agent combination is observed at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 98%, or at least 99% of individuals that are either partially or completely resistant or refractory to treatment with either anti-0D25 ADC or anti-BCL-2 agent, mTOR inhibitor, or secondary agent alone.
Increased response rate to treatment as used herein means that following treatment with the combination a complete response is observed in a greater proportion of individuals than is observed following treatment with either anti-0D25 ADC or anti-BCL-2 agent, mTOR inhibitor, or secondary agent alone. In some embodiments, a complete response following treatment with the anti-0D25 ADC / anti-BCL-2 agent, mTOR inhibitor, or secondary agent combination is observed at least 10% of treated individuals.
In some embodiments, a complete response following treatment with the anti-0D25 ADC /
anti-BCL-2 agent, mTOR inhibitor, or secondary agent combination is observed at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 98%, or at least 99% of treated individuals.
Increased durability of treatment as used herein means that average duration of complete response in individuals treated with the combination is longer than in individuals who achieve complete response following treatment with either anti-0D25 ADC or anti-BCL-2 agent, mTOR inhibitor, or secondary agent alone. In some embodiments, the average duration of a complete response following treatment with the anti-0D25 ADC /
anti-BCL-2 agent, mTOR inhibitor, or secondary agent combination is at least 6 months. In some embodiments, the average duration of a complete response following treatment with the anti-0D25 ADC / anti-BCL-2 agent, mTOR inhibitor, or secondary agent combination is at least 12 months, at least 18 months, at least 24 months, at least 3 years, at least 4 years, at least 5 years, at least 6 years, at least 7 years, at least 8 years, at least 9 years, at least 10 years, at least 15 years, or at least 20 years.
'Complete response' is used herein to mean the absence of any clinical evidence of disease in an individual. Evidence may be assessed using the appropriate methodology in the art, for example CT or PET scanning, or biopsy where appropriate. The number of doses required to achieve complete response may be one, two, three, four, five, ten or more. In some embodiments the individuals achieve complete response no more than a year after administration of the first dose, such as no more than 6 months, no more than 3 months, no more than a month, no more than a fortnight, or no more than a week after administration of the first dose.
Treated disorders The combined therapies described herein include those with utility for anticancer activity.
In particular, in certain aspects the therapies include an antibody conjugated, i.e.
covalently attached by a linker, to a PBD drug moiety, i.e. toxin. When the drug is not conjugated to an antibody, the PBD drug has a cytotoxic effect. The biological activity of the PBD drug moiety is thus modulated by conjugation to an antibody. The antibody-drug conjugates (ADC) of the disclosure selectively deliver an effective dose of a cytotoxic agent to tumor tissue whereby greater selectivity, i.e. a lower efficacious dose, may be achieved.
Thus, in one aspect, the present disclosure provides combined therapies comprising administering an anti-0D25 ADC which binds 0D25 for use in therapy, wherein the method comprises selecting a subject based on expression of the target protein.
In one aspect, the present disclosure provides a combined therapy with a label that specifies that the therapy is suitable for use with a subject determined to be suitable for such use. The label may specify that the therapy is suitable for use in a subject has expression of 0D25, such as overexpression of 0D25. The label may specify that the subject has a particular type of cancer.
In a further aspect there is also provided a combined therapy as described herein for use in the treatment of a proliferative disease. Another aspect of the present disclosure provides the use of a conjugate compound in the manufacture of a medicament for treating a proliferative disease.
One of ordinary skill in the art is readily able to determine whether or not a candidate combined therapy treats a proliferative condition for any particular cell type. For example, assays which may conveniently be used to assess the activity offered by a particular compound are described below.
The combined therapies described herein may be used to treat a proliferative disease.
The term "proliferative disease" pertains to an unwanted or uncontrolled cellular proliferation of excessive or abnormal cells which is undesired, such as, neoplastic or hyperplastic growth, whether in vitro or in vivo.
Examples of proliferative conditions include, but are not limited to, benign, pre-malignant, and malignant cellular proliferation, including but not limited to, neoplasms and tumours (e.g. histocytoma, glioma, astrocyoma, osteoma), cancers (e.g. lung cancer, small cell lung cancer, gastrointestinal cancer, bowel cancer, colon cancer, breast carinoma, ovarian carcinoma, prostate cancer, testicular cancer, liver cancer, kidney cancer, bladder cancer, pancreas cancer, brain cancer, sarcoma, osteosarcoma, Kaposi's sarcoma, melanoma), lymphomas, leukemias, psoriasis, bone diseases, fibroproliferative disorders (e.g. of connective tissues), and atherosclerosis. Cancers of interest include, but are not limited to, leukemias and ovarian cancers.
Any type of cell may be treated, including but not limited to, lung, gastrointestinal (including, e.g. bowel, colon), breast (mammary), ovarian, prostate, liver (hepatic), kidney (renal), bladder, pancreas, brain, and skin.
Proliferative disorders of particular interest include, but are not limited to, non-Hodgkin's Lymphoma, including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, (FL), Mantle Cell lymphoma (MCL), chronic lymphatic lymphoma (CLL), and Marginal Zone B-cell lymphoma (MZBL), and leukemias such as Hairy cell leukemia (HCL), Hairy cell leukemia variant (HCL-v), anaplastic large cell lymphoma (ALCL), and Acute Lymphoblastic Leukaemia (ALL) such as Philadelphia chromosome-positive ALL
(Ph+ALL) or Philadelphia chromosome-negative ALL (Ph-ALL).
[Fielding A., Haematologica. 2010 Jan; 95(1): 8-12].
The proliferative disease may be characterised by the presence of a neoplasm comprising both 0D25+ve and 0D25-ve cells.
The proliferative disease may be characterised by the presence of a neoplasm composed of 0D25-ve neoplastic cells, optionally wherein the 0D25-ve neoplastic cells are associated with 0D25+ve non-neoplastic cells such as 0D25+ve T-cells.
The target neoplasm or neoplastic cells may be all or part of a solid tumour.
"Solid tumor" herein will be understood to include solid haematological cancers such as lymphomas (Hodgkin's lymphoma or non-Hodgkin's lymphoma) which are discussed in more detail herein. The solid tumour may be an advanced solid tumour Solid tumors may be neoplasms, including non-haematological cancers, comprising or composed of 0D25+ve neoplastic cells. Solid tumors may be neoplasms, including non-haematological cancers, infiltrated with 0D25+ve cells, such as 0D25+ve T-cells; such solid tumours may lack expression of 0D25 (that is, comprise or be composed of ve neoplastic cells).
For example, the solid tumour may be a tumour with high levels of infiltrating T-cells, such as infiltrating regulatory T-cells (Treg; Menetrier-Caux, C., et al., Targ Oncol (2012) 7:15-28; Arce Vargas et al., 2017, Immunity 46, 1-10; Tanaka, A., et al., Cell Res.
Jan;27(1):109-118). Accordingly, the solid tumour may be pancreatic cancer, breast cancer, colorectal cancer, gastric and oesophageal cancer, leukemia and lymphoma, melanoma, non-small cell lung cancer, ovarian cancer, hepatocellular carcinoma, renal cell carcinoma, and head and neck cancer.
In some embodiments the proliferative disorder is a T-cell lymphoma. In some cases the disorder is anaplastic large cell lymphoma (ALCL), such as ALK-pos or ALK-neg ALCL.
It is contemplated that the combined therapies of the present disclosure may be used to treat various diseases or disorders, e.g. characterized by the overexpression of a tumor antigen. Exemplary conditions or hyperproliferative disorders include benign or malignant tumors; leukemia, haematological, and lymphoid malignancies. Others include neuronal, glial, astrocytal, hypothalamic, glandular, macrophagal, epithelial, stromal, blastocoelic, inflammatory, angiogenic and immunologic, including autoimmune disorders and graft-versus-host disease (GVHD).
Generally, the disease or disorder to be treated is a hyperproliferative disease such as cancer. Examples of cancer to be treated herein include, but are not limited to, carcinoma, lymphoma, blastoma, sarcoma, and leukemia or lymphoid malignancies.
More particular examples of such cancers include squamous cell cancer (e.g.
epithelial squamous cell cancer), lung cancer including small-cell lung cancer, non-small cell lung cancer, adenocarcinoma of the lung and squamous carcinoma of the lung, cancer of the peritoneum, hepatocellular cancer, gastric or stomach cancer including gastrointestinal cancer, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma, breast cancer, colon cancer, rectal cancer, colorectal cancer, endometrial or uterine carcinoma, salivary gland carcinoma, kidney or renal cancer, prostate cancer, vulval cancer, thyroid cancer, hepatic carcinoma, anal carcinoma, penile carcinoma, as well as head and neck cancer.
Autoimmune diseases for which the combined therapies may be used in treatment include rheumatologic disorders (such as, for example, rheumatoid arthritis, SjOgren's syndrome, scleroderma, lupus such as SLE and lupus nephritis, polymyositis/dermatomyositis, cryoglobulinemia, anti-phospholipid antibody syndrome, and psoriatic arthritis), osteoarthritis, autoimmune gastrointestinal and liver disorders (such as, for example, inflammatory bowel diseases (e.g. ulcerative colitis and Crohn's disease), autoimmune gastritis and pernicious anemia, autoimmune hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, and celiac disease), vasculitis (such as, for example, ANCA-associated vasculitis, including Churg-Strauss vasculitis, Wegener's granulomatosis, and polyarteriitis), autoimmune neurological disorders (such as, for example, multiple sclerosis, opsoclonus myoclonus syndrome, myasthenia gravis, neuromyelitis optica, Parkinson's disease, Alzheimer's disease, and autoimmune polyneuropathies), renal disorders (such as, for example, glomerulonephritis, Goodpasture's syndrome, and Berger's disease), autoimmune dermatologic disorders (such as, for example, psoriasis, urticaria, hives, pemphigus vulgaris, bullous pemphigoid, and cutaneous lupus erythematosus), hematologic disorders (such as, for example, thrombocytopenic purpura, thrombotic thrombocytopenic purpura, post-transfusion purpura, and autoimmune hemolytic anemia), atherosclerosis, uveitis, autoimmune hearing diseases (such as, for example, inner ear disease and hearing loss), Behcet's disease, Raynaud's syndrome, organ transplant, graft-versus-host disease (GVHD), and autoimmune endocrine disorders (such as, for example, diabetic-related autoimmune diseases such as insulin-dependent diabetes mellitus (IDDM), Addison's disease, and autoimmune thyroid disease (e.g. Graves' disease and thyroiditis)). More preferred such diseases include, for example, rheumatoid arthritis, ulcerative colitis, ANCA-associated vasculitis, lupus, multiple sclerosis, SjOgren's syndrome, Graves' disease, IDDM, pernicious anemia, thyroiditis, and glomerulonephritis.
In some aspects, the subject has a proliferative disorder selected from (classical) Hodgkin lymphomas, with mixed cellularity type (Hodgkin-/Reed-Sternbert-Cells: 0D25 +/-), or non-Hodgkin lymphoma, including B-cell chronic lymphatic leukemaia, diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, (FL), Mantle Cell lymphoma (MCL), chronic lymphatic lymphoma (CLL), Marginal Zone B-cell lymphoma (MZBL) and leukemias such as Hairy cell leukemia (HCL), Hairy cell leukemia variant (HCL-v), Acute Myeloid Leukaemia (AML), anaplastic large cell lymphoma (ALCL), Acute Lymphoblastic Leukaemia (ALL) such as Philadelphia chromosome-positive ALL (Ph+ALL) or Philadelphia chromosome-negative ALL (Ph-ALL) [Fielding A., Haematologica.
2010 Jan;
95(1): 8-12], small cell lymphocytic lymphoma, adult T-cell leukemia/lymphoma, or anaplastic large cell lymphoma.
In some aspects, the subject has a proliferative disease characterised by the presence of a neoplasm comprising both 0D25+ve and 0D25-ve cells.
The proliferative disease may be characterised by the presence of a neoplasm composed of 0D25-ve neoplastic cells, optionally wherein the 0D25-ve neoplastic cells are associated with 0D25+ve non-neoplastic cells such as 0D25+ve T-cells.
The target neoplasm or neoplastic cells may be all or part of a solid tumour.
Solid tumors may be neoplasms, including non-haematological cancers, comprising or composed of 0D25+ve neoplastic cells. Solid tumors may be neoplasms, including non-haematological cancers, infiltrated with 0D25+ve cells, such as 0D25+ve T-cells; such solid tumours may lack expression of 0D25 (that is, comprise or be composed of ve neoplastic cells). The solid tumour may be an advanced solid tumour.
For example, the solid tumour may be a tumour with high levels of infiltrating T-cells, such as infiltrating regulatory T-cells (Treg; Menetrier-Caux, C., et al., Targ Oncol (2012) 7:15-28; Arce Vargas et al., 2017, Immunity 46, 1-10; Tanaka, A., et al., Cell Res.
Jan;27(1):109-118). Accordingly, the solid tumour may be pancreatic cancer, breast cancer, colorectal cancer, gastric and oesophageal cancer, leukemia and lymphoma, melanoma, non-small cell lung cancer, ovarian cancer, hepatocellular carcinoma, renal cell carcinoma, and head and neck cancer.
Classical Hodgkins lymphoma includes the subtypes nodular sclerosing, lymphocyte predominant, lymphocyte depleted and mixed cellularity. The Hodgkins lymphoma subtype may not be defined. In certain aspects, the patients tested according to the methods here have Hodgkins lymphoma of the nodular sclerosing and mixed cellularity subtypes.
In certain aspects, the subject has diffuse large B cell lymphoma or peripheral T cell lymphoma, including the anaplastic large cell lymphoma and angioimmunoblastic T cell lymphoma subtypes.
Patient Selection In certain aspects, the individuals are selected as suitable for treatment with the combined treatments before the treatments are administered.
As used herein, individuals who are considered suitable for treatment are those individuals who are expected to benefit from, or respond to, the treatment.
Individuals may have, or be suspected of having, or be at risk of having cancer.
Individuals may have received a diagnosis of cancer. In particular, individuals may have, or be suspected of having, or be at risk of having, lymphoma. In some cases, individuals may have, or be suspected of having, or be at risk of having, a solid cancer that has tumour associated non-tumor cells that express 0D25, such as infiltrating cells that express 0D25.
In some aspects, subjects are selected on the basis of the amount or pattern of expression of 0D25. In some aspects, the selection is based on expression of 0D25 at the cell surface in a tissue or structure of interest. So, in some cases, subjects are selected on the basis they have, or are suspected of having, are at risk of having, or have received a diagnosis of a proliferative disease characterized by the presence of a neoplasm comprising or associated with cells having surface expression of 0D25. The neoplasm may be composed of cells having surface expression of 0D25.
In some aspects, subjects are selected on the basis they have a neoplasm comprising both 0D25+ve and 0D25-ve cells. The neoplasm may be composed of 0D25-ve neoplastic cells, optionally wherein the 0D25-ve neoplastic cells are associated with 0D25+ve non-neoplastic cells such as 0D25+ve Tregs. The neoplasm or neoplastic cells may be all or part of a solid tumour. The solid tumour may be partially or wholly 0D25-ve, and may be infiltrated with 0D25+ve cells, such as 0D25+ve Tregs. In preferred aspects, the solid tumour is associated with high-levels of 0D25+ve infiltrating cells, such as Treg cells. In some aspects, the solid tumour is associated with low-levels of 0D25+ve infiltrating cells, such as Treg cells. In some aspects, the solid tumour is not associated with 0D25+ve infiltrating cells, such as Treg cells; for example, the levels of 0D25+ve cells may be below the detection limit. The solid tumour may be an advanced solid tumour.
In some cases, expression of 0D25 in a particular tissue of interest is determined. For example, in a sample of tumor tissue. In some cases, systemic expression of 0D25 is determined. For example, in a sample of circulating fluid such as blood, plasma, serum or lymph.
In some aspects, the subject is selected as suitable for treatment due to the presence of 0D25 expression in a sample. In those cases, subjects without 0D25 expression may be considered not suitable for treatment.
In other aspects, the level of 0D25 expression is used to select a subject as suitable for treatment. Where the level of expression of the target is above a threshold level, the subject is determined to be suitable for treatment.
In some aspects, an subject is indicated as suitable for treatment if cells obtained from the tumour react with antibodies against 0D25 as determined by I HC.
In some aspects, a subject is determined to be suitable for treatment if at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90% or more of all cells in the sample express 0D25. In some aspects disclosed herein, a subject is determined to be suitable for treatment if at least at least 5%
of the cells in the sample express 0D25.
In certain aspects, the target is BCL-2, mTOR, or a secondary target protein.
In some aspects, the selection is based on expression of BCL-2, mTOR, or a secondary target protein.
In some aspects, the selection is based on levels of both 0D25 at the cell surface and BCL-2, mTOR, or the secondary target protein.
In some aspects, the presence of 0D25 and/or in cells in the sample indicates that the individual is suitable for treatment with a combination comprising an anti-0D25 ADC and an anti-BCL-2 agent, an mTOR inhibitor, or a secondary agent. In other aspects, the amount of 0D25 and/or expression must be above a threshold level to indicate that the individual is suitable for treatment. In some aspects, the observation that 0D25 and/or localisation is altered in the sample as compared to a control indicates that the individual is suitable for treatment.
In some aspects, an individual is indicated as suitable for treatment if cells obtained from lymph node or extra nodal sites react with antibodies against 0D25 and/or as determined by IHC.
In some aspects, a patient is determined to be suitable for treatment if at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90% or more of all cells in the sample express 0D25. In some aspects disclosed herein, a patient is determined to be suitable for treatment if at least at least 10%
of the cells in the sample express 0D25.
In some aspects, a patient is determined to be suitable for treatment if at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90% or more of all cells in the sample express. In some aspects disclosed herein, a patient is determined to be suitable for treatment if at least at least 10% of the cells in the sample express.
In some aspects, the individual is selected as suitable for treatment based on their current or previous treatment regime. In some embodiments the individual is selected for treatment with the anti-0D25 ADC if the individual has been treated with an anti-BCL-2 agent, an mTOR inhibitor, or a secondary agent. In some embodiments the individual is selected for treatment with the anti-0D25 ADC if the individual is being treated with an anti-BCL-2 agent, an mTOR inhibitor, or a secondary agent. In some cases the individual is selected for treatment if they are refractory to treatment (or further treatment) with the anti-BCL-2 agent, the mTOR inhibitor, or the secondary agent. In some cases the anti-BCL-2 agent may be Venetoclax. In some cases the mTOR inhibitor may be Everolimus.
In some cases the secondary agent may be bortezomib, In some cases the secondary agent may be Bendamustine, copanlisib, idelalisib, pralatrexate, romidepsin, or vorinostat. In embodiments where the individual is undergoing, or has undergone, treatment with an anti-BCL-2 agent, an mTOR inhibitor, or a secondary agent, the anti-0D25 ADC may be administered in combination with an anti-BCL-2 agent, an mTOR
inhibitor, or a secondary agent, or without continued administration of the anti-BCL-2 agent, an mTOR inhibitor, or a secondary agent.
In some embodiments the anti-0D25 ADC is administered to the selected individual in combination with an anti-BCL-2 agent, an mTOR inhibitor, or a secondary agent.
In some embodiments the anti-0D25 ADC is administered to the selected individual without continued administration of an anti-BCL-2 agent, an mTOR inhibitor, or a secondary agent. The anti-BCL-2 agent is preferably Venetoclax. The mTOR inhibitor is preferably Everolimus. In some cases the secondary agent may be bortezomib, In some cases the secondary agent may be Bendamustine, copanlisib, idelalisib, pralatrexate, romidepsin, or vorinostat.
The term 'refractory to treatment (or further treatment) with the anti-BCL-2 agent, mTOR
inhibitor, or secondary agent' is used herein to mean that the disorder (such as cancer) does not respond, or has ceased to respond, to administration of the anti-BCL-2 agent, mTOR inhibitor, or secondary agent when administered as a monotherapy. In some embodiments, individuals with refractory NHL are identified using the response criteria disclosed in Cheson at al., 2014 (South Asian J Cancer. 2014 Jan-Mar; 3(1): 66-70). In that document, non-responders are defined as individuals where there is either (i) a >50%
increase from nadir in the sum product of diameters of any previously identified abnormal node, or (ii) an appearance of any new lesion during or at the end of therapy.
In some embodiments, individuals with refractory leukaemia are identified as individuals with either stable or progressive disease who have completed one complete treatment cycle, or individual achieving partial response after two or more complete treatment cycles.
Samples The sample may comprise or may be derived from: a quantity of blood; a quantity of serum derived from the individual's blood which may comprise the fluid portion of the blood obtained after removal of the fibrin clot and blood cells; a quantity of pancreatic juice; a tissue sample or biopsy; or cells isolated from said individual.
A sample may be taken from any tissue or bodily fluid. In certain aspects, the sample may include or may be derived from a tissue sample, biopsy, resection or isolated cells from said individual.
In certain aspects, the sample is a tissue sample. The sample may be a sample of tumor tissue, such as cancerous tumor tissue. The sample may have been obtained by a tumor biopsy. In some aspects, the sample is a lymphoid tissue sample, such as a lymphoid lesion sample or lymph node biopsy. In some cases, the sample is a skin biopsy.
In some aspects the sample is taken from a bodily fluid, more preferably one that circulates through the body. Accordingly, the sample may be a blood sample or lymph sample. In some cases, the sample is a urine sample or a saliva sample.
In some cases, the sample is a blood sample or blood-derived sample. The blood derived sample may be a selected fraction of a individual's blood, e.g. a selected cell-containing fraction or a plasma or serum fraction.
A selected cell-containing fraction may contain cell types of interest which may include white blood cells (WBC), particularly peripheral blood mononuclear cells (PBC) and/or granulocytes, and/or red blood cells (RBC). Accordingly, methods according to the present disclosure may involve detection of a first target polypeptide or nucleic acid in the blood, in white blood cells, peripheral blood mononuclear cells, granulocytes and/or red blood cells.
The sample may be fresh or archival. For example, archival tissue may be from the first diagnosis of an individual, or a biopsy at a relapse. In certain aspects, the sample is a fresh biopsy.
The first target polypeptide may be 0D25.
Individual status The individual may be an animal, mammal, a placental mammal, a marsupial (e.g., kangaroo, wombat), a monotreme (e.g., duckbilled platypus), a rodent (e.g., a guinea pig, a hamster, a rat, a mouse), murine (e.g., a mouse), a lagomorph (e.g., a rabbit), avian (e.g., a bird), canine (e.g., a dog), feline (e.g., a cat), equine (e.g., a horse), porcine (e.g., a pig), ovine (e.g., a sheep), bovine (e.g., a cow), a primate, simian (e.g., a monkey or ape), a monkey (e.g., marmoset, baboon), an ape (e.g., gorilla, chimpanzee, orangutang, gibbon), or a human.
Furthermore, the individual may be any of its forms of development, for example, a foetus. In one preferred embodiment, the individual is a human. The terms "subject", "patient" and "individual" are used interchangeably herein.
In some aspects disclosed herein, an individual has, or is suspected as having, or has been identified as being at risk of, cancer. In some aspects disclosed herein, the individual has already received a diagnosis of cancer. The individual may have received a diagnosis of a proliferative disease characterised by the presence of a neoplasm comprising both 0D25+ve and 0D25-ve cells.
The proliferative disease may be characterised by the presence of a neoplasm composed of 0D25-ve neoplastic cells, optionally wherein the 0D25-ve neoplastic cells are associated with 0D25+ve non-neoplastic cells such as 0D25+ve T-cells.
In some cases, the individual has received a diagnosis of a solid tumour containing 0D25+ expressing infiltrating cells.
Solid tumors may be neoplasms, including non-haematological cancers, comprising or composed of 0D25+ve neoplastic cells. Solid tumors may be neoplasms, including non-haematological cancers, infiltrated with 0D25+ve cells, such as 0D25+ve T-cells; such solid tumours may lack expression of 0D25 (that is, comprise or be composed of ve neoplastic cells). The solid tumour may be an advanced solid tumour For example, the solid tumour may be a tumour with high levels of infiltrating T-cells, such as infiltrating regulatory T-cells (Treg; Menetrier-Caux, C., et al., Targ Oncol (2012) 7:15-28; Arce Vargas et al., 2017, Immunity 46, 1-10; Tanaka, A., et al., Cell Res.
Jan;27(1):109-118). Accordingly, the solid tumour may be pancreatic cancer, breast cancer, colorectal cancer, gastric and oesophageal cancer, leukemia and lymphoma, melanoma, non-small cell lung cancer, ovarian cancer, hepatocellular carcinoma, renal cell carcinoma, and head and neck cancer.
The Individual may be undergoing, or have undergone, a therapeutic treatment for that cancer. The subject may, or may not, have previously received ADCX25. In some cases the cancer is lymphoma, including non-Hodgkins lymphoma.
The Individual may be undergoing, or have undergone, treatment with an anti-agent, an mTOR inhibitor, or a secondary agent. In some cases the individual may be refractory to treatment (or further treatment) with the anti-BCL-2 agent, mTOR
inhibitor, or secondary agent. In some cases the anti-BCL-2 agent may be Venetoclax. In some cases the mTOR inhibitor may be Everolimus. In some cases the secondary agent may be bortezomib, In some cases the secondary agent may be Bendamustine, copanlisib, idelalisib, pralatrexate, romidepsin, or vorinostat. In embodiments where the individual is undergoing, or has undergone, treatment with an anti-BCL-2 agent, an mTOR
inhibitor, or a secondary agent, the anti-CD25 ADC may be administered in combination with an anti-BCL-2 agent, an mTOR inhibitor, or a secondary agent, or without continued administration of the anti-BCL-2 agent, an mTOR inhibitor, or a secondary agent.
Controls In some aspects, target expression in the individual is compared to target expression in a control. Controls are useful to support the validity of staining, and to identify experimental artefacts.
In some cases, the control may be a reference sample or reference dataset. The reference may be a sample that has been previously obtained from a individual with a known degree of suitability. The reference may be a dataset obtained from analyzing a reference sample.
Controls may be positive controls in which the target molecule is known to be present, or expressed at high level, or negative controls in which the target molecule is known to be absent or expressed at low level.
Controls may be samples of tissue that are from individuals who are known to benefit from the treatment. The tissue may be of the same type as the sample being tested. For example, a sample of tumor tissue from a individual may be compared to a control sample of tumor tissue from a individual who is known to be suitable for the treatment, such as a individual who has previously responded to the treatment.
In some cases the control may be a sample obtained from the same individual as the test sample, but from a tissue known to be healthy. Thus, a sample of cancerous tissue from a individual may be compared to a non-cancerous tissue sample.
In some cases, the control is a cell culture sample.
In some cases, a test sample is analyzed prior to incubation with an antibody to determine the level of background staining inherent to that sample.
In some cases an isotype control is used. lsotype controls use an antibody of the same class as the target specific antibody, but are not immunoreactive with the sample. Such controls are useful for distinguishing non-specific interactions of the target specific antibody.
The methods may include hematopathologist interpretation of morphology and immunohistochemistry, to ensure accurate interpretation of test results. The method may involve confirmation that the pattern of expression correlates with the expected pattern.
For example, where the amount of CD25 and/or BCL-2, mTOR, or secondary target protein expression is analyzed, the method may involve confirmation that in the test sample the expression is observed as membrane staining, with a cytoplasmic component.
The method may involve confirmation that the ratio of target signal to noise is above a threshold level, thereby allowing clear discrimination between specific and non-specific background signals.
Methods of Treatment The term "treatment," as used herein in the context of treating a condition, pertains generally to treatment and therapy, whether of a human or an animal (e.g., in veterinary applications), in which some desired therapeutic effect is achieved, for example, the inhibition of the progress of the condition, and includes a reduction in the rate of progress, a halt in the rate of progress, regression of the condition, amelioration of the condition, and cure of the condition. Treatment as a prophylactic measure (i.e., prophylaxis, prevention) is also included.
The term "therapeutically-effective amount" or "effective amount" as used herein, pertains to that amount of an active compound, or a material, composition or dosage from comprising an active compound, which is effective for producing some desired therapeutic effect, commensurate with a reasonable benefit/risk ratio, when administered in accordance with a desired treatment regimen.
Similarly, the term "prophylactically-effective amount," as used herein, pertains to that amount of an active compound, or a material, composition or dosage from comprising an active compound, which is effective for producing some desired prophylactic effect, commensurate with a reasonable benefit/risk ratio, when administered in accordance with a desired treatment regimen.
Disclosed herein are methods of therapy. Also provided is a method of treatment, comprising administering to a subject in need of treatment a therapeutically-effective amount of an anti-0D25 ADC and an anti-BCL-2 agent, an mTOR inhibitor, or a secondary agent. The term "therapeutically effective amount" is an amount sufficient to show benefit to a subject. Such benefit may be at least amelioration of at least one symptom. The actual amount administered, and rate and time-course of administration, will depend on the nature and severity of what is being treated. Prescription of treatment, e.g. decisions on dosage, is within the responsibility of general practitioners and other medical doctors. The subject may have been tested to determine their eligibility to receive the treatment according to the methods disclosed herein. The method of treatment may comprise a step of determining whether a subject is eligible for treatment, using a method disclosed herein.
The anti-0D25 ADC comprises an anti-0D25 antibody. The anti-0D25 antibody may be HuMax-TACTm. The ADC may comprise a drug which is a PBD dimer. The ADC may be an anti-0D25-ADC, and in particular, ADCX25 or ADCT-301 (c..micianIumab tesirine,. The ADC may be an ADC disclosed in W02014/057119.
The anti-BCL-2 agent may be Venetoclax (ABT-199), navitoclax (ABT-263), ABT-737, 555746/BCL201, and oblimersen (G3139). Preferably the anti-BCL-2 agent is Venetoclax (A BT-199).
The mTOR inhibitor may be everolimus (RAD001), sirolimus (Rapamycin), 00I-779 (temsirolimus), ridaforolimus (AP-23573), NVP-BEZ235 (dactolisib), BGT226, SF1126, Gedatolisib, Omipalisib, XL765, Ku-0063794, oleuropein aglycone, AZD8055, AZD2014, AZD 3147, sapanisertib (INK128/MLN0128), 0SI027, torin 1, torin 2, torkinib (PP242), VVYE687, ETP45658, PF05212384, PF04691502, XL388, eCF309, RapaLink-1, or Rapalink-2.
The secondary agent may be:
(a) Bendamustine;
(b) a phosphoinositide 3-kinase inhibitor such as copanlisib, idelalisib, duvelisib, Taselisib, Buparlisib, Alpelisib, Umbralisib, Dactolisib, and Voxtalisib;
(C) a proteasome inhibitor such as bortezomib, carfilzomib, lxazomib, Oprozomib, and Salinosporamide A;
(d) an anti-folate such as pralatrexate, methotrexate, pemetrexed, and raltitrexed;
or (e) a HDAC inhibitor such as romidepsin, vorinostat, Abexinostat, belinostat (PXD101), LAQ824, panobinostat (LBH589), entinostat (MS-275), tacedinaline (01994), and mocetinostat (MGCD0103).
The treatment may involve administration of the anti-0D25 ADC / anti-BCL-2 agent combination alone or in further combination with other treatments, either simultaneously or sequentially dependent upon the condition to be treated.
An example method of treatment with the anti-0D25 ADC plus anti-BCL2 combination involves:
(1) identifying an individual has been treated with, or is being treated with an anti-BCL-2 agent, such as Venetoclax;
(2) administering to the individual an anti-0D25 ADC, such as ADCx25; and, optionally (3) administering to the individual an anti-BCL-2 agent, such as Venetoclax in combination with the anti-0D25 ADC (for example, at the same time as the ADC, or after the ADC).
An example method of treatment with the anti-0D25 ADC plus mTOR inhibitor combination involves:
(1) identifying an individual has been treated with, or is being treated with an mTOR inhibitor, such as Everolimus;
(2) administering to the individual an anti-0D25 ADC, such as ADCx25; and, optionally (3) administering to the individual an mTOR inhibitor, such as Everolimus in combination with the anti-0D25 ADC (for example, at the same time as the ADC, or after the ADC).
An example method of treatment with the anti-0D25 ADC plus secondary agent combination iinvolves:
(1) identifying an individual has been treated with, or is being treated with an secondary agent, such as Bendamustine, copanlisib, idelalisib, bortezomib, pralatrexate, romidepsin, or vorinostat;
(2) administering to the individual an anti-0D25 ADC, such as ADCx25; and, optionally (3) administering to the individual an secondary agent, such as Bendamustine, copanlisib, idelalisib, bortezomib, pralatrexate, romidepsin, or vorinostat in combination with the anti-0D25 ADC (for example, at the same time as the ADC, or after the ADC).
Examples of treatments and therapies include, but are not limited to, chemotherapy (the administration of active agents, including, e.g. drugs, such as chemotherapeutics);
surgery; and radiation therapy.
A "chemotherapeutic agent" is a chemical compound useful in the treatment of cancer, regardless of mechanism of action. Classes of chemotherapeutic agents include, but are not limited to: alkylating agents, antimetabolites, spindle poison plant alkaloids, cytotoxic/antitumor antibiotics, topoisomerase inhibitors, antibodies, photosensitizers, and kinase inhibitors. Chemotherapeutic agents include compounds used in "targeted therapy" and conventional chemotherapy.
Examples of chemotherapeutic agents include: Lenalidomide (REVLIMIDO, Celgene), Vorinostat (ZOLINZAO, Merck), Panobinostat (FARYDAKO, Novartis), Mocetinostat (MGCD0103), Everolimus (ZORTRESSO, CERTICANO, Novartis), Bendamustine (TREAKISYMO, RIBOMUSTINO, LEVACTO, TREANDAO, Mundipharma International), erloti nib (TARCEVAO, Genentech/OSI Pharm.), docetaxel (TAXOTEREO, Sanofi-Aventis), 5-FU (fluorouracil, 5-fluorouracil, CAS No. 51-21-8), gemcitabine (GEMZARO, Lilly), PD-0325901 (CAS No. 391210-10-9, Pfizer), cisplatin (cis-diamine, dichloroplatinum(II), CAS No. 15663-27-1), carboplatin (CAS No. 41575-94-4), paclitaxel (TAXOLO, Bristol-Myers Squibb Oncology, Princeton, N.J.), trastuzumab (HERCEPTINO, Genentech), temozolomide (4-methyl-5-oxo- 2,3,4,6,8-pentazabicyclo [4.3.0]
nona-2,7,9-triene- 9-carboxamide, CAS No. 85622-93-1, TEMODARO, TEMODALO, Schering Plough), tamoxifen ((Z)-2-[4-(1,2-diphenylbut-1-enyl)phenoxy]-N,N-dimethylethanamine, NOLVADEXO, ISTUBALO, VALODEX0), and doxorubicin (ADRIAMYCINO), Akti-1/2, HPPD, and rapamycin.
More examples of chemotherapeutic agents include: oxaliplatin (ELOXATINO, Sanofi), bortezomib (VELCADEO, Millennium Pharm.), sutent (SUNITINIBO, 5U11248, Pfizer), letrozole (FEMARAO, Novartis), imatinib mesylate (GLEEVECO, Novartis), XL-518 (Mek inhibitor, Exelixis, WO 2007/044515), ARRY-886 (Mek inhibitor, AZD6244, Array BioPharma, Astra Zeneca), SF-1126 (PI3K inhibitor, Semafore Pharmaceuticals), BEZ-235 (PI3K inhibitor, Novartis), XL-147 (PI3K inhibitor, Exelixis), PTK787/ZK
(Novartis), fulvestrant (FASLODEXO, AstraZeneca), leucovorin (folinic acid), rapamycin (sirolimus, RAPAMUNEO, VVyeth), lapatinib (TYKERBO, G5K572016, Glaxo Smith Kline), lonafarnib (SARASARTM, SCH 66336, Schering Plough), sorafenib (NEXAVARO, BAY43-9006, Bayer Labs), gefitinib (IRESSAO, AstraZeneca), irinotecan (CAMPTOSARO, CPT-11, Pfizer), tipifarnib (ZARNESTRATm, Johnson & Johnson), ABRAXANETM
(Cremophor-free), albumin-engineered nanoparticle formulations of paclitaxel (American Pharmaceutical Partners, Schaumberg, II), vandetanib (rINN, ZD6474, ZACTIMAO, AstraZeneca), chloranmbucil, AG1478, AG1571 (SU 5271; Sugen), temsirolimus (TORISELO, Wyeth), pazopanib (GlaxoSmithKline), canfosfamide (TELCYTAO, Telik), thiotepa and cyclosphosphamide (CYTOXANO, NEOSARO); alkyl sulfonates such as busulfan, improsulfan and piposulfan; aziridines such as benzodopa, carboquone, meturedopa, and uredopa; ethylenimines and methylamelamines including altretamine, triethylenemelamine, triethylenephosphoramide, triethylenethiophosphoramide and trimethylomelamine; acetogenins (especially bullatacin and bullatacinone); a camptothecin (including the synthetic analog topotecan); bryostatin;
callystatin; CC-1065 (including its adozelesin, carzelesin and bizelesin synthetic analogs);
cryptophycins (particularly cryptophycin 1 and cryptophycin 8); dolastatin; duocarmycin (including the synthetic analogs, KW-2189 and CB1-TM1); eleutherobin; pancratistatin; a sarcodictyin;
spongistatin; nitrogen mustards such as chlorambucil, chlornaphazine, chlorophosphamide, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, novembichin, phenesterine, prednimustine, trofosfamide, uracil mustard; nitrosoureas such as carmustine, chlorozotocin, fotemustine, lomustine, nimustine, and ranimnustine; antibiotics such as the enediyne antibiotics (e.g.
calicheamicin, calicheamicin gamma11, calicheamicin omegal1 (Angew Chem. Intl.
Ed.
Engl. (1994) 33:183-186); dynemicin, dynemicin A; bisphosphonates, such as clodronate;
an esperamicin; as well as neocarzinostatin chromophore and related chromoprotein enediyne antibiotic chromophores), aclacinomysins, actinomycin, authramycin, azaserine, bleomycins, cactinomycin, carabicin, carminomycin, carzinophilin, chromomycinis, dactinomycin, daunorubicin, detorubicin, 6-diazo-5-oxo-L-norleucine, morpholino-doxorubicin, cyanomorpholino-doxorubicin, 2-pyrrolino-doxorubicin and deoxydoxorubicin), epirubicin, esorubicin, idarubicin, nemorubicin, marcellomycin, mitomycins such as mitomycin C, mycophenolic acid, nogalamycin, olivomycins, peplomycin, porfiromycin, puromycin, quelamycin, rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, zorubicin; anti-metabolites such as methotrexate and 5-fluorouracil (5-FU); folic acid analogs such as denopterin, methotrexate, pteropterin, trimetrexate; purine analogs such as fludarabine, 6-mercaptopurine, thiamiprine, thioguanine; pyrimidine analogs such as ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine; androgens such as cal usterone, dromostanolone propionate, epitiostanol, mepitiostane, testolactone; anti-adrenals such as aminoglutethimide, mitotane, trilostane; folic acid replenisher such as frolinic acid; aceglatone; aldophosphamide glycoside; aminolevulinic acid;
eniluracil;
amsacrine; bestrabucil; bisantrene; edatraxate; defofamine; demecolcine;
diaziquone;
elfornithine; elliptinium acetate; an epothilone; etoglucid; gallium nitrate;
hydroxyurea;
lentinan; lonidainine; maytansinoids such as maytansine and ansamitocins;
mitoguazone;
mitoxantrone; mopidanmol; nitraerine; pentostatin; phenamet; pirarubicin;
losoxantrone;
podophyllinic acid; 2-ethylhydrazide; procarbazine; PSKO polysaccharide complex (JHS
Natural Products, Eugene, OR); razoxane; rhizoxin; sizofiran; spirogermanium;
tenuazonic acid; triaziquone; 2,2',2"-trichlorotriethylamine; trichothecenes (especially T-2 toxin, verracurin A, roridin A and anguidine); urethan; vindesine;
dacarbazine;
mannomustine; mitobronitol; mitolactol; pipobroman; gacytosine; arabinoside ("Ara-C");
cyclophosphamide; thiotepa; 6-thioguanine; mercaptopurine; methotrexate;
platinum analogs such as cisplatin and carboplatin; vinblastine; etoposide (VP-16);
ifosfamide;
mitoxantrone; vincristine; vinorelbine (NAVELBINE0); novantrone; teniposide;
edatrexate;
daunomycin; aminopterin; capecitabine (XELODAO, Roche); ibandronate; CPT-11;
topoisomerase inhibitor RFS 2000; difluoromethylornithine (DMF0); retinoids such as retinoic acid; and pharmaceutically acceptable salts, acids and derivatives of any of the above. Combinations of agents may be used, such as CHP (doxorubicin, prednisone, cyclophosphamide), or CHOP (doxorubicin, prednisone, cyclophopsphamide, vincristine).
Also included in the definition of "chemotherapeutic agent" are: (i) anti-hormonal agents that act to regulate or inhibit hormone action on tumors such as anti-estrogens and selective estrogen receptor modulators (SERMs), including, for example, tamoxifen (including NOLVADEXO; tamoxifen citrate), raloxifene, droloxifene, 4-hydroxytamoxifen, trioxifene, keoxifene, LY117018, onapristone, and FARESTONO (toremifine citrate); (ii) aromatase inhibitors that inhibit the enzyme aromatase, which regulates estrogen production in the adrenal glands, such as, for example, 4(5)-imidazoles, aminoglutethimide, MEGASEO (megestrol acetate), AROMASINO (exemestane;
Pfizer), formestanie, fadrozole, RIVISORO (vorozole), FEMARAO (letrozole; Novartis), and ARIMIDEXO (anastrozole; AstraZeneca); (iii) anti-androgens such as flutamide, nilutamide, bicalutamide, leuprolide, and goserelin; as well as troxacitabine (a 1,3-dioxolane nucleoside cytosine analog); (iv) protein kinase inhibitors such as MEK
inhibitors (WO 2007/044515); (v) lipid kinase inhibitors; (vi) antisense oligonucleotides, particularly those which inhibit expression of genes in signaling pathways implicated in aberrant cell proliferation, for example, PKC-alpha, Raf and H-Ras, such as oblimersen (GENASENSEO, Genta Inc.); (vii) ribozymes such as VEGF expression inhibitors (e.g., ANGIOZYMEO) and HER2 expression inhibitors; (viii) vaccines such as gene therapy vaccines, for example, ALLOVECTINO, LEUVECTINO, and VAXIDO; PROLEUKINO rIL-2; topoisomerase 1 inhibitors such as LURTOTECANO; ABARELIXO rmRH; (ix) anti-angiogenic agents such as bevacizumab (AVASTINO, Genentech); and pharmaceutically acceptable salts, acids and derivatives of any of the above.
Also included in the definition of "chemotherapeutic agent" are therapeutic antibodies such as alemtuzumab (Campath), bevacizumab (AVASTINO, Genentech); cetuximab (ERBITUXO, lmclone); panitumumab (VECTIBIXO, Amgen), pertuzumab (PERJETATm, OMNITARGTm, 204, Genentech), trastuzumab (HERCEPTINO, Genentech), MDX-060 (Medarex) and the antibody drug conjugate, gemtuzumab ozogamicin (MYLOTARGO, Wyeth).
Humanized monoclonal antibodies with therapeutic potential as chemotherapeutic agents in combination with the conjugates of the disclosure include: alemtuzumab, apolizumab, aselizumab, atlizumab, bapineuzumab, bevacizumab, bivatuzumab mertansine, cantuzumab mertansine, cedelizumab, certolizumab pegol, cidfusituzumab, cidtuzumab, daclizumab, eculizumab, efalizumab, epratuzumab, erlizumab, felvizumab, fontolizumab, gemtuzumab ozogamicin, inotuzumab ozogamicin, ipilimumab, labetuzumab, lintuzumab, matuzumab, mepolizumab, motavizumab, motovizumab, natalizumab, nimotuzumab, nolovizumab, numavizumab, omalizumab, palivizumab, pascolizumab, pecfusituzumab, pectuzumab, pertuzumab, pexelizumab, ralivizumab, ranibizumab, reslivizumab, reslizumab, resyvizumab, rovelizumab, ruplizumab, sibrotuzumab, siplizumab, sontuzumab, tacatuzumab tetraxetan, tadocizumab, talizumab, tefibazumab, tocilizumab, toralizumab, trastuzumab, tucotuzumab celmoleukin, tucusituzumab, umavizumab, urtoxazumab, and visilizumab.
Compositions according to the present disclosure are preferably pharmaceutical compositions. Pharmaceutical compositions according to the present disclosure, and for use in accordance with the present disclosure, may comprise, in addition to the active ingredient, i.e. a conjugate compound, a pharmaceutically acceptable excipient, carrier, buffer, stabiliser or other materials well known to those skilled in the art.
Such materials should be non-toxic and should not interfere with the efficacy of the active ingredient.
The precise nature of the carrier or other material will depend on the route of administration, which may be oral, or by injection, e.g. cutaneous, subcutaneous, or intravenous.
Pharmaceutical compositions for oral administration may be in tablet, capsule, powder or liquid form. A tablet may comprise a solid carrier or an adjuvant. Liquid pharmaceutical compositions generally comprise a liquid carrier such as water, petroleum, animal or vegetable oils, mineral oil or synthetic oil. Physiological saline solution, dextrose or other saccharide solution or glycols such as ethylene glycol, propylene glycol or polyethylene glycol may be included. A capsule may comprise a solid carrier such a gelatin.
For intravenous, cutaneous or subcutaneous injection, or injection at the site of affliction, the active ingredient will be in the form of a parenterally acceptable aqueous solution which is pyrogen-free and has suitable pH, isotonicity and stability. Those of relevant skill in the art are well able to prepare suitable solutions using, for example, isotonic vehicles such as Sodium Chloride Injection, Ringer's Injection, Lactated Ringer's Injection.
Preservatives, stabilisers, buffers, antioxidants and/or other additives may be included, as required.
Dosage It will be appreciated by one of skill in the art that appropriate dosages of the anti-CD25 ADC and/or the anti-BCL-2 agent, mTOR inhibitor, or secondary agent, and compositions comprising these active elements, can vary from subject to subject.
Determining the optimal dosage will generally involve the balancing of the level of therapeutic benefit against any risk or deleterious side effects. The selected dosage level will depend on a variety of factors including, but not limited to, the activity of the particular compound, the route of administration, the time of administration, the rate of excretion of the compound, the duration of the treatment, other drugs, compounds, and/or materials used in combination, the severity of the condition, and the species, sex, age, weight, condition, general health, and prior medical history of the subject. The amount of compound and route of administration will ultimately be at the discretion of the physician, veterinarian, or clinician, although generally the dosage will be selected to achieve local concentrations at the site of action which achieve the desired effect without causing substantial harmful or deleterious side-effects.
In certain aspects, the dosage of anti-CD25 ADC is determined by the expression of CD25 observed in a sample obtained from the subject. Thus, the level or localisation of expression of CD25 in the sample may be indicative that a higher or lower dose of anti-CD25 ADC is required. For example, a high expression level of CD25 may indicate that a higher dose of anti-CD25 ADC would be suitable. In some cases, a high expression level of CD25 may indicate the need for administration of another agent in addition to the anti-CD25 ADC. For example, administration of the anti-CD25 ADC in conjunction with a chemotherapeutic agent. A high expression level of CD25 may indicate a more aggressive therapy.
In certain aspects, the dosage of the anti-BCL-2 agent, mTOR inhibitor, or secondary agent is determined by the expression of observed in a sample obtained from the subject.
Thus, the level or localisation of expression of in the sample may be indicative that a higher or lower dose of anti-BCL-2 agent, mTOR inhibitor, or secondary agent is required.
For example, a high expression level of BCL-2, mTOR, or secondary target protein may indicate that a higher dose of anti-BCL-2 agent, mTOR inhibitor, or secondary agent would be suitable. In some cases, a high expression level of BCL-2, mTOR, or secondary target protein may indicate the need for administration of another agent in addition to the anti-BCL-2 agent, mTOR inhibitor, or secondary agent. For example, administration of the anti-BCL-2 agent, mTOR inhibitor, or secondary agent in conjunction with a chemotherapeutic agent. A high expression level of BCL-2, mTOR, or secondary target protein may indicate a more aggressive therapy.
Administration can be effected in one dose, continuously or intermittently (e.g., in divided doses at appropriate intervals) throughout the course of treatment.
Methods of determining the most effective means and dosage of administration are well known to those of skill in the art and will vary with the formulation used for therapy, the purpose of the therapy, the target cell(s) being treated, and the subject being treated.
Single or multiple administrations can be carried out with the dose level and pattern being selected by the treating physician, veterinarian, or clinician.
In general, a suitable dose of each active compound is in the range of about 100 ng to about 25 mg (more typically about 1 pg to about 10 mg) per kilogram body weight of the subject per day. Where the active compound is a salt, an ester, an amide, a prodrug, or the like, the amount administered is calculated on the basis of the parent compound and so the actual weight to be used is increased proportionately.
In one embodiment, each active compound is administered to a human subject according to the following dosage regime: about 100 mg, 3 times daily.
In one embodiment, each active compound is administered to a human subject according to the following dosage regime: about 150 mg, 2 times daily.
In one embodiment, each active compound is administered to a human subject according to the following dosage regime: about 200 mg, 2 times daily.
However in one embodiment, each conjugate compound is administered to a human subject according to the following dosage regime: about 50 or about 75 mg, 3 or 4 times daily.
In one embodiment, each conjugate compound is administered to a human subject according to the following dosage regime: about 100 or about 125 mg, 2 times daily.
For the anti-0D25 ADC, where it is a PBD bearing ADC, the dosage amounts described above may apply to the conjugate (including the PBD moiety and the linker to the antibody) or to the effective amount of PBD compound provided, for example the amount of compound that is releasable after cleavage of the linker.
The anti-0D25 ADC comprises an anti-0D25 antibody. The anti-0D25 antibody may be HuMax-TACTM. The ADC may comprise a drug which is a PBD dimer. The ADC may be an anti-0D25-ADC, and in particular, ADCX25 or ADCT-301. The ADC may be an ADC disclosed in W02014/057119.
The anti-BCL-2 agent may be Venetoclax (ABT-199), navitoclax (ABT-263), ABT-737, S55746/BCL201, and oblimersen (G3139). Preferably the anti-BCL-2 agent is Venetoclax (A BT-199).
The mTOR inhibitor may be everolimus (RAD001), sirolimus (Rapamycin), 00I-779 (temsirolimus), ridaforolimus (AP-23573), NVP-BEZ235 (dactolisib), BGT226, SF1126, Gedatolisib, Omipalisib, XL765, Ku-0063794, oleuropein aglycone, AZD8055, AZD2014, AZD 3147, sapanisertib (INK128/MLN0128), 0SI027, torin 1, torin 2, torkinib (PP242), VVYE687, ETP45658, PF05212384, PF04691502, XL388, eCF309, RapaLink-1, or Rapalink-2.
The secondary agent may be:
(a) Bendamustine;
(b) a phosphoinositide 3-kinase inhibitor such as copanlisib, idelalisib, duvelisib, Taselisib, Buparlisib, Alpelisib, Umbralisib, Dactolisib, and Voxtalisib;
(c) a proteasome inhibitor such as bortezomib, carfilzomib, lxazomib, Oprozomib, and Salinosporamide A;
(d) an anti-folate such as pralatrexate, methotrexate, pemetrexed, and raltitrexed;
or (e) a HDAC inhibitor such as romidepsin, vorinostat, Abexinostat, belinostat (PXD101), LAQ824, panobinostat (LBH589), entinostat (MS-275), tacedinaline (01994), and mocetinostat (MGCD0103).
Antibodies The term "antibody" herein is used in the broadest sense and specifically covers monoclonal antibodies, polyclonal antibodies, dimers, multimers, multispecific antibodies (e.g., bispecific antibodies), intact antibodies (also described as "full-length" antibodies) and antibody fragments, so long as they exhibit the desired biological activity, for example, the ability to bind 0D25 (Miller et al (2003) Jour. of Immunology 170:4854-4861). Antibodies may be murine, human, humanized, chimeric, or derived from other species such as rabbit, goat, sheep, horse or camel.
An antibody is a protein generated by the immune system that is capable of recognizing and binding to a specific antigen. (Janeway, C., Travers, P., Walport, M., Shlomchik (2001) lmmuno Biology, 5th Ed., Garland Publishing, New York). A target antigen generally has numerous binding sites, also called epitopes, recognized by Complementarity Determining Regions (CDRs) on multiple antibodies. Each antibody that specifically binds to a different epitope has a different structure.
Thus, one antigen may have more than one corresponding antibody. An antibody may comprise a full-length immunoglobulin molecule or an immunologically active portion of a full-length immunoglobulin molecule, i.e., a molecule that contains an antigen binding site that immunospecifically binds an antigen of a target of interest or part thereof, such targets including but not limited to, cancer cell or cells that produce autoimmune antibodies associated with an autoimmune disease. The immunoglobulin can be of any type (e.g.
IgG, IgE, IgM, IgD, and IgA), class (e.g. IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2) or subclass, or allotype (e.g. human G1m1, G1m2, G1m3, non-G1m1 [that, is any allotype other than G1m1], G1m17, G2m23, G3m21, G3m28, G3m11, G3m5, G3m13, G3m14, G3m10, G3m15, G3m16, G3m6, G3m24, G3m26, G3m27, A2m1, A2m2, Km1, Km2 and Km3) of immunoglobulin molecule. The immunoglobulins can be derived from any species, including human, murine, or rabbit origin.
"Antibody fragments" comprise a portion of a full length antibody, generally the antigen binding or variable region thereof. Examples of antibody fragments include Fab, Fab', F(ab')2, and scFv fragments; diabodies; linear antibodies; fragments produced by a Fab expression library, anti-idiotypic (anti-Id) antibodies, CDR (complementary determining region), and epitope-binding fragments of any of the above which immunospecifically bind to cancer cell antigens, viral antigens or microbial antigens, single-chain antibody molecules; and multispecific antibodies formed from antibody fragments.
The term "monoclonal antibody" as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e. the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigenic site. Furthermore, in contrast to polyclonal antibody preparations which include different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen. In addition to their specificity, the monoclonal antibodies are advantageous in that they may be synthesized uncontaminated by other antibodies. The modifier "monoclonal" indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method. For example, the monoclonal antibodies to be used in accordance with the present disclosure may be made by the hybridoma method first described by Kohler eta! (1975) Nature 256:495, or may be made by recombinant DNA methods (see, US 4816567). The monoclonal antibodies may also be isolated from phage antibody libraries using the techniques described in Clackson et al (1991) Nature, 352:624-628; Marks et al (1991) J.
Mol. Biol., 222:581-597 or from transgenic mice carrying a fully human immunoglobulin system (Lonberg (2008) Curr. Opinion 20(4):450-459).
The monoclonal antibodies herein specifically include "chimeric" antibodies in which a portion of the heavy and/or light chain is identical with or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical with or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, so long as they exhibit the desired biological activity (US 4816567; and Morrison et al (1984) Proc. Natl. Acad. Sci. USA, 81:6851-6855).
Chimeric antibodies include "primatized" antibodies comprising variable domain antigen-binding sequences derived from a non-human primate (e.g. Old World Monkey or Ape) and human constant region sequences.
An "intact antibody" herein is one comprising VL and VH domains, as well as a light chain constant domain (CL) and heavy chain constant domains, CH1, CH2 and CH3. The constant domains may be native sequence constant domains (e.g. human native sequence constant domains) or amino acid sequence variant thereof. The intact antibody may have one or more "effector functions" which refer to those biological activities attributable to the Fc region (a native sequence Fc region or amino acid sequence variant Fc region) of an antibody. Examples of antibody effector functions include C1q binding;
complement dependent cytotoxicity; Fc receptor binding; antibody-dependent cell-mediated cytotoxicity (ADCC); phagocytosis; and down regulation of cell surface receptors such as B cell receptor and BCR.
Depending on the amino acid sequence of the constant domain of their heavy chains, intact antibodies can be assigned to different "classes." There are five major classes of intact antibodies: IgA, IgD, IgE, IgG, and IgM, and several of these may be further divided into "subclasses" (isotypes), e.g., IgG1, IgG2, IgG3, IgG4, IgA, and IgA2. The heavy-chain constant domains that correspond to the different classes of antibodies are called a,
6, c, y, and p, respectively. The subunit structures and three-dimensional configurations of different classes of immunoglobulins are well known.
Brief Description of the Figures Embodiments and experiments illustrating the principles of the disclosure will now be discussed with reference to the accompanying figures in which:
Figure 1. Sequences The disclosure includes the combination of the aspects and preferred features described except where such a combination is clearly impermissible or expressly avoided.
The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described.
Aspects and embodiments of the present disclosure will now be illustrated, by way of example, with reference to the accompanying figures. Further aspects and embodiments will be apparent to those skilled in the art. All documents mentioned in this text are incorporated herein by reference.
Throughout this specification, including the claims which follow, unless the context requires otherwise, the word "comprise," and variations such as "comprises"
and "comprising," will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps.
Brief Description of the Figures Embodiments and experiments illustrating the principles of the disclosure will now be discussed with reference to the accompanying figures in which:
Figure 1. Sequences The disclosure includes the combination of the aspects and preferred features described except where such a combination is clearly impermissible or expressly avoided.
The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described.
Aspects and embodiments of the present disclosure will now be illustrated, by way of example, with reference to the accompanying figures. Further aspects and embodiments will be apparent to those skilled in the art. All documents mentioned in this text are incorporated herein by reference.
Throughout this specification, including the claims which follow, unless the context requires otherwise, the word "comprise," and variations such as "comprises"
and "comprising," will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps.
7 It must be noted that, as used in the specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. Ranges may be expressed herein as from "about" one particular value, and/or to "about" another particular value. When such a range is expressed, another embodiment includes from the one particular value and/or to the other particular value.
Similarly, when values are expressed as approximations, by the use of the antecedent "about," it will be understood that the particular value forms another embodiment.
SOME EMBODIMENTS
The following paragraphs describe some specific embodiments of the anti-0D25 ADC
plus anti-BCL-2 agent aspect of the present disclosure:
1. A method of selecting an individual as suitable for treatment with ADCx25 or ADCT-301, wherein the individual is selected for treatment with ADCx25 or ADCT-301 if the individual has been treated with Venetoclax.
2. A method of selecting an individual as suitable for treatment with ADCx25 or ADCT-301, wherein the individual is selected for treatment with ADCx25 or ADCT-301 if the individual is being treated with Venetoclax.
3. The method according to any one of the preceding paragraphs, wherein the individual is selected for treatment if the individual is refractory to treatment, or further treatment, with Venetoclax.
4. A method for treating a disorder in an individual, the method comprising:
(i) selecting an individual as suitable for treatment by a method according to any one of paragraphs 1 to 3; and (ii) administering to the individual an effective amount of ADCx25 or ADCT-301.
5. The method according to paragraph 4, further comprising administering Venetoclax in combination with ADCx25 or ADCT-301.
6. A method for treating a disorder in an individual, the method comprising administering to the individual an effective amount of ADCx25 or ADCT-301 and Venetoclax.
7. The method according to paragraph 6, wherein the individual is selected for treatment according to a method according to any one of paragraphs 1 to 3.
Similarly, when values are expressed as approximations, by the use of the antecedent "about," it will be understood that the particular value forms another embodiment.
SOME EMBODIMENTS
The following paragraphs describe some specific embodiments of the anti-0D25 ADC
plus anti-BCL-2 agent aspect of the present disclosure:
1. A method of selecting an individual as suitable for treatment with ADCx25 or ADCT-301, wherein the individual is selected for treatment with ADCx25 or ADCT-301 if the individual has been treated with Venetoclax.
2. A method of selecting an individual as suitable for treatment with ADCx25 or ADCT-301, wherein the individual is selected for treatment with ADCx25 or ADCT-301 if the individual is being treated with Venetoclax.
3. The method according to any one of the preceding paragraphs, wherein the individual is selected for treatment if the individual is refractory to treatment, or further treatment, with Venetoclax.
4. A method for treating a disorder in an individual, the method comprising:
(i) selecting an individual as suitable for treatment by a method according to any one of paragraphs 1 to 3; and (ii) administering to the individual an effective amount of ADCx25 or ADCT-301.
5. The method according to paragraph 4, further comprising administering Venetoclax in combination with ADCx25 or ADCT-301.
6. A method for treating a disorder in an individual, the method comprising administering to the individual an effective amount of ADCx25 or ADCT-301 and Venetoclax.
7. The method according to paragraph 6, wherein the individual is selected for treatment according to a method according to any one of paragraphs 1 to 3.
8. The method according to any one of paragraphs 5 to 7, wherein the treatment comprises administering ADCx25 or ADCT-301 before Venetoclax, simultaneous with Venetoclax, or after Venetoclax.
9. The method according to any previous paragraph, wherein the treatment further comprises administering a chemotherapeutic agent.
10. The method according to any previous paragraph, wherein the individual is human.
11. The method according to any preceding paragraph, wherein the individual has a disorder or has been determined to have a disorder.
12. The method according to paragraph 11, wherein the individual has, or has been has been determined to have, a cancer which expresses 0D25 or 0D25+ tumour-associated non-tumour cells, such as 0D25+ infiltrating cells.
13. The method according to any previous paragraph, wherein the individual is undergoing treatment with Venetoclax.
14. The method according to any previous paragraph, wherein the individual has undergone treatment with Venetoclax.
15. The method according to any previous paragraph, wherein the individual is refractory to treatment, or further treatment, with Venetoclax.
16. The method according to any one of the preceding paragraphs, wherein the treatment has increased efficacy as compared to monotherapy with either ADCx25 or ADCT-301 or Venetoclax alone.
17. The method according to any previous paragraph, wherein the disorder is a proliferative disease.
18. The method of paragraph 17, wherein the disorder is cancer.
19. The method of paragraph 18, wherein the disorder is selected from the group comprising: non-Hodgkin's Lymphoma, including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, (FL), Mantle Cell lymphoma (MCL), chronic lymphatic lymphoma (CLL), and Marginal Zone B-cell lymphoma (MZBL), and leukemias such as Hairy cell leukemia (HCL), Hairy cell leukemia variant (HCL-v), anaplastic large cell lymphoma (ALCL), and Acute Lymphoblastic Leukaemia (ALL) such as Philadelphia chromosome-positive ALL (Ph+ALL) or Philadelphia chromosome-negative ALL (Ph-ALL).
20. ADCx25 or ADCT-301 for use in a method of treatment according to any one of paragraphs 4 to 19.
21. A composition comprising ADCx25 or ADCT-301, for use in a method of treatment according to any one of paragraphs 4 to 19.
22. Venetoclax for use in a method of treatment according to any one of paragraphs 5 to 19.
23. A composition comprising Venetoclax, for use in a method of treatment according to any one of paragraphs 5 to 19.
24. Use of ADCx25 or ADCT-301 in the manufacture of a medicament for treating a disorder in an individual, wherein the treatment comprises the method of any one of paragraphs 4 to 19.
25. Use of Venetoclax in the manufacture of a medicament for treating a disorder in an individual, wherein the treatment comprises the method of any one of paragraphs 5 to 19.
26. A kit comprising:
a first medicament comprising ADCx25 or ADCT-301;
a package insert comprising instructions for administration of the first medicament according to the method of any one or paragraphs 4 to 19.
a first medicament comprising ADCx25 or ADCT-301;
a package insert comprising instructions for administration of the first medicament according to the method of any one or paragraphs 4 to 19.
27. The kit according to paragraph 26, further comprising:
a second medicament comprising Venetoclax.
The following paragraphs describe some specific embodiments of the anti-0D25 ADC
plus mTOR inhibitor aspect of the present disclosure:
1. A method of selecting an individual as suitable for treatment with ADCx25 or ADCT-301, wherein the individual is selected for treatment with ADCx25 or ADCT-301 if the individual has been treated with Everolimus.
2. A method of selecting an individual as suitable for treatment with ADCx25 or ADCT-301, wherein the individual is selected for treatment with ADCx25 or ADCT-301 if the individual is being treated with Everolimus.
3. The method according to any one of the preceding paragraphs, wherein the individual is selected for treatment if the individual is refractory to treatment, or further treatment, with Everolimus.
4. A method for treating a disorder in an individual, the method comprising:
(i) selecting an individual as suitable for treatment by a method according to any one of paragraphs 1 to 3; and (ii) administering to the individual an effective amount of ADCx25 or ADCT-301.
5. The method according to paragraph 4, further comprising administering Everolimus in combination with ADCx25 or ADCT-301.
6. A method for treating a disorder in an individual, the method comprising administering to the individual an effective amount of ADCx25 or ADCT-301 and Everolimus.
7. The method according to paragraph 6, wherein the individual is selected for treatment according to a method according to any one of paragraphs 1 to 3.
8. The method according to any one of paragraphs 5 to 7, wherein the treatment comprises administering ADCx25 or ADCT-301 before Everolimus, simultaneous with Everolimus, or after Everolimus.
9. The method according to any previous paragraph, wherein the treatment further comprises administering a chemotherapeutic agent.
10. The method according to any previous paragraph, wherein the individual is human.
11. The method according to any preceding paragraph, wherein the individual has a disorder or has been determined to have a disorder.
12. The method according to paragraph 11, wherein the individual has, or has been has been determined to have, a cancer which expresses 0D25 or 0D25+ tumour-associated non-tumour cells, such as 0D25+ infiltrating cells.
13. The method according to any previous paragraph, wherein the individual is undergoing treatment with Everolimus.
14. The method according to any previous paragraph, wherein the individual has undergone treatment with Everolimus.
15. The method according to any previous paragraph, wherein the individual is refractory to treatment, or further treatment, with Everolimus.
16. The method according to any one of the preceding paragraphs, wherein the treatment has increased efficacy as compared to monotherapy with either ADCx25 or ADCT-301 or Everolimus alone.
17. The method according to any previous paragraph, wherein the disorder is a proliferative disease.
18. The method of paragraph 17, wherein the disorder is cancer.
19. The method of paragraph 18, wherein the disorder is selected from the group comprising: non-Hodgkin's Lymphoma, including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, (FL), Mantle Cell lymphoma (MCL), chronic lymphatic lymphoma (CLL), and Marginal Zone B-cell lymphoma (MZBL), and leukemias such as Hairy cell leukemia (HCL), Hairy cell leukemia variant (HCL-v), anaplastic large cell lymphoma (ALCL), and Acute Lymphoblastic Leukaemia (ALL) such as Philadelphia chromosome-positive ALL (Ph+ALL) or Philadelphia chromosome-negative ALL (Ph-ALL).
20. ADCx25 or ADCT-301 for use in a method of treatment according to any one of paragraphs 4 to 19.
21. A composition comprising ADCx25 or ADCT-301, for use in a method of treatment according to any one of paragraphs 4 to 19.
22. Everolimus for use in a method of treatment according to any one of paragraphs 5 to 19.
23. A composition comprising Everolimus, for use in a method of treatment according to any one of paragraphs 5 to 19.
24. Use of ADCx25 or ADCT-301 in the manufacture of a medicament for treating a disorder in an individual, wherein the treatment comprises the method of any one of paragraphs 4 to 19.
25. Use of Everolimus in the manufacture of a medicament for treating a disorder in an individual, wherein the treatment comprises the method of any one of paragraphs 5 to 19.
26. A kit comprising:
a first medicament comprising ADCx25 or ADCT-301;
a package insert comprising instructions for administration of the first medicament according to the method of any one or paragraphs 4 to 19.
27. The kit according to paragraph 26, further comprising:
a second medicament comprising Everolimus.
The following paragraphs describe some specific embodiments of the anti-0D25 ADC
plus secondary agent aspect of the present disclosure:
1. A method of selecting an individual as suitable for treatment with ADCx25 or ADCT-301, wherein the individual is selected for treatment with ADCx25 or ADCT-301 if the individual has been treated with Bendamustine, copanlisib, idelalisib, pralatrexate, romidepsin, or vorinostat.
2. A method of selecting an individual as suitable for treatment with ADCx25 or ADCT-301, wherein the individual is selected for treatment with ADCx25 or ADCT-301 if the individual is being treated with Bendamustine, copanlisib, idelalisib, pralatrexate, romidepsin, or vorinostat.
3. The method according to any one of the preceding paragraphs, wherein the individual is selected for treatment if the individual is refractory to treatment, or further treatment, with Bendamustine, copanlisib, idelalisib, pralatrexate, romidepsin, or vorinostat.
4. A method for treating a disorder in an individual, the method comprising:
(i) selecting an individual as suitable for treatment by a method according to any one of paragraphs 1 to 3; and (ii) administering to the individual an effective amount of ADCx25 or ADCT-301.
5. The method according to paragraph 4, further comprising administering Bendamustine, copanlisib, idelalisib, pralatrexate, romidepsin, or vorinostat in combination with ADCx25 or ADCT-301.
6. A method for treating a disorder in an individual, the method comprising administering to the individual an effective amount of ADCx25 or ADCT-301 and Bendamustine, copanlisib, idelalisib, pralatrexate, romidepsin, or vorinostat.
7. The method according to paragraph 6, wherein the individual is selected for treatment according to a method according to any one of paragraphs 1 to 3.
8. The method according to any one of paragraphs 5 to 7, wherein the treatment comprises administering ADCx25 or ADCT-301 before Bendamustine, copanlisib, idelalisib, pralatrexate, romidepsin, or vorinostat, simultaneous with Bendamustine, copanlisib, idelalisib, pralatrexate, romidepsin, or vorinostat, or after Bendamustine, copanlisib, idelalisib, pralatrexate, romidepsin, or vorinostat.
9. The method according to any previous paragraph, wherein the treatment further comprises administering a chemotherapeutic agent.
10. The method according to any previous paragraph, wherein the individual is human.
11. The method according to any preceding paragraph, wherein the individual has a disorder or has been determined to have a disorder.
12. The method according to paragraph 11, wherein the individual has, or has been has been determined to have, a cancer which expresses 0D25 or 0D25+ tumour-associated non-tumour cells, such as 0D25+ infiltrating cells.
13. The method according to any previous paragraph, wherein the individual is undergoing treatment with Bendamustine, copanlisib, idelalisib, pralatrexate, romidepsin, or vorinostat.
14. The method according to any previous paragraph, wherein the individual has undergone treatment with Bendamustine, copanlisib, idelalisib, pralatrexate, romidepsin, or vorinostat.
15. The method according to any previous paragraph, wherein the individual is refractory to treatment, or further treatment, with Bendamustine, copanlisib, idelalisib, pralatrexate, romidepsin, or vorinostat.
16. The method according to any one of the preceding paragraphs, wherein the treatment has increased efficacy as compared to monotherapy with either ADCx25 or ADCT-301 or Bendamustine, copanlisib, idelalisib, pralatrexate, romidepsin, or vorinostat alone.
17. The method according to any previous paragraph, wherein the disorder is a proliferative disease.
18. The method of paragraph 17, wherein the disorder is cancer.
19. The method of paragraph 18, wherein the disorder is selected from the group comprising: non-Hodgkin's Lymphoma, including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, (FL), Mantle Cell lymphoma (MCL), chronic lymphatic lymphoma (CLL), and Marginal Zone B-cell lymphoma (MZBL), and leukemias such as Hairy cell leukemia (HCL), Hairy cell leukemia variant (HCL-v), anaplastic large cell lymphoma (ALCL), and Acute Lymphoblastic Leukaemia (ALL) such as Philadelphia chromosome-positive ALL (Ph+ALL) or Philadelphia chromosome-negative ALL (Ph-ALL).
20. ADCx25 or ADCT-301 for use in a method of treatment according to any one of paragraphs 4 to 19.
21. A composition comprising ADCx25 or ADCT-301, for use in a method of treatment according to any one of paragraphs 4 to 19.
22. Bendamustine, copanlisib, idelalisib, pralatrexate, romidepsin, or vorinostat for use in a method of treatment according to any one of paragraphs 5 to 19.
23. A composition comprising Bendamustine, copanlisib, idelalisib, pralatrexate, romidepsin, or vorinostat, for use in a method of treatment according to any one of paragraphs 5 to 19.
24. Use of ADCx25 or ADCT-301 in the manufacture of a medicament for treating a disorder in an individual, wherein the treatment comprises the method of any one of paragraphs 4 to 19.
25. Use of Bendamustine, copanlisib, idelalisib, pralatrexate, romidepsin, or vorinostat in the manufacture of a medicament for treating a disorder in an individual, wherein the treatment comprises the method of any one of paragraphs 5 to 19.
26. A kit comprising:
a first medicament comprising ADCx25 or ADCT-301;
a package insert comprising instructions for administration of the first medicament according to the method of any one or paragraphs 4 to 19.
27. The kit according to paragraph 26, further comprising:
a second medicament comprising Bendamustine, copanlisib, idelalisib, pralatrexate, romidepsin, or vorinostat.
The following paragraphs describe some specific embodiments of the anti-0D25 ADC
plus secondary agent aspect of the present disclosure:
1. A method of selecting an individual as suitable for treatment with ADCx25 or ADCT-301, wherein the individual is selected for treatment with ADCx25 or ADCT-301 if the individual has been treated with bortezomib.
2. A method of selecting an individual as suitable for treatment with ADCx25 or ADCT-301, wherein the individual is selected for treatment with ADCx25 or ADCT-301 if the individual is being treated with bortezomib.
3. The method according to any one of the preceding paragraphs, wherein the individual is selected for treatment if the individual is refractory to treatment, or further treatment, with bortezomib.
4. A method for treating a disorder in an individual, the method comprising:
(i) selecting an individual as suitable for treatment by a method according to any one of paragraphs 1 to 3; and (ii) administering to the individual an effective amount of ADCx25 or ADCT-301.
5. The method according to paragraph 4, further comprising administering bortezomib in combination with ADCx25 or ADCT-301.
6. A method for treating a disorder in an individual, the method comprising administering to the individual an effective amount of ADCx25 or ADCT-301 and bortezomib.
7. The method according to paragraph 6, wherein the individual is selected for treatment according to a method according to any one of paragraphs 1 to 3.
8. The method according to any one of paragraphs 5 to 7, wherein the treatment comprises administering ADCx25 or ADCT-301 before bortezomib, simultaneous with bortezomib, or after bortezomib.
9. The method according to any previous paragraph, wherein the treatment further comprises administering a chemotherapeutic agent.
10. The method according to any previous paragraph, wherein the individual is human.
11. The method according to any preceding paragraph, wherein the individual has a disorder or has been determined to have a disorder.
12. The method according to paragraph 11, wherein the individual has, or has been has been determined to have, a cancer which expresses 0D25 or 0D25+ tumour-associated non-tumour cells, such as 0D25+ infiltrating cells.
13. The method according to any previous paragraph, wherein the individual is undergoing treatment with bortezomib.
14. The method according to any previous paragraph, wherein the individual has undergone treatment with bortezomib.
15. The method according to any previous paragraph, wherein the individual is refractory to treatment, or further treatment, with bortezomib.
16. The method according to any one of the preceding paragraphs, wherein the treatment has increased efficacy as compared to monotherapy with either ADCx25 or ADCT-301 or bortezomib alone.
17. The method according to any previous paragraph, wherein the disorder is a proliferative disease.
18. The method of paragraph 17, wherein the disorder is cancer.
19. The method of paragraph 18, wherein the disorder is selected from the group comprising: non-Hodgkin's Lymphoma, including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, (FL), Mantle Cell lymphoma (MCL), chronic lymphatic lymphoma (CLL), and Marginal Zone B-cell lymphoma (MZBL), and leukemias such as Hairy cell leukemia (HCL), Hairy cell leukemia variant (HCL-v), anaplastic large cell lymphoma (ALCL), and Acute Lymphoblastic Leukaemia (ALL) such as Philadelphia chromosome-positive ALL (Ph+ALL) or Philadelphia chromosome-negative ALL (Ph-ALL).
20. ADCx25 or ADCT-301 for use in a method of treatment according to any one of paragraphs 4 to 19.
21. A composition comprising ADCx25 or ADCT-301, for use in a method of treatment according to any one of paragraphs 4 to 19.
22. Bortezomib for use in a method of treatment according to any one of paragraphs 5 to 19.
23. A composition comprising bortezomib, for use in a method of treatment according to any one of paragraphs 5 to 19.
24. Use of ADCx25 or ADCT-301 in the manufacture of a medicament for treating a disorder in an individual, wherein the treatment comprises the method of any one of paragraphs 4 to 19.
25. Use of bortezomib in the manufacture of a medicament for treating a disorder in an individual, wherein the treatment comprises the method of any one of paragraphs 5 to 19.
26. A kit comprising:
a first medicament comprising ADCx25 or ADCT-301;
a package insert comprising instructions for administration of the first medicament according to the method of any one or paragraphs 4 to 19.
27. The kit according to paragraph 26, further comprising:
a second medicament comprising bortezomib.
STATEMENTS OF INVENTION (1) 1. A method of selecting an individual as suitable for treatment with an anti-0D25 ADC, wherein the individual is selected for treatment with the anti-0D25 ADC
if the individual has been treated with an anti-BCL-2 agent.
2. A method of selecting an individual as suitable for treatment with an anti-0D25 ADC, wherein the individual is selected for treatment with the anti-0D25 ADC
if the individual is being treated with an anti-BCL-2 agent.
3. The method according to any one of the preceding paragraphs, wherein the individual is selected for treatment if the individual is refractory to treatment, or further treatment, with the anti-BCL-2 agent.
4. A method for treating a disorder in an individual, the method comprising:
(i) selecting an individual as suitable for treatment by a method according to any one of paragraphs 1 to 3; and (ii) administering to the individual an effective amount of the anti-0D25 ADC.
5. The method according to paragraph 4, further comprising administering an anti-BCL-2 agent in combination with the anti-0D25 ADC.
6. A method for treating a disorder in an individual, the method comprising administering to the individual an effective amount of an anti-0D25 ADC and anti-BCL-2 agent.
7. The method according to paragraph 6, wherein the individual is selected for treatment according to a method according to any one of paragraphs 1 to 3.
8. The method according to any one of paragraphs 5 to 7, wherein the treatment comprises administering the anti-0D25 ADC before the anti-BCL-2 agent, simultaneous with the anti-BCL-2 agent, or after the anti-BCL-2 agent.
9. The method according to any previous paragraph, wherein the treatment further comprises administering a chemotherapeutic agent.
10. The method according to any previous paragraph, wherein the individual is human.
11. The method according to any preceding paragraph, wherein the individual has a disorder or has been determined to have a disorder.
12. The method according to paragraph 11, wherein the individual has, or has been has been determined to have, a cancer which expresses 0D25 or 0D25+ tumour-associated non-tumour cells, such as 0D25+ infiltrating cells.
13. The method according to any previous paragraph, wherein the individual is undergoing treatment with an anti-BCL-2 agent.
14. The method according to any previous paragraph, wherein the individual has undergone treatment with an anti-BCL-2 agent.
15. The method according to any previous paragraph, wherein the individual is refractory to treatment, or further treatment, with the anti-BCL-2 agent.
16. The method according to any one of the preceding paragraphs, wherein the treatment has increased efficacy as compared to monotherapy with either the anti-0D25 ADC or anti-BCL-2 agent alone.
17. The method according to any preceding paragraph, wherein the anti-0D25 ADC is ADCx25 or ADCT-301.
18. The method according to any previous paragraph, wherein the disorder is a proliferative disease.
19. The method of paragraph 18, wherein the disorder is cancer.
20. The composition, method, use, or kit according any previous paragraph, wherein the individual has, or has been has been determined to have, a disorder characterised by the presence of a neoplasm comprising both 0D25+ve and 0D25-ve cells.
21. The composition, method, use, or kit according any previous paragraph, wherein the individual has, or has been has been determined to have, a disorder characterised by the presence of a neoplasm comprising, or composed of, 0D25-ve neoplastic cells.
22. The composition, method, use, or kit according to either of paragraphs 20 or 21, wherein the neoplasm is all or part of a solid tumour.
23. The method of statements 22, wherein the solid tumour is associated with 0D25+ve infiltrating cells;
optionally wherein the solid tumour is associated with high levels of 0D25+ve infiltrating cells.
24. The method of statement 23, wherein the solid tumour is selected from the group consisting of pancreatic cancer, breast cancer (including triple negative breast cancer), colorectal cancer, gastric and oesophageal cancer, melanoma, non-small cell lung cancer, ovarian cancer, hepatocellular carcinoma, renal cell carcinoma, bladder, and head and neck cancer.
25. The composition, method, use, or kit of any previous paragraph, wherein the disorder is selected from the group comprising:
Hodgkin's and non-Hodgkin's Lymphoma, including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, (FL), Mantle Cell lymphoma (MCL), chronic lymphatic lymphoma (CLL), Marginal Zone B-cell lymphoma (MZBL);
leukemias such as Hairy cell leukemia (HCL), Hairy cell leukemia variant (HCL-v), Acute Myeloid Leukaemia (AML), anaplastic large cell lymphoma (ALCL), and Acute Lymphoblastic Leukaemia (ALL) such as Philadelphia chromosome-positive ALL
(Ph+ALL) or Philadelphia chromosome-negative ALL (Ph-ALL);
pancreatic cancer, breast cancer, colorectal cancer, gastric and oesophageal cancer, leukemia and lymphoma, melanoma, non-small cell lung cancer, ovarian cancer, hepatocellular carcinoma, renal cell carcinoma, and head and neck cancer.
26. The method according to any previous paragraph, wherein the anti-BCL-2 agent is selected from the group consisting of: Venetoclax (ABT-199), navitoclax (ABT-263), ABT-737, S55746/BCL201, and oblimersen (G3139).
27. The method according to any previous paragraph, wherein the anti-BCL-2 agent is Venetoclax.
a second medicament comprising Venetoclax.
The following paragraphs describe some specific embodiments of the anti-0D25 ADC
plus mTOR inhibitor aspect of the present disclosure:
1. A method of selecting an individual as suitable for treatment with ADCx25 or ADCT-301, wherein the individual is selected for treatment with ADCx25 or ADCT-301 if the individual has been treated with Everolimus.
2. A method of selecting an individual as suitable for treatment with ADCx25 or ADCT-301, wherein the individual is selected for treatment with ADCx25 or ADCT-301 if the individual is being treated with Everolimus.
3. The method according to any one of the preceding paragraphs, wherein the individual is selected for treatment if the individual is refractory to treatment, or further treatment, with Everolimus.
4. A method for treating a disorder in an individual, the method comprising:
(i) selecting an individual as suitable for treatment by a method according to any one of paragraphs 1 to 3; and (ii) administering to the individual an effective amount of ADCx25 or ADCT-301.
5. The method according to paragraph 4, further comprising administering Everolimus in combination with ADCx25 or ADCT-301.
6. A method for treating a disorder in an individual, the method comprising administering to the individual an effective amount of ADCx25 or ADCT-301 and Everolimus.
7. The method according to paragraph 6, wherein the individual is selected for treatment according to a method according to any one of paragraphs 1 to 3.
8. The method according to any one of paragraphs 5 to 7, wherein the treatment comprises administering ADCx25 or ADCT-301 before Everolimus, simultaneous with Everolimus, or after Everolimus.
9. The method according to any previous paragraph, wherein the treatment further comprises administering a chemotherapeutic agent.
10. The method according to any previous paragraph, wherein the individual is human.
11. The method according to any preceding paragraph, wherein the individual has a disorder or has been determined to have a disorder.
12. The method according to paragraph 11, wherein the individual has, or has been has been determined to have, a cancer which expresses 0D25 or 0D25+ tumour-associated non-tumour cells, such as 0D25+ infiltrating cells.
13. The method according to any previous paragraph, wherein the individual is undergoing treatment with Everolimus.
14. The method according to any previous paragraph, wherein the individual has undergone treatment with Everolimus.
15. The method according to any previous paragraph, wherein the individual is refractory to treatment, or further treatment, with Everolimus.
16. The method according to any one of the preceding paragraphs, wherein the treatment has increased efficacy as compared to monotherapy with either ADCx25 or ADCT-301 or Everolimus alone.
17. The method according to any previous paragraph, wherein the disorder is a proliferative disease.
18. The method of paragraph 17, wherein the disorder is cancer.
19. The method of paragraph 18, wherein the disorder is selected from the group comprising: non-Hodgkin's Lymphoma, including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, (FL), Mantle Cell lymphoma (MCL), chronic lymphatic lymphoma (CLL), and Marginal Zone B-cell lymphoma (MZBL), and leukemias such as Hairy cell leukemia (HCL), Hairy cell leukemia variant (HCL-v), anaplastic large cell lymphoma (ALCL), and Acute Lymphoblastic Leukaemia (ALL) such as Philadelphia chromosome-positive ALL (Ph+ALL) or Philadelphia chromosome-negative ALL (Ph-ALL).
20. ADCx25 or ADCT-301 for use in a method of treatment according to any one of paragraphs 4 to 19.
21. A composition comprising ADCx25 or ADCT-301, for use in a method of treatment according to any one of paragraphs 4 to 19.
22. Everolimus for use in a method of treatment according to any one of paragraphs 5 to 19.
23. A composition comprising Everolimus, for use in a method of treatment according to any one of paragraphs 5 to 19.
24. Use of ADCx25 or ADCT-301 in the manufacture of a medicament for treating a disorder in an individual, wherein the treatment comprises the method of any one of paragraphs 4 to 19.
25. Use of Everolimus in the manufacture of a medicament for treating a disorder in an individual, wherein the treatment comprises the method of any one of paragraphs 5 to 19.
26. A kit comprising:
a first medicament comprising ADCx25 or ADCT-301;
a package insert comprising instructions for administration of the first medicament according to the method of any one or paragraphs 4 to 19.
27. The kit according to paragraph 26, further comprising:
a second medicament comprising Everolimus.
The following paragraphs describe some specific embodiments of the anti-0D25 ADC
plus secondary agent aspect of the present disclosure:
1. A method of selecting an individual as suitable for treatment with ADCx25 or ADCT-301, wherein the individual is selected for treatment with ADCx25 or ADCT-301 if the individual has been treated with Bendamustine, copanlisib, idelalisib, pralatrexate, romidepsin, or vorinostat.
2. A method of selecting an individual as suitable for treatment with ADCx25 or ADCT-301, wherein the individual is selected for treatment with ADCx25 or ADCT-301 if the individual is being treated with Bendamustine, copanlisib, idelalisib, pralatrexate, romidepsin, or vorinostat.
3. The method according to any one of the preceding paragraphs, wherein the individual is selected for treatment if the individual is refractory to treatment, or further treatment, with Bendamustine, copanlisib, idelalisib, pralatrexate, romidepsin, or vorinostat.
4. A method for treating a disorder in an individual, the method comprising:
(i) selecting an individual as suitable for treatment by a method according to any one of paragraphs 1 to 3; and (ii) administering to the individual an effective amount of ADCx25 or ADCT-301.
5. The method according to paragraph 4, further comprising administering Bendamustine, copanlisib, idelalisib, pralatrexate, romidepsin, or vorinostat in combination with ADCx25 or ADCT-301.
6. A method for treating a disorder in an individual, the method comprising administering to the individual an effective amount of ADCx25 or ADCT-301 and Bendamustine, copanlisib, idelalisib, pralatrexate, romidepsin, or vorinostat.
7. The method according to paragraph 6, wherein the individual is selected for treatment according to a method according to any one of paragraphs 1 to 3.
8. The method according to any one of paragraphs 5 to 7, wherein the treatment comprises administering ADCx25 or ADCT-301 before Bendamustine, copanlisib, idelalisib, pralatrexate, romidepsin, or vorinostat, simultaneous with Bendamustine, copanlisib, idelalisib, pralatrexate, romidepsin, or vorinostat, or after Bendamustine, copanlisib, idelalisib, pralatrexate, romidepsin, or vorinostat.
9. The method according to any previous paragraph, wherein the treatment further comprises administering a chemotherapeutic agent.
10. The method according to any previous paragraph, wherein the individual is human.
11. The method according to any preceding paragraph, wherein the individual has a disorder or has been determined to have a disorder.
12. The method according to paragraph 11, wherein the individual has, or has been has been determined to have, a cancer which expresses 0D25 or 0D25+ tumour-associated non-tumour cells, such as 0D25+ infiltrating cells.
13. The method according to any previous paragraph, wherein the individual is undergoing treatment with Bendamustine, copanlisib, idelalisib, pralatrexate, romidepsin, or vorinostat.
14. The method according to any previous paragraph, wherein the individual has undergone treatment with Bendamustine, copanlisib, idelalisib, pralatrexate, romidepsin, or vorinostat.
15. The method according to any previous paragraph, wherein the individual is refractory to treatment, or further treatment, with Bendamustine, copanlisib, idelalisib, pralatrexate, romidepsin, or vorinostat.
16. The method according to any one of the preceding paragraphs, wherein the treatment has increased efficacy as compared to monotherapy with either ADCx25 or ADCT-301 or Bendamustine, copanlisib, idelalisib, pralatrexate, romidepsin, or vorinostat alone.
17. The method according to any previous paragraph, wherein the disorder is a proliferative disease.
18. The method of paragraph 17, wherein the disorder is cancer.
19. The method of paragraph 18, wherein the disorder is selected from the group comprising: non-Hodgkin's Lymphoma, including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, (FL), Mantle Cell lymphoma (MCL), chronic lymphatic lymphoma (CLL), and Marginal Zone B-cell lymphoma (MZBL), and leukemias such as Hairy cell leukemia (HCL), Hairy cell leukemia variant (HCL-v), anaplastic large cell lymphoma (ALCL), and Acute Lymphoblastic Leukaemia (ALL) such as Philadelphia chromosome-positive ALL (Ph+ALL) or Philadelphia chromosome-negative ALL (Ph-ALL).
20. ADCx25 or ADCT-301 for use in a method of treatment according to any one of paragraphs 4 to 19.
21. A composition comprising ADCx25 or ADCT-301, for use in a method of treatment according to any one of paragraphs 4 to 19.
22. Bendamustine, copanlisib, idelalisib, pralatrexate, romidepsin, or vorinostat for use in a method of treatment according to any one of paragraphs 5 to 19.
23. A composition comprising Bendamustine, copanlisib, idelalisib, pralatrexate, romidepsin, or vorinostat, for use in a method of treatment according to any one of paragraphs 5 to 19.
24. Use of ADCx25 or ADCT-301 in the manufacture of a medicament for treating a disorder in an individual, wherein the treatment comprises the method of any one of paragraphs 4 to 19.
25. Use of Bendamustine, copanlisib, idelalisib, pralatrexate, romidepsin, or vorinostat in the manufacture of a medicament for treating a disorder in an individual, wherein the treatment comprises the method of any one of paragraphs 5 to 19.
26. A kit comprising:
a first medicament comprising ADCx25 or ADCT-301;
a package insert comprising instructions for administration of the first medicament according to the method of any one or paragraphs 4 to 19.
27. The kit according to paragraph 26, further comprising:
a second medicament comprising Bendamustine, copanlisib, idelalisib, pralatrexate, romidepsin, or vorinostat.
The following paragraphs describe some specific embodiments of the anti-0D25 ADC
plus secondary agent aspect of the present disclosure:
1. A method of selecting an individual as suitable for treatment with ADCx25 or ADCT-301, wherein the individual is selected for treatment with ADCx25 or ADCT-301 if the individual has been treated with bortezomib.
2. A method of selecting an individual as suitable for treatment with ADCx25 or ADCT-301, wherein the individual is selected for treatment with ADCx25 or ADCT-301 if the individual is being treated with bortezomib.
3. The method according to any one of the preceding paragraphs, wherein the individual is selected for treatment if the individual is refractory to treatment, or further treatment, with bortezomib.
4. A method for treating a disorder in an individual, the method comprising:
(i) selecting an individual as suitable for treatment by a method according to any one of paragraphs 1 to 3; and (ii) administering to the individual an effective amount of ADCx25 or ADCT-301.
5. The method according to paragraph 4, further comprising administering bortezomib in combination with ADCx25 or ADCT-301.
6. A method for treating a disorder in an individual, the method comprising administering to the individual an effective amount of ADCx25 or ADCT-301 and bortezomib.
7. The method according to paragraph 6, wherein the individual is selected for treatment according to a method according to any one of paragraphs 1 to 3.
8. The method according to any one of paragraphs 5 to 7, wherein the treatment comprises administering ADCx25 or ADCT-301 before bortezomib, simultaneous with bortezomib, or after bortezomib.
9. The method according to any previous paragraph, wherein the treatment further comprises administering a chemotherapeutic agent.
10. The method according to any previous paragraph, wherein the individual is human.
11. The method according to any preceding paragraph, wherein the individual has a disorder or has been determined to have a disorder.
12. The method according to paragraph 11, wherein the individual has, or has been has been determined to have, a cancer which expresses 0D25 or 0D25+ tumour-associated non-tumour cells, such as 0D25+ infiltrating cells.
13. The method according to any previous paragraph, wherein the individual is undergoing treatment with bortezomib.
14. The method according to any previous paragraph, wherein the individual has undergone treatment with bortezomib.
15. The method according to any previous paragraph, wherein the individual is refractory to treatment, or further treatment, with bortezomib.
16. The method according to any one of the preceding paragraphs, wherein the treatment has increased efficacy as compared to monotherapy with either ADCx25 or ADCT-301 or bortezomib alone.
17. The method according to any previous paragraph, wherein the disorder is a proliferative disease.
18. The method of paragraph 17, wherein the disorder is cancer.
19. The method of paragraph 18, wherein the disorder is selected from the group comprising: non-Hodgkin's Lymphoma, including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, (FL), Mantle Cell lymphoma (MCL), chronic lymphatic lymphoma (CLL), and Marginal Zone B-cell lymphoma (MZBL), and leukemias such as Hairy cell leukemia (HCL), Hairy cell leukemia variant (HCL-v), anaplastic large cell lymphoma (ALCL), and Acute Lymphoblastic Leukaemia (ALL) such as Philadelphia chromosome-positive ALL (Ph+ALL) or Philadelphia chromosome-negative ALL (Ph-ALL).
20. ADCx25 or ADCT-301 for use in a method of treatment according to any one of paragraphs 4 to 19.
21. A composition comprising ADCx25 or ADCT-301, for use in a method of treatment according to any one of paragraphs 4 to 19.
22. Bortezomib for use in a method of treatment according to any one of paragraphs 5 to 19.
23. A composition comprising bortezomib, for use in a method of treatment according to any one of paragraphs 5 to 19.
24. Use of ADCx25 or ADCT-301 in the manufacture of a medicament for treating a disorder in an individual, wherein the treatment comprises the method of any one of paragraphs 4 to 19.
25. Use of bortezomib in the manufacture of a medicament for treating a disorder in an individual, wherein the treatment comprises the method of any one of paragraphs 5 to 19.
26. A kit comprising:
a first medicament comprising ADCx25 or ADCT-301;
a package insert comprising instructions for administration of the first medicament according to the method of any one or paragraphs 4 to 19.
27. The kit according to paragraph 26, further comprising:
a second medicament comprising bortezomib.
STATEMENTS OF INVENTION (1) 1. A method of selecting an individual as suitable for treatment with an anti-0D25 ADC, wherein the individual is selected for treatment with the anti-0D25 ADC
if the individual has been treated with an anti-BCL-2 agent.
2. A method of selecting an individual as suitable for treatment with an anti-0D25 ADC, wherein the individual is selected for treatment with the anti-0D25 ADC
if the individual is being treated with an anti-BCL-2 agent.
3. The method according to any one of the preceding paragraphs, wherein the individual is selected for treatment if the individual is refractory to treatment, or further treatment, with the anti-BCL-2 agent.
4. A method for treating a disorder in an individual, the method comprising:
(i) selecting an individual as suitable for treatment by a method according to any one of paragraphs 1 to 3; and (ii) administering to the individual an effective amount of the anti-0D25 ADC.
5. The method according to paragraph 4, further comprising administering an anti-BCL-2 agent in combination with the anti-0D25 ADC.
6. A method for treating a disorder in an individual, the method comprising administering to the individual an effective amount of an anti-0D25 ADC and anti-BCL-2 agent.
7. The method according to paragraph 6, wherein the individual is selected for treatment according to a method according to any one of paragraphs 1 to 3.
8. The method according to any one of paragraphs 5 to 7, wherein the treatment comprises administering the anti-0D25 ADC before the anti-BCL-2 agent, simultaneous with the anti-BCL-2 agent, or after the anti-BCL-2 agent.
9. The method according to any previous paragraph, wherein the treatment further comprises administering a chemotherapeutic agent.
10. The method according to any previous paragraph, wherein the individual is human.
11. The method according to any preceding paragraph, wherein the individual has a disorder or has been determined to have a disorder.
12. The method according to paragraph 11, wherein the individual has, or has been has been determined to have, a cancer which expresses 0D25 or 0D25+ tumour-associated non-tumour cells, such as 0D25+ infiltrating cells.
13. The method according to any previous paragraph, wherein the individual is undergoing treatment with an anti-BCL-2 agent.
14. The method according to any previous paragraph, wherein the individual has undergone treatment with an anti-BCL-2 agent.
15. The method according to any previous paragraph, wherein the individual is refractory to treatment, or further treatment, with the anti-BCL-2 agent.
16. The method according to any one of the preceding paragraphs, wherein the treatment has increased efficacy as compared to monotherapy with either the anti-0D25 ADC or anti-BCL-2 agent alone.
17. The method according to any preceding paragraph, wherein the anti-0D25 ADC is ADCx25 or ADCT-301.
18. The method according to any previous paragraph, wherein the disorder is a proliferative disease.
19. The method of paragraph 18, wherein the disorder is cancer.
20. The composition, method, use, or kit according any previous paragraph, wherein the individual has, or has been has been determined to have, a disorder characterised by the presence of a neoplasm comprising both 0D25+ve and 0D25-ve cells.
21. The composition, method, use, or kit according any previous paragraph, wherein the individual has, or has been has been determined to have, a disorder characterised by the presence of a neoplasm comprising, or composed of, 0D25-ve neoplastic cells.
22. The composition, method, use, or kit according to either of paragraphs 20 or 21, wherein the neoplasm is all or part of a solid tumour.
23. The method of statements 22, wherein the solid tumour is associated with 0D25+ve infiltrating cells;
optionally wherein the solid tumour is associated with high levels of 0D25+ve infiltrating cells.
24. The method of statement 23, wherein the solid tumour is selected from the group consisting of pancreatic cancer, breast cancer (including triple negative breast cancer), colorectal cancer, gastric and oesophageal cancer, melanoma, non-small cell lung cancer, ovarian cancer, hepatocellular carcinoma, renal cell carcinoma, bladder, and head and neck cancer.
25. The composition, method, use, or kit of any previous paragraph, wherein the disorder is selected from the group comprising:
Hodgkin's and non-Hodgkin's Lymphoma, including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, (FL), Mantle Cell lymphoma (MCL), chronic lymphatic lymphoma (CLL), Marginal Zone B-cell lymphoma (MZBL);
leukemias such as Hairy cell leukemia (HCL), Hairy cell leukemia variant (HCL-v), Acute Myeloid Leukaemia (AML), anaplastic large cell lymphoma (ALCL), and Acute Lymphoblastic Leukaemia (ALL) such as Philadelphia chromosome-positive ALL
(Ph+ALL) or Philadelphia chromosome-negative ALL (Ph-ALL);
pancreatic cancer, breast cancer, colorectal cancer, gastric and oesophageal cancer, leukemia and lymphoma, melanoma, non-small cell lung cancer, ovarian cancer, hepatocellular carcinoma, renal cell carcinoma, and head and neck cancer.
26. The method according to any previous paragraph, wherein the anti-BCL-2 agent is selected from the group consisting of: Venetoclax (ABT-199), navitoclax (ABT-263), ABT-737, S55746/BCL201, and oblimersen (G3139).
27. The method according to any previous paragraph, wherein the anti-BCL-2 agent is Venetoclax.
28. An anti-CD25 ADC for use in a method of treatment according to any one of paragraphs 4 to 27.
29. A composition comprising an anti-CD25 ADC, for use in a method of treatment according to any one of paragraphs 4 to 27.
30. An anti-BCL-2 agent for use in a method of treatment according to any one of paragraphs 5 to 27.
31. A composition comprising an anti-BCL-2 agent, for use in a method of treatment according to any one of paragraphs 5 to 27.
32. Use of an anti-CD25 ADC in the manufacture of a medicament for treating a disorder in an individual, wherein the treatment comprises the method of any one of paragraphs 4 to 27.
33. Use of an anti-BCL-2 agent in the manufacture of a medicament for treating a disorder in an individual, wherein the treatment comprises the method of any one of paragraphs 5 to 27.
34. A kit comprising:
a first medicament comprising an anti-CD25 ADC;
a package insert comprising instructions for administration of the first medicament according to the method of any one or paragraphs 4 to 27.
a first medicament comprising an anti-CD25 ADC;
a package insert comprising instructions for administration of the first medicament according to the method of any one or paragraphs 4 to 27.
35. The kit according to paragraph 34, further comprising:
A second medicament comprising an anti-BCL-2 agent.
STATEMENTS OF INVENTION (2) 1. A method of selecting an individual as suitable for treatment with an anti-0D25 ADC, wherein the individual is selected for treatment with the anti-0D25 ADC
if the individual has been treated with an mTOR inhibitor.
2. A method of selecting an individual as suitable for treatment with an anti-0D25 ADC, wherein the individual is selected for treatment with the anti-0D25 ADC
if the individual is being treated with an mTOR inhibitor.
3. The method according to any one of the preceding paragraphs, wherein the individual is selected for treatment if the individual is refractory to treatment, or further treatment, with the mTOR inhibitor.
4. A method for treating a disorder in an individual, the method comprising:
(i) selecting an individual as suitable for treatment by a method according to any one of paragraphs 1 to 3; and (ii) administering to the individual an effective amount of the anti-0D25 ADC.
5. The method according to paragraph 4, further comprising administering an mTOR
inhibitor in combination with the anti-0D25 ADC.
6. A method for treating a disorder in an individual, the method comprising administering to the individual an effective amount of an anti-0D25 ADC and mTOR
inhibitor.
7. The method according to paragraph 6, wherein the individual is selected for treatment according to a method according to any one of paragraphs 1 to 3.
8. The method according to any one of paragraphs 5 to 7, wherein the treatment comprises administering the anti-0D25 ADC before the mTOR inhibitor, simultaneous with the mTOR inhibitor, or after the mTOR inhibitor.
9. The method according to any previous paragraph, wherein the treatment further comprises administering a chemotherapeutic agent.
10. The method according to any previous paragraph, wherein the individual is human.
11. The method according to any preceding paragraph, wherein the individual has a disorder or has been determined to have a disorder.
12. The method according to paragraph 11, wherein the individual has, or has been has been determined to have, a cancer which expresses 0D25 or 0D25+ tumour-associated non-tumour cells, such as 0D25+ infiltrating cells.
13. The method according to any previous paragraph, wherein the individual is undergoing treatment with an mTOR inhibitor.
14. The method according to any previous paragraph, wherein the individual has undergone treatment with an mTOR inhibitor.
15. The method according to any previous paragraph, wherein the individual is refractory to treatment, or further treatment, with the mTOR inhibitor.
16. The method according to any one of the preceding paragraphs, wherein the treatment has increased efficacy as compared to monotherapy with either the anti-0D25 ADC or mTOR inhibitor alone.
17. The method according to any preceding paragraph, wherein the anti-0D25 ADC is ADCx25 or ADCT-301.
18. The method according to any previous paragraph, wherein the disorder is a proliferative disease.
19. The method of paragraph 18, wherein the disorder is cancer.
20. The method according to any previous paragraph, wherein the individual has, or has been has been determined to have, a disorder characterised by the presence of a neoplasm comprising both 0D25+ve and 0D25-ve cells.
21. The method according to any previous paragraph, wherein the individual has, or has been has been determined to have, a disorder characterised by the presence of a neoplasm comprising, or composed of, 0D25-ve neoplastic cells.
22. The method according to according to either of paragraphs 20 or 21, wherein the neoplasm is all or part of a solid tumour.
23. The method according to statement 22, wherein the solid tumour is associated with 0D25+ve infiltrating cells;
optionally wherein the solid tumour is associated with high levels of 0D25+ve infiltrating cells.
24. The method of statement 23, wherein the solid tumour is selected from the group consisting of pancreatic cancer, breast cancer (including triple negative breast cancer), colorectal cancer, gastric and oesophageal cancer, melanoma, non-small cell lung cancer, ovarian cancer, hepatocellular carcinoma, renal cell carcinoma, bladder, and head and neck cancer.
25. The method according to any previous paragraph, wherein the disorder is selected from the group comprising:
Hodgkin's and non-Hodgkin's Lymphoma, including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, (FL), Mantle Cell lymphoma (MCL), chronic lymphatic lymphoma (CLL), Marginal Zone B-cell lymphoma (MZBL);
leukemias such as Hairy cell leukemia (HCL), Hairy cell leukemia variant (HCL-v), Acute Myeloid Leukaemia (AML), anaplastic large cell lymphoma (ALCL), and Acute Lymphoblastic Leukaemia (ALL) such as Philadelphia chromosome-positive ALL
(Ph+ALL) or Philadelphia chromosome-negative ALL (Ph-ALL);
pancreatic cancer, breast cancer, colorectal cancer, gastric and oesophageal cancer, leukemia and lymphoma, melanoma, non-small cell lung cancer, ovarian cancer, hepatocellular carcinoma, renal cell carcinoma, and head and neck cancer.
26. The method according to any previous paragraph, wherein the mTOR
inhibitor is everolimus (RAD001), sirolimus (Rapamycin), CCI-779 (temsirolimus), ridaforolimus (AP-23573), NVP-BEZ235 (dactolisib), BGT226, SF1126, Gedatolisib, Omipalisib, XL765, Ku-0063794, oleuropein aglycone, AZD8055, AZD2014, AZD 3147, sapanisertib (INK128/MLN0128), 0SI027, torin 1, torin 2, torkinib (PP242), VVYE687, ETP45658, PF05212384, PF04691502, XL388, eCF309, RapaLink-1, or Rapalink-2.
27. The method according to any previous paragraph, wherein the mTOR
inhibitor is Everolim us.
28. An anti-CD25 ADC for use in a method of treatment according to any one of paragraphs 4 to 27.
29. A composition comprising an anti-CD25 ADC, for use in a method of treatment according to any one of paragraphs 4 to 27.
30. An mTOR inhibitor for use in a method of treatment according to any one of paragraphs 5 to 27.
31. A composition comprising an mTOR inhibitor, for use in a method of treatment according to any one of paragraphs 5 to 27.
32. Use of an anti-CD25 ADC in the manufacture of a medicament for treating a disorder in an individual, wherein the treatment comprises the method of any one of paragraphs 4 to 27.
33. Use of an mTOR inhibitor in the manufacture of a medicament for treating a disorder in an individual, wherein the treatment comprises the method of any one of paragraphs 5 to 27.
34. A kit comprising:
a first medicament comprising an anti-CD25 ADC;
a package insert comprising instructions for administration of the first medicament according to the method of any one or paragraphs 4 to 27.
35. The kit according to paragraph 34, further comprising:
A second medicament comprising an mTOR inhibitor.
STATEMENTS OF INVENTION (3) 1. A method of selecting an individual as suitable for treatment with an anti-0D25 ADC, wherein the individual is selected for treatment with the anti-0D25 ADC
if the individual has been treated with an secondary agent.
2. A method of selecting an individual as suitable for treatment with an anti-0D25 ADC, wherein the individual is selected for treatment with the anti-0D25 ADC
if the individual is being treated with an secondary agent.
3. The method according to any one of the preceding paragraphs, wherein the individual is selected for treatment if the individual is refractory to treatment, or further treatment, with the secondary agent.
4. A method for treating a disorder in an individual, the method comprising:
(i) selecting an individual as suitable for treatment by a method according to any one of paragraphs 1 to 3; and (ii) administering to the individual an effective amount of the anti-0D25 ADC.
5. The method according to paragraph 4, further comprising administering an secondary agent in combination with the anti-0D25 ADC.
6. A method for treating a disorder in an individual, the method comprising administering to the individual an effective amount of an anti-0D25 ADC and secondary agent.
7. The method according to paragraph 6, wherein the individual is selected for treatment according to a method according to any one of paragraphs 1 to 3.
8. The method according to any one of paragraphs 5 to 7, wherein the treatment comprises administering the anti-0D25 ADC before the secondary agent, simultaneous with the secondary agent, or after the secondary agent.
9. The method according to any previous paragraph, wherein the treatment further comprises administering a chemotherapeutic agent.
10. The method according to any previous paragraph, wherein the individual is human.
11. The method according to any preceding paragraph, wherein the individual has a disorder or has been determined to have a disorder.
12. The method according to paragraph 11, wherein the individual has, or has been has been determined to have, a cancer which expresses 0D25 or 0D25+ tumour-associated non-tumour cells, such as 0D25+ infiltrating cells.
13. The method according to any previous paragraph, wherein the individual is undergoing treatment with an secondary agent.
14. The method according to any previous paragraph, wherein the individual has undergone treatment with an secondary agent.
15. The method according to any previous paragraph, wherein the individual is refractory to treatment, or further treatment, with the secondary agent.
16. The method according to any one of the preceding paragraphs, wherein the treatment has increased efficacy as compared to monotherapy with either the anti-0D25 ADC or secondary agent alone.
17. The method according to any preceding paragraph, wherein the anti-0D25 ADC is ADCx25 or ADCT-301.
18. The method according to any previous paragraph, wherein the disorder is a proliferative disease.
19. The method of paragraph 18, wherein the disorder is cancer.
20. The method according to any previous paragraph, wherein the individual has, or has been has been determined to have, a disorder characterised by the presence of a neoplasm comprising both 0D25+ve and 0D25-ve cells.
21. The method according to any previous paragraph, wherein the individual has, or has been has been determined to have, a disorder characterised by the presence of a neoplasm comprising, or composed of, 0D25-ve neoplastic cells.
22. The method according to either of paragraphs 20 or 21, wherein the neoplasm is all or part of a solid tumour.
23. The method of statement 22, wherein the solid tumour is associated with 0D25+ve infiltrating cells;
optionally wherein the solid tumour is associated with high levels of 0D25+ve infiltrating cells.
24. The method of statement 23, wherein the solid tumour is selected from the group consisting of pancreatic cancer, breast cancer (including triple negative breast cancer), colorectal cancer, gastric and oesophageal cancer, melanoma, non-small cell lung cancer, ovarian cancer, hepatocellular carcinoma, renal cell carcinoma, bladder, and head and neck cancer.
25. The method according to any previous paragraph, wherein the disorder is selected from the group comprising:
Hodgkin's and non-Hodgkin's Lymphoma, including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, (FL), Mantle Cell lymphoma (MCL), chronic lymphatic lymphoma (CLL), Marginal Zone B-cell lymphoma (MZBL);
leukemias such as Hairy cell leukemia (HCL), Hairy cell leukemia variant (HCL-v), Acute Myeloid Leukaemia (AML), anaplastic large cell lymphoma (ALCL), and Acute Lymphoblastic Leukaemia (ALL) such as Philadelphia chromosome-positive ALL
(Ph+ALL) or Philadelphia chromosome-negative ALL (Ph-ALL);
pancreatic cancer, breast cancer, colorectal cancer, gastric and oesophageal cancer, leukemia and lymphoma, melanoma, non-small cell lung cancer, ovarian cancer, hepatocellular carcinoma, renal cell carcinoma, and head and neck cancer.
26. The method according to any one of paragraphs 1 to 25, wherein the secondary agent is bendamustine.
27. The method according to any one of paragraphs 1 to 25, wherein the secondary agent is a phosphoinositide 3-kinase inhibitor.
28. The method according to paragraph 27, wherein the phosphoinositide 3-kinase inhibitor is copanlisib, idelalisib, duvelisib, Taselisib, Buparlisib, Alpelisib, Umbralisib, Dactolisib, or Voxtalisib.
29. The method according to paragraph 27, wherein the phosphoinositide 3-kinase inhibitor is copanlisib or idelalisib.
30. The method according to any one of paragraphs 1 to 25, wherein the secondary agent is a proteasome inhibitor.
31. The method according to paragraph 30, wherein the proteasome inhibitor is bortezomib, carfilzomib, lxazomib, Oprozomib, or Salinosporamide A.
32. The method according to paragraph 30, wherein the wherein the proteasome inhibitor is bortezomib.
33. The method according to any one of paragraphs 1 to 25, wherein the secondary agent is an anti-folate.
34. The method according to paragraph 33, wherein the anti-folate is pralatrexate, methotrexate, pemetrexed, or raltitrexed.
35. The method according to paragraph 33, wherein the anti-folate is pralatrexate.
A second medicament comprising an anti-BCL-2 agent.
STATEMENTS OF INVENTION (2) 1. A method of selecting an individual as suitable for treatment with an anti-0D25 ADC, wherein the individual is selected for treatment with the anti-0D25 ADC
if the individual has been treated with an mTOR inhibitor.
2. A method of selecting an individual as suitable for treatment with an anti-0D25 ADC, wherein the individual is selected for treatment with the anti-0D25 ADC
if the individual is being treated with an mTOR inhibitor.
3. The method according to any one of the preceding paragraphs, wherein the individual is selected for treatment if the individual is refractory to treatment, or further treatment, with the mTOR inhibitor.
4. A method for treating a disorder in an individual, the method comprising:
(i) selecting an individual as suitable for treatment by a method according to any one of paragraphs 1 to 3; and (ii) administering to the individual an effective amount of the anti-0D25 ADC.
5. The method according to paragraph 4, further comprising administering an mTOR
inhibitor in combination with the anti-0D25 ADC.
6. A method for treating a disorder in an individual, the method comprising administering to the individual an effective amount of an anti-0D25 ADC and mTOR
inhibitor.
7. The method according to paragraph 6, wherein the individual is selected for treatment according to a method according to any one of paragraphs 1 to 3.
8. The method according to any one of paragraphs 5 to 7, wherein the treatment comprises administering the anti-0D25 ADC before the mTOR inhibitor, simultaneous with the mTOR inhibitor, or after the mTOR inhibitor.
9. The method according to any previous paragraph, wherein the treatment further comprises administering a chemotherapeutic agent.
10. The method according to any previous paragraph, wherein the individual is human.
11. The method according to any preceding paragraph, wherein the individual has a disorder or has been determined to have a disorder.
12. The method according to paragraph 11, wherein the individual has, or has been has been determined to have, a cancer which expresses 0D25 or 0D25+ tumour-associated non-tumour cells, such as 0D25+ infiltrating cells.
13. The method according to any previous paragraph, wherein the individual is undergoing treatment with an mTOR inhibitor.
14. The method according to any previous paragraph, wherein the individual has undergone treatment with an mTOR inhibitor.
15. The method according to any previous paragraph, wherein the individual is refractory to treatment, or further treatment, with the mTOR inhibitor.
16. The method according to any one of the preceding paragraphs, wherein the treatment has increased efficacy as compared to monotherapy with either the anti-0D25 ADC or mTOR inhibitor alone.
17. The method according to any preceding paragraph, wherein the anti-0D25 ADC is ADCx25 or ADCT-301.
18. The method according to any previous paragraph, wherein the disorder is a proliferative disease.
19. The method of paragraph 18, wherein the disorder is cancer.
20. The method according to any previous paragraph, wherein the individual has, or has been has been determined to have, a disorder characterised by the presence of a neoplasm comprising both 0D25+ve and 0D25-ve cells.
21. The method according to any previous paragraph, wherein the individual has, or has been has been determined to have, a disorder characterised by the presence of a neoplasm comprising, or composed of, 0D25-ve neoplastic cells.
22. The method according to according to either of paragraphs 20 or 21, wherein the neoplasm is all or part of a solid tumour.
23. The method according to statement 22, wherein the solid tumour is associated with 0D25+ve infiltrating cells;
optionally wherein the solid tumour is associated with high levels of 0D25+ve infiltrating cells.
24. The method of statement 23, wherein the solid tumour is selected from the group consisting of pancreatic cancer, breast cancer (including triple negative breast cancer), colorectal cancer, gastric and oesophageal cancer, melanoma, non-small cell lung cancer, ovarian cancer, hepatocellular carcinoma, renal cell carcinoma, bladder, and head and neck cancer.
25. The method according to any previous paragraph, wherein the disorder is selected from the group comprising:
Hodgkin's and non-Hodgkin's Lymphoma, including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, (FL), Mantle Cell lymphoma (MCL), chronic lymphatic lymphoma (CLL), Marginal Zone B-cell lymphoma (MZBL);
leukemias such as Hairy cell leukemia (HCL), Hairy cell leukemia variant (HCL-v), Acute Myeloid Leukaemia (AML), anaplastic large cell lymphoma (ALCL), and Acute Lymphoblastic Leukaemia (ALL) such as Philadelphia chromosome-positive ALL
(Ph+ALL) or Philadelphia chromosome-negative ALL (Ph-ALL);
pancreatic cancer, breast cancer, colorectal cancer, gastric and oesophageal cancer, leukemia and lymphoma, melanoma, non-small cell lung cancer, ovarian cancer, hepatocellular carcinoma, renal cell carcinoma, and head and neck cancer.
26. The method according to any previous paragraph, wherein the mTOR
inhibitor is everolimus (RAD001), sirolimus (Rapamycin), CCI-779 (temsirolimus), ridaforolimus (AP-23573), NVP-BEZ235 (dactolisib), BGT226, SF1126, Gedatolisib, Omipalisib, XL765, Ku-0063794, oleuropein aglycone, AZD8055, AZD2014, AZD 3147, sapanisertib (INK128/MLN0128), 0SI027, torin 1, torin 2, torkinib (PP242), VVYE687, ETP45658, PF05212384, PF04691502, XL388, eCF309, RapaLink-1, or Rapalink-2.
27. The method according to any previous paragraph, wherein the mTOR
inhibitor is Everolim us.
28. An anti-CD25 ADC for use in a method of treatment according to any one of paragraphs 4 to 27.
29. A composition comprising an anti-CD25 ADC, for use in a method of treatment according to any one of paragraphs 4 to 27.
30. An mTOR inhibitor for use in a method of treatment according to any one of paragraphs 5 to 27.
31. A composition comprising an mTOR inhibitor, for use in a method of treatment according to any one of paragraphs 5 to 27.
32. Use of an anti-CD25 ADC in the manufacture of a medicament for treating a disorder in an individual, wherein the treatment comprises the method of any one of paragraphs 4 to 27.
33. Use of an mTOR inhibitor in the manufacture of a medicament for treating a disorder in an individual, wherein the treatment comprises the method of any one of paragraphs 5 to 27.
34. A kit comprising:
a first medicament comprising an anti-CD25 ADC;
a package insert comprising instructions for administration of the first medicament according to the method of any one or paragraphs 4 to 27.
35. The kit according to paragraph 34, further comprising:
A second medicament comprising an mTOR inhibitor.
STATEMENTS OF INVENTION (3) 1. A method of selecting an individual as suitable for treatment with an anti-0D25 ADC, wherein the individual is selected for treatment with the anti-0D25 ADC
if the individual has been treated with an secondary agent.
2. A method of selecting an individual as suitable for treatment with an anti-0D25 ADC, wherein the individual is selected for treatment with the anti-0D25 ADC
if the individual is being treated with an secondary agent.
3. The method according to any one of the preceding paragraphs, wherein the individual is selected for treatment if the individual is refractory to treatment, or further treatment, with the secondary agent.
4. A method for treating a disorder in an individual, the method comprising:
(i) selecting an individual as suitable for treatment by a method according to any one of paragraphs 1 to 3; and (ii) administering to the individual an effective amount of the anti-0D25 ADC.
5. The method according to paragraph 4, further comprising administering an secondary agent in combination with the anti-0D25 ADC.
6. A method for treating a disorder in an individual, the method comprising administering to the individual an effective amount of an anti-0D25 ADC and secondary agent.
7. The method according to paragraph 6, wherein the individual is selected for treatment according to a method according to any one of paragraphs 1 to 3.
8. The method according to any one of paragraphs 5 to 7, wherein the treatment comprises administering the anti-0D25 ADC before the secondary agent, simultaneous with the secondary agent, or after the secondary agent.
9. The method according to any previous paragraph, wherein the treatment further comprises administering a chemotherapeutic agent.
10. The method according to any previous paragraph, wherein the individual is human.
11. The method according to any preceding paragraph, wherein the individual has a disorder or has been determined to have a disorder.
12. The method according to paragraph 11, wherein the individual has, or has been has been determined to have, a cancer which expresses 0D25 or 0D25+ tumour-associated non-tumour cells, such as 0D25+ infiltrating cells.
13. The method according to any previous paragraph, wherein the individual is undergoing treatment with an secondary agent.
14. The method according to any previous paragraph, wherein the individual has undergone treatment with an secondary agent.
15. The method according to any previous paragraph, wherein the individual is refractory to treatment, or further treatment, with the secondary agent.
16. The method according to any one of the preceding paragraphs, wherein the treatment has increased efficacy as compared to monotherapy with either the anti-0D25 ADC or secondary agent alone.
17. The method according to any preceding paragraph, wherein the anti-0D25 ADC is ADCx25 or ADCT-301.
18. The method according to any previous paragraph, wherein the disorder is a proliferative disease.
19. The method of paragraph 18, wherein the disorder is cancer.
20. The method according to any previous paragraph, wherein the individual has, or has been has been determined to have, a disorder characterised by the presence of a neoplasm comprising both 0D25+ve and 0D25-ve cells.
21. The method according to any previous paragraph, wherein the individual has, or has been has been determined to have, a disorder characterised by the presence of a neoplasm comprising, or composed of, 0D25-ve neoplastic cells.
22. The method according to either of paragraphs 20 or 21, wherein the neoplasm is all or part of a solid tumour.
23. The method of statement 22, wherein the solid tumour is associated with 0D25+ve infiltrating cells;
optionally wherein the solid tumour is associated with high levels of 0D25+ve infiltrating cells.
24. The method of statement 23, wherein the solid tumour is selected from the group consisting of pancreatic cancer, breast cancer (including triple negative breast cancer), colorectal cancer, gastric and oesophageal cancer, melanoma, non-small cell lung cancer, ovarian cancer, hepatocellular carcinoma, renal cell carcinoma, bladder, and head and neck cancer.
25. The method according to any previous paragraph, wherein the disorder is selected from the group comprising:
Hodgkin's and non-Hodgkin's Lymphoma, including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, (FL), Mantle Cell lymphoma (MCL), chronic lymphatic lymphoma (CLL), Marginal Zone B-cell lymphoma (MZBL);
leukemias such as Hairy cell leukemia (HCL), Hairy cell leukemia variant (HCL-v), Acute Myeloid Leukaemia (AML), anaplastic large cell lymphoma (ALCL), and Acute Lymphoblastic Leukaemia (ALL) such as Philadelphia chromosome-positive ALL
(Ph+ALL) or Philadelphia chromosome-negative ALL (Ph-ALL);
pancreatic cancer, breast cancer, colorectal cancer, gastric and oesophageal cancer, leukemia and lymphoma, melanoma, non-small cell lung cancer, ovarian cancer, hepatocellular carcinoma, renal cell carcinoma, and head and neck cancer.
26. The method according to any one of paragraphs 1 to 25, wherein the secondary agent is bendamustine.
27. The method according to any one of paragraphs 1 to 25, wherein the secondary agent is a phosphoinositide 3-kinase inhibitor.
28. The method according to paragraph 27, wherein the phosphoinositide 3-kinase inhibitor is copanlisib, idelalisib, duvelisib, Taselisib, Buparlisib, Alpelisib, Umbralisib, Dactolisib, or Voxtalisib.
29. The method according to paragraph 27, wherein the phosphoinositide 3-kinase inhibitor is copanlisib or idelalisib.
30. The method according to any one of paragraphs 1 to 25, wherein the secondary agent is a proteasome inhibitor.
31. The method according to paragraph 30, wherein the proteasome inhibitor is bortezomib, carfilzomib, lxazomib, Oprozomib, or Salinosporamide A.
32. The method according to paragraph 30, wherein the wherein the proteasome inhibitor is bortezomib.
33. The method according to any one of paragraphs 1 to 25, wherein the secondary agent is an anti-folate.
34. The method according to paragraph 33, wherein the anti-folate is pralatrexate, methotrexate, pemetrexed, or raltitrexed.
35. The method according to paragraph 33, wherein the anti-folate is pralatrexate.
36. The method according to any one of paragraphs 1 to 25, wherein the secondary agent is a HDAC inhibitor.
37. The method according to paragraph 36, wherein the HDAC inhibitor is romidepsin, vorinostat, Abexinostat, belinostat (PXD101), LAQ824, panobinostat (LBH589), entinostat (MS-275), tacedinaline (01994), or mocetinostat (MGCD0103).
38. The method according to paragraph 36, wherein the HDAC inhibitor is romidepsin or vorinostat.
39. An anti-0D25 ADC for use in a method of treatment according to any one of paragraphs 4 to 38.
40. A composition comprising an anti-0D25 ADC, for use in a method of treatment according to any one of paragraphs 4 to 38.
41. An secondary agent for use in a method of treatment according to any one of paragraphs 5 to 38.
42. A composition comprising an secondary agent, for use in a method of treatment according to any one of paragraphs 5 to 38.
43. Use of an anti-0D25 ADC in the manufacture of a medicament for treating a disorder in an individual, wherein the treatment comprises the method of any one of paragraphs 4 to 38.
44. Use of an secondary agent in the manufacture of a medicament for treating a disorder in an individual, wherein the treatment comprises the method of any one of paragraphs 5 to 38.
45. A kit comprising:
a first medicament comprising an anti-0D25 ADC;
a package insert comprising instructions for administration of the first medicament according to the method of any one or paragraphs 4 to 38.
a first medicament comprising an anti-0D25 ADC;
a package insert comprising instructions for administration of the first medicament according to the method of any one or paragraphs 4 to 38.
46. The kit according to paragraph 45, further comprising:
A second medicament comprising an secondary agent.
EXAM P L ES
Example 1 Introduction Camidanlumab tesirine (ADCT-301) is an anti-0D25 antibody-drug conjugate (ADC) conjugated via a protease cleavable linker to SG3199, a highly cytotoxic DNA
minor groove crosslinking pyrrolobenzodiazepine dimer (Flynn et al. Mol Cancer Ther 2016, and as described herein).
ADCT-301 is currently in phase I as single agent in relapsed/refractory lymphomas (NCT02432235), advanced solid tumors (NCT03621982) and in acute myeloid leukemia (NCT02588092). It has preclinical activity as single agent in 57 lymphoma cell lines and in combination with selected drugs in T-cell lymphomas-derived cell lines.
Methods Cell lines were exposed to increasing concentrations of ADCT-301 for 96h followed by MU proliferation assay. CD25 expression was measured both at cell surface level via fluorescence quantitation (Quantum Simply Cellular microspheres) and at RNA
level (Illumina HT-12 arrays and HTG EdgeSeq Oncology Biomarker Panel). Combination studies of increasing doses of ADCT-301 and increasing doses of additional drugs were assessed by MT1" proliferation assay over 96h in FE-PD, Karpas-299, KI-JK and cell lines.
Chou-Talalay method was used to calculate median combination index (Cl) (synergism Cl<0.9, additive CI=0.9-1.1, antagonism/no benefit CI> 1.1).
Results ADCT-301 presented a much stronger activity in T- (n=9, median IC50=4 pM; 95%
Cl., 1.6pM-0.9nM) than B-cell lymphomas (n=48, 0.7 nM; 95% CI., 0.4-2.6 nM) (P=0.047). In vitro activity was highly correlated with CD25 expression both at cell surface level (n=53, Pearson r = -0.50, P=0.0001) and RNA level (n=53, Pearson r = -0.52, P<0.0001). CD25 was also more highly expressed in T- than B-cell lymphoma (P<0.0001), in agreement with the 1050s differences, and the correlation was still maintained within the subgroups (T-cell lymphomas, Pearson r = -0.90, P=0.0021; B-cell lymphomas; Pearson r = -0.3, P=0.05).
Based on the higher activity in T-cell lymphomas, ADCT-301-containing combinations were evaluated in 4 cell lines derived from peripheral T cell lymphoma not otherwise specified (n=1), ALK-pos (n=2) or ALK-neg (n=1) anaplastic large cell lymphoma (ALCL).
ADCT-301 plus the BCL2 inhibitor venetoclax was synergistic in all but one cell line. As shown by the data tables shown below.
Cell line: FE-PD
RRID cell accession identifier: CVOL_H614 Reference: del Mistro et al., Leukemia, 1994, Jul;8(7): pp.1214-9 ADCx25 Venetoclax ADCx25 Venetoclax Fa CI Fa CI
(PM) (nM) (PM) (nM) 0.02 2.4 1.0 0.02 1.56 2.4 0.9 0.74 0.02 9.8 0.9 0.02 1.56 9.8 0.8 0.49 0.02 39.1 0.9 0.04 1.56 39.1 0.8 0.49 0.02 156.3 0.9 0.15 1.56 156.3 0.9 0.73 0.02 625.0 0.9 0.66 1.56 625.0 0.8 1.03 0.02 2500.0 0.9 2.10 1.56 2500.0 0.8 2.10 0.02 10000.0 0.4 3.08 1.56 10000.0 0.3 2.94 0.1 2.4 0.9 0.04 6.25 2.4 0.8 1.94 0.1 9.8 0.9 0.04 6.25 9.8 0.8 1.77 0.1 39.1 0.8 0.06 6.25 39.1 0.7 1.59 0.1 156.3 0.9 0.18 6.25 156.3 0.8 1.92 0.1 625.0 0.9 0.73 6.25 625.0 0.7 2.00 0.1 2500.0 0.8 1.81 6.25 2500.0 0.7 2.75 0.1 10000.0 0.3 2.96 6.25 10000.0 0.2 2.97 0.39 2.4 0.9 0.21 25 2.4 0.3 2.79 0.39 9.8 0.9 0.15 25 9.8 0.3 2.69 0.39 39.1 0.9 0.17 25 39.1 0.3 2.56 0.39 156.3 0.9 0.27 25 156.3 0.3 2.81 0.39 625.0 0.9 0.84 25 625.0 0.3 2.67 0.39 2500.0 0.8 2.16 25 2500.0 0.3 3.09 0.39 10000.0 0.3 2.85 25 10000.0 0.1 2.77 Cell line: Karpas-299 RRID cell accession identifier: CVOL_1324 Reference: Fischer et al., Blood, 1988, Jul;72(1):pp.234-40.
ADCx25 Venetoclax ADCx25 Venetoclax Fa CI Fa CI
(PM) (nM) (PM) (nM) 0.02 2.4 0.9 0.04 1.56 625.0 0.8 0.68 0.02 9.8 0.9 0.06 1.56 2500.0 0.8 1.72 0.02 39.1 0.8 0.05 1.56 10000.0 0.5 0.40 0.02 156.3 0.9 0.27 6.25 2.4 0.9 3.71 0.02 625.0 0.9 1.09 6.25 9.8 0.8 1.44 0.02 2500.0 0.8 1.20 6.25 39.1 0.8 1.91 0.02 10000.0 0.5 0.37 6.25 156.3 0.8 2.80 0.1 2.4 0.9 0.14 6.25 625.0 0.8 2.14 0.1 9.8 0.9 0.17 6.25 2500.0 0.8 2.83 0.1 39.1 0.8 0.08 6.25 10000.0 0.4 0.22 0.1 156.3 0.8 0.20 25 2.4 0.6 0.63 0.1 625.0 0.8 0.46 25 9.8 0.7 0.67 0.1 2500.0 0.8 2.27 25 39.1 0.6 0.45 0.1 10000.0 0.5 0.40 25 156.3 0.7 0.78 0.39 2.4 0.9 0.36 25 625.0 0.6 0.67 0.39 9.8 0.9 1.25 25 2500.0 0.6 0.91 0.39 39.1 0.8 0.21 25 10000.0 0.3 0.10 0.39 156.3 0.8 0.34 100 2.4 0.3 0.05 0.39 625.0 0.8 0.75 100 9.8 0.3 0.05 0.39 2500.0 0.8 1.52 100 39.1 0.3 0.05 0.39 10000.0 0.4 0.32 100 156.3 0.3 0.07 1.56 2.4 0.9 1.29 100 625.0 0.3 0.06 1.56 9.8 0.9 1.21 100 2500.0 0.3 0.08 1.56 39.1 0.8 0.45 100 10000.0 0.2 0.08 1.56 156.3 0.8 0.60 Cell line: Ki-JK
RRID cell accession identifier: CVOL_2093 Reference: Shimakage et al., lntervirology, 1993;36(4):pp.215-24.
ADCx25 Venetoclax ADCx25 Venetoclax Fa CI Fa CI
(PM) (nM) (PM) (nM) 0.02 2.4 1.0 0.01 1.56 2.4 0.9 0.35 0.02 9.8 1.0 0.01 1.56 9.8 1.0 0.56 0.02 39.1 0.9 0.02 1.56 39.1 0.9 0.38 0.02 156.3 0.9 0.07 1.56 156.3 0.9 0.51 0.02 625.0 0.9 0.26 1.56 625.0 0.8 0.43 0.02 2500.0 0.9 0.97 1.56 2500.0 0.8 0.97 0.02 10000.0 0.4 1.54 1.56 10000.0 0.4 1.60 0.1 2.4 1.0 0.07 6.25 2.4 0.8 0.74 0.1 9.8 1.0 0.21 6.25 9.8 0.8 0.64 0.1 39.1 1.0 0.09 6.25 39.1 0.8 0.73 0.1 156.3 1.0 0.12 6.25 156.3 0.7 0.55 0.1 625.0 0.9 0.33 6.25 625.0 0.7 0.68 0.1 2500.0 0.9 1.12 6.25 2500.0 0.6 0.95 0.1 10000.0 0.4 1.55 6.25 10000.0 0.2 1.18 0.39 2.4 1.0 0.22 25 2.4 0.4 0.67 0.39 9.8 1.0 7077.08 25 9.8 0.3 0.65 0.39 39.1 1.0 0.50 25 39.1 0.3 0.61 0.39 156.3 1.0 0.37 25 156.3 0.3 0.57 0.39 625.0 0.9 0.33 25 625.0 0.2 0.53 0.39 2500.0 0.9 0.97 25 2500.0 0.2 0.57 0.39 10000.0 0.4 1.49 25 10000.0 0.0 0.52 Cell line: Mac-1 RRID cell accession identifier: CVCL_H631 Reference: Su et al., Am J Pathol, 1988 Aug;132(2):pp.192-8.
ADCx25 Venetoclax ADCx25 Venetoclax Fa CI Fa CI
(PM) (nM) (PM) (nM) 0.02 2.4 0.9 0.23 1.56 2.4 0.8 0.72 0.02 9.8 0.9 0.23 1.56 9.8 0.7 0.51 0.02 39.1 0.8 0.21 1.56 39.1 0.8 0.80 0.02 156.3 0.7 0.32 1.56 156.3 0.7 0.48 0.02 625.0 0.7 0.97 1.56 625.0 0.6 0.36 0.02 2500.0 0.6 0.89 1.56 2500.0 0.5 0.33 0.1 2.4 0.9 0.21 6.25 2.4 0.7 1.88 0.1 9.8 0.8 0.10 6.25 9.8 0.7 1.61 0.1 39.1 0.8 0.21 6.25 39.1 0.7 1.05 0.1 156.3 0.8 0.42 6.25 156.3 0.7 0.73 0.1 625.0 0.7 0.51 6.25 625.0 0.6 0.41 0.1 2500.0 0.6 0.57 6.25 2500.0 0.5 0.30 0.39 2.4 0.8 0.23 25 2.4 0.5 0.59 0.39 9.8 0.8 0.43 25 9.8 0.5 0.37 0.39 39.1 0.8 0.64 25 39.1 0.5 0.32 0.39 156.3 0.8 0.52 25 156.3 0.4 0.19 0.39 625.0 0.7 0.59 25 625.0 0.4 0.19 0.39 2500.0 0.5 0.42 25 2500.0 0.3 0.09 Conclusion The strong single agent anti-lymphoma activity and the observed in vitro synergism with targeted agents support the current ADCT-301 clinical development and identify potential combination partners for future clinical studies.
Example 2 Introduction Camidanlumab tesirine (ADCT-301) is an anti-CD25 antibody-drug conjugate (ADC) conjugated via a protease cleavable linker to SG3199, a highly cytotoxic DNA
minor groove crosslinking pyrrolobenzodiazepine dimer (Flynn et al. Mol Cancer Ther 2016, and as described herein).
ADCT-301 is currently in phase I as single agent in relapsed/refractory lymphomas (NCT02432235), advanced solid tumors (NCT03621982) and in acute myeloid leukemia (N0T02588092). It has preclinical activity as single agent in 57 lymphoma cell lines and in combination with selected drugs in T-cell lymphomas-derived cell lines.
Methods Cell lines were exposed to increasing concentrations of ADCT-301 for 96h followed by MU proliferation assay. 0D25 expression was measured both at cell surface level via fluorescence quantitation (Quantum Simply Cellular microspheres) and at RNA
level (IIlumina HT-12 arrays and HTG EdgeSeq Oncology Biomarker Panel). Combination studies of increasing doses of ADCT-301 and increasing doses of additional drugs were assessed by MT1- proliferation assay over 96h in FE-PD, Karpas-299, KI-JK and cell lines.
Chou-Talalay method was used to calculate median combination index (CI) (synergism Cl<0.9, additive CI=0.9-1.1, antagonism/no benefit CI> 1.1).
Results ADCT-301 presented a much stronger activity in T- (n=9, median IC50=4 PM; 95%
CI., 1.6pM-0.9nM) than B-cell lymphomas (n=48, 0.7 nM; 95% Cl., 0.4-2.6 nM) (P=0.047). In vitro activity was highly correlated with CD25 expression both at cell surface level (n=53, Pearson r = -0.50, P=0.0001) and RNA level (n=53, Pearson r = -0.52, P<0.0001). CD25 was also more highly expressed in T- than B-cell lymphoma (P<0.0001), in agreement with the 1050s differences, and the correlation was still maintained within the subgroups (T-cell lymphomas, Pearson r = -0.90, P=0.0021; B-cell lymphomas; Pearson r = -0.3, P=0.05).
Based on the higher activity in T-cell lymphomas, ADCT-301-containing combinations were evaluated in 4 cell lines derived from peripheral T cell lymphoma not otherwise specified (n=1), ALK-pos (n=2) or ALK-neg (n=1) anaplastic large cell lymphoma (ALCL).
ADCT-301 plus the mTOR inhibitor everolimus showed synergism in 4/4 cell lines, as shown by the data tables shown below.
Cell line: FE-PD
RRID cell accession identifier: CVOL_H614 Reference: del Mistro et al., Leukemia, 1994, Jul;8(7): pp.1214-9 ADCx25 Everolimus ADCx25 Everolimus Fa CI Fa CI
(PM) (nM) (PM) (nM) 0.02 0.24 0.41 255.98 0.39 62.50 0.29 0.02 0.02 0.98 0.39 17.76 0.39 250 0.30 0.02 0.02 3.91 0.34 0.03 0.39 1000 0.30 0.03 0.02 15.63 0.33 0.04 1.56 0.24 0.30 0.07 0.02 62.50 0.35 1.89 1.56 0.98 0.59 349407000000000.0 0.02 250 0.34 5.69 1.56 3.91 0.28 0.06 0.02 1000 0.33 2.44 1.56 15.63 0.26 0.05 0.1 0.24 0.39 12.35 1.56 62.50 0.24 0.05 0.1 0.98 0.34 0.01 1.56 250 0.25 0.05 0.1 3.91 0.34 0.03 1.56 1000 0.26 0.05 0.1 15.63 0.31 0.01 6.25 0.24 0.11 0.05 0.1 62.50 0.34 0.39 6.25 0.98 0.11 0.05 0.1 250 0.33 1.03 6.25 3.91 0.10 0.04 0.1 1000 0.34 21.50 6.25 15.63 0.10 0.05 0.39 0.24 0.37 0.30 6.25 62.50 0.08 0.03 0.39 0.98 0.35 0.07 6.25 250 0.08 0.03 0.39 3.91 0.31 0.02 6.25 1000 0.07 0.03 0.39 15.63 0.30 0.02 Cell line: Karpas-299 RRID cell accession identifier: CVOL_1324 Reference: Fischer et al., Blood, 1988, Jul;72(1):pp.234-40.
ADCx25 Everolimus ADCx25 Everolimus Fa CI Fa CI
(PM) (nM) (PM) (nM) 0.02 0.24 0.39 1.79 1.56 62.50 0.23 0.02 0.02 0.98 0.35 0.63 1.56 250 0.21 0.01 0.02 3.91 0.30 0.10 1.56 1000 0.21 0.05 0.02 15.63 0.27 0.07 6.25 0.24 0.28 0.02 0.02 62.50 0.25 0.05 6.25 0.98 0.24 0.01 0.02 250 0.26 0.63 6.25 3.91 0.21 0.01 0.02 1000 0.26 2.55 6.25 15.63 0.20 0.01 0.1 0.24 0.37 0.62 6.25 62.50 0.18 0.00 0.1 0.98 0.33 0.28 6.25 250 0.19 0.01 0.1 3.91 0.28 0.02 6.25 1000 0.20 0.03 0.1 15.63 0.26 0.04 25 0.24 0.22 0.03 0.1 62.50 0.24 0.02 25 0.98 0.21 0.03 0.1 250 0.23 0.04 25 3.91 0.17 0.02 0.1 1000 0.25 0.79 25 15.63 0.18 0.02 0.39 0.24 0.36 0.37 25 62.50 0.16 0.01 0.39 0.98 0.31 0.07 25 250 0.16 0.01 0.39 3.91 0.27 0.01 25 1000 0.17 0.01 0.39 15.63 0.26 0.02 100 0.24 0.15 0.03 0.39 62.50 0.22 0.01 100 0.98 0.14 0.03 0.39 250 0.23 0.07 100 3.91 0.14 0.03 0.39 1000 0.22 0.07 100 15.63 0.14 0.03 1.56 0.24 0.32 0.04 100 62.50 0.13 0.03 1.56 0.98 0.29 0.02 100 250 0.13 0.02 1.56 3.91 0.25 0.01 100 1000 0.13 0.02 1.56 15.63 0.23 0.01 Cell line: Ki-JK
RRID cell accession identifier: CVOL_2093 Reference: Shimakage et al., lntervirology, 1993;36(4):pp.215-24.
ADCx25 Everolimus ADCx25 Everolimus Fa CI Fa CI
(PM) (nM) (PM) (nM) 0.02 0.24 0.53 0.448 0.39 62.5 0.35 0.021 0.02 0.98 0.50 0.231 0.39 250 0.35 0.022 0.02 3.91 0.46 0.066 0.39 1000 0.34 0.025 0.02 15.63 0.44 0.053 1.56 0.24 0.35 0.087 0.02 62.5 0.42 0.077 1.56 0.98 0.32 0.066 0.02 250 0.42 0.201 1.56 3.91 0.28 0.042 0.02 1000 0.41 0.605 1.56 15.63 0.26 0.032 0.1 0.24 0.49 0.046 1.56 62.5 0.25 0.029 0.1 0.98 0.46 0.035 1.56 250 0.22 0.020 0.1 3.91 0.41 0.012 1.56 1000 0.21 0.017 0.1 15.63 0.40 0.013 6.25 0.24 0.11 0.011 0.1 62.5 0.39 0.016 6.25 0.98 0.10 0.009 0.1 250 0.37 0.017 6.25 3.91 0.08 0.005 0.1 1000 0.39 0.120 6.25 15.63 0.07 0.004 0.39 0.24 0.45 0.055 6.25 62.5 0.06 0.003 0.39 0.98 0.40 0.037 6.25 250 0.06 0.003 0.39 3.91 0.37 0.027 6.25 1000 0.06 0.003 0.39 15.63 0.39 0.033 Cell line: Mac-1 RRID cell accession identifier: CVCL_H631 Reference: Su et al., Am J Pathol, 1988 Aug;132(2):pp.192-8.
ADCx25 Everolimus ADCx25 Everolimus Fa CI Fa CI
(PM) (nM) (PM) (nM) 0.02 0.24 0.47 9.93E+04 1.56 0.24 0.41 0.84 0.02 0.98 0.42 25.40 1.56 0.98 0.37 0.25 0.02 3.91 0.36 0.00 1.56 3.91 0.34 0.23 0.02 15.63 0.39 2.00 1.56 15.63 0.35 0.24 0.02 62.50 0.39 12.36 1.56 62.50 0.34 0.23 0.02 250 0.40 408.51 1.56 250 0.35 0.25 0.02 1000 0.40 253.77 1.56 1000 0.35 0.25 0.1 0.24 0.44 420.27 6.25 0.24 0.28 0.82 0.1 0.98 0.39 0.05 6.25 0.98 0.20 0.67 0.1 3.91 0.38 0.05 6.25 3.91 0.19 0.64 0.1 15.63 0.38 0.27 6.25 15.63 0.19 0.64 0.1 62.50 0.39 7.06 6.25 62.50 0.22 0.70 0.1 250 0.38 4.29 6.25 250 0.22 0.69 0.1 1000 0.39 64.12 6.25 1000 0.21 0.68 0.39 0.24 0.44 350.66 25 0.24 0.07 1.51 0.39 0.98 0.39 0.22 25 0.98 0.06 1.37 0.39 3.91 0.38 0.08 25 3.91 0.04 1.18 0.39 15.63 0.36 0.07 25 15.63 0.06 1.40 0.39 62.50 0.36 0.08 25 62.50 0.04 1.13 0.39 250 0.37 0.78 25 250 0.04 1.12 0.39 1000 0.35 0.08 25 1000 0.03 0.96 Conclusion The strong single agent anti-lymphoma activity and the observed in vitro synergism with targeted agents support the current ADCT-301 clinical development and identify potential combination partners for future clinical studies.
Example 3 Introduction Camidanlumab tesirine (ADCT-301) is an anti-CD25 antibody-drug conjugate (ADC) conjugated via a protease cleavable linker to SG3199, a highly cytotoxic DNA
minor groove crosslinking pyrrolobenzodiazepine dimer (Flynn et al. Mol Cancer Ther 2016, and as described herein).
ADCT-301 is currently in phase I as single agent in relapsed/refractory lymphomas (NCT02432235), advanced solid tumors (NCT03621982) and in acute myeloid leukemia (NCT02588092). It has preclinical activity as single agent in 57 lymphoma cell lines and in combination with selected drugs in T-cell lymphomas-derived cell lines.
Methods Cell lines were exposed to increasing concentrations of ADCT-301 for 96h followed by MU proliferation assay. CD25 expression was measured both at cell surface level via fluorescence quantitation (Quantum Simply Cellular microspheres) and at RNA
level (IIlumina HT-12 arrays and HTG EdgeSeq Oncology Biomarker Panel). Combination studies of increasing doses of ADCT-301 and increasing doses of additional drugs were assessed by MT1- proliferation assay over 96h in FE-PD, Karpas-299, KI-JK and cell lines.
Chou-Talalay method was used to calculate median combination index (CI) (synergism Cl<0.9, additive CI=0.9-1.1, antagonism/no benefit CI> 1.1).
Results ADCT-301 presented a much stronger activity in T- (n=9, median IC50=4 PM; 95%
Cl., 1.6pM-0.9nM) than B-cell lymphomas (n=48, 0.7 nM; 95% Cl., 0.4-2.6 nM) (P=0.047). In vitro activity was highly correlated with CD25 expression both at cell surface level (n=53, Pearson r = -0.50, P=0.0001) and RNA level (n=53, Pearson r = -0.52, P<0.0001). CD25 was also more highly expressed in T- than B-cell lymphoma (P<0.0001), in agreement with the 1050s differences, and the correlation was still maintained within the subgroups (T-cell lymphomas, Pearson r = -0.90, P=0.0021; B-cell lymphomas; Pearson r = -0.3, P=0.05).
Based on the higher activity in T-cell lymphomas, ADCT-301-containing combinations were evaluated in 4 cell lines derived from peripheral T cell lymphoma not otherwise specified (n=1), ALK-pos (n=2) or ALK-neg (n=1) anaplastic large cell lymphoma (ALCL).
ADCT-301 plus the PI3K inhibitor copanlisib was synergistic in all but one cell line.
ADCT-301 plus the HDAC inhibitor vorinostat was also synergistic in all but one cell line.
ADCT-301 plus the H DAC inhibitor romidepsin led to synergism in 2/4 cell lines.
The combination of ADCT-301 with the anti-folate pralatrexate was synergistic in 2/2 ALK-pos ALCL cell lines.
The combination of ADCT-301 with the proteasome inhibitor bortezomib led to synergism in 2/4 cell lines.
Finally, the combination of ADCT-301 with bendamustine achieved synergism in 1 out 4 cell lines.
Data is shown in the tables below.
Combination: ADCT-301 + copanlisib Cell line: FE-PD
RRID cell accession identifier: CVCL_H614 Reference: del Mistro et al., Leukemia, 1994, Jul;8(7): pp.1214-9 ADCx25 Copanlisib ADCx25 Copanlisib Fa CI Fa CI
(PM) (nM) (PM) (nM) 0.02 0.5 0.87 0.07 0.39 125 0.82 3.13 0.02 2.0 0.92 0.42 0.39 500 0.75 4.66 0.02 7.8 0.83 0.22 0.39 2000 0.16 0.05 0.02 31 0.85 1.01 1.56 0.5 0.91 5.97 0.02 125 0.80 2.04 1.56 2.0 0.86 2.90 0.02 500 0.79 6.74 1.56 7.8 0.82 2.11 0.02 2000 0.18 0.06 1.56 31 0.78 1.69 0.1 0.5 0.90 0.36 1.56 125 0.70 1.35 0.1 2.0 0.83 0.19 1.56 500 0.54 0.85 0.1 7.8 0.88 0.66 1.56 2000 0.13 0.04 0.1 31 0.79 0.55 6.25 0.5 0.33 0.33 0.1 125 0.79 1.89 6.25 2.0 0.25 0.19 0.1 500 0.78 6.03 6.25 7.8 0.19 0.12 0.1 2000 0.17 0.06 6.25 31 0.26 0.22 0.39 0.5 0.92 1.69 6.25 125 0.18 0.11 0.39 2.0 0.87 0.88 6.25 500 0.12 0.06 0.39 7.8 0.86 1.03 6.25 2000 0.05 0.02 0.39 31 0.84 1.48 Cell line: Karpas-299 RRID cell accession identifier: CVCL_1324 Reference: Fischer et al., Blood, 1988, Jul;72(1):pp.234-40.
ADCx25 Copanlisib ADCx25 Copanlisib Fa CI Fa CI
(PM) (nM) (PM) (nM) 0.02 0.5 0.99 47.36 1.56 125 0.86 14.80 0.02 2.0 0.95 3.14 1.56 500 0.49 0.86 0.02 7.8 0.94 7.01 1.56 2000 0.16 0.08 0.02 31 0.92 12.92 6.25 0.5 0.88 2.31 0.02 125 0.95 153.10 6.25 2.0 0.42 0.11 0.02 500 0.67 4.52 6.25 7.8 0.41 0.11 0.02 2000 0.15 0.07 6.25 31 0.42 0.13 0.1 0.5 0.95 0.92 6.25 125 0.65 1.25 0.1 2.0 0.93 1.41 6.25 500 0.32 0.22 0.1 7.8 0.92 3.74 6.25 2000 0.15 0.09 0.1 31 0.90 9.56 25 0.5 0.50 0.64 0.1 125 0.90 34.02 25 2.0 0.47 0.55 0.1 500 0.65 3.86 25 7.8 0.43 0.45 0.1 2000 0.16 0.08 25 31 0.42 0.46 0.39 0.5 0.98 8.02 25 125 0.35 0.34 0.39 2.0 0.91 0.82 25 500 0.21 0.16 0.39 7.8 0.96 18.19 25 2000 0.11 0.07 0.39 31 0.93 17.72 100 0.5 0.23 0.52 0.39 125 0.91 48.65 100 2.0 0.24 0.55 0.39 500 0.62 2.86 100 7.8 0.22 0.47 0.39 2000 0.16 0.08 100 31 0.21 0.47 1.56 0.5 0.92 1.25 100 125 0.20 0.43 1.56 2.0 0.88 0.84 100 500 0.12 0.20 1.56 7.8 0.88 1.85 100 2000 0.09 0.13 1.56 31 0.86 4.26 Cell line: Ki-JK
RRID cell accession identifier: CVCL_2093 Reference: Shimakage et al., lntervirology, 1993;36(4):pp.215-24.
ADCx25 Copanlisib ADCx25 Copanlisib Fa CI Fa CI
(PM) (nM) (PM) (nM) 0.02 0.2 1.00 3.99E+08 0.39 15.6 0.85 1.68 0.02 1.0 0.95 0.56 0.39 62.5 0.70 1.79 0.02 3.9 0.98 5.81 0.39 250.0 0.32 0.77 0.02 15.6 0.88 1.94 1.56 0.2 0.74 1.00 0.02 62.5 0.76 2.48 1.56 1.0 0.72 0.98 0.02 250.0 0.36 0.84 1.56 3.9 0.78 1.23 0.1 0.2 0.93 0.17 1.56 15.6 0.69 1.27 0.1 1.0 0.87 0.19 1.56 62.5 0.58 1.51 0.1 3.9 0.92 1.12 1.56 250.0 0.17 0.61 0.1 15.6 0.84 1.25 6.25 0.2 0.43 2.51 0.1 62.5 0.75 2.27 6.25 1.0 0.46 2.62 0.1 250.0 0.33 0.72 6.25 3.9 0.39 2.41 0.39 0.2 0.87 0.35 6.25 15.6 0.39 2.46 0.39 1.0 0.87 0.44 6.25 62.5 0.14 1.54 0.39 3.9 0.95 2.27 6.25 250.0 0.02 0.76 Cell line: Mac-1 RRID cell accession identifier: CVCL_H631 Reference: Su et al., Am J Pathol, 1988 Aug;132(2):pp.192-8.
ADCx25 Copanlisib ADCx25 Copanlisib Fa CI Fa CI
(PM) (nM) (PM) (nM) 0.02 0.2 0.92 0.50 1.56 0.2 0.90 1.96 0.02 1.0 0.80 0.06 1.56 1.0 0.87 1.58 0.02 3.9 0.76 0.10 1.56 3.9 0.83 1.13 0.02 15.6 0.81 0.96 1.56 15.6 0.83 2.44 0.02 62.5 0.76 1.58 1.56 62.5 0.78 2.70 0.02 250.0 0.52 0.18 1.56 250.0 0.49 0.18 0.1 0.2 0.87 0.14 6.25 0.2 0.70 0.89 0.1 1.0 0.81 0.10 6.25 1.0 0.73 1.22 0.1 3.9 0.80 0.22 6.25 3.9 0.63 0.57 0.1 15.6 0.78 0.60 6.25 15.6 0.54 0.33 0.1 62.5 0.76 1.53 6.25 62.5 0.43 0.17 0.1 250.0 0.57 0.37 6.25 250.0 0.24 0.04 0.39 0.2 0.98 95.14 25 0.2 0.19 0.10 0.39 1.0 0.82 0.23 25 1.0 0.09 0.03 0.39 3.9 0.84 0.79 25 3.9 0.04 0.01 0.39 15.6 0.82 1.52 25 15.6 0.06 0.01 0.39 62.5 0.77 1.99 25 62.5 0.02 0.00 0.39 250.0 0.57 0.40 25 250.0 0.01 0.00 Combination: ADCT-301 + vorinostat Cell line: FE-PD
RRID cell accession identifier: CVCL_H614 Reference: del Mistro et al., Leukemia, 1994, Jul;8(7): pp.1214-9 ADCx25 Vorinostat ADCx25 Vorinostat Fa CI Fa CI
(PM) (nM) (PM) (nM) 0.02 31 0.86 0.41 0.39 250 0.84 3.54 0.02 62 0.83 0.57 0.39 500 0.35 0.92 0.02 125 0.84 1.14 0.39 1000 0.12 0.70 0.02 250 0.87 2.65 1.56 31 0.78 2.93 0.02 500 0.38 1.00 1.56 62 0.80 4.08 0.02 1000 0.12 0.71 1.56 125 0.80 4.42 0.1 31 0.84 0.64 1.56 250 0.56 1.13 0.1 62 0.82 0.79 1.56 500 0.23 0.63 0.1 125 0.94 6.04 1.56 1000 0.11 0.66 0.1 250 0.91 4.90 6.25 31 0.43 0.55 0.1 500 0.41 1.09 6.25 62 0.40 0.51 0.1 1000 0.12 0.70 6.25 125 0.30 0.35 0.39 31 0.85 2.09 6.25 250 0.16 0.25 0.39 62 0.88 3.95 6.25 500 0.09 0.29 0.39 125 0.91 7.46 6.25 1000 0.09 0.58 Cell line: Karpas-299 RRID cell accession identifier: CVCL_1324 Reference: Fischer et al., Blood, 1988, Jul;72(1):pp.234-40.
ADCx25 Vorinostat ADCx25 Vorinostat Fa CI Fa CI
(PM) (nM) (PM) (nM) 0.02 31 0.95 0.66 1.56 250 0.78 1.40 0.02 62 0.96 1.45 1.56 500 0.27 0.37 0.02 125 0.92 1.58 6.25 31 0.86 1.76 0.02 250 0.86 1.91 6.25 62 0.82 1.32 0.02 500 0.33 0.48 6.25 125 0.75 1.03 0.1 31 0.96 0.95 6.25 250 0.61 0.82 0.1 62 0.93 1.03 6.25 500 0.23 0.33 0.1 125 0.95 2.45 25 31 0.46 0.39 0.1 250 0.86 1.92 25 62 0.40 0.32 0.1 500 0.32 0.46 25 125 0.38 0.36 0.39 31 0.99 5.00 25 250 0.33 0.40 0.39 62 0.98 5.57 25 500 0.18 0.30 0.39 125 0.97 4.86 100 31 0.25 0.39 0.39 250 0.86 2.01 100 62 0.25 0.40 0.39 500 0.29 0.41 100 125 0.25 0.43 1.56 31 0.95 2.30 100 250 0.23 0.48 1.56 62 0.89 1.10 100 500 0.12 0.27 1.56 125 0.94 3.25 Cell line: Ki-JK
RRID cell accession identifier: CVCL_2093 Reference: Shimakage et al., lntervirology, 1993;36(4):pp.215-24.
ADCx25 Vorinostat ADCx25 Vorinostat Fa CI Fa CI
(PM) (nM) (PM) (nM) 0.02 31 0.95 0.24 1.56 31 0.83 1.92 0.02 62 0.97 0.48 1.56 62 0.72 0.98 0.02 125 0.90 0.41 1.56 125 0.69 0.94 0.02 250 0.77 0.55 1.56 250 0.50 0.63 0.02 500 0.32 0.58 1.56 500 0.18 0.50 0.1 31 0.90 0.35 6.25 31 0.39 0.65 0.1 62 0.89 0.39 6.25 62 0.39 0.67 0.1 125 0.84 0.43 6.25 125 0.33 0.59 0.1 250 0.73 0.56 6.25 250 0.26 0.55 0.1 500 0.30 0.57 6.25 500 0.07 0.38 0.39 31 0.91 1.19 25 31 0.13 0.45 0.39 62 0.90 1.15 25 62 0.12 0.44 0.39 125 0.89 1.20 25 125 0.12 0.48 0.39 250 0.66 0.59 25 250 0.10 0.48 0.39 500 0.26 0.55 25 500 0.04 0.36 Cell line: Mac-1 RRID cell accession identifier: CVCL_H631 Reference: Su et al., Am J Pathol, 1988 Aug;132(2):pp.192-8.
ADCx25 Vorinostat ADCx25 Vorinostat Fa CI Fa CI
(PM) (nM) (PM) (nM) 0.02 31 0.84 0.15 1.56 31 0.77 0.95 0.02 62 0.85 0.35 1.56 62 0.77 0.98 0.02 125 0.90 1.56 1.56 125 0.76 0.93 0.02 250 0.98 83.46 1.56 250 0.71 0.65 0.02 500 0.40 0.04 1.56 500 0.24 0.01 0.1 31 0.83 0.24 6.25 31 0.69 1.47 0.1 62 0.84 0.40 6.25 62 0.63 0.78 0.1 125 0.81 0.43 6.25 125 0.62 0.72 0.1 250 0.90 3.77 6.25 250 0.45 0.15 0.1 500 0.40 0.03 6.25 500 0.07 0.00 0.39 31 0.79 0.38 25 31 0.31 0.12 0.39 62 0.82 0.62 25 62 0.19 0.02 0.39 125 0.80 0.61 25 125 0.12 0.01 0.39 250 0.78 0.75 25 250 0.04 0.00 0.39 500 0.32 0.02 25 500 0.0024 9.17E-Combination: ADCT-301 + romidepsin Cell line: FE-PD
RRID cell accession identifier: CVCL_H614 Reference: del Mistro et al., Leukemia, 1994, Jul;8(7): pp.1214-9 ADCx25 Romidepsin ADCx25 Romidepsin Fa CI Fa CI
(PM) (nM) (PM) (nM) 0.02 0.156 1.000 2.59E+22 0.39 0.625 0.79 0.95 0.02 0.312 1.000 2.59E+22 0.39 1.25 0.13 1.22 0.02 0.625 0.85 0.92 1.56 0.156 1.0 2.02E+24 0.02 1.25 0.15 1.24 1.56 0.312 0.91 8.30 0.1 0.156 0.91 0.77 1.56 0.625 0.61 0.81 0.1 0.312 0.90 0.81 1.56 1.25 0.12 1.21 0.1 0.625 0.87 1.06 6.25 0.156 0.56 0.23 0.1 1.25 0.15 1.24 6.25 0.312 0.54 0.41 0.39 0.156 1.0 5.06E+23 6.25 0.625 0.27 0.67 0.39 0.312 0.98 268.02 6.25 1.25 0.06 1.11 Cell line: Karpas-299 RRID cell accession identifier: CVCL_1324 Reference: Fischer et al., Blood, 1988, Jul;72(1):pp.234-40.
ADCx25 Romidepsin ADCx25 Romidepsin Fa CI Fa CI
(PM) (nM) (PM) (nM) 0.02 0.156 0.98 0.37 1.56 0.625 0.72 1.19 0.02 0.312 0.90 0.64 6.25 0.156 0.92 0.88 0.02 0.625 0.76 1.18 6.25 0.312 0.83 0.83 0.1 0.156 1.0 1.26E+05 6.25 0.625 0.60 1.17 0.1 0.312 0.94 0.68 25 0.156 0.39 0.37 0.1 0.625 0.80 1.20 25 0.312 0.29 0.57 0.39 0.156 1.0 4.90E+05 25 0.625 0.22 1.01 0.39 0.312 0.93 0.70 100 0.156 0.13 0.33 0.39 0.625 0.78 1.20 100 0.312 0.12 0.55 1.56 0.156 1.0 1.96E+06 100 0.625 0.04 0.85 1.56 0.312 0.85 0.68 Cell line: Ki-JK
RRID cell accession identifier: CVCL_2093 Reference: Shimakage et al., lntervirology, 1993;36(4):pp.215-24.
ADCx25 Romidepsin ADCx25 Romidepsin Fa CI Fa CI
(PM) (nM) (PM) (nM) 0.02 0.156 0.95 0.80 1.56 0.156 0.88 0.93 0.02 0.312 0.82 0.72 1.56 0.312 0.73 0.86 0.02 0.625 0.61 0.79 1.56 0.625 0.52 0.89 0.1 0.156 0.93 0.70 6.25 0.156 0.50 1.12 0.1 0.312 0.78 0.64 6.25 0.312 0.44 1.15 0.1 0.625 0.65 0.87 6.25 0.625 0.28 1.07 0.39 0.156 0.88 0.58 25 0.156 0.12 2.13 0.39 0.312 0.84 0.89 25 0.312 0.08 1.85 0.39 0.625 0.63 0.89 25 0.625 0.04 1.56 Cell line: Mac-1 RRID cell accession identifier: CVCL_H631 Reference: Su et al., Am J Pathol, 1988 Aug;132(2):pp.192-8.
ADCx25 Romidepsin ADCx25 Romidepsin Fa CI Fa CI
(PM) (nM) (PM) (nM) 0.02 0.156 1.000 3.14E+03 1.56 0.156 1.000 3.15E+03 0.02 0.312 0.951 1.069 1.56 0.312 1.000 6.29E+03 0.02 0.625 0.817 0.942 1.56 0.625 0.840 1.089 0.1 0.156 1.000 3.14E+03 6.25 0.156 0.792 0.417 0.1 0.312 0.988 2.384 6.25 0.312 0.725 0.528 0.1 0.625 0.901 1.406 6.25 0.625 0.338 0.382 0.39 0.156 1.000 3.14E+03 25 0.156 0.266 0.423 0.39 0.312 1.000 6.28E+03 25 0.312 0.006 0.104 0.39 0.625 0.919 1.613 25 0.625 0.141 0.428 Combination: ADCT-301 + pralatrexate Cell line: Karpas-299 RRID cell accession identifier: CVCL_1324 Reference: Fischer et al., Blood, 1988, Jul;72(1):pp.234-40.
ADCx25 Pralatrexate ADCx25 Pralatrexate Fa CI Fa CI
(PM) (nM) (PM) (nM) 0.02 0.013 0.94 9.05 1.56 1.1 0.18 0.48 0.02 0.04 0.42 0.12 1.56 3.3 0.18 1.35 0.02 0.12 0.19 0.06 1.56 10 0.21 5.59 0.02 0.37 0.19 0.17 6.25 0.013 0.73 4.87 0.02 1.1 0.20 0.55 6.25 0.04 0.34 0.14 0.02 3.3 0.20 1.72 6.25 0.12 0.19 0.07 0.02 10 0.21 5.93 6.25 0.37 0.19 0.18 0.1 0.013 0.91 4.62 6.25 1.1 0.19 0.51 0.1 0.04 0.39 0.10 6.25 3.3 0.17 1.29 0.1 0.12 0.20 0.06 6.25 10 0.21 5.60 0.1 0.37 0.19 0.18 25 0.013 0.43 0.81 0.1 1.1 0.19 0.52 25 0.04 0.37 0.50 0.1 3.3 0.19 1.64 25 0.12 0.20 0.12 0.1 10 0.22 6.28 25 0.37 0.19 0.22 0.39 0.013 0.89 6.78 25 1.1 0.20 0.63 0.39 0.04 0.39 0.11 25 3.3 0.18 1.49 0.39 0.12 0.19 0.06 25 10 0.19 4.76 0.39 0.37 0.19 0.17 100 0.013 0.15 0.10 0.39 1.1 0.20 0.57 100 0.04 0.15 0.11 0.39 3.3 0.19 1.57 100 0.12 0.14 0.10 0.39 10 0.21 5.90 100 0.37 0.14 0.18 1.56 0.013 0.80 3.49 100 1.1 0.13 0.30 1.56 0.04 0.33 0.08 100 3.3 0.13 0.77 1.56 0.12 0.18 0.06 100 10 0.14 2.73 1.56 0.37 0.18 0.17 Cell line: Ki-JK
RRID cell accession identifier: CVCL_2093 Reference: Shimakage et al., lntervirology, 1993;36(4):pp.215-24.
ADCx25 Pralatrexate ADCx25 Pralatrexate Fa CI Fa CI
(PM) (nM) (PM) (nM) 0.02 0.013 0.61 109.64 0.39 1.1 0.18 0.48 0.02 0.04 0.22 0.07 0.39 3.3 0.18 1.36 0.02 0.12 0.20 0.09 0.39 10 0.18 4.56 0.02 0.37 0.19 0.24 1.56 0.013 0.52 18.55 0.02 1.1 0.19 0.56 1.56 0.04 0.20 0.04 0.02 3.3 0.18 1.44 1.56 0.12 0.19 0.07 0.02 10 0.19 4.95 1.56 0.37 0.18 0.14 0.1 0.013 0.62 141.49 1.56 1.1 0.17 0.37 0.1 0.04 0.22 0.06 1.56 3.3 0.17 1.07 0.1 0.12 0.20 0.10 1.56 10 0.18 3.98 0.1 0.37 0.19 0.23 6.25 0.013 0.40 1.61 0.1 1.1 0.19 0.56 6.25 0.04 0.22 0.09 0.1 3.3 0.18 1.60 6.25 0.12 0.19 0.11 0.1 10 0.19 6.05 6.25 0.37 0.18 0.20 0.39 0.013 0.60 82.07 6.25 1.1 0.18 0.50 0.39 0.04 0.22 0.05 6.25 3.3 0.18 1.32 0.39 0.12 0.19 0.08 6.25 10 0.186 5.020 0.39 0.37 0.19 0.19 Combination: ADCT-301 + bortezomib Cell line: FE-PD
RRID cell accession identifier: CVCL_H614 Reference: del Mistro et al., Leukemia, 1994, Jul;8(7): pp.1214-9 ADCx25 Bortezomib ADCx25 Bortezomib Fa CI Fa CI
(PM) (nM) (PM) (nM) 0.02 0.003 0.95 0.04 0.39 0.07 0.89 0.14 0.02 0.008 0.92 0.01 0.39 0.22 0.89 0.13 0.02 0.025 0.93 0.02 0.39 0.66 0.85 0.06 0.02 0.07 0.92 0.02 1.56 0.003 0.92 1.04 0.02 0.22 0.94 0.10 1.56 0.008 0.89 0.56 0.02 0.66 0.92 0.01 1.56 0.025 0.88 0.47 0.1 0.003 0.94 0.13 1.56 0.07 0.88 0.41 0.1 0.008 0.91 0.06 1.56 0.22 0.85 0.25 0.1 0.025 0.94 0.12 1.56 0.66 0.81 0.15 0.1 0.07 0.91 0.05 6.25 0.003 0.75 0.30 0.1 0.22 0.91 0.05 6.25 0.008 0.71 0.20 0.1 0.66 0.83 0.01 6.25 0.025 0.71 0.19 0.39 0.003 0.94 0.49 6.25 0.07 0.71 0.20 0.39 0.008 0.91 0.19 6.25 0.22 0.64 0.10 0.39 0.025 0.91 0.20 6.25 0.66 0.49 0.03 Cell line: Karpas-299 RRID cell accession identifier: CVCL_1324 Reference: Fischer et al., Blood, 1988, Jul;72(1):pp.234-40.
ADCx25 Bortezomib ADCx25 Bortezomib Fa CI Fa CI
(PM) (nM) (PM) (nM) 0.02 0.003 0.97 0.04 1.56 0.07 0.63 0.38 0.02 0.008 0.90 0.06 1.56 0.22 0.76 1.23 0.02 0.025 0.88 0.17 1.56 0.66 0.47 1.96 0.02 0.07 0.86 0.44 6.25 0.003 0.79 0.74 0.02 0.22 0.88 1.49 6.25 0.008 0.60 0.46 0.02 0.66 0.68 2.69 6.25 0.025 0.71 0.67 0.1 0.003 0.95 0.06 6.25 0.07 0.56 0.62 0.1 0.008 0.90 0.08 6.25 0.22 0.49 0.98 0.1 0.025 0.77 0.13 6.25 0.66 0.48 2.21 0.1 0.07 0.90 0.54 25 0.003 0.49 1.31 0.1 0.22 0.82 1.24 25 0.008 0.46 1.23 0.1 0.66 0.67 2.65 25 0.025 0.37 1.03 0.39 0.003 0.92 0.11 25 0.07 0.42 1.29 0.39 0.008 0.88 0.12 25 0.22 0.40 1.59 0.39 0.025 0.69 0.14 25 0.66 0.32 2.28 0.39 0.07 0.65 0.30 100 0.003 0.27 2.97 0.39 0.22 0.65 0.89 100 0.008 0.26 2.87 0.39 0.66 0.60 2.38 100 0.025 0.24 2.69 1.56 0.003 0.90 0.34 100 0.07 0.23 2.72 1.56 0.008 0.86 0.29 100 0.22 0.22 2.94 1.56 0.025 0.79 0.31 100 0.66 0.18 3.22 Cell line: Ki-JK
RRID cell accession identifier: CVCL_2093 Reference: Shimakage et al., lntervirology, 1993;36(4):pp.215-24.
ADCx25 Bortezomib ADCx25 Bortezomib Fa CI Fa CI
(PM) (nM) (PM) (nM) 0.02 0.003 0.89 0.31 1.56 0.003 0.79 5.35 0.02 0.008 0.89 0.37 1.56 0.008 0.75 3.34 0.02 0.025 0.83 0.25 1.56 0.025 0.73 2.79 0.02 0.07 0.79 0.43 1.56 0.07 0.67 1.96 0.02 0.22 0.81 1.30 1.56 0.22 0.61 1.73 0.02 0.66 0.56 2.21 1.56 0.66 0.44 2.06 0.1 0.003 0.90 1.71 6.25 0.003 0.40 0.75 0.1 0.008 0.86 0.88 6.25 0.008 0.37 0.62 0.1 0.025 0.82 0.62 6.25 0.025 0.35 0.58 0.1 0.07 0.81 0.79 6.25 0.07 0.35 0.66 0.1 0.22 0.70 1.08 6.25 0.22 0.30 0.81 0.1 0.66 0.55 2.20 6.25 0.66 0.26 1.52 0.39 0.003 0.83 2.31 25 0.003 0.13 0.17 0.39 0.008 0.83 2.15 25 0.008 0.12 0.15 0.39 0.025 0.82 2.07 25 0.025 0.12 0.18 0.39 0.07 0.78 1.56 25 0.07 0.12 0.24 0.39 0.22 0.72 1.61 25 0.22 0.10 0.37 0.39 0.66 0.49 2.05 25 0.66 0.11 0.99 Cell line: Mac-1 RRID cell accession identifier: CVCL_H631 Reference: Su et al., Am J Pathol, 1988 Aug;132(2):pp.192-8.
ADCx25 Bortezomib ADCx25 Bortezomib Fa CI Fa CI
(PM) (nM) (PM) (nM) 0.02 0.003 0.883 1.225 1.56 0.003 0.874 0.970 0.02 0.008 0.829 0.494 1.56 0.008 0.817 0.380 0.02 0.025 0.806 0.802 1.56 0.025 0.766 0.301 0.02 0.07 0.772 0.931 1.56 0.07 0.722 0.311 0.02 0.22 0.751 1.815 1.56 0.22 0.676 0.383 0.02 0.66 0.524 0.075 1.56 0.66 0.542 0.103 0.1 0.003 0.854 0.410 6.25 0.003 0.892 2.536 0.1 0.008 0.813 0.309 6.25 0.008 0.794 0.254 0.1 0.025 0.794 0.582 6.25 0.025 0.754 0.255 0.1 0.07 0.747 0.530 6.25 0.07 0.689 0.168 0.1 0.22 0.710 0.745 6.25 0.22 0.640 0.197 0.1 0.66 0.443 0.019 6.25 0.66 0.477 0.035 0.39 0.003 0.879 1.053 25 0.003 0.545 0.007 0.39 0.008 0.813 0.314 25 0.008 0.557 0.009 0.39 0.025 0.777 0.381 25 0.025 0.577 0.017 0.39 0.07 0.733 0.390 25 0.07 0.552 0.020 0.39 0.22 0.678 0.391 25 0.22 0.448 0.009 0.39 0.66 0.391 0.008 25 0.66 0.291 0.001 Combination: ADCT-301 + bendamustine Cell line: FE-PD
RRID cell accession identifier: CVCL_H614 Reference: del Mistro et al., Leukemia, 1994, Jul;8(7): pp.1214-9 ADCx25 Bendamustine ADCx25 Bendamustine Fa CI Fa CI
(PM) (nM) (PM) (nM) 0.02 4.88 1.00 1.17E+03 0.39 312.50 1.00 7.48E+04 0.02 19.53 1.00 4.67E+03 0.39 1250 1.00 2.99E+05 0.02 78.13 0.97 0.13 0.39 5000 0.84 1.75 0.02 312.50 0.97 0.45 1.56 4.88 0.94 0.35 0.02 1250 0.93 0.91 1.56 19.53 0.97 0.45 0.02 5000 0.87 2.05 1.56 78.13 0.95 0.43 0.1 4.88 0.97 0.03 1.56 312.50 0.97 0.84 0.1 19.53 0.95 0.04 1.56 1250 0.94 1.27 0.1 78.13 0.96 0.11 1.56 5000 0.82 1.68 0.1 312.50 0.94 0.28 6.25 4.88 0.73 0.86 0.1 1250 0.98 2.41 6.25 19.53 0.73 0.86 0.1 5000 0.87 1.97 6.25 78.13 0.70 0.84 0.39 4.88 0.99 0.17 6.25 312.50 0.72 0.90 0.39 19.53 1.00 4.68E+03 6.25 1250 0.74 1.13 0.39 78.13 1.00 1.87E+04 6.25 5000 0.47 1.01 Cell line: Karpas-299 RRID cell accession identifier: CVCL_1324 Reference: Fischer et al., Blood, 1988, Jul;72(1):pp.234-40.
ADCx25 Bendamustine ADCx25 Bendamustine Fa CI Fa CI
(PM) (nM) (PM) (nM) 0.02 4.883 0.92 0.00 1.56 1250.0 0.86 0.31 0.02 19.531 0.99 0.01 1.56 5000.0 0.82 0.98 0.02 78.125 0.93 0.03 1.56 20000.0 0.65 2.60 0.02 312.5 0.88 0.07 6.25 4.883 0.86 0.16 0.02 1250.0 0.92 0.35 6.25 19.531 0.91 0.21 0.02 5000.0 0.93 1.49 6.25 78.125 0.86 0.18 0.02 20000.0 0.70 2.84 6.25 312.5 0.80 0.19 0.1 4.883 1.00 9.37 6.25 1250.0 0.78 0.34 0.1 19.531 1.00 14.00 6.25 5000.0 0.76 0.93 0.1 78.125 1.00 32.52 6.25 20000.0 0.47 1.95 0.1 312.5 0.94 0.11 25 4.883 0.55 0.29 0.1 1250.0 0.97 0.57 25 19.531 0.52 0.28 0.1 5000.0 0.97 2.27 25 78.125 0.54 0.30 0.1 20000.0 0.74 3.14 25 312.5 0.51 0.30 0.39 4.883 0.94 0.02 25 1250.0 0.47 0.36 0.39 19.531 1.00 36.70 25 5000.0 0.44 0.68 0.39 78.125 0.95 0.04 25 20000.0 0.28 1.49 0.39 312.5 0.96 0.14 100 4.883 0.24 0.61 0.39 1250.0 1.00 1.41 100 19.531 0.24 0.61 0.39 5000.0 0.89 1.27 100 78.125 0.24 0.61 0.39 20000.0 0.68 2.77 100 312.5 0.24 0.62 1.56 4.883 0.94 0.07 100 1250.0 0.23 0.66 1.56 19.531 0.96 0.08 100 5000.0 0.21 0.84 1.56 78.125 0.93 0.08 100 20000.0 0.17 1.47 1.56 312.5 0.87 0.11 Cell line: Ki-JK
RRID cell accession identifier: CVCL_2093 Reference: Shimakage et al., lntervirology, 1993;36(4):pp.215-24.
ADCx25 Bendamustine ADCx25 Bendamustine Fa CI Fa CI
(PM) (nM) (PM) (nM) 0.02 4.883 1.00 1.30 1.56 4.883 0.93 0.48 0.02 19.531 1.00 0.02 1.56 19.531 0.96 0.57 0.02 78.125 0.94 0.01 1.56 78.125 0.98 0.70 0.02 312.5 0.98 0.02 1.56 312.5 1.00 99.28 0.02 1250.0 0.97 0.04 1.56 1250.0 0.97 0.67 0.02 5000.0 0.98 0.16 1.56 5000.0 0.95 0.64 0.02 20000.0 0.59 0.12 1.56 20000.0 0.56 0.33 0.1 4.883 1.00 5.94 6.25 4.883 0.74 1.14 0.1 19.531 1.00 6.35 6.25 19.531 0.75 1.16 0.1 78.125 0.99 0.06 6.25 78.125 0.76 1.18 0.1 312.5 1.00 14.54 6.25 312.5 0.78 1.24 0.1 1250.0 1.00 40.74 6.25 1250.0 0.77 1.21 0.1 5000.0 0.97 0.17 6.25 5000.0 0.76 1.23 0.1 20000.0 0.61 0.13 6.25 20000.0 0.41 0.80 0.39 4.883 1.00 22.77 25 4.883 0.32 2.51 0.39 19.531 1.00 23.18 25 19.531 0.32 2.50 0.39 78.125 1.00 24.82 25 78.125 0.33 2.53 0.39 312.5 1.00 31.37 25 312.5 0.32 2.51 0.39 1250.0 0.97 0.20 25 1250.0 0.32 2.49 0.39 5000.0 0.98 0.32 25 5000.0 0.29 2.42 0.39 20000.0 0.56 0.16 25 20000.0 0.15 1.87 Cell line: Mac-1 RRID cell accession identifier: CVCL_H631 Reference: Su et al., Am J Pathol, 1988 Aug;132(2):pp.192-8.
ADCx25 Bendamustine ADCx25 Bendamustine Fa CI Fa CI
(PM) (nM) (PM) (nM) 0.02 4.883 0.81 1.80 1.56 4.883 0.68 5.84 0.02 19.531 0.72 0.12 1.56 19.531 0.71 8.04 0.02 78.125 0.66 0.06 1.56 78.125 0.65 4.20 0.02 312.5 0.93 1.59E+10 1.56 312.5 0.70 7.36 0.02 1250.0 0.77 15.35 1.56 1250.0 0.73 11.72 0.02 5000.0 0.63 0.04 1.56 5000.0 0.54 1.27 0.1 4.883 0.71 0.56 6.25 4.883 0.63 13.08 0.1 19.531 0.75 0.96 6.25 19.531 0.55 5.91 0.1 78.125 0.58 0.12 6.25 78.125 0.53 4.46 0.1 312.5 0.67 0.33 6.25 312.5 0.58 7.74 0.1 1250.0 0.76 5.71 6.25 1250.0 0.58 7.56 0.1 5000.0 0.64 0.24 6.25 5000.0 0.37 0.92 0.39 4.883 0.74 2.97 25 4.883 0.14 0.15 0.39 19.531 0.74 3.05 25 19.531 0.13 0.11 0.39 78.125 0.78 7.18 25 78.125 0.09 0.04 0.39 312.5 0.75 3.73 25 312.5 0.08 0.03 0.39 1250.0 0.69 1.65 25 1250.0 0.08 0.03 0.39 5000.0 0.60 0.62 25 5000.0 0.03 0.00 Conclusion The strong single agent anti-lymphoma activity and the observed in vitro synergism with targeted agents support the current ADCT-301 clinical development and identify combination partners for future clinical treatment.
Example 4 The purpose of this proposed study is to preliminarily assess the safety, tolerability, pharmacological and clinical activity of this combination The following cancer types have been chosen for study: Disease A, Disease B, and Disease C
Evidence for efficacy as single agents exists for both drugs:
= anti CD25 ADC (see, for example, see, for example, W02014/057119, W02016/083468, and W02016/166341) = Anti-BCL-2 agent, an mTOR inhibitor, or a secondary agent (see KS Peggs et al.2009, Clinical and Experimental Immunology, 157: 9-19 [doi:10.1111/j.1 365-2249.2009.03912.4 This primary purpose of this study is to explore whether these agents can be safely combined, and if so, will identify the dose(s) and regimens appropriate for further study. The study will also assess whether each combination induces pharmacologic changes in tumor that would suggest potential clinical benefit.
In addition, it will provide preliminary evidence that a combination may increase the response rate and durability of response compared with published data for treatment with single agent anti-CD25 ADC or anti-BCL-2 agent, mTOR inhibitor, or secondary agent.
Each disease group may include a subset of patients previously treated with the anti-BCL-2 agent, mTOR inhibitor, or secondary agent to explore whether combination therapy might overcome resistance to anti-BCL-2 agent, mTOR inhibitor, or secondary agent therapy. For each disease, it is not intended to apply specific molecular selection as the data available at present generally do not support excluding patients on the basis of approved molecular diagnostic tests.
Rationale for anti 0D25 ADC starting dose The RDE for already established for ADC (in ug/kg administered every three weeks) will be used for all patients in this study. To ensure patient safety, a starting dose below the RDE will be used; the starting dose level will be one where patient benefit could still be demonstrated in study ADC1, suggesting that patients enrolled at such dose level will gain at least some benefit by taking part.
Rationale for anti-BCL-2 agent, mTOR inhibitor, or secondary agent starting dose The RDE for already estE/blished for the anti-BCL-2 agent, mTOR inhibitor, or secondary agent (in ug/kg administered every three weeks) will be used for all patients in this study. To ensure patient safety, a starting dose below the RDE will be used; the starting dose level will be one where patient benefit could still be demonstrated in study SA1, suggesting that patients enrolled at such dose level will gain at least some benefit by taking part.
Objectives and related endpoints Objective Endpoint Primary Objective Frequency and severity of treatment-To characterize the safety and tolerability emergent AEs and SAEs of ADC in combination with the anti-BCL-2 Changes between baseline and post-agent, mTOR inhibitor, or secondary agent, baseline laboratory parameters and vital and to identify the recommended dose and signs schedules for future studies Incidence of dose limiting toxicities (DLTs) during the first cycle of treatment (dose escalation only) Frequency of dose interruptions and dose reductions Secondary Objectives To evaluate the clinical activity of the ORR, DOR, PFS, OS
combination of ADC with the anti-BCL-2 agent, mTOR inhibitor, or secondary agent AUC and Cmax for each compound To characterize the pharmacokinetic (PK) profile of each of the two compounds ADC
and the anti-BCL-2 agent, mTOR inhibitor, or secondary agent Evidence for Anti-Drug-Antibodies (ADAs) before, during immunogenicity and ADAs to ADC and after treatment with ADC
Exploratory Objectives To examine potential correlation of PK Correlation coefficients between AUC
profiles with safety/tolerability and efficacy and/or Cmax of each compound or a compound measure and any of the safety To characterize changes in the immune or efficacy variables infiltrate in tumors lmmunohistochemistry of pre- and on-treatment tumor biopsies, To characterize changes in circulating levels of cytokines in plasma and markers Measurements (e.g. via ELISA) of of activation in circulating immune cells immunologically relevant cytokines in plasma or serum; staining levels for activation markers of circulating immune cells (e.g. FACS) Study design This phase lb, multi-center, open-label study to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of the ADC
in combination with the anti-BCL-2 agent, mTOR inhibitor, or secondary agent, in patients with disease A, disease B, and disease C.
The study is comprised of a dose escalation part followed by a dose expansion part.
Dose escalation will start with reduced starting doses (compared to their respective recommended phase 2 or licensed dose levels), for both ADC and the anti-BCL-2 agent, mTOR inhibitor, or secondary agent, to guarantee patient safety. Starting doses will be 33% (or 50%) of the RDE for each compound. Subsequently, doses will be first escalated for the anti-BCL-2 agent, mTOR inhibitor, or secondary agent until the RDE or licensed dose has been reached, or a lower dose if necessary for tolerability reasons.
Then, the dose for ADC will be escalated, until the RDE for combination treatment is reached. This is visualized in the below diagram:
=
Increase dose of 100 compund 2 /100% A
perceived safe starting dose of 33% of the intended efficacious dose is proposed for both compounds, but this may Ho% need adaptation to lower or higher, as the individual risk profile for the combination may 33/ 33/ 33/ be.
33% 66% 109%
Compound 1 should be the Increase dose of compound for which an compound 1 efficatious clinical dose has been firmly established (at 100%), and which is therefore aimed to be reached quickly in the trial patients by first escalating the dose of this compound.
If the dose combination is determined to be safe, it may be tested in additional patients to confirm the safety and tolerability at that dose level. Further tailoring of the dose of each compound may be conducted, and/or the regimen may be modified.
The dose escalation of the combination will be guided by a Bayesian Logistic Regression Model (BLRM) based on any Dose Limiting Toxicities (DLTs) observed in the first (or first two, TBC) cycles of therapy. Use of a BLRM is a well-established method to estimate the maximum tolerated dose (MTD)/ recommended dose for expansion (RDE) in cancer patients. The adaptive BLRM will be guided by the Escalation With Overdose Control (EWOC) principle to control the risk of DLT in future patients on the study.
The use of Bayesian response adaptive models for small datasets has been accepted by FDA
and EMEA ("Guideline on clinical trials in small populations", February 1, 2007) and endorsed by numerous publications (Babb et al. 1998, Neuenschwander et al. 2008).
The decisions on new dose combinations are made by the Investigators and sponsor study personnel in a dose escalation safety call (DESC) based upon the review of patient tolerability and safety information (including the BLRM summaries of DLT risk, if applicable) along with PK, PD and preliminary activity information available at the time of the decision.
Once the MTD(s)/RDE is determined for the combination, the expansion part of the study may be initiated to further assess the safety, tolerability and preliminary efficacy.
= For combinations with 10, changes in the immune infiltrate in tumors will also be characterized following combination treatment in the target disease indications.
Given the available prior clinical experience with the agents in this study, it is expected that in most cases a combination dose can be identified without testing a large number of dose levels or schedules. To assess the pharmacodynamic activity of the combinations, patients will be asked to undergo a tumor biopsy at baseline and again after approximately two cycles of therapy.
= For 10 combo: The extent of the change in tumor infiltration by immune cells including lymphocytes and macrophages will contribute to a decision on any potential benefit.
Dose escalation part During the dose escalation part of the study, patients will be treated with a fixed dose of ADC administered iv., and increasing doses of the anti-BCL-2 agent, mTOR
inhibitor, or secondary agent until the RDE for the anti-BCL-2 agent, mTOR inhibitor, or secondary agent has been reached. Subsequently, doses of ADC are increased (in different cohorts) while the dose for the anti-BCL-2 agent, mTOR inhibitor, or secondary agent is kept constant.
Two to approximately 3 or 4 patients with disease A, disease B or disease C
will be treated in each escalation cohort until the determination of MTD(s)/RDE(s) is determined.
There will be a 24-hour observation before enrolling the second patient at Dose Level 1.
The DLT observation period at each dose level is either 1 cycle (3 weeks) or 2 cycles (6 weeks) as mandated by the appropriate authorities for 10 therapies, after which it will be determined whether to escalate to the next dose level, stay at the current dose level, or de-escalate to the previous dose level for the next cohort. There will be no de-escalation from Dose Level 1. lntrapatient dose escalation is not permitted.
Dose escalation is not permitted unless 2 or more patients have complete DLT
information through the first cycle in any given dose level. Dose escalation will be determined by using a mCRM with a target DLT rate of 30% and an equivalence interval of 20% to 35%, and with dose escalation-with-overdose-control (EWOC) and no dose skipping.
Patients will be assigned to a cohort that is actively enrolling. Dose escalation will be performed in each combination following the completion of one cycle of treatment.
Safety assessments including adverse events (AEs) and laboratory values will be closely monitored for all enrolled patients in order to identify any DLTs. A single MTD/RDE will be defined; a disease-specific MTD/RDE will not be established.
The mCRM will be implemented for DE under the oversight of a Dose Escalation Steering Committee (DESC). The DESC will confirm each escalating dose level after reviewing all available safety data. PK data from patients in that dose level and prior dose levels may also inform decision making. The DESC may halt dose escalation prior to determining the MTD based on emerging PK, PD, toxicity or response data.
Additional patients may be included at any dose level to further assess the safety and tolerability if at least 1 patient in the study has achieved a partial response or better, or if further evaluation of PK or PD data is deemed necessary by the DESC to determine the RDE.
Dose Escalation will be stopped after 3 cohorts (or at least 6 patients) are consecutively assigned to the same dose level. If the MTD is not reached, the recommended dose for expansion (RDE) will be determined. Prior to the determination of the MTD/RDE
a minimum of 6 patients must have been treated with the combination.
It is intended that paired tumor biopsies will be obtained from patients during dose escalation. Analysis of these biopsies will contribute to a better understanding of the relationship between the dose and the pharmacodynamic activity of the combination.
Safety Oversight by the Dose Escalation Steering Committee A DESC comprised of ADC Therapeutics and the investigators will review patient safety on an ongoing basis during the DE to determine if the dose escalation schedule prescribed by the mCRM warrants modification. In addition to safety observations, PK
and/or PD data may also inform decision making. Intermediate doses may be assigned after agreement between ADC Therapeutics and investigators. The DESC may continue to provide oversight during Part 2. No formal Data Safety Monitoring Board (DSMB) will be used.
Dose expansion part Once the MTD/RDE has been declared, dose expansion part may begin. The main objective of the expansion part is to further assess the safety and tolerability of the study treatment at the MTD/RDE and to gain a preliminary understanding of the efficacy of the combination compared to historical single agent efficacy data.
An important exploratory objective is to assess changes in the immune infiltrate in tumor in response to treatment. This will be assessed in paired tumor biopsies collected from patients, with a minimum of ten evaluable biopsy pairs (biopsy specimens must contain sufficient tumor for analysis) in patients treated at the MTD/RDE. If this is not feasible, collection of these biopsies may be stopped. A minimum of 10 to 20 patients are planned to be treated in each investigational arm, Several different investigational arms will open, one per disease. A total of nine investigational arms may be run in the dose expansion. Should enrollment for any of these groups not be feasible, then enrollment to that group may be closed before the 10 to 20 patients target is met.
In each treatment group a maximum of approximately six patients who have received and progressed on prior single administration (i.e. not in combination) anti-BCL-2 agent, mTOR inhibitor, or secondary agent therapy will be allowed to be treated. This number may be increased if a combination shows promise of overcoming resistance to prior treatment with single administration anti-BCL-2 agent, mTOR inhibitor, or secondary agent.
Patient Population The study will be conducted in adult patients with advanced Disease A, Disease B or Disease C as outlined above. The investigator or designee must ensure that only patients who meet all the following inclusion and none of the exclusion criteria are offered treatment in the study.
Inclusion criteria Patients eligible for inclusion in this study have to meet all of the following criteria:
1. Written informed consent must be obtained prior to any procedures 2. Age 18 years.
3. Patients with advanced/metastatic cancer, with measurable disease as determined by RECIST version 1.1, who have progressed despite standard therapy or are intolerant to standard therapy, or for whom no standard therapy exists.
Patients must fit into one of the following groups:
= Disease A
= Disease B
= Disease C
4. ECOG Performance Status 0 ¨ 1 (or 2 TBC) 5. TBC: Patient must have a site of disease amenable to biopsy, and be a candidate for tumor biopsy according to the treating institution's guidelines. Patient must be willing to undergo a new tumor biopsy at baseline, and again during therapy on this study.
6. Prior therapy with the anti-BCL-2 agent, mTOR inhibitor, or secondary agent or related compounds (i.e. same MOA) is allowed Exclusion criteria Patients eligible for this study must not meet any of the following criteria:
1. History of severe hypersensitivity reactions to other mAbs (OR to same backbone mAb as in ADC OR to same 10 mAb if applicable) 2. Known history of positive serum human ADA to backbone of mAb as in ADC
3. Central Nervous System (CNS) disease only (if applicable) 4. Symptomatic CNS metastases or evidence of leptomeningeal disease (brain MRI
or previously documented cerebrospinal fluid (CSF) cytology) Previously treated asymptomatic CNS metastases are permitted provided that the last treatment (systemic anticancer therapy and-or local radiotherapy) was completed >= 8 weeks prior to 1st day of dosing, except usage of low dose steroids on a taper is allowed) Patients with discrete dural metastases are eligible.
5. Patient having out of range laboratory values defined as:
= Serum creatinine <= 1.5x ULN. If serum creatinine > 1.5, the creatinine clearance (calculated using Cockcroft-Gault formula, or measured) must be > 60 mlimin/1.73m2 for a patient to be eligible = Total bilirubin > 1.5 x ULN, except for patients with Gilbert's syndrome who are excluded if total bilirubin > 3.0 x ULN or direct bilirubin > 1.5 x ULN
= Alanine aminotransferase (ALT) > 3 x ULN, except for patients that have tumor involvement of the liver, who are excluded if ALT > 5 x ULN
= Aspartate aminotransferase (AST) > 3 x ULN, except for patients that have tumor involvement of the liver, who are excluded if AST > 5 x ULN
= Absolute neutrophil count< 1.0 x 10e9/L
= Platelet count< 75 x 10e9/L
= Hemoglobin (Hgb) <8 g/dL
= Potassium, magnesium, calcium or phosphate abnormality > CTCAE grade 1 despite appropriate replacement therapy 6. Impaired cardiac function or clinically significant cardiac disease, including any of the following:
= Clinically significant and/or uncontrolled heart disease such as congestive heart failure requiring treatment (NYHA grade III or IV) or uncontrolled hypertension defined by a Systolic Blood Pressure (SBP) 160 mm Hg and/or Diastolic Blood Pressure (DBP) 100 mm Hg, with or without anti-hypertensive medication.
= QTcF >470 msec for females or >450 msec for males on screening ECG using Fridericia's correction, congenital long QT syndrome = Acute myocardial infarction or unstable angina pectoris < 3 months (months prior to study entry = Clinically significant valvualr disease with documented compromise in cardiac function = Symptomatic pericarditis = History of or ongoing documented cardiomyopathy = Left Ventricular Ejection Fraction (LVEF) <40%, as determined by echocardiogram (ECHO) or Multi gated acquisition (MUGA) scan = History or presence of any clinically significant cardiac arrhythmias, e.g.
ventricular, supraventricular, nodal arrhythmias, or conduction abnormality (TBC qualifier: ... requiring a pacemaker or not controlled with medication) = Presence of unstable atrial fibrillation (ventricular response rate> 100 bpm).
NOTE: Patients with stable atrial fibrillation can be enrolled provided they do not meet other cardiac exclusion criteria.
= Complete left bundle branch block (LBBB), bifascicular block = Any clinically significant ST segment and/or T-wave abnormalities 7. Toxicity attributed to prior 10 therapy that led to discontinuation of therapy.
Adequately treated patients for drug-related skin rash or with replacement therapy for endocrinopathies are not excluded, provided these toxicities did not lead to the discontinuation of prior treatment.
8. Patients with active, known or suspected autoimmune disease. Subjects with vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll, provided the trigger can be avoided.
9. Human Immunodeficiency Virus (HIV), or active Hepatitis B (HBV) or Hepatitis C (HCV) virus infection Testing is not mandatory to be eligible. Testing for HCV should be considered if the patient is at risk for having undiagnosed HCV
(e.g. history of injection drug use).
10. Malignant disease, other than that being treated in this study.
Exceptions to this exclusion include the following: malignancies that were treated curatively and have not recurred within 2 years prior to study treatment; completely resected basal cell and squamous cell skin cancers; any malignancy considered to be indolent and that has never required therapy; and completely resected carcinoma in situ of any type.
11. Systemic anti-cancer therapy within 2 weeks of the first dose of study treatment. For cytotoxic agents that have major delayed toxicity, e.g.
mitomycin C
and nitrosoureas, 4 weeks is indicated as washout period. For patients receiving anticancer immunotherapies such as CTLA-4 antagonists, 6 weeks is indicated as the washout period.
12. Active diarrhea CTCAE grade 2 or a medical condition associated with chronic diarrhea (such as irritable bowel syndrome, inflammatory bowel disease) 13. Presence of 2: CTCAE grade 2 toxicity (except alopecia, peripheral neuropathy and ototoxicity, which are excluded if >= CTCAE grade 3) due to prior cancer therapy.
14. Active infection requiring systemic antibiotic therapy.
15. Active ulceration of the upper GI tract or GI bleeding 16. Active bleeding diathesis or on oral anti-vitamin K medication (except low-dose warfarin and aspirin or equivalent, as long as the I NR <= 2.0) 17. Active autoimmune disease, motor neuropathy considered of autoimmune origin, and other CNS autoimmune disease 18. Patients requiring concomitant immunosuppressive agents or chronic treatment with corticoids except:
> replacement dose steroids in the setting of adrenal insufficiency = topical, inhaled, nasal and ophthalmic steroids are allowed 19. Use of any live vaccines against infectious diseases (e.g. influenza, varicella, pneumococcus) within 4 weeks of initiation of study treatment (NB the use of live vaccines is not allowed through the whole duration of the study) 20. Use of hematopoietic colony-stimulating growth factors (e.g. G-CSF, GMCSF, M-CSF) <2 weeks prior start of study drug. An erythroid stimulating agent is allowed as long as it was initiated at least 2 weeks prior to the first dose of study treatment.
21. Major surgery within 2 weeks of the first dose of study treatment (NB
mediastinoscopy, insertion of a central venous access device, or insertion of a feeding tube are not considered major surgery).
22. Radiotherapy within 2 weeks of the first dose of study drug, except for palliative radiotherapy to a limited field, such as for the treatment of bone pain or a focally painful tun1or mass. To allow for assessment of response to treatment, patients must have remaining measurable disease that has not been irradiated 23. Participation in an interventional, investigational study within 2 weeks of the first dose of study treatment.
24. Any medical condition that would, in the investigator's judgment, prevent the patient's participation in the clinical study due to safety concerns, compliance with clinical study procedures or interpretation of study results.
25. Sexually active males unless they use a condom during intercourse while taking drug and for 90 days after stopping study treatment and should not father a child in this period. A condom is required to be used also by vasectomized men in order to prevent delivery of the drug via seminal fluid.
26. Pregnant or lactating women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test. In rare cases of an endocrine-secreting tumor, hCG
levels may be above normal limits but with no pregnancy in the patient. In these cases, there should be a repeat serum hCG test (with a non-rising result) and a vaginal/pelvic ultrasound to rule out pregnancy. Upon confirmation of results and discussion with the Medical representative, these patients may enter the study.
27. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during study treatment and for 90 days after the last any dose of study treatment. Highly effective contraception methods include:
= Total abstinence (when this is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception = Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy), total hysterectomy or tubal ligation at least 6 weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment = Male sterilization (at least 6 months prior to screening). For female patients on the study the vasectomized male partner should be the sole partner for that patient.
= Use of oral (estrogen and progesterone), injected or implanted combined hormonal methods of contraception or placement of an intrauterine device (IUD) or intrauterine system (I US) or other forms of hormonal contraception that have comparable efficacy (failure rate <1%), for example hormone vaginal ring or transdermal hormone contraception.
= In case of use of oral contraception, women should have been stable on the same pill for a minimum of 3 months before taking study treatment.
= Women are considered post-menopausal and not of child bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least 6 weeks ago. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of child bearing potential.
Dose-Limiting Toxicities and Dose modification guidelines A dose-limiting toxicity (DLT) is defined as any of the following events thought to be at least possibly related to ADC per investigator judgment that occurs during the 21-day DLT evaluation period. Toxicity that is clearly and directly related to the primary disease or to another etiology is excluded from this definition.
DLT Definitions A hematologic DLT is defined as:
= Grade 3 or 4 febrile neutropenia or neutropenic infection = Grade 4 neutropenia lasting >7 days = Grade 4 thrombocytopenia = Grade 3 thrombocytopenia with clinically significant bleeding, or Grade 3 thrombocytopenia requiring a platelet transfusion = Grade 3 anemia that requires transfusion = Grade 4 anemia A non-hematologic DLT is defined as:
= Grade 4 non-hematologic toxicity = Grade 3 non-hematologic toxicity lasting >3 days despite optimal supportive care or medical intervention = A case of Hy's law (AST and/or ALT > 3x ULN and bilirubin > 2x ULN, and without initial findings of cholestasis (serum alkaline phosphatase (ALP) activity <
2x ULN) and no other reason that could explain the combination of increased transaminases and serum total bilirubin, such as viral hepatitis A, B, or C, preexisting or acute liver disease, or another drug capable of causing the observed injury) = Grade 3 or higher hypersensitivity/infusion-related reaction (regardless of premedication). A grade 3 hypersensitivity / infusion-related reaction that resolves within 8 hours after onset with appropriate clinical management does not qualify as a DLT.
= LVEF decrease to <40% or >20% decrease from baseline = Grade 4 tumor lysis syndrome (Grade 3 TLS will not constitute DLT unless it leads to irreversible end-organ damage) The following conditions are not considered non-hematologic DLT:
= Grade 3 fatigue for 7 days = Grade 3 diarrhea, nausea, or vomiting in the absence of premedication that responds to therapy and improves by at least 1 grade within 3 days for Grade 3 events or to Grade 1 within 7 days.
= AST or ALT elevation 5 x ULN but 8 x ULN, without concurrent elevation in bilirubin, that downgrades to Grade 2 within 5 days after onset.
= Grade 3 serum lipase or serum amylase for 7 days if without clinical signs or symptoms of pancreatitis Patients who experience a DLT that resolves or stabilizes with appropriate medical management may continue treatment at the discretion of the investigator in consultation with the sponsor.
Dose modifications Guidelines for management of specific toxicities are detailed in the table below. For management of events not specified in the tables, the following may serve as a guidance to investigators:
AE Grade ADC Management Guideline 1 No dose adjustment is required.
2 First occurrence:
Consider holding one or both drugs until improvement to Grade 1 or baseline. Up to 1 dose of one or both drugs may be skipped to permit improvement. If improvement to Grade 1 or baseline occurs within 21 days from the last scheduled (but missed) dose of one or both drugs, continue one or both drugs at the original assigned dose level in subsequent treatment cycles.
If improvement to Grade 1 or baseline does not occur within 21 days from the last scheduled (but missed) dose, permanently discontinue one or both drugs.
Second occurrence:
Hold one or both drugs until improvement to Grade 1 or baseline. Up to 1 dose of one or both drugs may be skipped to permit resolution. If improvement to Grade 1 or baseline occurs within 21 days from the last scheduled (but missed) dose, continue one or both drugs at 1 dose level below the original assigned dose in subsequent treatment cycles. If improvement to Grade 1 or baseline does not occur within 21 days from the last scheduled (but missed) dose, permanently discontinue one or both drugs.
Third occurrence:
Permanently discontinue one or both drugs.
3 First occurrence:
Hold one or both drugs until improvement to Grade 1 or baseline. Up to 1 dose of one or both drugs may be skipped to permit improvement, then continue at 1 dose level below the original assigned dose in subsequent treatment cycles.
Second occurrence:
Permanently discontinue one or both drugs 4 Permanently discontinue one or both drugs.
A second medicament comprising an secondary agent.
EXAM P L ES
Example 1 Introduction Camidanlumab tesirine (ADCT-301) is an anti-0D25 antibody-drug conjugate (ADC) conjugated via a protease cleavable linker to SG3199, a highly cytotoxic DNA
minor groove crosslinking pyrrolobenzodiazepine dimer (Flynn et al. Mol Cancer Ther 2016, and as described herein).
ADCT-301 is currently in phase I as single agent in relapsed/refractory lymphomas (NCT02432235), advanced solid tumors (NCT03621982) and in acute myeloid leukemia (NCT02588092). It has preclinical activity as single agent in 57 lymphoma cell lines and in combination with selected drugs in T-cell lymphomas-derived cell lines.
Methods Cell lines were exposed to increasing concentrations of ADCT-301 for 96h followed by MU proliferation assay. CD25 expression was measured both at cell surface level via fluorescence quantitation (Quantum Simply Cellular microspheres) and at RNA
level (Illumina HT-12 arrays and HTG EdgeSeq Oncology Biomarker Panel). Combination studies of increasing doses of ADCT-301 and increasing doses of additional drugs were assessed by MT1" proliferation assay over 96h in FE-PD, Karpas-299, KI-JK and cell lines.
Chou-Talalay method was used to calculate median combination index (Cl) (synergism Cl<0.9, additive CI=0.9-1.1, antagonism/no benefit CI> 1.1).
Results ADCT-301 presented a much stronger activity in T- (n=9, median IC50=4 pM; 95%
Cl., 1.6pM-0.9nM) than B-cell lymphomas (n=48, 0.7 nM; 95% CI., 0.4-2.6 nM) (P=0.047). In vitro activity was highly correlated with CD25 expression both at cell surface level (n=53, Pearson r = -0.50, P=0.0001) and RNA level (n=53, Pearson r = -0.52, P<0.0001). CD25 was also more highly expressed in T- than B-cell lymphoma (P<0.0001), in agreement with the 1050s differences, and the correlation was still maintained within the subgroups (T-cell lymphomas, Pearson r = -0.90, P=0.0021; B-cell lymphomas; Pearson r = -0.3, P=0.05).
Based on the higher activity in T-cell lymphomas, ADCT-301-containing combinations were evaluated in 4 cell lines derived from peripheral T cell lymphoma not otherwise specified (n=1), ALK-pos (n=2) or ALK-neg (n=1) anaplastic large cell lymphoma (ALCL).
ADCT-301 plus the BCL2 inhibitor venetoclax was synergistic in all but one cell line. As shown by the data tables shown below.
Cell line: FE-PD
RRID cell accession identifier: CVOL_H614 Reference: del Mistro et al., Leukemia, 1994, Jul;8(7): pp.1214-9 ADCx25 Venetoclax ADCx25 Venetoclax Fa CI Fa CI
(PM) (nM) (PM) (nM) 0.02 2.4 1.0 0.02 1.56 2.4 0.9 0.74 0.02 9.8 0.9 0.02 1.56 9.8 0.8 0.49 0.02 39.1 0.9 0.04 1.56 39.1 0.8 0.49 0.02 156.3 0.9 0.15 1.56 156.3 0.9 0.73 0.02 625.0 0.9 0.66 1.56 625.0 0.8 1.03 0.02 2500.0 0.9 2.10 1.56 2500.0 0.8 2.10 0.02 10000.0 0.4 3.08 1.56 10000.0 0.3 2.94 0.1 2.4 0.9 0.04 6.25 2.4 0.8 1.94 0.1 9.8 0.9 0.04 6.25 9.8 0.8 1.77 0.1 39.1 0.8 0.06 6.25 39.1 0.7 1.59 0.1 156.3 0.9 0.18 6.25 156.3 0.8 1.92 0.1 625.0 0.9 0.73 6.25 625.0 0.7 2.00 0.1 2500.0 0.8 1.81 6.25 2500.0 0.7 2.75 0.1 10000.0 0.3 2.96 6.25 10000.0 0.2 2.97 0.39 2.4 0.9 0.21 25 2.4 0.3 2.79 0.39 9.8 0.9 0.15 25 9.8 0.3 2.69 0.39 39.1 0.9 0.17 25 39.1 0.3 2.56 0.39 156.3 0.9 0.27 25 156.3 0.3 2.81 0.39 625.0 0.9 0.84 25 625.0 0.3 2.67 0.39 2500.0 0.8 2.16 25 2500.0 0.3 3.09 0.39 10000.0 0.3 2.85 25 10000.0 0.1 2.77 Cell line: Karpas-299 RRID cell accession identifier: CVOL_1324 Reference: Fischer et al., Blood, 1988, Jul;72(1):pp.234-40.
ADCx25 Venetoclax ADCx25 Venetoclax Fa CI Fa CI
(PM) (nM) (PM) (nM) 0.02 2.4 0.9 0.04 1.56 625.0 0.8 0.68 0.02 9.8 0.9 0.06 1.56 2500.0 0.8 1.72 0.02 39.1 0.8 0.05 1.56 10000.0 0.5 0.40 0.02 156.3 0.9 0.27 6.25 2.4 0.9 3.71 0.02 625.0 0.9 1.09 6.25 9.8 0.8 1.44 0.02 2500.0 0.8 1.20 6.25 39.1 0.8 1.91 0.02 10000.0 0.5 0.37 6.25 156.3 0.8 2.80 0.1 2.4 0.9 0.14 6.25 625.0 0.8 2.14 0.1 9.8 0.9 0.17 6.25 2500.0 0.8 2.83 0.1 39.1 0.8 0.08 6.25 10000.0 0.4 0.22 0.1 156.3 0.8 0.20 25 2.4 0.6 0.63 0.1 625.0 0.8 0.46 25 9.8 0.7 0.67 0.1 2500.0 0.8 2.27 25 39.1 0.6 0.45 0.1 10000.0 0.5 0.40 25 156.3 0.7 0.78 0.39 2.4 0.9 0.36 25 625.0 0.6 0.67 0.39 9.8 0.9 1.25 25 2500.0 0.6 0.91 0.39 39.1 0.8 0.21 25 10000.0 0.3 0.10 0.39 156.3 0.8 0.34 100 2.4 0.3 0.05 0.39 625.0 0.8 0.75 100 9.8 0.3 0.05 0.39 2500.0 0.8 1.52 100 39.1 0.3 0.05 0.39 10000.0 0.4 0.32 100 156.3 0.3 0.07 1.56 2.4 0.9 1.29 100 625.0 0.3 0.06 1.56 9.8 0.9 1.21 100 2500.0 0.3 0.08 1.56 39.1 0.8 0.45 100 10000.0 0.2 0.08 1.56 156.3 0.8 0.60 Cell line: Ki-JK
RRID cell accession identifier: CVOL_2093 Reference: Shimakage et al., lntervirology, 1993;36(4):pp.215-24.
ADCx25 Venetoclax ADCx25 Venetoclax Fa CI Fa CI
(PM) (nM) (PM) (nM) 0.02 2.4 1.0 0.01 1.56 2.4 0.9 0.35 0.02 9.8 1.0 0.01 1.56 9.8 1.0 0.56 0.02 39.1 0.9 0.02 1.56 39.1 0.9 0.38 0.02 156.3 0.9 0.07 1.56 156.3 0.9 0.51 0.02 625.0 0.9 0.26 1.56 625.0 0.8 0.43 0.02 2500.0 0.9 0.97 1.56 2500.0 0.8 0.97 0.02 10000.0 0.4 1.54 1.56 10000.0 0.4 1.60 0.1 2.4 1.0 0.07 6.25 2.4 0.8 0.74 0.1 9.8 1.0 0.21 6.25 9.8 0.8 0.64 0.1 39.1 1.0 0.09 6.25 39.1 0.8 0.73 0.1 156.3 1.0 0.12 6.25 156.3 0.7 0.55 0.1 625.0 0.9 0.33 6.25 625.0 0.7 0.68 0.1 2500.0 0.9 1.12 6.25 2500.0 0.6 0.95 0.1 10000.0 0.4 1.55 6.25 10000.0 0.2 1.18 0.39 2.4 1.0 0.22 25 2.4 0.4 0.67 0.39 9.8 1.0 7077.08 25 9.8 0.3 0.65 0.39 39.1 1.0 0.50 25 39.1 0.3 0.61 0.39 156.3 1.0 0.37 25 156.3 0.3 0.57 0.39 625.0 0.9 0.33 25 625.0 0.2 0.53 0.39 2500.0 0.9 0.97 25 2500.0 0.2 0.57 0.39 10000.0 0.4 1.49 25 10000.0 0.0 0.52 Cell line: Mac-1 RRID cell accession identifier: CVCL_H631 Reference: Su et al., Am J Pathol, 1988 Aug;132(2):pp.192-8.
ADCx25 Venetoclax ADCx25 Venetoclax Fa CI Fa CI
(PM) (nM) (PM) (nM) 0.02 2.4 0.9 0.23 1.56 2.4 0.8 0.72 0.02 9.8 0.9 0.23 1.56 9.8 0.7 0.51 0.02 39.1 0.8 0.21 1.56 39.1 0.8 0.80 0.02 156.3 0.7 0.32 1.56 156.3 0.7 0.48 0.02 625.0 0.7 0.97 1.56 625.0 0.6 0.36 0.02 2500.0 0.6 0.89 1.56 2500.0 0.5 0.33 0.1 2.4 0.9 0.21 6.25 2.4 0.7 1.88 0.1 9.8 0.8 0.10 6.25 9.8 0.7 1.61 0.1 39.1 0.8 0.21 6.25 39.1 0.7 1.05 0.1 156.3 0.8 0.42 6.25 156.3 0.7 0.73 0.1 625.0 0.7 0.51 6.25 625.0 0.6 0.41 0.1 2500.0 0.6 0.57 6.25 2500.0 0.5 0.30 0.39 2.4 0.8 0.23 25 2.4 0.5 0.59 0.39 9.8 0.8 0.43 25 9.8 0.5 0.37 0.39 39.1 0.8 0.64 25 39.1 0.5 0.32 0.39 156.3 0.8 0.52 25 156.3 0.4 0.19 0.39 625.0 0.7 0.59 25 625.0 0.4 0.19 0.39 2500.0 0.5 0.42 25 2500.0 0.3 0.09 Conclusion The strong single agent anti-lymphoma activity and the observed in vitro synergism with targeted agents support the current ADCT-301 clinical development and identify potential combination partners for future clinical studies.
Example 2 Introduction Camidanlumab tesirine (ADCT-301) is an anti-CD25 antibody-drug conjugate (ADC) conjugated via a protease cleavable linker to SG3199, a highly cytotoxic DNA
minor groove crosslinking pyrrolobenzodiazepine dimer (Flynn et al. Mol Cancer Ther 2016, and as described herein).
ADCT-301 is currently in phase I as single agent in relapsed/refractory lymphomas (NCT02432235), advanced solid tumors (NCT03621982) and in acute myeloid leukemia (N0T02588092). It has preclinical activity as single agent in 57 lymphoma cell lines and in combination with selected drugs in T-cell lymphomas-derived cell lines.
Methods Cell lines were exposed to increasing concentrations of ADCT-301 for 96h followed by MU proliferation assay. 0D25 expression was measured both at cell surface level via fluorescence quantitation (Quantum Simply Cellular microspheres) and at RNA
level (IIlumina HT-12 arrays and HTG EdgeSeq Oncology Biomarker Panel). Combination studies of increasing doses of ADCT-301 and increasing doses of additional drugs were assessed by MT1- proliferation assay over 96h in FE-PD, Karpas-299, KI-JK and cell lines.
Chou-Talalay method was used to calculate median combination index (CI) (synergism Cl<0.9, additive CI=0.9-1.1, antagonism/no benefit CI> 1.1).
Results ADCT-301 presented a much stronger activity in T- (n=9, median IC50=4 PM; 95%
CI., 1.6pM-0.9nM) than B-cell lymphomas (n=48, 0.7 nM; 95% Cl., 0.4-2.6 nM) (P=0.047). In vitro activity was highly correlated with CD25 expression both at cell surface level (n=53, Pearson r = -0.50, P=0.0001) and RNA level (n=53, Pearson r = -0.52, P<0.0001). CD25 was also more highly expressed in T- than B-cell lymphoma (P<0.0001), in agreement with the 1050s differences, and the correlation was still maintained within the subgroups (T-cell lymphomas, Pearson r = -0.90, P=0.0021; B-cell lymphomas; Pearson r = -0.3, P=0.05).
Based on the higher activity in T-cell lymphomas, ADCT-301-containing combinations were evaluated in 4 cell lines derived from peripheral T cell lymphoma not otherwise specified (n=1), ALK-pos (n=2) or ALK-neg (n=1) anaplastic large cell lymphoma (ALCL).
ADCT-301 plus the mTOR inhibitor everolimus showed synergism in 4/4 cell lines, as shown by the data tables shown below.
Cell line: FE-PD
RRID cell accession identifier: CVOL_H614 Reference: del Mistro et al., Leukemia, 1994, Jul;8(7): pp.1214-9 ADCx25 Everolimus ADCx25 Everolimus Fa CI Fa CI
(PM) (nM) (PM) (nM) 0.02 0.24 0.41 255.98 0.39 62.50 0.29 0.02 0.02 0.98 0.39 17.76 0.39 250 0.30 0.02 0.02 3.91 0.34 0.03 0.39 1000 0.30 0.03 0.02 15.63 0.33 0.04 1.56 0.24 0.30 0.07 0.02 62.50 0.35 1.89 1.56 0.98 0.59 349407000000000.0 0.02 250 0.34 5.69 1.56 3.91 0.28 0.06 0.02 1000 0.33 2.44 1.56 15.63 0.26 0.05 0.1 0.24 0.39 12.35 1.56 62.50 0.24 0.05 0.1 0.98 0.34 0.01 1.56 250 0.25 0.05 0.1 3.91 0.34 0.03 1.56 1000 0.26 0.05 0.1 15.63 0.31 0.01 6.25 0.24 0.11 0.05 0.1 62.50 0.34 0.39 6.25 0.98 0.11 0.05 0.1 250 0.33 1.03 6.25 3.91 0.10 0.04 0.1 1000 0.34 21.50 6.25 15.63 0.10 0.05 0.39 0.24 0.37 0.30 6.25 62.50 0.08 0.03 0.39 0.98 0.35 0.07 6.25 250 0.08 0.03 0.39 3.91 0.31 0.02 6.25 1000 0.07 0.03 0.39 15.63 0.30 0.02 Cell line: Karpas-299 RRID cell accession identifier: CVOL_1324 Reference: Fischer et al., Blood, 1988, Jul;72(1):pp.234-40.
ADCx25 Everolimus ADCx25 Everolimus Fa CI Fa CI
(PM) (nM) (PM) (nM) 0.02 0.24 0.39 1.79 1.56 62.50 0.23 0.02 0.02 0.98 0.35 0.63 1.56 250 0.21 0.01 0.02 3.91 0.30 0.10 1.56 1000 0.21 0.05 0.02 15.63 0.27 0.07 6.25 0.24 0.28 0.02 0.02 62.50 0.25 0.05 6.25 0.98 0.24 0.01 0.02 250 0.26 0.63 6.25 3.91 0.21 0.01 0.02 1000 0.26 2.55 6.25 15.63 0.20 0.01 0.1 0.24 0.37 0.62 6.25 62.50 0.18 0.00 0.1 0.98 0.33 0.28 6.25 250 0.19 0.01 0.1 3.91 0.28 0.02 6.25 1000 0.20 0.03 0.1 15.63 0.26 0.04 25 0.24 0.22 0.03 0.1 62.50 0.24 0.02 25 0.98 0.21 0.03 0.1 250 0.23 0.04 25 3.91 0.17 0.02 0.1 1000 0.25 0.79 25 15.63 0.18 0.02 0.39 0.24 0.36 0.37 25 62.50 0.16 0.01 0.39 0.98 0.31 0.07 25 250 0.16 0.01 0.39 3.91 0.27 0.01 25 1000 0.17 0.01 0.39 15.63 0.26 0.02 100 0.24 0.15 0.03 0.39 62.50 0.22 0.01 100 0.98 0.14 0.03 0.39 250 0.23 0.07 100 3.91 0.14 0.03 0.39 1000 0.22 0.07 100 15.63 0.14 0.03 1.56 0.24 0.32 0.04 100 62.50 0.13 0.03 1.56 0.98 0.29 0.02 100 250 0.13 0.02 1.56 3.91 0.25 0.01 100 1000 0.13 0.02 1.56 15.63 0.23 0.01 Cell line: Ki-JK
RRID cell accession identifier: CVOL_2093 Reference: Shimakage et al., lntervirology, 1993;36(4):pp.215-24.
ADCx25 Everolimus ADCx25 Everolimus Fa CI Fa CI
(PM) (nM) (PM) (nM) 0.02 0.24 0.53 0.448 0.39 62.5 0.35 0.021 0.02 0.98 0.50 0.231 0.39 250 0.35 0.022 0.02 3.91 0.46 0.066 0.39 1000 0.34 0.025 0.02 15.63 0.44 0.053 1.56 0.24 0.35 0.087 0.02 62.5 0.42 0.077 1.56 0.98 0.32 0.066 0.02 250 0.42 0.201 1.56 3.91 0.28 0.042 0.02 1000 0.41 0.605 1.56 15.63 0.26 0.032 0.1 0.24 0.49 0.046 1.56 62.5 0.25 0.029 0.1 0.98 0.46 0.035 1.56 250 0.22 0.020 0.1 3.91 0.41 0.012 1.56 1000 0.21 0.017 0.1 15.63 0.40 0.013 6.25 0.24 0.11 0.011 0.1 62.5 0.39 0.016 6.25 0.98 0.10 0.009 0.1 250 0.37 0.017 6.25 3.91 0.08 0.005 0.1 1000 0.39 0.120 6.25 15.63 0.07 0.004 0.39 0.24 0.45 0.055 6.25 62.5 0.06 0.003 0.39 0.98 0.40 0.037 6.25 250 0.06 0.003 0.39 3.91 0.37 0.027 6.25 1000 0.06 0.003 0.39 15.63 0.39 0.033 Cell line: Mac-1 RRID cell accession identifier: CVCL_H631 Reference: Su et al., Am J Pathol, 1988 Aug;132(2):pp.192-8.
ADCx25 Everolimus ADCx25 Everolimus Fa CI Fa CI
(PM) (nM) (PM) (nM) 0.02 0.24 0.47 9.93E+04 1.56 0.24 0.41 0.84 0.02 0.98 0.42 25.40 1.56 0.98 0.37 0.25 0.02 3.91 0.36 0.00 1.56 3.91 0.34 0.23 0.02 15.63 0.39 2.00 1.56 15.63 0.35 0.24 0.02 62.50 0.39 12.36 1.56 62.50 0.34 0.23 0.02 250 0.40 408.51 1.56 250 0.35 0.25 0.02 1000 0.40 253.77 1.56 1000 0.35 0.25 0.1 0.24 0.44 420.27 6.25 0.24 0.28 0.82 0.1 0.98 0.39 0.05 6.25 0.98 0.20 0.67 0.1 3.91 0.38 0.05 6.25 3.91 0.19 0.64 0.1 15.63 0.38 0.27 6.25 15.63 0.19 0.64 0.1 62.50 0.39 7.06 6.25 62.50 0.22 0.70 0.1 250 0.38 4.29 6.25 250 0.22 0.69 0.1 1000 0.39 64.12 6.25 1000 0.21 0.68 0.39 0.24 0.44 350.66 25 0.24 0.07 1.51 0.39 0.98 0.39 0.22 25 0.98 0.06 1.37 0.39 3.91 0.38 0.08 25 3.91 0.04 1.18 0.39 15.63 0.36 0.07 25 15.63 0.06 1.40 0.39 62.50 0.36 0.08 25 62.50 0.04 1.13 0.39 250 0.37 0.78 25 250 0.04 1.12 0.39 1000 0.35 0.08 25 1000 0.03 0.96 Conclusion The strong single agent anti-lymphoma activity and the observed in vitro synergism with targeted agents support the current ADCT-301 clinical development and identify potential combination partners for future clinical studies.
Example 3 Introduction Camidanlumab tesirine (ADCT-301) is an anti-CD25 antibody-drug conjugate (ADC) conjugated via a protease cleavable linker to SG3199, a highly cytotoxic DNA
minor groove crosslinking pyrrolobenzodiazepine dimer (Flynn et al. Mol Cancer Ther 2016, and as described herein).
ADCT-301 is currently in phase I as single agent in relapsed/refractory lymphomas (NCT02432235), advanced solid tumors (NCT03621982) and in acute myeloid leukemia (NCT02588092). It has preclinical activity as single agent in 57 lymphoma cell lines and in combination with selected drugs in T-cell lymphomas-derived cell lines.
Methods Cell lines were exposed to increasing concentrations of ADCT-301 for 96h followed by MU proliferation assay. CD25 expression was measured both at cell surface level via fluorescence quantitation (Quantum Simply Cellular microspheres) and at RNA
level (IIlumina HT-12 arrays and HTG EdgeSeq Oncology Biomarker Panel). Combination studies of increasing doses of ADCT-301 and increasing doses of additional drugs were assessed by MT1- proliferation assay over 96h in FE-PD, Karpas-299, KI-JK and cell lines.
Chou-Talalay method was used to calculate median combination index (CI) (synergism Cl<0.9, additive CI=0.9-1.1, antagonism/no benefit CI> 1.1).
Results ADCT-301 presented a much stronger activity in T- (n=9, median IC50=4 PM; 95%
Cl., 1.6pM-0.9nM) than B-cell lymphomas (n=48, 0.7 nM; 95% Cl., 0.4-2.6 nM) (P=0.047). In vitro activity was highly correlated with CD25 expression both at cell surface level (n=53, Pearson r = -0.50, P=0.0001) and RNA level (n=53, Pearson r = -0.52, P<0.0001). CD25 was also more highly expressed in T- than B-cell lymphoma (P<0.0001), in agreement with the 1050s differences, and the correlation was still maintained within the subgroups (T-cell lymphomas, Pearson r = -0.90, P=0.0021; B-cell lymphomas; Pearson r = -0.3, P=0.05).
Based on the higher activity in T-cell lymphomas, ADCT-301-containing combinations were evaluated in 4 cell lines derived from peripheral T cell lymphoma not otherwise specified (n=1), ALK-pos (n=2) or ALK-neg (n=1) anaplastic large cell lymphoma (ALCL).
ADCT-301 plus the PI3K inhibitor copanlisib was synergistic in all but one cell line.
ADCT-301 plus the HDAC inhibitor vorinostat was also synergistic in all but one cell line.
ADCT-301 plus the H DAC inhibitor romidepsin led to synergism in 2/4 cell lines.
The combination of ADCT-301 with the anti-folate pralatrexate was synergistic in 2/2 ALK-pos ALCL cell lines.
The combination of ADCT-301 with the proteasome inhibitor bortezomib led to synergism in 2/4 cell lines.
Finally, the combination of ADCT-301 with bendamustine achieved synergism in 1 out 4 cell lines.
Data is shown in the tables below.
Combination: ADCT-301 + copanlisib Cell line: FE-PD
RRID cell accession identifier: CVCL_H614 Reference: del Mistro et al., Leukemia, 1994, Jul;8(7): pp.1214-9 ADCx25 Copanlisib ADCx25 Copanlisib Fa CI Fa CI
(PM) (nM) (PM) (nM) 0.02 0.5 0.87 0.07 0.39 125 0.82 3.13 0.02 2.0 0.92 0.42 0.39 500 0.75 4.66 0.02 7.8 0.83 0.22 0.39 2000 0.16 0.05 0.02 31 0.85 1.01 1.56 0.5 0.91 5.97 0.02 125 0.80 2.04 1.56 2.0 0.86 2.90 0.02 500 0.79 6.74 1.56 7.8 0.82 2.11 0.02 2000 0.18 0.06 1.56 31 0.78 1.69 0.1 0.5 0.90 0.36 1.56 125 0.70 1.35 0.1 2.0 0.83 0.19 1.56 500 0.54 0.85 0.1 7.8 0.88 0.66 1.56 2000 0.13 0.04 0.1 31 0.79 0.55 6.25 0.5 0.33 0.33 0.1 125 0.79 1.89 6.25 2.0 0.25 0.19 0.1 500 0.78 6.03 6.25 7.8 0.19 0.12 0.1 2000 0.17 0.06 6.25 31 0.26 0.22 0.39 0.5 0.92 1.69 6.25 125 0.18 0.11 0.39 2.0 0.87 0.88 6.25 500 0.12 0.06 0.39 7.8 0.86 1.03 6.25 2000 0.05 0.02 0.39 31 0.84 1.48 Cell line: Karpas-299 RRID cell accession identifier: CVCL_1324 Reference: Fischer et al., Blood, 1988, Jul;72(1):pp.234-40.
ADCx25 Copanlisib ADCx25 Copanlisib Fa CI Fa CI
(PM) (nM) (PM) (nM) 0.02 0.5 0.99 47.36 1.56 125 0.86 14.80 0.02 2.0 0.95 3.14 1.56 500 0.49 0.86 0.02 7.8 0.94 7.01 1.56 2000 0.16 0.08 0.02 31 0.92 12.92 6.25 0.5 0.88 2.31 0.02 125 0.95 153.10 6.25 2.0 0.42 0.11 0.02 500 0.67 4.52 6.25 7.8 0.41 0.11 0.02 2000 0.15 0.07 6.25 31 0.42 0.13 0.1 0.5 0.95 0.92 6.25 125 0.65 1.25 0.1 2.0 0.93 1.41 6.25 500 0.32 0.22 0.1 7.8 0.92 3.74 6.25 2000 0.15 0.09 0.1 31 0.90 9.56 25 0.5 0.50 0.64 0.1 125 0.90 34.02 25 2.0 0.47 0.55 0.1 500 0.65 3.86 25 7.8 0.43 0.45 0.1 2000 0.16 0.08 25 31 0.42 0.46 0.39 0.5 0.98 8.02 25 125 0.35 0.34 0.39 2.0 0.91 0.82 25 500 0.21 0.16 0.39 7.8 0.96 18.19 25 2000 0.11 0.07 0.39 31 0.93 17.72 100 0.5 0.23 0.52 0.39 125 0.91 48.65 100 2.0 0.24 0.55 0.39 500 0.62 2.86 100 7.8 0.22 0.47 0.39 2000 0.16 0.08 100 31 0.21 0.47 1.56 0.5 0.92 1.25 100 125 0.20 0.43 1.56 2.0 0.88 0.84 100 500 0.12 0.20 1.56 7.8 0.88 1.85 100 2000 0.09 0.13 1.56 31 0.86 4.26 Cell line: Ki-JK
RRID cell accession identifier: CVCL_2093 Reference: Shimakage et al., lntervirology, 1993;36(4):pp.215-24.
ADCx25 Copanlisib ADCx25 Copanlisib Fa CI Fa CI
(PM) (nM) (PM) (nM) 0.02 0.2 1.00 3.99E+08 0.39 15.6 0.85 1.68 0.02 1.0 0.95 0.56 0.39 62.5 0.70 1.79 0.02 3.9 0.98 5.81 0.39 250.0 0.32 0.77 0.02 15.6 0.88 1.94 1.56 0.2 0.74 1.00 0.02 62.5 0.76 2.48 1.56 1.0 0.72 0.98 0.02 250.0 0.36 0.84 1.56 3.9 0.78 1.23 0.1 0.2 0.93 0.17 1.56 15.6 0.69 1.27 0.1 1.0 0.87 0.19 1.56 62.5 0.58 1.51 0.1 3.9 0.92 1.12 1.56 250.0 0.17 0.61 0.1 15.6 0.84 1.25 6.25 0.2 0.43 2.51 0.1 62.5 0.75 2.27 6.25 1.0 0.46 2.62 0.1 250.0 0.33 0.72 6.25 3.9 0.39 2.41 0.39 0.2 0.87 0.35 6.25 15.6 0.39 2.46 0.39 1.0 0.87 0.44 6.25 62.5 0.14 1.54 0.39 3.9 0.95 2.27 6.25 250.0 0.02 0.76 Cell line: Mac-1 RRID cell accession identifier: CVCL_H631 Reference: Su et al., Am J Pathol, 1988 Aug;132(2):pp.192-8.
ADCx25 Copanlisib ADCx25 Copanlisib Fa CI Fa CI
(PM) (nM) (PM) (nM) 0.02 0.2 0.92 0.50 1.56 0.2 0.90 1.96 0.02 1.0 0.80 0.06 1.56 1.0 0.87 1.58 0.02 3.9 0.76 0.10 1.56 3.9 0.83 1.13 0.02 15.6 0.81 0.96 1.56 15.6 0.83 2.44 0.02 62.5 0.76 1.58 1.56 62.5 0.78 2.70 0.02 250.0 0.52 0.18 1.56 250.0 0.49 0.18 0.1 0.2 0.87 0.14 6.25 0.2 0.70 0.89 0.1 1.0 0.81 0.10 6.25 1.0 0.73 1.22 0.1 3.9 0.80 0.22 6.25 3.9 0.63 0.57 0.1 15.6 0.78 0.60 6.25 15.6 0.54 0.33 0.1 62.5 0.76 1.53 6.25 62.5 0.43 0.17 0.1 250.0 0.57 0.37 6.25 250.0 0.24 0.04 0.39 0.2 0.98 95.14 25 0.2 0.19 0.10 0.39 1.0 0.82 0.23 25 1.0 0.09 0.03 0.39 3.9 0.84 0.79 25 3.9 0.04 0.01 0.39 15.6 0.82 1.52 25 15.6 0.06 0.01 0.39 62.5 0.77 1.99 25 62.5 0.02 0.00 0.39 250.0 0.57 0.40 25 250.0 0.01 0.00 Combination: ADCT-301 + vorinostat Cell line: FE-PD
RRID cell accession identifier: CVCL_H614 Reference: del Mistro et al., Leukemia, 1994, Jul;8(7): pp.1214-9 ADCx25 Vorinostat ADCx25 Vorinostat Fa CI Fa CI
(PM) (nM) (PM) (nM) 0.02 31 0.86 0.41 0.39 250 0.84 3.54 0.02 62 0.83 0.57 0.39 500 0.35 0.92 0.02 125 0.84 1.14 0.39 1000 0.12 0.70 0.02 250 0.87 2.65 1.56 31 0.78 2.93 0.02 500 0.38 1.00 1.56 62 0.80 4.08 0.02 1000 0.12 0.71 1.56 125 0.80 4.42 0.1 31 0.84 0.64 1.56 250 0.56 1.13 0.1 62 0.82 0.79 1.56 500 0.23 0.63 0.1 125 0.94 6.04 1.56 1000 0.11 0.66 0.1 250 0.91 4.90 6.25 31 0.43 0.55 0.1 500 0.41 1.09 6.25 62 0.40 0.51 0.1 1000 0.12 0.70 6.25 125 0.30 0.35 0.39 31 0.85 2.09 6.25 250 0.16 0.25 0.39 62 0.88 3.95 6.25 500 0.09 0.29 0.39 125 0.91 7.46 6.25 1000 0.09 0.58 Cell line: Karpas-299 RRID cell accession identifier: CVCL_1324 Reference: Fischer et al., Blood, 1988, Jul;72(1):pp.234-40.
ADCx25 Vorinostat ADCx25 Vorinostat Fa CI Fa CI
(PM) (nM) (PM) (nM) 0.02 31 0.95 0.66 1.56 250 0.78 1.40 0.02 62 0.96 1.45 1.56 500 0.27 0.37 0.02 125 0.92 1.58 6.25 31 0.86 1.76 0.02 250 0.86 1.91 6.25 62 0.82 1.32 0.02 500 0.33 0.48 6.25 125 0.75 1.03 0.1 31 0.96 0.95 6.25 250 0.61 0.82 0.1 62 0.93 1.03 6.25 500 0.23 0.33 0.1 125 0.95 2.45 25 31 0.46 0.39 0.1 250 0.86 1.92 25 62 0.40 0.32 0.1 500 0.32 0.46 25 125 0.38 0.36 0.39 31 0.99 5.00 25 250 0.33 0.40 0.39 62 0.98 5.57 25 500 0.18 0.30 0.39 125 0.97 4.86 100 31 0.25 0.39 0.39 250 0.86 2.01 100 62 0.25 0.40 0.39 500 0.29 0.41 100 125 0.25 0.43 1.56 31 0.95 2.30 100 250 0.23 0.48 1.56 62 0.89 1.10 100 500 0.12 0.27 1.56 125 0.94 3.25 Cell line: Ki-JK
RRID cell accession identifier: CVCL_2093 Reference: Shimakage et al., lntervirology, 1993;36(4):pp.215-24.
ADCx25 Vorinostat ADCx25 Vorinostat Fa CI Fa CI
(PM) (nM) (PM) (nM) 0.02 31 0.95 0.24 1.56 31 0.83 1.92 0.02 62 0.97 0.48 1.56 62 0.72 0.98 0.02 125 0.90 0.41 1.56 125 0.69 0.94 0.02 250 0.77 0.55 1.56 250 0.50 0.63 0.02 500 0.32 0.58 1.56 500 0.18 0.50 0.1 31 0.90 0.35 6.25 31 0.39 0.65 0.1 62 0.89 0.39 6.25 62 0.39 0.67 0.1 125 0.84 0.43 6.25 125 0.33 0.59 0.1 250 0.73 0.56 6.25 250 0.26 0.55 0.1 500 0.30 0.57 6.25 500 0.07 0.38 0.39 31 0.91 1.19 25 31 0.13 0.45 0.39 62 0.90 1.15 25 62 0.12 0.44 0.39 125 0.89 1.20 25 125 0.12 0.48 0.39 250 0.66 0.59 25 250 0.10 0.48 0.39 500 0.26 0.55 25 500 0.04 0.36 Cell line: Mac-1 RRID cell accession identifier: CVCL_H631 Reference: Su et al., Am J Pathol, 1988 Aug;132(2):pp.192-8.
ADCx25 Vorinostat ADCx25 Vorinostat Fa CI Fa CI
(PM) (nM) (PM) (nM) 0.02 31 0.84 0.15 1.56 31 0.77 0.95 0.02 62 0.85 0.35 1.56 62 0.77 0.98 0.02 125 0.90 1.56 1.56 125 0.76 0.93 0.02 250 0.98 83.46 1.56 250 0.71 0.65 0.02 500 0.40 0.04 1.56 500 0.24 0.01 0.1 31 0.83 0.24 6.25 31 0.69 1.47 0.1 62 0.84 0.40 6.25 62 0.63 0.78 0.1 125 0.81 0.43 6.25 125 0.62 0.72 0.1 250 0.90 3.77 6.25 250 0.45 0.15 0.1 500 0.40 0.03 6.25 500 0.07 0.00 0.39 31 0.79 0.38 25 31 0.31 0.12 0.39 62 0.82 0.62 25 62 0.19 0.02 0.39 125 0.80 0.61 25 125 0.12 0.01 0.39 250 0.78 0.75 25 250 0.04 0.00 0.39 500 0.32 0.02 25 500 0.0024 9.17E-Combination: ADCT-301 + romidepsin Cell line: FE-PD
RRID cell accession identifier: CVCL_H614 Reference: del Mistro et al., Leukemia, 1994, Jul;8(7): pp.1214-9 ADCx25 Romidepsin ADCx25 Romidepsin Fa CI Fa CI
(PM) (nM) (PM) (nM) 0.02 0.156 1.000 2.59E+22 0.39 0.625 0.79 0.95 0.02 0.312 1.000 2.59E+22 0.39 1.25 0.13 1.22 0.02 0.625 0.85 0.92 1.56 0.156 1.0 2.02E+24 0.02 1.25 0.15 1.24 1.56 0.312 0.91 8.30 0.1 0.156 0.91 0.77 1.56 0.625 0.61 0.81 0.1 0.312 0.90 0.81 1.56 1.25 0.12 1.21 0.1 0.625 0.87 1.06 6.25 0.156 0.56 0.23 0.1 1.25 0.15 1.24 6.25 0.312 0.54 0.41 0.39 0.156 1.0 5.06E+23 6.25 0.625 0.27 0.67 0.39 0.312 0.98 268.02 6.25 1.25 0.06 1.11 Cell line: Karpas-299 RRID cell accession identifier: CVCL_1324 Reference: Fischer et al., Blood, 1988, Jul;72(1):pp.234-40.
ADCx25 Romidepsin ADCx25 Romidepsin Fa CI Fa CI
(PM) (nM) (PM) (nM) 0.02 0.156 0.98 0.37 1.56 0.625 0.72 1.19 0.02 0.312 0.90 0.64 6.25 0.156 0.92 0.88 0.02 0.625 0.76 1.18 6.25 0.312 0.83 0.83 0.1 0.156 1.0 1.26E+05 6.25 0.625 0.60 1.17 0.1 0.312 0.94 0.68 25 0.156 0.39 0.37 0.1 0.625 0.80 1.20 25 0.312 0.29 0.57 0.39 0.156 1.0 4.90E+05 25 0.625 0.22 1.01 0.39 0.312 0.93 0.70 100 0.156 0.13 0.33 0.39 0.625 0.78 1.20 100 0.312 0.12 0.55 1.56 0.156 1.0 1.96E+06 100 0.625 0.04 0.85 1.56 0.312 0.85 0.68 Cell line: Ki-JK
RRID cell accession identifier: CVCL_2093 Reference: Shimakage et al., lntervirology, 1993;36(4):pp.215-24.
ADCx25 Romidepsin ADCx25 Romidepsin Fa CI Fa CI
(PM) (nM) (PM) (nM) 0.02 0.156 0.95 0.80 1.56 0.156 0.88 0.93 0.02 0.312 0.82 0.72 1.56 0.312 0.73 0.86 0.02 0.625 0.61 0.79 1.56 0.625 0.52 0.89 0.1 0.156 0.93 0.70 6.25 0.156 0.50 1.12 0.1 0.312 0.78 0.64 6.25 0.312 0.44 1.15 0.1 0.625 0.65 0.87 6.25 0.625 0.28 1.07 0.39 0.156 0.88 0.58 25 0.156 0.12 2.13 0.39 0.312 0.84 0.89 25 0.312 0.08 1.85 0.39 0.625 0.63 0.89 25 0.625 0.04 1.56 Cell line: Mac-1 RRID cell accession identifier: CVCL_H631 Reference: Su et al., Am J Pathol, 1988 Aug;132(2):pp.192-8.
ADCx25 Romidepsin ADCx25 Romidepsin Fa CI Fa CI
(PM) (nM) (PM) (nM) 0.02 0.156 1.000 3.14E+03 1.56 0.156 1.000 3.15E+03 0.02 0.312 0.951 1.069 1.56 0.312 1.000 6.29E+03 0.02 0.625 0.817 0.942 1.56 0.625 0.840 1.089 0.1 0.156 1.000 3.14E+03 6.25 0.156 0.792 0.417 0.1 0.312 0.988 2.384 6.25 0.312 0.725 0.528 0.1 0.625 0.901 1.406 6.25 0.625 0.338 0.382 0.39 0.156 1.000 3.14E+03 25 0.156 0.266 0.423 0.39 0.312 1.000 6.28E+03 25 0.312 0.006 0.104 0.39 0.625 0.919 1.613 25 0.625 0.141 0.428 Combination: ADCT-301 + pralatrexate Cell line: Karpas-299 RRID cell accession identifier: CVCL_1324 Reference: Fischer et al., Blood, 1988, Jul;72(1):pp.234-40.
ADCx25 Pralatrexate ADCx25 Pralatrexate Fa CI Fa CI
(PM) (nM) (PM) (nM) 0.02 0.013 0.94 9.05 1.56 1.1 0.18 0.48 0.02 0.04 0.42 0.12 1.56 3.3 0.18 1.35 0.02 0.12 0.19 0.06 1.56 10 0.21 5.59 0.02 0.37 0.19 0.17 6.25 0.013 0.73 4.87 0.02 1.1 0.20 0.55 6.25 0.04 0.34 0.14 0.02 3.3 0.20 1.72 6.25 0.12 0.19 0.07 0.02 10 0.21 5.93 6.25 0.37 0.19 0.18 0.1 0.013 0.91 4.62 6.25 1.1 0.19 0.51 0.1 0.04 0.39 0.10 6.25 3.3 0.17 1.29 0.1 0.12 0.20 0.06 6.25 10 0.21 5.60 0.1 0.37 0.19 0.18 25 0.013 0.43 0.81 0.1 1.1 0.19 0.52 25 0.04 0.37 0.50 0.1 3.3 0.19 1.64 25 0.12 0.20 0.12 0.1 10 0.22 6.28 25 0.37 0.19 0.22 0.39 0.013 0.89 6.78 25 1.1 0.20 0.63 0.39 0.04 0.39 0.11 25 3.3 0.18 1.49 0.39 0.12 0.19 0.06 25 10 0.19 4.76 0.39 0.37 0.19 0.17 100 0.013 0.15 0.10 0.39 1.1 0.20 0.57 100 0.04 0.15 0.11 0.39 3.3 0.19 1.57 100 0.12 0.14 0.10 0.39 10 0.21 5.90 100 0.37 0.14 0.18 1.56 0.013 0.80 3.49 100 1.1 0.13 0.30 1.56 0.04 0.33 0.08 100 3.3 0.13 0.77 1.56 0.12 0.18 0.06 100 10 0.14 2.73 1.56 0.37 0.18 0.17 Cell line: Ki-JK
RRID cell accession identifier: CVCL_2093 Reference: Shimakage et al., lntervirology, 1993;36(4):pp.215-24.
ADCx25 Pralatrexate ADCx25 Pralatrexate Fa CI Fa CI
(PM) (nM) (PM) (nM) 0.02 0.013 0.61 109.64 0.39 1.1 0.18 0.48 0.02 0.04 0.22 0.07 0.39 3.3 0.18 1.36 0.02 0.12 0.20 0.09 0.39 10 0.18 4.56 0.02 0.37 0.19 0.24 1.56 0.013 0.52 18.55 0.02 1.1 0.19 0.56 1.56 0.04 0.20 0.04 0.02 3.3 0.18 1.44 1.56 0.12 0.19 0.07 0.02 10 0.19 4.95 1.56 0.37 0.18 0.14 0.1 0.013 0.62 141.49 1.56 1.1 0.17 0.37 0.1 0.04 0.22 0.06 1.56 3.3 0.17 1.07 0.1 0.12 0.20 0.10 1.56 10 0.18 3.98 0.1 0.37 0.19 0.23 6.25 0.013 0.40 1.61 0.1 1.1 0.19 0.56 6.25 0.04 0.22 0.09 0.1 3.3 0.18 1.60 6.25 0.12 0.19 0.11 0.1 10 0.19 6.05 6.25 0.37 0.18 0.20 0.39 0.013 0.60 82.07 6.25 1.1 0.18 0.50 0.39 0.04 0.22 0.05 6.25 3.3 0.18 1.32 0.39 0.12 0.19 0.08 6.25 10 0.186 5.020 0.39 0.37 0.19 0.19 Combination: ADCT-301 + bortezomib Cell line: FE-PD
RRID cell accession identifier: CVCL_H614 Reference: del Mistro et al., Leukemia, 1994, Jul;8(7): pp.1214-9 ADCx25 Bortezomib ADCx25 Bortezomib Fa CI Fa CI
(PM) (nM) (PM) (nM) 0.02 0.003 0.95 0.04 0.39 0.07 0.89 0.14 0.02 0.008 0.92 0.01 0.39 0.22 0.89 0.13 0.02 0.025 0.93 0.02 0.39 0.66 0.85 0.06 0.02 0.07 0.92 0.02 1.56 0.003 0.92 1.04 0.02 0.22 0.94 0.10 1.56 0.008 0.89 0.56 0.02 0.66 0.92 0.01 1.56 0.025 0.88 0.47 0.1 0.003 0.94 0.13 1.56 0.07 0.88 0.41 0.1 0.008 0.91 0.06 1.56 0.22 0.85 0.25 0.1 0.025 0.94 0.12 1.56 0.66 0.81 0.15 0.1 0.07 0.91 0.05 6.25 0.003 0.75 0.30 0.1 0.22 0.91 0.05 6.25 0.008 0.71 0.20 0.1 0.66 0.83 0.01 6.25 0.025 0.71 0.19 0.39 0.003 0.94 0.49 6.25 0.07 0.71 0.20 0.39 0.008 0.91 0.19 6.25 0.22 0.64 0.10 0.39 0.025 0.91 0.20 6.25 0.66 0.49 0.03 Cell line: Karpas-299 RRID cell accession identifier: CVCL_1324 Reference: Fischer et al., Blood, 1988, Jul;72(1):pp.234-40.
ADCx25 Bortezomib ADCx25 Bortezomib Fa CI Fa CI
(PM) (nM) (PM) (nM) 0.02 0.003 0.97 0.04 1.56 0.07 0.63 0.38 0.02 0.008 0.90 0.06 1.56 0.22 0.76 1.23 0.02 0.025 0.88 0.17 1.56 0.66 0.47 1.96 0.02 0.07 0.86 0.44 6.25 0.003 0.79 0.74 0.02 0.22 0.88 1.49 6.25 0.008 0.60 0.46 0.02 0.66 0.68 2.69 6.25 0.025 0.71 0.67 0.1 0.003 0.95 0.06 6.25 0.07 0.56 0.62 0.1 0.008 0.90 0.08 6.25 0.22 0.49 0.98 0.1 0.025 0.77 0.13 6.25 0.66 0.48 2.21 0.1 0.07 0.90 0.54 25 0.003 0.49 1.31 0.1 0.22 0.82 1.24 25 0.008 0.46 1.23 0.1 0.66 0.67 2.65 25 0.025 0.37 1.03 0.39 0.003 0.92 0.11 25 0.07 0.42 1.29 0.39 0.008 0.88 0.12 25 0.22 0.40 1.59 0.39 0.025 0.69 0.14 25 0.66 0.32 2.28 0.39 0.07 0.65 0.30 100 0.003 0.27 2.97 0.39 0.22 0.65 0.89 100 0.008 0.26 2.87 0.39 0.66 0.60 2.38 100 0.025 0.24 2.69 1.56 0.003 0.90 0.34 100 0.07 0.23 2.72 1.56 0.008 0.86 0.29 100 0.22 0.22 2.94 1.56 0.025 0.79 0.31 100 0.66 0.18 3.22 Cell line: Ki-JK
RRID cell accession identifier: CVCL_2093 Reference: Shimakage et al., lntervirology, 1993;36(4):pp.215-24.
ADCx25 Bortezomib ADCx25 Bortezomib Fa CI Fa CI
(PM) (nM) (PM) (nM) 0.02 0.003 0.89 0.31 1.56 0.003 0.79 5.35 0.02 0.008 0.89 0.37 1.56 0.008 0.75 3.34 0.02 0.025 0.83 0.25 1.56 0.025 0.73 2.79 0.02 0.07 0.79 0.43 1.56 0.07 0.67 1.96 0.02 0.22 0.81 1.30 1.56 0.22 0.61 1.73 0.02 0.66 0.56 2.21 1.56 0.66 0.44 2.06 0.1 0.003 0.90 1.71 6.25 0.003 0.40 0.75 0.1 0.008 0.86 0.88 6.25 0.008 0.37 0.62 0.1 0.025 0.82 0.62 6.25 0.025 0.35 0.58 0.1 0.07 0.81 0.79 6.25 0.07 0.35 0.66 0.1 0.22 0.70 1.08 6.25 0.22 0.30 0.81 0.1 0.66 0.55 2.20 6.25 0.66 0.26 1.52 0.39 0.003 0.83 2.31 25 0.003 0.13 0.17 0.39 0.008 0.83 2.15 25 0.008 0.12 0.15 0.39 0.025 0.82 2.07 25 0.025 0.12 0.18 0.39 0.07 0.78 1.56 25 0.07 0.12 0.24 0.39 0.22 0.72 1.61 25 0.22 0.10 0.37 0.39 0.66 0.49 2.05 25 0.66 0.11 0.99 Cell line: Mac-1 RRID cell accession identifier: CVCL_H631 Reference: Su et al., Am J Pathol, 1988 Aug;132(2):pp.192-8.
ADCx25 Bortezomib ADCx25 Bortezomib Fa CI Fa CI
(PM) (nM) (PM) (nM) 0.02 0.003 0.883 1.225 1.56 0.003 0.874 0.970 0.02 0.008 0.829 0.494 1.56 0.008 0.817 0.380 0.02 0.025 0.806 0.802 1.56 0.025 0.766 0.301 0.02 0.07 0.772 0.931 1.56 0.07 0.722 0.311 0.02 0.22 0.751 1.815 1.56 0.22 0.676 0.383 0.02 0.66 0.524 0.075 1.56 0.66 0.542 0.103 0.1 0.003 0.854 0.410 6.25 0.003 0.892 2.536 0.1 0.008 0.813 0.309 6.25 0.008 0.794 0.254 0.1 0.025 0.794 0.582 6.25 0.025 0.754 0.255 0.1 0.07 0.747 0.530 6.25 0.07 0.689 0.168 0.1 0.22 0.710 0.745 6.25 0.22 0.640 0.197 0.1 0.66 0.443 0.019 6.25 0.66 0.477 0.035 0.39 0.003 0.879 1.053 25 0.003 0.545 0.007 0.39 0.008 0.813 0.314 25 0.008 0.557 0.009 0.39 0.025 0.777 0.381 25 0.025 0.577 0.017 0.39 0.07 0.733 0.390 25 0.07 0.552 0.020 0.39 0.22 0.678 0.391 25 0.22 0.448 0.009 0.39 0.66 0.391 0.008 25 0.66 0.291 0.001 Combination: ADCT-301 + bendamustine Cell line: FE-PD
RRID cell accession identifier: CVCL_H614 Reference: del Mistro et al., Leukemia, 1994, Jul;8(7): pp.1214-9 ADCx25 Bendamustine ADCx25 Bendamustine Fa CI Fa CI
(PM) (nM) (PM) (nM) 0.02 4.88 1.00 1.17E+03 0.39 312.50 1.00 7.48E+04 0.02 19.53 1.00 4.67E+03 0.39 1250 1.00 2.99E+05 0.02 78.13 0.97 0.13 0.39 5000 0.84 1.75 0.02 312.50 0.97 0.45 1.56 4.88 0.94 0.35 0.02 1250 0.93 0.91 1.56 19.53 0.97 0.45 0.02 5000 0.87 2.05 1.56 78.13 0.95 0.43 0.1 4.88 0.97 0.03 1.56 312.50 0.97 0.84 0.1 19.53 0.95 0.04 1.56 1250 0.94 1.27 0.1 78.13 0.96 0.11 1.56 5000 0.82 1.68 0.1 312.50 0.94 0.28 6.25 4.88 0.73 0.86 0.1 1250 0.98 2.41 6.25 19.53 0.73 0.86 0.1 5000 0.87 1.97 6.25 78.13 0.70 0.84 0.39 4.88 0.99 0.17 6.25 312.50 0.72 0.90 0.39 19.53 1.00 4.68E+03 6.25 1250 0.74 1.13 0.39 78.13 1.00 1.87E+04 6.25 5000 0.47 1.01 Cell line: Karpas-299 RRID cell accession identifier: CVCL_1324 Reference: Fischer et al., Blood, 1988, Jul;72(1):pp.234-40.
ADCx25 Bendamustine ADCx25 Bendamustine Fa CI Fa CI
(PM) (nM) (PM) (nM) 0.02 4.883 0.92 0.00 1.56 1250.0 0.86 0.31 0.02 19.531 0.99 0.01 1.56 5000.0 0.82 0.98 0.02 78.125 0.93 0.03 1.56 20000.0 0.65 2.60 0.02 312.5 0.88 0.07 6.25 4.883 0.86 0.16 0.02 1250.0 0.92 0.35 6.25 19.531 0.91 0.21 0.02 5000.0 0.93 1.49 6.25 78.125 0.86 0.18 0.02 20000.0 0.70 2.84 6.25 312.5 0.80 0.19 0.1 4.883 1.00 9.37 6.25 1250.0 0.78 0.34 0.1 19.531 1.00 14.00 6.25 5000.0 0.76 0.93 0.1 78.125 1.00 32.52 6.25 20000.0 0.47 1.95 0.1 312.5 0.94 0.11 25 4.883 0.55 0.29 0.1 1250.0 0.97 0.57 25 19.531 0.52 0.28 0.1 5000.0 0.97 2.27 25 78.125 0.54 0.30 0.1 20000.0 0.74 3.14 25 312.5 0.51 0.30 0.39 4.883 0.94 0.02 25 1250.0 0.47 0.36 0.39 19.531 1.00 36.70 25 5000.0 0.44 0.68 0.39 78.125 0.95 0.04 25 20000.0 0.28 1.49 0.39 312.5 0.96 0.14 100 4.883 0.24 0.61 0.39 1250.0 1.00 1.41 100 19.531 0.24 0.61 0.39 5000.0 0.89 1.27 100 78.125 0.24 0.61 0.39 20000.0 0.68 2.77 100 312.5 0.24 0.62 1.56 4.883 0.94 0.07 100 1250.0 0.23 0.66 1.56 19.531 0.96 0.08 100 5000.0 0.21 0.84 1.56 78.125 0.93 0.08 100 20000.0 0.17 1.47 1.56 312.5 0.87 0.11 Cell line: Ki-JK
RRID cell accession identifier: CVCL_2093 Reference: Shimakage et al., lntervirology, 1993;36(4):pp.215-24.
ADCx25 Bendamustine ADCx25 Bendamustine Fa CI Fa CI
(PM) (nM) (PM) (nM) 0.02 4.883 1.00 1.30 1.56 4.883 0.93 0.48 0.02 19.531 1.00 0.02 1.56 19.531 0.96 0.57 0.02 78.125 0.94 0.01 1.56 78.125 0.98 0.70 0.02 312.5 0.98 0.02 1.56 312.5 1.00 99.28 0.02 1250.0 0.97 0.04 1.56 1250.0 0.97 0.67 0.02 5000.0 0.98 0.16 1.56 5000.0 0.95 0.64 0.02 20000.0 0.59 0.12 1.56 20000.0 0.56 0.33 0.1 4.883 1.00 5.94 6.25 4.883 0.74 1.14 0.1 19.531 1.00 6.35 6.25 19.531 0.75 1.16 0.1 78.125 0.99 0.06 6.25 78.125 0.76 1.18 0.1 312.5 1.00 14.54 6.25 312.5 0.78 1.24 0.1 1250.0 1.00 40.74 6.25 1250.0 0.77 1.21 0.1 5000.0 0.97 0.17 6.25 5000.0 0.76 1.23 0.1 20000.0 0.61 0.13 6.25 20000.0 0.41 0.80 0.39 4.883 1.00 22.77 25 4.883 0.32 2.51 0.39 19.531 1.00 23.18 25 19.531 0.32 2.50 0.39 78.125 1.00 24.82 25 78.125 0.33 2.53 0.39 312.5 1.00 31.37 25 312.5 0.32 2.51 0.39 1250.0 0.97 0.20 25 1250.0 0.32 2.49 0.39 5000.0 0.98 0.32 25 5000.0 0.29 2.42 0.39 20000.0 0.56 0.16 25 20000.0 0.15 1.87 Cell line: Mac-1 RRID cell accession identifier: CVCL_H631 Reference: Su et al., Am J Pathol, 1988 Aug;132(2):pp.192-8.
ADCx25 Bendamustine ADCx25 Bendamustine Fa CI Fa CI
(PM) (nM) (PM) (nM) 0.02 4.883 0.81 1.80 1.56 4.883 0.68 5.84 0.02 19.531 0.72 0.12 1.56 19.531 0.71 8.04 0.02 78.125 0.66 0.06 1.56 78.125 0.65 4.20 0.02 312.5 0.93 1.59E+10 1.56 312.5 0.70 7.36 0.02 1250.0 0.77 15.35 1.56 1250.0 0.73 11.72 0.02 5000.0 0.63 0.04 1.56 5000.0 0.54 1.27 0.1 4.883 0.71 0.56 6.25 4.883 0.63 13.08 0.1 19.531 0.75 0.96 6.25 19.531 0.55 5.91 0.1 78.125 0.58 0.12 6.25 78.125 0.53 4.46 0.1 312.5 0.67 0.33 6.25 312.5 0.58 7.74 0.1 1250.0 0.76 5.71 6.25 1250.0 0.58 7.56 0.1 5000.0 0.64 0.24 6.25 5000.0 0.37 0.92 0.39 4.883 0.74 2.97 25 4.883 0.14 0.15 0.39 19.531 0.74 3.05 25 19.531 0.13 0.11 0.39 78.125 0.78 7.18 25 78.125 0.09 0.04 0.39 312.5 0.75 3.73 25 312.5 0.08 0.03 0.39 1250.0 0.69 1.65 25 1250.0 0.08 0.03 0.39 5000.0 0.60 0.62 25 5000.0 0.03 0.00 Conclusion The strong single agent anti-lymphoma activity and the observed in vitro synergism with targeted agents support the current ADCT-301 clinical development and identify combination partners for future clinical treatment.
Example 4 The purpose of this proposed study is to preliminarily assess the safety, tolerability, pharmacological and clinical activity of this combination The following cancer types have been chosen for study: Disease A, Disease B, and Disease C
Evidence for efficacy as single agents exists for both drugs:
= anti CD25 ADC (see, for example, see, for example, W02014/057119, W02016/083468, and W02016/166341) = Anti-BCL-2 agent, an mTOR inhibitor, or a secondary agent (see KS Peggs et al.2009, Clinical and Experimental Immunology, 157: 9-19 [doi:10.1111/j.1 365-2249.2009.03912.4 This primary purpose of this study is to explore whether these agents can be safely combined, and if so, will identify the dose(s) and regimens appropriate for further study. The study will also assess whether each combination induces pharmacologic changes in tumor that would suggest potential clinical benefit.
In addition, it will provide preliminary evidence that a combination may increase the response rate and durability of response compared with published data for treatment with single agent anti-CD25 ADC or anti-BCL-2 agent, mTOR inhibitor, or secondary agent.
Each disease group may include a subset of patients previously treated with the anti-BCL-2 agent, mTOR inhibitor, or secondary agent to explore whether combination therapy might overcome resistance to anti-BCL-2 agent, mTOR inhibitor, or secondary agent therapy. For each disease, it is not intended to apply specific molecular selection as the data available at present generally do not support excluding patients on the basis of approved molecular diagnostic tests.
Rationale for anti 0D25 ADC starting dose The RDE for already established for ADC (in ug/kg administered every three weeks) will be used for all patients in this study. To ensure patient safety, a starting dose below the RDE will be used; the starting dose level will be one where patient benefit could still be demonstrated in study ADC1, suggesting that patients enrolled at such dose level will gain at least some benefit by taking part.
Rationale for anti-BCL-2 agent, mTOR inhibitor, or secondary agent starting dose The RDE for already estE/blished for the anti-BCL-2 agent, mTOR inhibitor, or secondary agent (in ug/kg administered every three weeks) will be used for all patients in this study. To ensure patient safety, a starting dose below the RDE will be used; the starting dose level will be one where patient benefit could still be demonstrated in study SA1, suggesting that patients enrolled at such dose level will gain at least some benefit by taking part.
Objectives and related endpoints Objective Endpoint Primary Objective Frequency and severity of treatment-To characterize the safety and tolerability emergent AEs and SAEs of ADC in combination with the anti-BCL-2 Changes between baseline and post-agent, mTOR inhibitor, or secondary agent, baseline laboratory parameters and vital and to identify the recommended dose and signs schedules for future studies Incidence of dose limiting toxicities (DLTs) during the first cycle of treatment (dose escalation only) Frequency of dose interruptions and dose reductions Secondary Objectives To evaluate the clinical activity of the ORR, DOR, PFS, OS
combination of ADC with the anti-BCL-2 agent, mTOR inhibitor, or secondary agent AUC and Cmax for each compound To characterize the pharmacokinetic (PK) profile of each of the two compounds ADC
and the anti-BCL-2 agent, mTOR inhibitor, or secondary agent Evidence for Anti-Drug-Antibodies (ADAs) before, during immunogenicity and ADAs to ADC and after treatment with ADC
Exploratory Objectives To examine potential correlation of PK Correlation coefficients between AUC
profiles with safety/tolerability and efficacy and/or Cmax of each compound or a compound measure and any of the safety To characterize changes in the immune or efficacy variables infiltrate in tumors lmmunohistochemistry of pre- and on-treatment tumor biopsies, To characterize changes in circulating levels of cytokines in plasma and markers Measurements (e.g. via ELISA) of of activation in circulating immune cells immunologically relevant cytokines in plasma or serum; staining levels for activation markers of circulating immune cells (e.g. FACS) Study design This phase lb, multi-center, open-label study to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of the ADC
in combination with the anti-BCL-2 agent, mTOR inhibitor, or secondary agent, in patients with disease A, disease B, and disease C.
The study is comprised of a dose escalation part followed by a dose expansion part.
Dose escalation will start with reduced starting doses (compared to their respective recommended phase 2 or licensed dose levels), for both ADC and the anti-BCL-2 agent, mTOR inhibitor, or secondary agent, to guarantee patient safety. Starting doses will be 33% (or 50%) of the RDE for each compound. Subsequently, doses will be first escalated for the anti-BCL-2 agent, mTOR inhibitor, or secondary agent until the RDE or licensed dose has been reached, or a lower dose if necessary for tolerability reasons.
Then, the dose for ADC will be escalated, until the RDE for combination treatment is reached. This is visualized in the below diagram:
=
Increase dose of 100 compund 2 /100% A
perceived safe starting dose of 33% of the intended efficacious dose is proposed for both compounds, but this may Ho% need adaptation to lower or higher, as the individual risk profile for the combination may 33/ 33/ 33/ be.
33% 66% 109%
Compound 1 should be the Increase dose of compound for which an compound 1 efficatious clinical dose has been firmly established (at 100%), and which is therefore aimed to be reached quickly in the trial patients by first escalating the dose of this compound.
If the dose combination is determined to be safe, it may be tested in additional patients to confirm the safety and tolerability at that dose level. Further tailoring of the dose of each compound may be conducted, and/or the regimen may be modified.
The dose escalation of the combination will be guided by a Bayesian Logistic Regression Model (BLRM) based on any Dose Limiting Toxicities (DLTs) observed in the first (or first two, TBC) cycles of therapy. Use of a BLRM is a well-established method to estimate the maximum tolerated dose (MTD)/ recommended dose for expansion (RDE) in cancer patients. The adaptive BLRM will be guided by the Escalation With Overdose Control (EWOC) principle to control the risk of DLT in future patients on the study.
The use of Bayesian response adaptive models for small datasets has been accepted by FDA
and EMEA ("Guideline on clinical trials in small populations", February 1, 2007) and endorsed by numerous publications (Babb et al. 1998, Neuenschwander et al. 2008).
The decisions on new dose combinations are made by the Investigators and sponsor study personnel in a dose escalation safety call (DESC) based upon the review of patient tolerability and safety information (including the BLRM summaries of DLT risk, if applicable) along with PK, PD and preliminary activity information available at the time of the decision.
Once the MTD(s)/RDE is determined for the combination, the expansion part of the study may be initiated to further assess the safety, tolerability and preliminary efficacy.
= For combinations with 10, changes in the immune infiltrate in tumors will also be characterized following combination treatment in the target disease indications.
Given the available prior clinical experience with the agents in this study, it is expected that in most cases a combination dose can be identified without testing a large number of dose levels or schedules. To assess the pharmacodynamic activity of the combinations, patients will be asked to undergo a tumor biopsy at baseline and again after approximately two cycles of therapy.
= For 10 combo: The extent of the change in tumor infiltration by immune cells including lymphocytes and macrophages will contribute to a decision on any potential benefit.
Dose escalation part During the dose escalation part of the study, patients will be treated with a fixed dose of ADC administered iv., and increasing doses of the anti-BCL-2 agent, mTOR
inhibitor, or secondary agent until the RDE for the anti-BCL-2 agent, mTOR inhibitor, or secondary agent has been reached. Subsequently, doses of ADC are increased (in different cohorts) while the dose for the anti-BCL-2 agent, mTOR inhibitor, or secondary agent is kept constant.
Two to approximately 3 or 4 patients with disease A, disease B or disease C
will be treated in each escalation cohort until the determination of MTD(s)/RDE(s) is determined.
There will be a 24-hour observation before enrolling the second patient at Dose Level 1.
The DLT observation period at each dose level is either 1 cycle (3 weeks) or 2 cycles (6 weeks) as mandated by the appropriate authorities for 10 therapies, after which it will be determined whether to escalate to the next dose level, stay at the current dose level, or de-escalate to the previous dose level for the next cohort. There will be no de-escalation from Dose Level 1. lntrapatient dose escalation is not permitted.
Dose escalation is not permitted unless 2 or more patients have complete DLT
information through the first cycle in any given dose level. Dose escalation will be determined by using a mCRM with a target DLT rate of 30% and an equivalence interval of 20% to 35%, and with dose escalation-with-overdose-control (EWOC) and no dose skipping.
Patients will be assigned to a cohort that is actively enrolling. Dose escalation will be performed in each combination following the completion of one cycle of treatment.
Safety assessments including adverse events (AEs) and laboratory values will be closely monitored for all enrolled patients in order to identify any DLTs. A single MTD/RDE will be defined; a disease-specific MTD/RDE will not be established.
The mCRM will be implemented for DE under the oversight of a Dose Escalation Steering Committee (DESC). The DESC will confirm each escalating dose level after reviewing all available safety data. PK data from patients in that dose level and prior dose levels may also inform decision making. The DESC may halt dose escalation prior to determining the MTD based on emerging PK, PD, toxicity or response data.
Additional patients may be included at any dose level to further assess the safety and tolerability if at least 1 patient in the study has achieved a partial response or better, or if further evaluation of PK or PD data is deemed necessary by the DESC to determine the RDE.
Dose Escalation will be stopped after 3 cohorts (or at least 6 patients) are consecutively assigned to the same dose level. If the MTD is not reached, the recommended dose for expansion (RDE) will be determined. Prior to the determination of the MTD/RDE
a minimum of 6 patients must have been treated with the combination.
It is intended that paired tumor biopsies will be obtained from patients during dose escalation. Analysis of these biopsies will contribute to a better understanding of the relationship between the dose and the pharmacodynamic activity of the combination.
Safety Oversight by the Dose Escalation Steering Committee A DESC comprised of ADC Therapeutics and the investigators will review patient safety on an ongoing basis during the DE to determine if the dose escalation schedule prescribed by the mCRM warrants modification. In addition to safety observations, PK
and/or PD data may also inform decision making. Intermediate doses may be assigned after agreement between ADC Therapeutics and investigators. The DESC may continue to provide oversight during Part 2. No formal Data Safety Monitoring Board (DSMB) will be used.
Dose expansion part Once the MTD/RDE has been declared, dose expansion part may begin. The main objective of the expansion part is to further assess the safety and tolerability of the study treatment at the MTD/RDE and to gain a preliminary understanding of the efficacy of the combination compared to historical single agent efficacy data.
An important exploratory objective is to assess changes in the immune infiltrate in tumor in response to treatment. This will be assessed in paired tumor biopsies collected from patients, with a minimum of ten evaluable biopsy pairs (biopsy specimens must contain sufficient tumor for analysis) in patients treated at the MTD/RDE. If this is not feasible, collection of these biopsies may be stopped. A minimum of 10 to 20 patients are planned to be treated in each investigational arm, Several different investigational arms will open, one per disease. A total of nine investigational arms may be run in the dose expansion. Should enrollment for any of these groups not be feasible, then enrollment to that group may be closed before the 10 to 20 patients target is met.
In each treatment group a maximum of approximately six patients who have received and progressed on prior single administration (i.e. not in combination) anti-BCL-2 agent, mTOR inhibitor, or secondary agent therapy will be allowed to be treated. This number may be increased if a combination shows promise of overcoming resistance to prior treatment with single administration anti-BCL-2 agent, mTOR inhibitor, or secondary agent.
Patient Population The study will be conducted in adult patients with advanced Disease A, Disease B or Disease C as outlined above. The investigator or designee must ensure that only patients who meet all the following inclusion and none of the exclusion criteria are offered treatment in the study.
Inclusion criteria Patients eligible for inclusion in this study have to meet all of the following criteria:
1. Written informed consent must be obtained prior to any procedures 2. Age 18 years.
3. Patients with advanced/metastatic cancer, with measurable disease as determined by RECIST version 1.1, who have progressed despite standard therapy or are intolerant to standard therapy, or for whom no standard therapy exists.
Patients must fit into one of the following groups:
= Disease A
= Disease B
= Disease C
4. ECOG Performance Status 0 ¨ 1 (or 2 TBC) 5. TBC: Patient must have a site of disease amenable to biopsy, and be a candidate for tumor biopsy according to the treating institution's guidelines. Patient must be willing to undergo a new tumor biopsy at baseline, and again during therapy on this study.
6. Prior therapy with the anti-BCL-2 agent, mTOR inhibitor, or secondary agent or related compounds (i.e. same MOA) is allowed Exclusion criteria Patients eligible for this study must not meet any of the following criteria:
1. History of severe hypersensitivity reactions to other mAbs (OR to same backbone mAb as in ADC OR to same 10 mAb if applicable) 2. Known history of positive serum human ADA to backbone of mAb as in ADC
3. Central Nervous System (CNS) disease only (if applicable) 4. Symptomatic CNS metastases or evidence of leptomeningeal disease (brain MRI
or previously documented cerebrospinal fluid (CSF) cytology) Previously treated asymptomatic CNS metastases are permitted provided that the last treatment (systemic anticancer therapy and-or local radiotherapy) was completed >= 8 weeks prior to 1st day of dosing, except usage of low dose steroids on a taper is allowed) Patients with discrete dural metastases are eligible.
5. Patient having out of range laboratory values defined as:
= Serum creatinine <= 1.5x ULN. If serum creatinine > 1.5, the creatinine clearance (calculated using Cockcroft-Gault formula, or measured) must be > 60 mlimin/1.73m2 for a patient to be eligible = Total bilirubin > 1.5 x ULN, except for patients with Gilbert's syndrome who are excluded if total bilirubin > 3.0 x ULN or direct bilirubin > 1.5 x ULN
= Alanine aminotransferase (ALT) > 3 x ULN, except for patients that have tumor involvement of the liver, who are excluded if ALT > 5 x ULN
= Aspartate aminotransferase (AST) > 3 x ULN, except for patients that have tumor involvement of the liver, who are excluded if AST > 5 x ULN
= Absolute neutrophil count< 1.0 x 10e9/L
= Platelet count< 75 x 10e9/L
= Hemoglobin (Hgb) <8 g/dL
= Potassium, magnesium, calcium or phosphate abnormality > CTCAE grade 1 despite appropriate replacement therapy 6. Impaired cardiac function or clinically significant cardiac disease, including any of the following:
= Clinically significant and/or uncontrolled heart disease such as congestive heart failure requiring treatment (NYHA grade III or IV) or uncontrolled hypertension defined by a Systolic Blood Pressure (SBP) 160 mm Hg and/or Diastolic Blood Pressure (DBP) 100 mm Hg, with or without anti-hypertensive medication.
= QTcF >470 msec for females or >450 msec for males on screening ECG using Fridericia's correction, congenital long QT syndrome = Acute myocardial infarction or unstable angina pectoris < 3 months (months prior to study entry = Clinically significant valvualr disease with documented compromise in cardiac function = Symptomatic pericarditis = History of or ongoing documented cardiomyopathy = Left Ventricular Ejection Fraction (LVEF) <40%, as determined by echocardiogram (ECHO) or Multi gated acquisition (MUGA) scan = History or presence of any clinically significant cardiac arrhythmias, e.g.
ventricular, supraventricular, nodal arrhythmias, or conduction abnormality (TBC qualifier: ... requiring a pacemaker or not controlled with medication) = Presence of unstable atrial fibrillation (ventricular response rate> 100 bpm).
NOTE: Patients with stable atrial fibrillation can be enrolled provided they do not meet other cardiac exclusion criteria.
= Complete left bundle branch block (LBBB), bifascicular block = Any clinically significant ST segment and/or T-wave abnormalities 7. Toxicity attributed to prior 10 therapy that led to discontinuation of therapy.
Adequately treated patients for drug-related skin rash or with replacement therapy for endocrinopathies are not excluded, provided these toxicities did not lead to the discontinuation of prior treatment.
8. Patients with active, known or suspected autoimmune disease. Subjects with vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll, provided the trigger can be avoided.
9. Human Immunodeficiency Virus (HIV), or active Hepatitis B (HBV) or Hepatitis C (HCV) virus infection Testing is not mandatory to be eligible. Testing for HCV should be considered if the patient is at risk for having undiagnosed HCV
(e.g. history of injection drug use).
10. Malignant disease, other than that being treated in this study.
Exceptions to this exclusion include the following: malignancies that were treated curatively and have not recurred within 2 years prior to study treatment; completely resected basal cell and squamous cell skin cancers; any malignancy considered to be indolent and that has never required therapy; and completely resected carcinoma in situ of any type.
11. Systemic anti-cancer therapy within 2 weeks of the first dose of study treatment. For cytotoxic agents that have major delayed toxicity, e.g.
mitomycin C
and nitrosoureas, 4 weeks is indicated as washout period. For patients receiving anticancer immunotherapies such as CTLA-4 antagonists, 6 weeks is indicated as the washout period.
12. Active diarrhea CTCAE grade 2 or a medical condition associated with chronic diarrhea (such as irritable bowel syndrome, inflammatory bowel disease) 13. Presence of 2: CTCAE grade 2 toxicity (except alopecia, peripheral neuropathy and ototoxicity, which are excluded if >= CTCAE grade 3) due to prior cancer therapy.
14. Active infection requiring systemic antibiotic therapy.
15. Active ulceration of the upper GI tract or GI bleeding 16. Active bleeding diathesis or on oral anti-vitamin K medication (except low-dose warfarin and aspirin or equivalent, as long as the I NR <= 2.0) 17. Active autoimmune disease, motor neuropathy considered of autoimmune origin, and other CNS autoimmune disease 18. Patients requiring concomitant immunosuppressive agents or chronic treatment with corticoids except:
> replacement dose steroids in the setting of adrenal insufficiency = topical, inhaled, nasal and ophthalmic steroids are allowed 19. Use of any live vaccines against infectious diseases (e.g. influenza, varicella, pneumococcus) within 4 weeks of initiation of study treatment (NB the use of live vaccines is not allowed through the whole duration of the study) 20. Use of hematopoietic colony-stimulating growth factors (e.g. G-CSF, GMCSF, M-CSF) <2 weeks prior start of study drug. An erythroid stimulating agent is allowed as long as it was initiated at least 2 weeks prior to the first dose of study treatment.
21. Major surgery within 2 weeks of the first dose of study treatment (NB
mediastinoscopy, insertion of a central venous access device, or insertion of a feeding tube are not considered major surgery).
22. Radiotherapy within 2 weeks of the first dose of study drug, except for palliative radiotherapy to a limited field, such as for the treatment of bone pain or a focally painful tun1or mass. To allow for assessment of response to treatment, patients must have remaining measurable disease that has not been irradiated 23. Participation in an interventional, investigational study within 2 weeks of the first dose of study treatment.
24. Any medical condition that would, in the investigator's judgment, prevent the patient's participation in the clinical study due to safety concerns, compliance with clinical study procedures or interpretation of study results.
25. Sexually active males unless they use a condom during intercourse while taking drug and for 90 days after stopping study treatment and should not father a child in this period. A condom is required to be used also by vasectomized men in order to prevent delivery of the drug via seminal fluid.
26. Pregnant or lactating women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test. In rare cases of an endocrine-secreting tumor, hCG
levels may be above normal limits but with no pregnancy in the patient. In these cases, there should be a repeat serum hCG test (with a non-rising result) and a vaginal/pelvic ultrasound to rule out pregnancy. Upon confirmation of results and discussion with the Medical representative, these patients may enter the study.
27. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during study treatment and for 90 days after the last any dose of study treatment. Highly effective contraception methods include:
= Total abstinence (when this is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception = Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy), total hysterectomy or tubal ligation at least 6 weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment = Male sterilization (at least 6 months prior to screening). For female patients on the study the vasectomized male partner should be the sole partner for that patient.
= Use of oral (estrogen and progesterone), injected or implanted combined hormonal methods of contraception or placement of an intrauterine device (IUD) or intrauterine system (I US) or other forms of hormonal contraception that have comparable efficacy (failure rate <1%), for example hormone vaginal ring or transdermal hormone contraception.
= In case of use of oral contraception, women should have been stable on the same pill for a minimum of 3 months before taking study treatment.
= Women are considered post-menopausal and not of child bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least 6 weeks ago. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of child bearing potential.
Dose-Limiting Toxicities and Dose modification guidelines A dose-limiting toxicity (DLT) is defined as any of the following events thought to be at least possibly related to ADC per investigator judgment that occurs during the 21-day DLT evaluation period. Toxicity that is clearly and directly related to the primary disease or to another etiology is excluded from this definition.
DLT Definitions A hematologic DLT is defined as:
= Grade 3 or 4 febrile neutropenia or neutropenic infection = Grade 4 neutropenia lasting >7 days = Grade 4 thrombocytopenia = Grade 3 thrombocytopenia with clinically significant bleeding, or Grade 3 thrombocytopenia requiring a platelet transfusion = Grade 3 anemia that requires transfusion = Grade 4 anemia A non-hematologic DLT is defined as:
= Grade 4 non-hematologic toxicity = Grade 3 non-hematologic toxicity lasting >3 days despite optimal supportive care or medical intervention = A case of Hy's law (AST and/or ALT > 3x ULN and bilirubin > 2x ULN, and without initial findings of cholestasis (serum alkaline phosphatase (ALP) activity <
2x ULN) and no other reason that could explain the combination of increased transaminases and serum total bilirubin, such as viral hepatitis A, B, or C, preexisting or acute liver disease, or another drug capable of causing the observed injury) = Grade 3 or higher hypersensitivity/infusion-related reaction (regardless of premedication). A grade 3 hypersensitivity / infusion-related reaction that resolves within 8 hours after onset with appropriate clinical management does not qualify as a DLT.
= LVEF decrease to <40% or >20% decrease from baseline = Grade 4 tumor lysis syndrome (Grade 3 TLS will not constitute DLT unless it leads to irreversible end-organ damage) The following conditions are not considered non-hematologic DLT:
= Grade 3 fatigue for 7 days = Grade 3 diarrhea, nausea, or vomiting in the absence of premedication that responds to therapy and improves by at least 1 grade within 3 days for Grade 3 events or to Grade 1 within 7 days.
= AST or ALT elevation 5 x ULN but 8 x ULN, without concurrent elevation in bilirubin, that downgrades to Grade 2 within 5 days after onset.
= Grade 3 serum lipase or serum amylase for 7 days if without clinical signs or symptoms of pancreatitis Patients who experience a DLT that resolves or stabilizes with appropriate medical management may continue treatment at the discretion of the investigator in consultation with the sponsor.
Dose modifications Guidelines for management of specific toxicities are detailed in the table below. For management of events not specified in the tables, the following may serve as a guidance to investigators:
AE Grade ADC Management Guideline 1 No dose adjustment is required.
2 First occurrence:
Consider holding one or both drugs until improvement to Grade 1 or baseline. Up to 1 dose of one or both drugs may be skipped to permit improvement. If improvement to Grade 1 or baseline occurs within 21 days from the last scheduled (but missed) dose of one or both drugs, continue one or both drugs at the original assigned dose level in subsequent treatment cycles.
If improvement to Grade 1 or baseline does not occur within 21 days from the last scheduled (but missed) dose, permanently discontinue one or both drugs.
Second occurrence:
Hold one or both drugs until improvement to Grade 1 or baseline. Up to 1 dose of one or both drugs may be skipped to permit resolution. If improvement to Grade 1 or baseline occurs within 21 days from the last scheduled (but missed) dose, continue one or both drugs at 1 dose level below the original assigned dose in subsequent treatment cycles. If improvement to Grade 1 or baseline does not occur within 21 days from the last scheduled (but missed) dose, permanently discontinue one or both drugs.
Third occurrence:
Permanently discontinue one or both drugs.
3 First occurrence:
Hold one or both drugs until improvement to Grade 1 or baseline. Up to 1 dose of one or both drugs may be skipped to permit improvement, then continue at 1 dose level below the original assigned dose in subsequent treatment cycles.
Second occurrence:
Permanently discontinue one or both drugs 4 Permanently discontinue one or both drugs.
Claims (50)
1. A method of selecting an individual as suitable for treatment with an anti-0D25 ADC, wherein the individual is selected for treatment with the anti-CD25 ADC
if the individual has been treated with an anti-BCL-2 agent, a mTOR inhibitor, or a secondary agent.
if the individual has been treated with an anti-BCL-2 agent, a mTOR inhibitor, or a secondary agent.
2. A method of selecting an individual as suitable for treatment with an anti-CD25 ADC, wherein the individual is selected for treatment with the anti-CD25 ADC
if the individual is being treated with an anti-BCL-2 agent, a mTOR inhibitor, or a secondary agent.
if the individual is being treated with an anti-BCL-2 agent, a mTOR inhibitor, or a secondary agent.
3. The method according to any one of the preceding claims, wherein the individual is selected for treatment if the individual is refractory to treatment, or further treatment, with the anti-BCL-2 agent, mTOR inhibitor, or secondary agent.
4. A method for treating a disorder in an individual, the method comprising:
(i) selecting an individual as suitable for treatment by a method according to any one of claims 1 to 3; and (ii) administering to the individual an effective amount of the anti-CD25 ADC.
(i) selecting an individual as suitable for treatment by a method according to any one of claims 1 to 3; and (ii) administering to the individual an effective amount of the anti-CD25 ADC.
5. The method according to claim 4, further comprising administering a an anti-BCL-2 agent, a mTOR inhibitor, or a secondary agent in combination with the anti-CD25 ADC.
6. A method for treating a disorder in an individual, the method comprising administering to the individual an effective amount of an anti-CD25 ADC and an anti-BCL-2 agent, a mTOR inhibitor, or a secondary agent.
7. The method according to claim 6, wherein the individual is selected for treatment according to a method according to any one of claims 1 to 3.
8. The method according to any one of claims 5 to 7, wherein the treatment comprises administering the anti-CD25 ADC before the anti-BCL-2 agent, mTOR
inhibitor, or secondary agent secondary agent, simultaneous with the anti-BCL-2 agent, mTOR inhibitor, or secondary agent, or after the anti-BCL-2 agent, mTOR
inhibitor, or secondary agent.
inhibitor, or secondary agent secondary agent, simultaneous with the anti-BCL-2 agent, mTOR inhibitor, or secondary agent, or after the anti-BCL-2 agent, mTOR
inhibitor, or secondary agent.
9. The method according to any previous claim, wherein the treatment further comprises administering a chemotherapeutic agent.
10. The method according to any previous claim, wherein the individual is human.
11. The method according to any preceding claim, wherein the individual has a disorder or has been determined to have a disorder.
12. The method according to claim 11, wherein the individual has, or has been has been determined to have, a cancer which expresses 0D25 or CD25+ tumour-associated non-tumour cells, such as CD25+ infiltrating cells.
13. The method according to any previous claim, wherein the individual is undergoing treatment with an anti-BCL-2 agent, a mTOR inhibitor, or a secondary agent.
14. The method according to any previous claim, wherein the individual has undergone treatment with an anti-BCL-2 agent, a mTOR inhibitor, or a secondary agent.
15. The method according to any previous claim, wherein the individual is refractory to treatment, or further treatment, with the anti-BCL-2 agent, mTOR inhibitor, or secondary agent.
16. The method according to any one of the preceding claims, wherein the treatment has increased efficacy as compared to monotherapy with either the anti-CD25 ADC or anti-BCL-2 agent, mTOR inhibitor, or secondary agent alone.
17. The method according to any preceding claim, wherein the anti-CD25 ADC
is ADCx25 or ADCT-301.
is ADCx25 or ADCT-301.
18. The method according to any previous claim, wherein the disorder is a proliferative disease.
19. The method of claim 18, wherein the disorder is cancer.
20. The method according to any previous claim, wherein the individual has, or has been has been determined to have, a disorder characterised by the presence of a neoplasm comprising both CD25+ve and CD25-ve cells.
21. The method according to any previous claim, wherein the individual has, or has been has been determined to have, a disorder characterised by the presence of a neoplasm comprising, or composed of, CD25-ve neoplastic cells.
22. The method according to either of claims 20 or 21, wherein the neoplasm is all or part of a solid tumour.
23. The method of statement 22, wherein the solid tumour is associated with CD25+ve infiltrating cells;
optionally wherein the solid tumour is associated with high levels of CD25+ve infiltrating cells.
optionally wherein the solid tumour is associated with high levels of CD25+ve infiltrating cells.
24. The method of statement 23, wherein the solid tumour is selected from the group consisting of pancreatic cancer, breast cancer (including triple negative breast cancer), colorectal cancer, gastric and oesophageal cancer, melanoma, non-small cell lung cancer, ovarian cancer, hepatocellular carcinoma, renal cell carcinoma, bladder, and head and neck cancer.
25. The method according to any previous claim, wherein the disorder is selected from the group comprising:
Hodgkin's and non-Hodgkin's Lymphoma, including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, (FL), Mantle Cell lymphoma (MCL), chronic lymphatic lymphoma (CLL), Marginal Zone B-cell lymphoma (MZBL);
leukemias such as Hairy cell leukemia (HCL), Hairy cell leukemia variant (HCL-v), Acute Myeloid Leukaemia (AML), anaplastic large cell lymphoma (ALCL), and Acute Lymphoblastic Leukaemia (ALL) such as Philadelphia chromosome-positive ALL
(Ph+ALL) or Philadelphia chromosome-negative ALL (Ph-ALL);
pancreatic cancer, breast cancer, colorectal cancer, gastric and oesophageal cancer, leukemia and lymphoma, melanoma, non-small cell lung cancer, ovarian cancer, hepatocellular carcinoma, renal cell carcinoma, and head and neck cancer.
Hodgkin's and non-Hodgkin's Lymphoma, including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, (FL), Mantle Cell lymphoma (MCL), chronic lymphatic lymphoma (CLL), Marginal Zone B-cell lymphoma (MZBL);
leukemias such as Hairy cell leukemia (HCL), Hairy cell leukemia variant (HCL-v), Acute Myeloid Leukaemia (AML), anaplastic large cell lymphoma (ALCL), and Acute Lymphoblastic Leukaemia (ALL) such as Philadelphia chromosome-positive ALL
(Ph+ALL) or Philadelphia chromosome-negative ALL (Ph-ALL);
pancreatic cancer, breast cancer, colorectal cancer, gastric and oesophageal cancer, leukemia and lymphoma, melanoma, non-small cell lung cancer, ovarian cancer, hepatocellular carcinoma, renal cell carcinoma, and head and neck cancer.
26. The method according to any one of claims 1 to 25, wherein the secondary agent is bendamustine.
27. The method according to any one of claims 1 to 25, wherein the secondary agent is a phosphoinositide 3-kinase inhibitor.
28. The method according to claim 27, wherein the phosphoinositide 3-kinase inhibitor is copanlisib, idelalisib, duvelisib, Taselisib, Buparlisib, Alpelisib, Umbralisib, Dactolisib, or Voxtalisib.
29. The method according to claim 27, wherein the phosphoinositide 3-kinase inhibitor is copanlisib or idelalisib.
30. The method according to any one of claims 1 to 25, wherein the secondary agent is a proteasome inhibitor.
31. The method according to claim 30, wherein the proteasome inhibitor is bortezomib, carfilzomib, lxazomib, Oprozomib, or Salinosporamide A.
32. The method according to claim 30, wherein the wherein the proteasome inhibitor is bortezomib.
33. The method according to any one of claims 1 to 25, wherein the secondary agent is an anti-folate.
34. The method according to claim 33, wherein the anti-folate is pralatrexate, methotrexate, pemetrexed, or raltitrexed.
35. The method according to claim 33, wherein the anti-folate is pralatrexate.
36. The method according to any one of claims 1 to 25, wherein the secondary agent is a HDAC inhibitor.
37. The method according to claim 36, wherein the HDAC inhibitor is romidepsin, vorinostat, Abexinostat, belinostat (PXD101), LAQ824, panobinostat (LBH589), entinostat (MS-275), tacedinaline (CI994), or mocetinostat (MGCD0103).
38. The method according to claim 36, wherein the HDAC inhibitor is romidepsin or vorinostat.
39. The method according to any one of claims 1 to 25, wherein the anti-BCL-2 agent is selected from the group consisting of: Venetoclax (ABT-199), navitoclax (ABT-263), ABT-737, 555746/BCL201, and oblimersen (G3139).
40. The method according to claim 39, wherein the anti-BCL-2 agent is Venetoclax.
41. The method according to any one of claims 1 to 25, wherein the mTOR
inhibitor is everolimus (RAD001), sirolimus (Rapamycin), CCI-779 (temsirolimus), ridaforolimus (AP-23573), NVP-BEZ235 (dactolisib), BGT226, 5F1126, Gedatolisib, Omipalisib, XL765, Ku-0063794, oleuropein aglycone, AZD8055, AZD2014, AZD 3147, sapanisertib (INK128/MLN0128), 0SI027, torin 1, torin 2, torkinib (PP242), WYE687, ETP45658, PF05212384, PF04691502, XL388, eCF309, RapaLink-1, or Rapalink-2.
inhibitor is everolimus (RAD001), sirolimus (Rapamycin), CCI-779 (temsirolimus), ridaforolimus (AP-23573), NVP-BEZ235 (dactolisib), BGT226, 5F1126, Gedatolisib, Omipalisib, XL765, Ku-0063794, oleuropein aglycone, AZD8055, AZD2014, AZD 3147, sapanisertib (INK128/MLN0128), 0SI027, torin 1, torin 2, torkinib (PP242), WYE687, ETP45658, PF05212384, PF04691502, XL388, eCF309, RapaLink-1, or Rapalink-2.
42. The method according to claim 41, wherein the mTOR inhibitor is Everolimus.
43. An anti-CD25 ADC for use in a method of treatment according to any one of claims 4 to 42.
44. A composition comprising an anti-CD25 ADC, for use in a method of treatment according to any one of claims 4 to 42.
45. An anti-BCL-2 agent, a mTOR inhibitor, or a secondary agent for use in a method of treatment according to any one of claims 5 to 42.
46. A composition comprising an anti-BCL-2 agent, a mTOR inhibitor, or a secondary agent for use in a method of treatment according to any one of claims 5 to 42.
47. Use of an anti-CD25 ADC in the manufacture of a medicament for treating a disorder in an individual, wherein the treatment comprises the method of any one of claims 4 to 42.
48. Use of an anti-BCL-2 agent, a mTOR inhibitor, or a secondary agent in the manufacture of a medicament for treating a disorder in an individual, wherein the treatment comprises the method of any one of claims 5 to 42.
49. A kit comprising:
a first medicament comprising an anti-0D25 ADC;
a package insert comprising instructions for administration of the first medicament according to the method of any one or claims 4 to 42.
a first medicament comprising an anti-0D25 ADC;
a package insert comprising instructions for administration of the first medicament according to the method of any one or claims 4 to 42.
50. The kit according to claim 49, further comprising:
A second medicament comprising an anti-BCL-2 agent, a mTOR inhibitor, or a secondary agent.
A second medicament comprising an anti-BCL-2 agent, a mTOR inhibitor, or a secondary agent.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1908231.2 | 2019-06-10 | ||
GBGB1908227.0A GB201908227D0 (en) | 2019-06-10 | 2019-06-10 | Combination therapy |
GBGB1908232.0A GB201908232D0 (en) | 2019-06-10 | 2019-06-10 | Combination Therapy |
GB1908232.0 | 2019-06-10 | ||
GBGB1908231.2A GB201908231D0 (en) | 2019-06-10 | 2019-06-10 | Combination therapy |
GB1908227.0 | 2019-06-10 | ||
PCT/EP2020/065879 WO2020249527A1 (en) | 2019-06-10 | 2020-06-08 | Combination therapy comprising an anti-cd25 antibody drug conjugate and a further agent |
Publications (1)
Publication Number | Publication Date |
---|---|
CA3142664A1 true CA3142664A1 (en) | 2020-12-17 |
Family
ID=71103359
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA3142664A Pending CA3142664A1 (en) | 2019-06-10 | 2020-06-08 | Combination therapy comprising an anti-cd25 antibody drug conjugate and a further agent |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP3980078A1 (en) |
JP (1) | JP2022536140A (en) |
KR (1) | KR20220020331A (en) |
CN (1) | CN114302746A (en) |
AU (1) | AU2020289961A1 (en) |
CA (1) | CA3142664A1 (en) |
IL (1) | IL288717A (en) |
MX (1) | MX2021015401A (en) |
SG (1) | SG11202113293XA (en) |
WO (1) | WO2020249527A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113082212A (en) * | 2021-04-15 | 2021-07-09 | 中山大学肿瘤防治中心(中山大学附属肿瘤医院、中山大学肿瘤研究所) | Pharmaceutical composition containing mTOR inhibitor and application thereof |
WO2022272060A1 (en) * | 2021-06-24 | 2022-12-29 | Reservoir Neuroscience, Inc. | Ep2 antagonist compounds |
WO2023031403A1 (en) * | 2021-09-02 | 2023-03-09 | F. Hoffmann-La Roche Ag | Antibodies for the treatment of aml |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003295471B2 (en) | 2002-11-15 | 2011-08-25 | Genmab A/S | Human monoclonal antibodies against CD25 |
EA019983B1 (en) | 2005-10-07 | 2014-07-30 | Экселиксис, Инк. | Mek inhibitors and methods of using same |
AU2013328625B2 (en) | 2012-10-12 | 2016-12-15 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
CN107148285B (en) | 2014-11-25 | 2022-01-04 | Adc治疗股份有限公司 | Pyrrolobenzodiazepine-antibody conjugates |
GB201506405D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
WO2017160954A1 (en) * | 2016-03-15 | 2017-09-21 | Seattle Genetics, Inc. | Combinations of pbd-based antibody drug conjugates with bcl-2 inhibitors |
JP7402691B2 (en) * | 2017-04-20 | 2023-12-21 | アーデーセー セラピューティクス ソシエテ アノニム | Combination therapy with anti-CD25 antibody drug conjugate |
BR112019026498A2 (en) * | 2017-06-14 | 2020-07-14 | Adc Therapeutics Sa | dosing regimens for administration of an anti-cd25 adc |
-
2020
- 2020-06-08 EP EP20733375.8A patent/EP3980078A1/en active Pending
- 2020-06-08 SG SG11202113293XA patent/SG11202113293XA/en unknown
- 2020-06-08 WO PCT/EP2020/065879 patent/WO2020249527A1/en unknown
- 2020-06-08 KR KR1020227000168A patent/KR20220020331A/en unknown
- 2020-06-08 MX MX2021015401A patent/MX2021015401A/en unknown
- 2020-06-08 JP JP2021573163A patent/JP2022536140A/en active Pending
- 2020-06-08 CA CA3142664A patent/CA3142664A1/en active Pending
- 2020-06-08 CN CN202080043019.8A patent/CN114302746A/en active Pending
- 2020-06-08 AU AU2020289961A patent/AU2020289961A1/en active Pending
-
2021
- 2021-12-06 IL IL288717A patent/IL288717A/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR20220020331A (en) | 2022-02-18 |
MX2021015401A (en) | 2022-01-24 |
IL288717A (en) | 2022-02-01 |
SG11202113293XA (en) | 2021-12-30 |
AU2020289961A1 (en) | 2022-01-27 |
EP3980078A1 (en) | 2022-04-13 |
CN114302746A (en) | 2022-04-08 |
WO2020249527A1 (en) | 2020-12-17 |
JP2022536140A (en) | 2022-08-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230149556A1 (en) | Combination therapy | |
US11596696B2 (en) | Combination therapy with an anti-CD25 antibody-drug conjugate | |
CA3142664A1 (en) | Combination therapy comprising an anti-cd25 antibody drug conjugate and a further agent | |
CA3064681A1 (en) | Dosage regimes for the administration of an anti-cd25 adc | |
US20220305132A1 (en) | Combination therapy comprising an anti-cd19 antibody drug conjugate and a pi3k inhibitor or a secondary agent | |
US20210322564A1 (en) | Combination therapy | |
US20230132256A1 (en) | Combination therapy | |
US20200129638A1 (en) | Combination therapy with an anti-psma antibody-drug conjugate | |
WO2022074033A1 (en) | Combination therapy | |
WO2022029223A1 (en) | Combination therapy comprising anti-kaag1 antibody drug conjugate and parp inhibitor | |
AU2022302769A1 (en) | Combination therapy using antibody-drug conjugates | |
EP4065169A1 (en) | Combination therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |
Effective date: 20220920 |
|
EEER | Examination request |
Effective date: 20220920 |
|
EEER | Examination request |
Effective date: 20220920 |
|
EEER | Examination request |
Effective date: 20220920 |